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Abstract 
 
The development of a library of novel amphiphiles towards targeted drug delivery for 
the treatment of breast cancer was the focus of this thesis.  As such, a range of 
norbornane based amphiphiles, which possess a rigid ‘kink’ in the centre of the 
amphiphilic structure, were accessed via a concise six step synthesis as discussed in 
Chapter 2. The self-assembly properties of these novel compounds were then 
investigated in Chapter 3, and the critical aggregation concentration (CAC), 
hydrodynamic diameter (DH) by dynamic light scattering (DLS) and their morphology 
by cryogenic transmission electron microscopy (cryo-TEM) and negatively stained 
transmission electron microscopy (TEM) were determined.  These compounds, while 
possessing similar CAC values (50-70 μM), exhibited a wide variety of particle size (60 
nm-140 nm) and morphologies, including spherical, cigar-shaped and rod-like vesicles, 
and spherical micelles.  Considering the similarities in molecular structure it is proposed 
that the unique nature of the molecular ‘kink’ is affecting molecular assembly in which 
subtle changes in molecular structure have large ramifications on aggregate size and 
morphology. 
Chapter 4 describes the development of a second generation of amphiphiles 
incorporating the estrogen receptor antagonist Tamoxifen at the polar head group.  
Synthesis of these functionalised amphiphiles was achieved through two different linker 
groups; tertiary amine and a triazole linker moiety, with the hydrophobic region also 
being varied (C12 and C16).  While the amine linker compounds could not be synthesised 
in adequate quantity, the triazole functionalised novel amphiphiles possessed CAC 
values of 510 μM and 19 μM, with aqueous self-assemblies of 56 nm and 106 nm 
xix 
 
observed, respectively.  Imaging by cryo-TEM showed the shorter C12 hydrophobic 
portion to possess liposomal morphology, while the C16 hydrophobic portion-containing 
compound formed non-defined amorphous aggregates.  
Finally, the response to temperature of a range of the 1st and 2nd generation assemblies 
was investigated in Chapter 5, to provide insight into the stimuli controlled release 
potential of these systems. It was found that the hydrodynamic diameter (DH) expansion 
or contraction of these assemblies in response to increasing temperature was determined 
by the length of hydrophobic region possessed by the amphiphile (C12 or C16 chain, 
respectively).  The C16 variant of the Tamoxifen functionalised amphiphiles was found 
to possess no temperature response in the 5-55 °C thermal window investigated. 
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Introduction 
“From little things, big things grow” 
-Paul Kelly and Kev Carmody  
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Introduction 
1.1 Nanomedicine - “There’s Plenty of Room at the Bottom” 
Nanotechnology was first conceptualised in 1959 when Richard Feynman first 
introduced the idea of manipulating and controlling molecules and atoms on a nano-
scale.1 He was inspired by natural processes observed in biology to produce things on 
this nanoscale which could be manufactured to move and carry out functions we desire. 
Since many diseases arise from modifications in the biological processes at this 
nanoscopic scale, it is no surprise that nanotechnology applied to medicine is fast 
building on Feynman’s original concept. 
Feynman’s description of the potential of nanotechnology - “There’s plenty of room at 
the bottom” – has certainly come true as this technology has rapidly grown over the last 
few decades and the potential for the development and manipulation of nano-sized 
structures has become increasingly more apparent for a wide range of fields and 
applications.1-6 From materials and manufacture, to transportation and energy, 
“technology on the nano-scale” is fast becoming the modern answer to solving problems 
and improving current technologies, with dramatic progress over the last few decades 
occurring in the medical field and giving rise to the recent concept of nanomedicine. 
Nanomedicine utilises nanotechnology to develop treatments for diseases on a molecular 
level, specifically focusing on the level where the changes in biological processes occur 
in a multitude of diseases.7  Nanotechnology can be utilised for developing imaging 
agents and diagnostic techniques but most prominently the development of novel 
nanoparticle drug delivery. 
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1.2 Nanomaterials for Drug Delivery 
The manner in which a pharmaceutical is delivered can have a significant effect on its 
efficacy.  Many pharmaceuticals are limited by their poor bio-pharmacological 
properties, for example, inadequate aqueous solubility.  For a pharmaceutical to be 
therapeutically active, a specific concentration must be reached and maintained in the 
blood stream, however, in many cases the solubility of the pharmaceutical is actually 
lower than this required concentration, rendering them ineffective.8  By controlling the 
pharmacokinetics, pharmacodynamics and non-specific toxicity, new drug delivery 
methods can improve the performance of pharmaceuticals by increasing their efficacy, 
safety and patient coherence.  To achieve such a goal, the delivery system should be not 
only able to increase the pharmaceuticals’ aqueous solubility but, ideally, also protect it 
from metabolic pathways, essentially slowing down its degradation and metabolic 
clearance from the body.  Optimising pharmaceutical delivery to targeted locations in 
conjunction with limiting the accumulation in healthy organs is also desirable as this can 
reduce off-target toxicity dramatically. The ultimate scenario in drug delivery is to 
additionally control the pharmaceuticals’ release by either natural process within the 
body or by external stimuli at a specific location and given time. 
There are various drug delivery systems currently under investigation in academia and 
industry worldwide, most of which utilise nanotechnology by employing different types 
of nanoparticles.  Nanoparticles possess a high surface to volume ratio giving them 
unique physical properties that aid their application in drug delivery, as such, colloidal 
drug delivery systems that incorporate nanoparticles are gaining an increasing amount of 
attention in the scientific literature.9-15 These colloidal drug delivery systems employ a 
wide range of different types of nanoparticles, from organic nanoparticles such as 
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micelles and liposomes to inorganic nanoparticle dispersions like gold nanoparticles 
(Figure 1). Such systems can be further divided into two categories, nanospheres and 
nanocarriers, depending on the nanoparticle employed. Nanospheres are matrix systems 
in which the drug is physically and uniformly dispersed, whereas nanocarriers are either 
vesicular, with a membrane that encapsulates the pharmaceutical, or adhere to a typical 
‘core/shell’ structure.16  
 
Figure 1. Schematic interpretations of some common nanoparticle systems  
1.2.1 Inorganic Nanoparticle Dispersions 
Nanoparticle dispersions consisting of inorganic materials, such as iron oxide, calcium 
phosphate, mesoporous silica and colloidal gold, are commonly employed as drug 
delivery systems.17-22 They share a common core/shell structure where the core contains 
metals (iron oxide, gold and quantum dots for example) while the shell generally consist 
of metals or organic polymers that protect the core (and the pharmaceutical payload) 
from chemical and environmental interactions.  
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Superparamagnetic Iron Oxide Nanoparticles 
Superparamagnetic iron oxide nanoparticles (SPION) have maghemite (γ-Fe2O3), 
magnetite (Fe3O4) or hermatite (α-Fe2O3) cores surrounded by either an inorganic or 
organic coating where pharmaceuticals can be loaded into or attached to the surface and 
then guided to the target organ or tissue using a magnet external to the body.23 The 
payload can then be released using external oscillating magnetic fields or via the 
hyperthermia effect, where the particle can be heated after internalisation, causing it to 
release the incorporated pharmaceutical.  Although very promising for the treatment of 
several diseases, the development of a suitable magnetic field gradient for effective 
localisation of the SPIONs within the tissue has proven problematic.  It has been found 
that blood flow in the arteries and veins causes resistance to the magnetic field gradient 
and, as such, only areas that are close to the surface can be properly targeted at this 
stage.  Together with toxicity issues that include iron overload at the targeted tissue site, 
premature release of the pharmaceutical payload and low bio-availability, SPIONs still 
face significant challenges before becoming a viable drug delivery system. 
Colloidal Gold Nanoparticles  
Alternatively, gold nanoparticles have the inertness and low toxicity that SPIONs lack. 
They are easily synthesised and have a well-established surface functionalization, 
through thiol linkages, making colloidal gold nanoparticle dispersions a potential drug 
delivery system.24 Pharmaceuticals can easily be tethered to the gold nanoparticles 
increasing their circulation time and improving their overall stability, however, they 
cannot be incorporated into the core of the gold nanoparticle making the tethered 
pharmaceutical just as susceptible to biological degradation and metabolic clearance as 
the free pharmaceutical would be.  
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Carbon Nanotubes 
Carbon based nanotubes as drug delivery models have gained momentum in recent 
years. These rolled graphene sheets, held together by Van der Waals interactions, can be 
surface functionalised for the conjugation of proteins, enzymes, nucleic acids and 
pharmaceuticals and possess the size and geometry required for nanoparticle drug 
carriers.25 Although there are many promising studies in which carbon nanotubes have 
shown adequate delivery potential, toxicity problems have hampered the full realisation 
of these potential delivery systems.15 Studies have shown that carbon nanotubes can lead 
to cell proliferation inhibition and apoptosis and although surface functionalisation can 
help overcome these issues, concerns have been raised as to whether the carbon 
nanotube will revert back to its toxic state if the added functional groups are cleaved in 
vivo. 
These inorganic nanoparticle dispersions tend to be less bio-degradable than their 
organic counterparts and so are more suited for diagnosis rather than treatment of 
diseases.  
1.2.2 Organic Nanoparticles 
Liquid Crystals 
Liquid crystals have both crystalline solid and isotropic liquid properties at ambient 
temperatures and pressures, enabling them to possess both order and mobility.26  They 
can be manufactured to assemble into various geometries that include a bicontinuous 
aqueous channel and lipid domains of roughly equal areas, allowing the encapsulation of 
pharmaceuticals with differing polarities.27 They have gained recent attention as they 
have the potential to improve the bio-availability of both hydrophobic and hydrophilic 
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pharmaceuticals and are also highly stable to dilution.28 However, they are limited by 
their inadequate robustness and insufficient stability as colloidal particles and are 
plagued by scalability issues.29  
Dendrimers 
Dendrimers are synthetically branched macromolecules with a tree-like structure. They 
have a globular configuration with internal cavities where pharmaceuticals can be 
encapsulated for controlled release or loaded onto the outside surface via covalent bonds 
or electrostatic interactions.15 These nanospheres can be precisely controlled, which is 
advantageous as it makes it relatively easy to predict the bio-compatibility and 
pharmacokinetics of the dendrimers and allows very uniform particles to be formed, 
however, preparation can be quite tedious in some cases.15a Toxicity and 
immunogenicity issues have hampered clinical research preventing a clear understanding 
of whether dendrimers are safe or toxic.  
Lipid based Nanoparticles (Liposomes and Micelles) 
Lipid-derived nanostructures form the focus of this thesis and consequently, will be 
discussed in more detail than those systems previously mentioned. For more detail on 
the previously discussed nanoparticles, the reader is referred to the literature.15,23-25,29  
Liposomes are, to date, the most clinically established nanosystem for drug delivery. 
The term ‘liposome’ is derived from the Greek words ‘lipos’ meaning fat and ‘soma’ for 
body or structure, indicating that liposomes are nanoscopic vesicles composed of lipid 
membranes, typically arrange in a bilayer, surrounding an inner aqueous compartment.30  
Liposomes were first discovered by Bangham in the early 1960’s,31 however, it wasn’t 
until nearly a decade later when the use of liposomes as a drug delivery system was first 
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hypothesised by Gregoriadis in 1972.32 Micelles are very similar in structure to 
liposomes, however, they lack the lipid bilayer that liposomes possess, embodying 
instead a lipid core surrounded by a hydrophilic shell,27 as denoted in Figure 2 below. 
 
Figure 2. Structure of a liposome and a micelle  
Micelles and liposomes offer protection and delivery of a wide variety of different 
materials including nutraceuticals, pesticides, genetic cargo (DNA, siRNA etc) and 
small molecular drugs and, as such, are currently utilised in the food, cosmetic, 
agricultural, gene therapy and pharmaceutical industries.33-39 These particular 
nanoparticles have the ability to encapsulate small molecules or genetic material and are 
therefore classified as nanocarriers. Of particular interest is their ability to deliver 
pharmaceuticals to target cells via liposomal and micellular encapsulation.  Liposomes 
can encapsulate polar molecules within the aqueous core or absorb non-polar molecules 
within the lipid bilayer, while micelles encapsulate non-polar molecules within their 
lipid core.40 When these nanocarriers are incorporated into a colloidal drug delivery 
system the unfavorable properties of the encapsulated pharmaceutical, such as aqueous 
insolubility, are masked and replaced with the more desirable properties of the 
nanocarrier. This encapsulation overcomes a myriad of problems associated with 
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traditional drug administration, such as solubility and in vivo stability.41 Lipophilic drugs 
that are problematic when administered intravenously can be solubilised using 
liposomes or micelles whilst also protecting tissue at the injection site from the entire 
dose of the drug, by a slowed or controlled release of the encapsulated pharmaceutical 
into only the desired site.  
Liposomes also have the added benefit of being able to encapsulate genetic material 
such as DNA and siRNA allowing them to serve as vectors for gene therapy. In 1987, 
Felgner hypothesised that electrostatic interactions between cationic head groups of 
cationic liposomes and negatively charged phosphate groups of nucleic acids on DNA 
allow liposomes to spontaneously form complexes called lipoplexes.42  This 
encapsulation of genetic cargo protects it from metabolic degradation thus extending its 
circulation half-life and allowing it to cross the cellular membrane.  The design aspects 
of liposomes and micelles on a molecular level will be discussed in more detail in 
Section 1.6. 
These nanoparticle drug delivery systems all hold great promise in enhancing 
pharmaceutical delivery and research into developing these systems is highly 
advantageous, especially for liposomal and micellar formulations. Investigating these 
systems for the treatment of cancer is particularly important as current treatments are 
plagued with toxicity issues and serious side effects. The application of liposomes and 
micelles to the treatment of breast cancer is the focus of this work and, as such, the 
following section will address the challenges of drug delivery specific to this disease. 
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1.3 Breast Cancer Epidemiology and Current Treatments 
Breast cancer represents a significant global burden as the most common cancer in 
women worldwide with an estimated 1.38 million new cases diagnosed in 2008 and 
accounting for 23% of all cancers.43,44 The term ‘cancer’ represents the group of diseases 
that feature uncontrolled and abnormal cell division, giving rise to tumours with 
malignant characteristics, such as metastasis and invasion of surrounding healthy tissue 
and organs.45 Breast cancer is simply this malignant, uncontrolled growth of cells found 
in the breast tissue. 
Although there is a high incidence of breast cancer in women, the prognosis is relatively 
good for most cases if diagnosed at a localised stage, prior to metastasis.  Between 2001 
and 2007, 98.6% of women diagnosed with localised breast cancer survived past five 
years after the initial diagnosis.46 The relatively high survival rates can be attributed to 
effective early diagnostic tools and a variety of aggressive treatments including 
chemotherapies, radiotherapies, hormonal therapies and surgery. 
1.3.1 Surgery 
In most cases, surgery is the first step of treatment for a patient diagnosed with early-
stage invasive breast cancer. Surgery aims to remove the cancer as well as determine the 
stage of the disease to help direct further treatment as it is routinely coupled with a 
secondary treatment of either radiotherapy, chemotherapy or hormone therapy.47 Breast 
cancer staging, like most cancers, is based on the TNM system where (T) indicates the 
tumour size, the extent of regional lymph node involvement is denoted by (N) and the 
presence or absence of metastasis beyond the regional lymph nodes is dictated by (M).47 
The tumour is staged from 0 – IV where stage 0 implies in situ cancer meaning the 
cancer has not invaded the surrounding healthy tissue, while stages I and II indicate 
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invasive cancer of varying degrees.  Stage III describes locally advanced cancer where 
the tumour is larger than 5 cm with extensive lymph node involvement and/or direct 
implication of the underlying chest wall or skin and is generally considered inoperable 
but has not yet metastasised.48 Stage IV indicates distant metastases, most commonly to 
the bone, brain, liver and lungs.49 Two common approaches to the surgical removal of 
breast cancer are breast conservation therapy or mastectomy.  
Breast conservation therapy (also called a partial mastectomy) is the removal of only the 
tumour tissue and a small margin around it that, ideally, tests negative for cancer. Since 
this option does not remove excess healthy breast tissue it has a far more aesthetically 
pleasing outcome which can improve the patients state of mind and overall outlook.  
However, this surgery does need to be coupled with aggressive radiation therapy to 
ensure any remaining tissue is cancer free,48 and is only recommended for patients that 
are deemed a candidate for such radiotherapy. Due to a high possibility of local 
reoccurrence such patients will need to be closely monitored over time, typically 2-5 
years. 
Mastectomy covers several sub types of surgery, all of which involve the full removal of 
the breast and is performed when breast conservation therapy is not appropriate, due to 
large or multiple tumours, poor cosmetic outcome, or when specifically requested by the 
patient.50 A modified radical mastectomy involves the removal of breast tissue and the 
lymph nodes but aims to preserve the major and minor pectoral muscles while a simple 
mastectomy avoids the removal of the lymph nodes.  
As with all surgical procedures there are risks involved with these options, with patients 
reporting bleeding, infection, seroma, arm morbidity, phantom breast syndrome and 
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injury to the motor nerves. There is also a likelihood of reoccurrence of the breast cancer 
after surgery with 15% of women developing a reoccurrence within 10 years, regardless 
of the type of surgery undertaken.47  
1.3.2 Radiotherapy 
Radiation therapy uses an externally generated beam of radiation, commonly composed 
of X-rays, gamma-rays or charged particles, to destroy cancerous cells.51 The cells are 
bombarded with high levels of radiation energy which damages DNA and subsequently 
destroys the cell. When coupled with surgery, radiation therapy can reduce the 5-year 
recurrence rate in breast cancer patients, however, since the radiation doesn’t 
discriminate between healthy cells and the cancerous cells there are common side effects 
limiting its overall efficacy. Patients can experience a wide range of acute and chronic 
side effects, such as extreme fatigue, nausea, skin irritation, hair loss, anemia, 
cardiovascular disease, cognitive impairment and the development of secondary cancers 
from radiation exposure.52  
1.3.3 Hormonal Therapy 
The majority of breast cancer tumours (75-80%) over express cellular estrogen 
receptors,53,54  allowing the rapid growth and development of the tumour. The binding of 
estrogen to the receptor promotes a conformational change that allows the tumour to 
recruit the required growth factors it needs to proliferate.53,55,56 These hormonally 
sensitive tumours are deemed estrogen receptor (ER) positive and can be treated with 
hormone therapy. The basis of hormone therapy is to either decrease the amount of 
estrogen in the body, generally by stopping the production of estrogen by either 
medication or surgically removing the ovaries, or alternatively, to block the action 
estrogen has on breast cancer cells, using various therapeutics. Unfortunately, ER-
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negative breast cancers cannot be treated by hormonal therapy due to their physiological 
independence from estrogen. 
One class of hormone therapeutics that actively block the effects of estrogen is the 
selective estrogen receptor modulators (SERMs). This group of anti-estrogens 
antagonistically bind to the estrogen receptor creating an inactive complex, that then 
blocks estrogen-mediated protein synthesis. Hormone therapy can be used as an initial 
therapy to shrink a tumour before surgery, or after other treatments to further destroy the 
cancer and decrease the likelihood of recurrence.57  There are various other classes of 
hormone therapy used for breast cancer, such as the selective estrogen receptor down-
regulators (SERDs), aromatase inhibitiors and leutinizing hormone releasing hormone 
antagonists, however, the gold standard for such therapy, Tamoxifen, belongs to the 
SERM class. 
Tamoxifen 
In the mid 1960’s scientists at the Imperial Chemical Industries were investigating 
potential birth control agents, and while the non-steroidal Tamoxifen 1 (Figure 3) was 
found to be ineffective for this particular purpose, it was observed to be anti-
estrogenic.58 This discovery subsequently led to Tamoxifen being studied for its 
application in treating breast cancer and has since become the standard to which other 
hormone therapeutics have been compared over the last 35 years.59  
Figure 3. Structure of Tamoxifen citrate  
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Studies have since shown that treating women with 20 mg a day of Tamoxifen for five 
years decreased the incidence of ER-positive breast cancer by 66% and can effectively 
reduce the risk of the cancer returning.60 The National Institutes of Health (NIH), the 
National Comprehensive Cancer Network (NCCN), and the Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) still currently recommend Tamoxifen as the 
primary hormone therapeutic for women with ER-positive breast cancer despite severe 
side effects such as an increased risk of thromboembolism and endometrial cancer.61 
Due to these increased risks of severe complications and common side effects, including 
nausea, hot flashes, fatigue, headaches, mood swings, depression, hair thinning and 
constipation, new generations of pharmaceuticals have been developed but are yet to 
display the efficacy to replace Tamoxifen as the leading hormone therapeutic.57 
1.3.4 Chemotherapy 
Chemotherapy is the use of anticancer pharmaceuticals to treat cancer which do not 
operate via hormone receptors. Unlike surgery and radiation therapy, chemotherapy is a 
systemic treatment, meaning it is not localised to the area of the tumour and therefore 
affects the whole body. Chemotherapy can be utilised at two different stages of a 
multidiscipline treatment plan; the first, and most widely used, is after an initial localised 
procedure (usually surgery and/or radiation) has been undertaken and is referred to as 
adjuvant chemotherapy. The idea of adjuvant chemotherapy was first conceptualised in 
the 1950’s, where a combined approach of local and systemic chemotherapy treatment 
resulted in a lower recurrence incidence and higher survival rates. The second stage is 
before a localised procedure, typically known as induction chemotherapy, and is 
generally reserved for those patients with stage III localised advanced breast cancer. As 
these tumours are usually large, widespread and generally inoperable, induction 
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chemotherapy aims to reduce the size of these tumours to a surgically viable size. Both 
types of chemotherapies employ the same therapeutics, the only difference is when 
throughout the treatment plan they are administered.   
As most chemotherapeutics target fast growing cells, there are common side effects that 
include nausea, vomiting, mucosistis, diarrhea, alopecia and premature menopause due 
to healthy cells, e.g. the stomach lining or hair follicles, getting caught in the 
chemotherapy cross-fire. These side effects can actually make a patient feel significantly 
worse during treatment than before, making patient compliance difficult, and in some 
cases the treatment can cause the patient irreparable damage. Therefore, the dose of 
chemotherapy can often be a balance between treating the cancer effectively and 
attaining the best quality of life for the patient. 
Breast cancer chemotherapy has been found to be more effective for women under 50 
years of age than those that are older. Given that the probability of developing breast 
cancer is almost 5 times more likely for women over 65, this is a real concern.62 Early 
diagnosis via free mammogram initiatives for women of this age bracket are helping to 
overcome this issue, however, the lack of effectiveness in older women remains a major 
downfall in chemotherapy treatments. 
As described previously, breast cancer tumours can be hormone receptor positive or 
negative. This classification not only has implications for the possibility of hormonal 
therapy, but also the effectiveness of chemotherapy as this type of treatment can be more 
effective for hormone negative breast cancers than hormone receptor positive tumours.48 
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Chemotherapeutics- Anthracyclines and Taxanes   
There are two commonly used types of anticancer pharmaceuticals for the treatment of 
breast cancer, anthracyclines and taxanes.  Anthracyclines are among the most effective 
anticancer agents, with the first two isolated from the fermented broth of the 
actinobacteria Streptomyces peucetius in the early 1960’s.63 They possess a planar 
polyaromatic ring system incorporating a quinone moiety via an O-glycosidic bond to an 
aminosugar portion as shown in Figure 4.64 This class of chemotherapeutics are able to 
inhibit RNA and DNA synthesis by directly interacting with DNA molecules via 
intercalation of the planar ring system between the base pairs of the DNA, whilst the 
sugar moiety interacts with the negatively charged phosphate groups. There has been 
much debate over the primary target of cytotoxicity, however, the exact mode of action 
has recently been deduced as targeting the nuclear enzyme DNA topoisomerase II (topo 
II), which is responsible for the modifications of the tertiary structure of DNA.64 
Figure 4. Chemical Structures of Doxorubicin and Daunorubicin showing structural 
differences in blue 
The first two agents of this class, doxorubicin (DOX) 2 and daunorubicin (DNR) 3 
(Figure 4), are still in wide use today with DOX also showing great promise in 
liposomal form as will be discussed further in Section 1.5. Interestingly, the two 
structures differ only in the side chain, α - to the exocyclic ketone (Figure 4 in blue), 
where DOX possesses a primary alcohol whilst DNR has a methyl group. This small 
17 
 
structural difference has large ramifications on their application to chemotherapy 
treatments as DOX is efficient in treating breast cancer and solid childhood tumours, 
whilst DNR is only useful in the treatment of leukemias.63 
Although quite effective in eliminating cancer cells and reducing tumour size, these 
anthracyclines have been plagued by resistance and systemic toxicity issues, the most 
concerning being chronic cardiomyopathy and congestive heart failure and, as such, 
have been limited to a maximum dose of 500 and 600 mg/m2 for DNR and DOX, 
respectively. Consequently, over 2000 analogs have been synthesised to develop better 
anthracyclines, however, only a handful have progressed to clinical development and 
approval.63 Two of these include Epinibicin (EPI) 4 and Idarubicin (IDA) 5, both of 
which have shown equivalent activity without any cardiovascular issues and therefore 
can be used at much higher doses. Interestingly, the lack of cardiovascular side effects 
arises due to subtle structural modifications to their parent compound (DOX and DNR, 
respectively).  EPI consists of a small change in the orientation of the hydroxyl group at 
the C-4' position from an axial to an equatorial position while IDA lacks the 4'-methoxy 
group on the D-ring. 
 
Figure 5. Chemical Structures of Epirubicin and Idanrubicin  
As a class, taxanes have recently proved to be just as effective, if not more, as 
anthracyclines in treating breast cancer and a wide range of other cancers.65 Whether 
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used singularly, or in combination with an anthracycline, taxanes have been found to 
significantly increase response, disease free and overall survival rates. These antimitotic 
pharmaceuticals are microtubule stabilisers which disrupt microtubule dynamics causing 
apoptosis due to induced mitotic arrest.66  
The two most commonly used taxanes, paclitaxal 6 and docetaxel 7, gained FDA 
approval in 1994 and 1996 respectively, however, were first discovered in the early 
1970’s as part of the US National Cancer Institute’s screening program of cytotoxic 
plant extracts. Paclitaxal was isolated from the bark of the pacific yew, Taxus brevifolia, 
and characterised by Wani et al,67 however, its low extract yield was initially limiting,  
and prompted the development of the semi-synthetic analogue, docetaxal, by Sanofi et 
al.68 using a precursor extracted from the needles of the European yew, Taxus baccata.68 
These two taxanes differ only by two small chemical variations in their structure (Figure 
6, in blue and purple), however, the replacement of a phenyl group with a t-BuO moiety 
and the lack of an acetyl group results in docetaxel having better water solubility than its 
original counterpart.  Furthermore, docetaxel was found to have favourable widespread 
preclinical in vivo and in vitro properties that further encouraged its clinical 
development.  
Although considered to be among the most effective chemotherapeutics, both paclitaxal 
6 and docetaxel 7 have exhibited negative side effects that have hampered their use. 
Cardiac arryhythmia and peripheral neuropathy are the most concerning toxic effects 
associated with both chemotherapeutics and the use of premedication to circumvent 
hypersensitivity is common with this class.  
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Figure 6. Chemical structures of paclitaxal and d ocetaxel, highlighting the two structural 
modifications in blue and purple  
The combination of both hormonal and chemotherapies has been found quite effective 
for both early stage breast cancer and preventing cancer recurrence for women with ER-
receptor positive breast tumours.61 Significant increases in disease free and overall 
survival rates were seen for women with hormone-receptor positive breast cancer when 
Tamoxifen therapy was added to a routine chemotherapy regime. Additionally, when a 
chemotherapy was given alongside Tamoxifen therapy, it was found that this 
combination approach was far more beneficial than just Tamoxifen alone.69 Given this 
outcome it is recommended that patients that are diagnosed with ER-positive breast 
cancer are treated with a combination of chemotherapy and five years of Tamoxifen 
therapy, however, there are issues with concurrent administration of the two treatments 
and, as such, chemotherapy is usually given first followed by Tamoxifen therapy.  
1.4 Drug Delivery for the Treatment of Breast Cancer 
Although all current cancer treatments achieve quite high survival rates, they are limited 
primarily by their non-specific modes of action that cause toxicity towards both healthy 
and cancerous cells.45 This results in dosage restrictions to avoid toxicity that can be 
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lower than the dosage needed for optimal outcomes, whilst still causing severe side 
effects that have major implications on a patient’s quality of life.  
Unique structural properties of tumours have, however, allowed for the development of 
new cancer therapy approaches using nanoparticle drug delivery. In fact, using these 
systems, the physical characteristics that give tumours their competitive edge over 
normal cells have the potential to ultimately bring about their downfall.  
Normal cells have systems in place to ensure that they only divide when needed, 
undergo apoptosis (cell death) when required and maintain their appropriate size and 
place within the body.  Cancer emerges from violations of these basic principles of cell 
behaviour, with cells proliferating (dividing) with complete disregard of the normal 
cellular life cycle, invading into healthy cell spaces and having a smaller likelihood of 
undergoing apoptosis.70  
The fundamental step in the transition of a tumour from benign to malignant is the 
occurrence of angiogenesis. Tumour angiogenesis is the formation of neovessels (new 
blood vessels) from pre-existing vessels which are critical for tumour growth as they 
supply the nutrients, oxygen and growth factors required for their continued dominance 
over healthy cells.71 It is these additional blood vessels that allow metastatic cells into 
circulation, spreading the cancer to other areas of the body,72a however, this rapid 
formation creates defective vascular architecture that gives rise to ‘leaky’ blood vessels 
that are often dilated and contain large gaps, or pores, in the endothelial cells. These 
pores are typically 100-600 nm in size and enable nanoparticles to accumulate within the 
tumour tissue while inadequate lymphatic drainage aids retention of these molecules 
(Figure 7).45,72a,b This phenomenon is known as the enhanced permeability and retention 
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(EPR) effect and can be utilised to passively deliver chemotherapeutics encapsulated in 
a nanoparticle, most often a liposome or micelle, directly into the tumour site.72b Once 
the liposome is circulating within the tumour it will eventually succumb to endosomal 
attack, releasing its contents inside the tumour tissue and subsequently avoiding the 
damage to healthy surrounding tissue. The EPR effect also prolongs the duration that the 
tissue is exposed to the chemotherapeutic enabling the same if not better outcomes with 
a lower dosage. 
Figure 7. Liposomal tumour targeting via  passive and active targeting  
There are three main liposomal formulated chemotherapies currently approved for 
clinical use, non-PEGylated liposomal doxorubicin (Myocet®), PEGylated liposomal 
doxorubicin (DOXIL®/Caelyx®) and liposomal daunorubicin (DaunoXome®). 
Myocet® contains vesicles of approximately 150 nm in diameter and has a circulation 
half-life of 2-3 hours, improving on the half-life of less than 5 minutes for the free (non-
encapsulated) doxorubicin while the PEGylated liposomal doxorubicin further improved 
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the circulation half-life to 2-3 days.73  Coating the liposome with PEG (polyethylene 
glycol) creates a hydrophilic shell that prevents serum proteins binding to the liposomal 
surface, effectively masking the liposome from the mononuclear phagocytic system and 
thus improving the stability and circulation half-life.35,74,75 Both formulations 
significantly decreased  the dose-limiting cardiac toxicity associated with doxorubicin as 
well as the common side effects of nausea, vomiting and alopecia,76,77 and are currently 
recommended for the treatment of breast cancer. The liposomal daunorubicin is also 
effective in increasing therapeutic efficiency, however, is currently only approved for 
treatment of AIDS-related Kaposi’s sarcoma.73  
Active targeting to a particular site can also enhance current chemotherapy treatments as 
delivering a pharmaceutical directly into tumour tissue can not only increase the 
localised dosage but also reduce the exposure to normal, healthy tissue and potentially 
minimising side effects.72b 
The over expressed hormone receptors give tumour cells a competitive proliferation 
advantage over normal cells, however, the overabundance of the receptors also present a 
unique opportunity to actively target these tumour cells. Active targeting using 
liposomes or micelles can be achieved with the use of surface ligands, such as antibodies 
and small molecules that are complementary to these receptors, resulting in preferential 
uptake by the cancer cells due to receptor-mediated endocytosis (Figure 7).  Mukherjee 
et al. have demonstrated the ability to use the neuroleptic compound Haloperidol to 
target sigma receptor carrying cancer cells,78 while small molecules such as folic acid 
have been utilised to deliver chemotherapeutic, Doxorubicin, directly to cancerous cells 
using stealth (PEGylated) liposomes.79 Reddy et al. have also utilised stealth liposomes 
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to deliver anticancer genes to cancer cells expressing estrogen receptors using estrogen 
as the liposomal surface ligand.54  
1.5 Designing Self-assembled Nanocarriers for Drug Delivery 
1.5.1 Cationic Lipids 
Cationic lipids are the building blocks of positively charged micelles and liposomes and 
possess hydrophobic and hydrophilic regions.  The opposing forces of the hydrophobic 
and hydrophilic domains allow the cationic lipids to spontaneously self-assemble into 
liposomes or micelles when subjected to an aqueous environment (Figure 8). 34 
 
Figure 8. Schematic of the formation of liposomes and micelles from cationic lipids 
Cationic lipids are typically composed of a cationic head group attached via a linker to a 
large hydrophobic domain, usually a double chain hydrocarbon of 12-20 carbon units in 
length (Figure 9).80  Functionalisation of each separate domain allows the study of the 
correlation between lipid structure and the ability to penetrate the cell, termed 
‘transfection efficiency’.42  Since the first reported lipid DOTMA (N-(1-(2,3-
24 
 
dioleyloxy)propyl)-N,N,N-trimethyl-ammonium chloride) 8, consisting of a quaternary 
amine connected via ether groups to two unsaturated aliphatic hydrocarbon chains,81 
many modifications of each of the domains have been reported.82 As this field has been 
extensively researched, it is beyond the scope of this thesis to cover all areas, thus the 
reader is referred to recent literature.34,35,83,84   
 
Figure 9. Structure of cationic lipid DOTMA showing the three domains  
The cationic head group is usually a single ammonium group as shown by Felgner’s 42 
DOTMA 8 and its ester bond derivative DOTAP 9 (N-[1-(2,3dioleoyloxy) propyl]-
N,N,N-trimethylammonium), polyamine moieties as seen in DOSPA 10 (2,3-
dioleoyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-
propanaminiumtrifluoroacetate), and amidinium or guanidium salts (di-C14-amidine and 
BGTC 11 respectively) (Figure 10). However, cationic lipids with nitrogenous 
heterocyclic head groups like pyridinium and imidazole as well as amino acid head 
groups have been reported.85,86 Hoekstra et al. determined that incorporating a 
pyridinium head group that is capable of delocalising the cationic charge can reduce 
potential toxic effects of the lipid.35 
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Figure 10. Structures of common cationic lipid s;  A. Quaternary ammonium group B. 
Ether vs Ester group C. Polyamine group D. Guanidium salt as a head  group 
The linker moiety used to tether the alkyl regions determines conformational flexibility, 
stability and the overall cellular toxicity. Usually, bio-degradable moieties such as 
esters, carbamates, amides and disulfides are employed, however, non-degradable ether 
bonds are also utilised. As an example, Felgner et al. determined that (compared to 
esters) ether linker groups are more chemically stable in vivo, but as they are non-bio-
degradable they tend to be more cytotoxic. Ester linking groups, that are bio-degradable, 
but not as chemically stable under physiological conditions, tend to show reduced 
cytotoxicity, e.g. DOTMA vs. DOTAP (Figure 10).87  
The hydrophobic region has a significant influence on the self-assembly and transfection 
abilities of cationic lipids and, consequently, extensive research of this aspect has been 
undertaken. Felgner et al. initially deduced that double chained hydrocarbons of varying 
lengths had differing transfection abilities, with myristyl (C14) chains having better 
transfection than palmityl (C16) and stearyl (C18) chains.87 Further structure activity 
AB A
D 
C 
B 
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studies show that in most cases lauryl (C12), myristyl and palmityl chains have high in 
vitro transfection efficiencies, however, stearyl chains, are the most favourable for in 
vivo transfection.83 Byk et al. published conflicting results after synthesising and 
evaluating C12, C13, C14 and C18 derivatives of the cationic lipid 12 shown in Figure 11, 
and concluded that the latter C18 derivative demonstrated the best transfection ability in 
vivo.88  
 
Figure 11 . Structure of Byk’s ca tionic lipid (n=12, 13, 14, 18)  
Such inconsistencies are common amongst the literature and can be accounted for when 
considering that the transfection efficiency of a cationic lipid is not a direct function of 
the structure of a single domain, but a subtle combination of many effects which 
determine the overall lipid structure. As such, a strict correlation of molecular structure 
and transfection efficiency does not exist.  Thus, as novel cationic lipids are synthesised 
and evaluated each are considered on a case-by-case scenario. 
An excellent example on the importance of overall lipid structure was demonstrated by 
Ren et al.,89 who investigated the key structural differences of DOTMA 8 and DOTAP 
9.  Previous work had found that although both exhibited equal transfection ability in 
vitro, DOTMA has a significantly higher transfection efficiency in vivo.89 It was 
observed that the close proximity of the hydrocarbon chains and the head group on 
DOTMA analogues correlated to the higher in vivo transfection efficiency.  However, 
this proximity effect was not observed for analogues of DOTAP due to the ester bond 
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linkage employed in this case.90 It was also observed that paired identical oleyl chains 
for both DOTMA and DOTAP derivatives had better transfection efficiency than 
asymmetric or non-paired chains. 
1.5.2 Designing Self-assembly Systems for Drug Delivery 
When designing amphiphilic molecules for drug delivery systems, several 
considerations need to be applied.  The size, shape and surface properties of the resulting 
self-assemblies can have huge ramifications on the success of such delivery systems. As 
the previous section has shown, small structural modifications in the individual 
components of these self-assemblies can have a great effect on transfection efficiency. 
However, it is the effect that these modifications have on the overall properties of the 
self-assemblies that can provide the greatest distinctions of the suitability towards drug 
delivery. 
Aggregate Size 
The size of the resulting self-assembly is very important when considering a drug 
delivery system as a successful vehicle must be internalised by cells, avoid clearance 
from the body and, if used to target tumour cells, be able to pass through the pores 
present in the tumour vasculature.  
The most important factor in liposomal size is the ability to circulate within the blood 
stream undetected for long enough to reach the desired cell target, as liposomal vehicles 
are subject to clearance from the body by the mononuclear phagocyte system (MPS). 
Phagocytes in the blood stream can distinguish between sizes of foreign particles, 
resulting in larger liposomes being cleared from the blood stream at a faster rate than 
smaller liposomes.91 Small vesicles with sizes below 200 nm have a longer circulation 
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life-time compared to larger vesicles (200-500 nm), with the MPS clearance increasing 
with an increase in size.92,93  
The internal uptake of liposomes into cells is not fully understood, however, it is 
currently accepted that a variety of endocytic pathways are involved in the liposomal 
passage into the cell with  strong dependency on particle size as to which endocytic 
pathway is employed. Hoekstra et al have shown that particles that are less than 200 nm 
are internalized into a cell almost solely via clatherin-mediated endocytosis while larger 
particles (500 nm) employ caveolae-mediated endocytosis for entry into the cell.94  
In order for the liposome to gain full potential of the EPR effect for successful tumour 
targeting, the ideal liposomal size range is 30-200 nm as smaller particles (less than 30 
nm) will diffuse back into the circulating blood resulting in poor retention, while larger 
particles are unable to permeate through the capillary walls in the first place.95 
Furthermore, as the size of a liposome decreases from 400 nm to 100 nm, the 
accumulation within the vascular tissue of a tumour increases sevenfold.9 Although there 
is evidence to show that as the total size decreases the uptake into tumour tissue 
increases, it is not solely a size dependent phenomenon and the total chemical and 
physical composition of the liposome plays a significant role. 
Given these factors the optimum particle size range can be deduced as between 50-
250 nm for use as a chemotherapeutic delivery system. The size of a lipid nanoparticle 
can be influenced primarily by the length of the hydrophobic region since this denotes 
the size of the internal core of a micelle or the thickness of the bilayer of the liposome, 
however, charge-repulsion of the head group can increase the micelle or liposome size. 
Several formulation techniques can have significant impact on the final assembly size 
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including filtering, sonication, extrusion and thin-film hydration methods and will be 
discussed in detail in Section 3.2. 
Aggregate Shape 
It is widely accepted that the shape of a nanoparticle is an important function of how that 
particle is transported through fluid, particularly within narrow tubes such as blood 
vessels in the body.96 Self-assemblies can be formed in a number of geometries 
including vesicles, spheres, cylinders, discs and ellipsoids. Currently, lipid based drug 
delivery systems typically employ spherical assemblies, however, the concept of using 
additional geometries has merit especially when considering that the gram-negative 
bacteria Salmonella is rod-shaped and exhibits excellent ability to transfect cells.97  
Recently, Gratton et al. examined the effect shape had on non-specific internalization 
and found that indeed, rod-shape nanoparticles displayed more efficient uptake than 
spherical nanoparticles of similar volumes.98  
Since the shape of the nanostructure is driven by the molecular structure of its 
corresponding amphiphile and the shape of the assembly has an effect on function, it is 
paramount to attempt to understand the relationship amphiphilic architecture has on the 
overall morphology of the self-assembly. 
In 1986 Szleifer et al. published a mathematical method that correlated surfactant 
structure with aggregate morphology in terms of geometric shape constraints.99  This 
dimensionless factor, outlined below in Equation 1, was deemed the Critical Packing 
Parameter (CPP) and is still used to predict the assembly outcomes of many amphiphiles 
using the relationships between the volume of the hydrophobic region (v), the area of the 
hydrophilic head group (a) and the length of the hydrophobic block (l). 
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Equation 1. Determination of the Critical Packing Parameter (CPP)  
Although the calculation of the CPP seems like a trivial task, determination of each 
parameter is filled with difficulties and requires extensive theoretical calculations which 
are beyond the scope of this thesis and, as such, the reader is directed to the original 
manuscripts and some excellent overviews for a more detailed foray into the calculation 
of the CPP.27,99-104  
The values obtained for the CPP can be associated with the type of aggregate that would 
be expected to assemble in an aqueous solution. For example, an amphiphile that has a 
CPP value of less than ⅓ would be expected to assemble into spherical micelles, 
similarly, a CPP value between ⅓ − ½ would indicate that the amphiphile would 
aggregate into cylindrical micelles and amphiphiles with a CPP value above ½ would 
start to form bilayers, either vesicular (½ − 1) or planar (~1) (Table 1). 
Since the determination of the CPP is difficult, the amphiphilic design is also a good 
indicator of the morphology of its aggregates. Generally, a singled hydrocarbon chained 
amphiphile with a large head group (e.g. sugar polyamine) will form spherical micelles 
while an amphiphile with the same hydrocarbon chain but with a smaller head group 
(e.g. NH4) will arrange into a cylindrical shaped micelle. This difference in structure can 
where;  v = volume of hydrophobic region 
              a = area of hydrophilic head group 
              l  = length of hydrophobic region 
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be attributed to the individual shape that such amphiphiles conform. A single chained 
amphiphile with a large head group has a cone shape while a smaller head group will 
have a truncated cone shape. Double chained amphiphiles typically form bilayers, and 
depending on the size of the head group, will either form vesicles or planar bilayers. 
Table 1. Critical Packing Parameter and the predicted shape of assembly  
Amphiphile 
Design 
Critical Packing 
Parameter 
Individual 
Amphiphile Shape 
Predicted Assembly 
Structure 
Single Chained 
Large Head group 
< ⅓ 
  
Single Chained 
Small Head group 
⅓ – ½ 
 
 
Double Chained 
Large Head group 
½ − 1 
  
Double Chained 
Small Head group 
~ 1 
  
 
These predictions using CPP values, amphiphilic structure and shape are just a guide, as 
there are an abundance of exceptions to these rules.  An excellent example was 
demonstrated by Kunitake et al. who found that single chained amphiphiles can form 
CYLINDRICAL MICELLE 
MICELLE 
VESICLES 
BILAYER 
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vesicles despite the CPP prediction.105 These amphiphiles generally contained a rigid 
segment between the hydrophobic region and a spacer group to the head group and it 
was found that at least two benzene rings within the single chain were required to 
facilitate bilayer assemblies (Figure 12). The effect of the rigid segment was investigated 
thoroughly with a set of amphiphiles identical except for the rigid region which 
accommodated diphenylazomethine, biphenyl azobenzene, azoxybenzene or 2-3 
benzene rings.105 Surprisingly, it was determined that the critical micelle concentrations 
(CMC, a parameter that will be discussed in detail in Section 3.3) for these amphiphiles 
were insensitive to the variations in chemical structure which is unusual, as it has been 
shown that even slight modifications in structure can have large ramifications for this 
value.106,107 Bent rigid sections were also investigated and shown to give rise to rod-like 
and tubular structures. 
 
Figure 12. Structure of bilayer forming single -chain amphiphile demonstrating rigid 
linker section 
Similarily, Barclay et al. showed that amphiphiles that have a rigid section within an 
otherwise flexible hydrocarbon chain form tubes or rods as the rigidity present 
encourages bilayer assembly.108 Such rigidity in this case was formed by the use of 
sequential (2-3) double or triple bonds situated along the aliphatic hydrophobic chain. 
Interestingly, these additions gave rise to a ‘kinked’ or bent section of the amphiphile 
which is believed to have a role in the bilayer formation.  This evidence supports 
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Kunitake’s theory that the rigid segment in an amphiphile could be the single most 
important structural element in determining assembly morphology.105 
By making systematic modifications to the structure of an amphiphile, in particular the 
addition of a rigid or ‘kinked’ section, the shape, and in turn, the function of the 
assemblies derived from it can be tailored. 
Surface Properties 
The surface properties of self-assemblies can also have significant impact on their 
feasibility as a drug delivery system. The charge of the hydrophilic head group plays an 
important role in the vesicle/cell interaction, and MPS clearance and size. 
To date, one of the most significant improvements in liposomal drug delivery was the 
grafting of polyethylene glycol (PEG) onto the liposome surface. PEGylation creates a 
hydrophilic shell around the liposome which prevents serum proteins binding to the 
assembly, effectively masking it from the MPS.35,74,75 This ‘stealth’ property increases 
the circulation time for the liposome within the body, with studies reporting a marked 
improvement in the liposome half-life,9 and highlights the significance in surface 
properties of assemblies.  
Ligands can also be incorporated onto the assemblies surface and can aid targeted 
delivery, as previously discussed in Section 1.4. 
1.6 Research Design 
As discussed in the previous section, the morphology of a self-assembly is driven by the 
molecular architecture of the amphiphile. The structure of the head group, linker and 
hydrophobic regions all play important roles in determining the shape of the assembly, 
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however, it has been determined that the inclusion of a rigid segment can be one of the 
most influential modifications on overall aggregation morphology. 
Recently, Bordes et al. employed a norbornene scaffold bearing a primary amine as a 
counter ion in a study of amphiphilic aggregation (Figure 13) and found that minor 
changes in the molecular structure resulted in large variations in assembly behavior that 
contradicted the typical assembly findings.109,110 Despite having a single hydrocarbon 
chain and a large head group, vesicles were formed rather than the expected micelles. 
This outcome was largely attributed to the unique bicyclic structure of the norbornene 
scaffold and its effect on ion pairing and assembly.  
 
Figure 13. Norbornene counterion and fatty acids used by Bordes et al.  
The norbornane scaffold has been utilised extensively in medicinal chemistry, making it  
suitable for drug delivery applications,111-116 and since it is commonly employed in our 
laboratory it was hypothesised that the inclusion of norbornane as a rigid linker in an 
amphiphilic molecule could have interesting implications on self-assembly morphology, 
especially considering the ‘kinked’ architecture this incorporation induces (Figure 14).  
It was deduced that systematic variations in the spacer length connecting the linker 
section to a small cationic head group (n) and modifications to the hydrophobic domain 
(m) would aid investigations into self-assembly behaviour of these unique norbornane 
amphiphiles. 
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Figure 14. General structure of envisioned norbornane amphiphiles  
It was also envisioned that a “one-two punch” approach to combining chemotherapy and 
hormonal therapy could be developed by building on the initial amphiphilic library and 
incorporating Tamoxifen to the periphery of the assembly (Figure 15).  
 
Figure 15. Incorporation of Tamoxifen to the periphery of liposome as a recognition 
ligand for the estrogen receptor  
Recently, Shao and co-workers have shown that a Daunorubicin/Tamoxifen liposomal 
suspension had a better targeting bio-distribution profile than just liposomal 
Daunorubicin, indicating that the addition of Tamoxifen to a liposomal system could 
improve breast cancer treatments and decrease adverse side effects.117 With our 
envisioned system, a current chemotherapeutic agent could be encapsulated into the core 
or bilayer of the assembly, circumnavigating the common side effects of the ‘naked’ 
pharmaceutical, whilst avoiding the implications associated with simultaneous 
administration of hormone and chemotherapeutics. The Tamoxifen can, not only, act as 
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a hormonal therapy, but also as a recognition ligand, enhancing the cellular uptake via 
estrogen receptor interaction to effectively create a targeted drug delivery system.  
1.7 Aims 
1. Design and synthesise a library of novel amphiphiles bearing a rigid, ‘kinked’ 
norbornane core with variations in the hydrophobic and hydrophilic regions; 
2. Evaluate the physicochemical properties of the self-assemblies formed by the first 
generation of norbornane amphiphiles to investigate the critical aggregation 
concentrations, aggregation diameter and morphology; 
3. Design and synthesise a second generation of amphiphiles functionalised with a 
Tamoxifen unit towards the active targeting of ER-positive breast cancer cells; 
4. Evaluate the physicochemical properties of these second generation ‘targeting’ 
amphiphiles in the same manner as the first generation; 
5. Investigate the potential response to stimuli possessed by both generations of 
assemblies towards a potential controlled release drug delivery system. 
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Chapter 2 
Synthesis of 1st generation amphiphilic library 
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Chapter 2 
2.1 Design of 1st Generation Norbornane Amphiphiles 
To investigate the affect a rigid norbornane scaffold would have on the self-assembling 
properties of amphiphiles bearing this moiety, a synthetic pathway was devised. It was 
designed to allow modifications of the hydrophilic and hydrophobic portions in an easy 
and versatile manner to permit systematic changes in the position of the “kink” imparted 
by the rigid norbornane scaffold as detailed by Scheme 1, below. 
 
Scheme 1.Retrosynthetic design of 1s t generation amphiphiles  
The ammonium head group can be modified to incorporate different spacer lengths (n) 
via dehydration of norbornane anhydride 21 with various diamines 22 to afford a suite of 
imides 20 that can then undergo dihydroxylation to afford a vic-diol moiety, such as in 
19. This provides a synthetic ‘handle’ to connect the hydrophobic region to through a 
cyclodehydration reaction giving a 1, 3-dioxolane (acetal) 17. This hydrophobic region 
can be easily modified with aldehydes of varying (m) lengths to give one, or replaced 
with a ketone, to provide two hydrophobic chains. 
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2.2 Synthesis of Linker Scaffold 
2.2.1 Norbornene Anhydride Synthesis 
In order to access the norbornene anhydride required for the first step of the synthesis, a 
Diels-Alder cycloaddition with cyclopentadiene 24 and maleic anhydride 23 was 
undertaken. 
 
Scheme 2. Reversible dimerization of cyclopentadiene  
Since cyclopentadiene is highly reactive, it does not exist as a single molecule but 
undergoes a Diels-Alder cycloaddition with itself and, as such, it was necessary to obtain 
the required monomer from the  dicyclopentadiene dimer 25 (Scheme 2). A retro Diels-
Alder of dicyclopentadiene (commonly referred to as ‘cracking’) to obtain two 
monomers of cyclopentadiene was carried out by fractional distillation where the lower 
boiling cyclopentadiene fraction was collected in a cooled vessel, subsequently 
identified by 1H NMR spectroscopy and used immediately in the following Diels-Alder 
cycloaddition. 
2.2.2 Diels-Alder Cycloaddition 
The Diels-Alder cycloaddition reaction is one of the most important organic reactions 
and since its first discovery, in 1928 by Otto Diels and Kurt Alder,118 over 17,000 papers 
have been published that feature the synthetic, mechanistic and theoretical aspects of this 
reaction.119  
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Scheme 3. Mechanism of Diels Alder reaction showing endo  product 
The classical Diels-Alder involves a [4+2] cycloaddition between a conjugated diene 
and a dienophile containing at least one π bond to yield a six membered ring. This 
reaction is widely used to generate norbornenes particularly for its high stereo-selectivity 
whereby the endo product 21 is the major component (Scheme 3), despite the exo 
product 26 possessing fewer steric repulsive interactions.120  The endo product is 
preferred due to stabilising secondary orbital interactions in the transition state (Scheme 
4), though it is possible to obtain the exo product 26 by carrying out this reaction for an 
extended period of time at high temperatures. Fortuitously, the endo product possesses 
the desired “kink” needed for this project, as such, it is the preferred product in this case. 
 
Scheme 4.  Endo/Exo  Diels-Alder Cycloaddition  
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Maleic anhydride 23 was added to a solution of ethyl acetate and petroleum spirits (1:1) 
and cooled to 0 °C before the drop wise addition of fresh, cool cyclopentadiene 24. The 
solution was then stirred for 30 minutes at 0 °C followed by a recrystallisation to give a 
product showing key 1H NMR spectroscopy resonances consistent with the literature for 
the desired norbornene anhydride 21 in an 87% yield.121 
2.3 Incorporation of Head Group Moiety 
The chosen head group was designed to be an ammonium moiety derived from the 
corresponding primary amine. This head group was chosen due to the ease of installation 
and potential synthetic versatility and availability. Kunitake et al.105 have shown that the 
incorporation of a flexible chain connecting the head group to the rigid segment of an 
amphiphile can improve molecular alignment and have interesting implications on the 
morphology of the corresponding aggregates.105 As such, investigating the effect of a 
spacer group of differing lengths was of interest given the novel rigid linker in this case.  
 
Scheme 5. Proposed installation of protected head  group moiety  
Imide formation between norbornene anhydride 21 and an alkyl diamine would give an 
easy and robust strategy to affix the head group (Scheme 5), whilst maintaining 
neutrality and rigidity within the linker scaffold, and enables the desired modification in 
the spacer chain length. Five aliphatic diamines were originally selected for 
investigation, ethylenediamine (n = 1), 1, 4-diaminobutane (n = 2), 1, 8-diaminooctane 
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(n = 4), 1, 10-diaminodecane (n = 5) and 1, 12-diaminododecane (n = 6), giving a range 
of spacer lengths to investigate.  
2.3.1 Mono-protection of Diamines 
In order for the planned imide formation to proceed, the selected diamines required 
suitable protection at one terminus that would carry through to the end of the synthetic 
pathway. Since its first use in 1932 by Bergman and Zervas,122 carboxybenzyl (Cbz) 
protection has become an important part of modern synthetic chemistry.123 It is a widely 
used protecting group for amines especially in the field of peptide synthesis and 
carbohydrate chemistry.124 The resulting benzyl carbamate is inert to moderately acidic 
and basic environments and so is suitable in this case, given the foreseen acid catalysed 
acetal formation step later in the synthesis (Scheme 1). The Cbz group was chosen in 
preference to the equally as popular tert-Butyl carbamate  (Boc) as it is readily cleaved 
in acidic environments and is therefore unsuitable in this case.125 The benzyl carbamate 
unit can also be cleaved using pH neutral means such as hydrogenolysis, giving the 
neutral amine which then can be converted to the cation or used in subsequent structural 
elaboration. 
Carboxybenzyl protection can be readily accessed from the cheap and commercially 
available benzyl chloroformate, however, other benzyloxy carbonylating  agents have 
been used such as dibenzyl carbonate and N-Cbz-imidazole, although benzyl 
chloroformate still remains the preferred reagent.124 Benzyl chloroformate 28 reacts with 
an amine, typically in the presence of a weak base to produce the carbamate protecting 
group, as detailed in Scheme 6, usually in good yields (typically > 75%). 
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Scheme 6. Carboxybenzyl protection of diamines using benzyl chloroformate  
In order to mono-protect the diamines, a vast excess (5 equivalents) of amine 27 was 
used, and the reaction was conducted at a low temperature (0 °C) and at high dilution to 
prevent the potential formation of the bis-protected adduct. The use of excess diamine 
negates the need for an additional amine base, and after stirring this solution at room 
temperature overnight, aqueous work-up removed both the diamine hydrochloride by-
product and the excess diamine which were water soluble, therefore minimising the need 
for further purification via silica gel column chromatography. 1H NMR spectroscopic 
analysis of the product showed resonances that indicated the formation of the desired 
benzyl carbamate, notably the presence of a characteristic aromatic resonance  at δ 7.2 
ppm and a singlet at  δ 5.1 ppm, which were consistent with the spectra reported in the 
literature.126  Excellent yields were obtained for most compounds as outlined in Table 2, 
however, the yield obtained for N-(benzyloxy carbonyl)-1,10-decyldiamine 37 was 
slightly lower than its counterparts at only 57%. While this yield is moderate, substantial 
quantities were still obtained given the good scalability of this reaction. 
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. Table 2. Mono-Cbz protection yields of the five selected diamines 
Entry Product n Yield (%) 
1 N-(benzyloxy carbonyl)-1,2-diaminoethane 34 1 90 
2 N-(benzyloxy carbonyl)-1,4-butanediamine 35 2 82 
3 N-(benzyloxy carbonyl)-1,8-octyldiamine 36 4 84 
4 N-(benzyloxy carbonyl)-1,10-decyldiamine 37 5 57 
5 N-(benzyloxy carbonyl)-1,12-dodecyldiamine 38 6 83 
2.3.2 Imide Formation 
Dehydration of an anhydride by an amine at high temperatures is a common and 
typically easy method of synthesising imides.127 The reaction commences with 
nucleophilic nitrogen attack at the carbonyl and subsequent ring opening, followed by a 
hydrogen shift to form a carboxylic acid 39. The slower second step is that of the amide 
nitrogen attacking the carboxylic carbon to then produce the desired imide 20 and water  
as a by-product (Scheme 7).127 
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Scheme 7. Mechanism of general imide formation with N-benzyl amine 22 and norbornene 
anhydride 21  
In this study, microwave heating was used as it can increase the rate of reaction from 
days to, in some cases, just minutes and furnish products of greater purity than 
conventional heating methods. These benefits have resulted in an improved efficiency 
for many reactions such as Diels-Alder, Claisen rearrangement, oxidation and 
esterification reactions.128-132 The accelerated reaction rates can be attributed to the 
dielectric polarisation heating effect that is utilised in microwave irradiation. A molecule 
will rotate to align itself with the applied field when it is irradiated by microwaves and 
as the frequency of the molecular rotation is similar to the frequency of the microwave 
irradiation the molecule will continuously attempt to realign itself with the changing 
field and, consequently, energy is absorbed.133 N-substituted cyclic imides have been 
previously synthesised using anhydrides and corresponding amines via microwave 
irradiation with shortened reaction times and increases in yields being reported.122,134 As 
such, the use of microwave irradiation for this synthetic reaction was deemed 
appropriate. 
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Scheme 8. Imide formation to synthesis compounds 43-47  
Mono-protected diamines 34-38 and norbornene anhydride 21 were individually 
dissolved in toluene and subjected to microwave irradiation at 100 °C for 20 minutes 
before an aqueous workup gave yellow oils that showed one resonance for the double 
bond at ~ δ 6.0 ppm, when analysed by 1H NMR spectroscopy, an indication of 
symmetry and confirmation of the desired imides 43-47. Excellent yields were achieved 
for compounds 43 (94%) and 44 (93%) with compound 46 produced in a good yield 
(79%), however, disappointing yields were obtained for imides 45 and 47 (13% and 
15%, respectively).  
Optimisation of the reaction for compound 45 was then carried out with increases in 
reaction time, temperature and the solvent used (Table 3). Initially an increase in 
temperature (120 °C) and a small increase in reaction time (30 mins) did not increase the 
yield significantly, (Table 3, entry 2), giving 16%. However, an extension of time (45 
mins) and an increase in diamine equivalents (2 eq.) (Table 3, entry 3) doubled the yield 
(30%). By further extending the reaction time (55 mins) a synthetically viable yield of 
64% was achieved (Table 3, entry 4). A slightly better yield of 66% was obtained with 
less time (45 mins) and with the use of ethyl acetate as the solvent (Table 3, entry 5), 
however, the product obtained was of a lower purity to that obtained using toluene, 
when analysed by 1H NMR spectroscopy. Thus, a small (2%) sacrifice in yield for a 
better quality product was deemed appropriate.  
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Further increases in temperature and reaction times (Table 3, entries 6-9) failed to 
increase the yield above 64%, and so, the conditions cited in entry 5 were determined to 
be optimal for compound 45. 
 
Table 3. Optimisation of compounds 45-47  
Entry Product n Temp (°C) Time (mins) Eq. of amine Yield (%) 
1 45 4 100 20 1.5 13 
2 45 4 120 30 1.5 16 
3 45 4 120 45 2 30 
4 45 4 120 55 2 64 
5a 45 4 120 45 2 66 
6 45 4 140 30 1.5 14 
7 45 4 140 40 2 31 
8 45 4 140 45 2 40 
9 45 4 140 50 2 38 
10 47 6 100 20 1.5 15 
11 47 6 100 30 1.5 22 
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12 47 6 100 40 2 35 
13 47 6 120 40 2 26 
14 47 6 120 55 2 52 
15 46 5 120b 16 2 76 
a Ethyl Acetate used as solvent 
b Conventional heating  
 
Optimisation was also undertaken concurrently on compound 47 as detailed in Table 3. 
As with compound 45, an improvement in yield to 35% was not observed until the 
reaction time was extended significantly (40 mins) and the equivalents of 21 was 
increased (Table 3, entry 12). Raising the reaction temperature (120 °C) at this more 
successful time (Table 3, entry 13) gave a decrease in yield (26%), the reason for which 
is not known but with additional time (55 mins) at this temperature the yield was 
significantly increased to a synthetically viable 52% (Table 3, entry 14). These 
successful conditions were, interestingly, the same conditions found to be ideal for 
compound 45. The explicit reason for the synthetic challenges observed for compounds 
45 and 47 are unknown, however, it is hypothesised that the longer chained amines 
produced lower yields due to possible aggregation in the non-polar, aprotic solvent. By 
increasing the heat and an extending the reaction time this aggregation was overcome to 
allow the reaction to proceed to a further extent. 
There have been numerous comparisons of imide formation performed through 
traditional heating and the use of microwave irradiation,134-136 and so a comparison 
reaction was undertaken to elucidate the advantages of microwave heating in this case, if 
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any. Previous experience within our group had shown synthesis of compound 43 without 
the use of microwave irradiation had produced significantly lower yields (51%) and 
impure product. As compound 44 gave excellent yields at moderate temperatures and 
compounds 45 and 47 required significant increases in time and temperature to obtain 
good yields it was decided that compound 46 was an ideal candidate for the comparison 
of traditional heating and microwave irradiation.  As such, the mono-protected diamine 
37 and norbornene anhydride 21 were dissolved in toluene and heated to reflux using 
conventional heating and stirred overnight (Table 3, entry 15). The product was obtained 
in a 76% yield after workup which was comparable to that of the microwave product 46 
(78%), however, analysis by 1H NMR showed the crude product was of inferior purity to 
that obtained by microwave irradiation. In light of these results, the microwave synthesis 
was indeed superior given the shortened length of reaction time and that purification was 
not required. 
2.4 Installation of Hydrophobic Region 
With compounds 43-47 containing the protected head group, attention turned to 
installing the desired hydrophobic region consisting of either a single or double aliphatic 
hydrocarbon chain of varying lengths that would allow the investigation into the effect 
the length of hydrocarbon chain would have on self-assembly.  
 
Scheme 9. Proposed synthesis of dihydroxylation and installation of the hydrophobic 
region 
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The connection of this hydrophobic region through a common carbon for both a single 
or double hydrocarbon chain can be achieved through an acetal moiety. Aldehyde or 
ketone dehydration with a diol is a well-established method of forming the required 
acetal that also gives the desired versatility in modification of both the chain length 
(determined by the length or acetal/ketone used) and the number of chains present 
(aldehyde 18 for single chain, ketone 48 for double).123,137,138 Access to the desired diol 
can be easily achieved from the alkene moiety already present in the norbornene scaffold 
through osmium catalysed dihydroxylation. This will afford the selective formation of 
the syn-vicinal diol moiety in an orientation that will give rise to the overarching 
‘kinked’ architecture to be explored (Scheme 9).  
2.4.1 Osmium Tetroxide Dihydroxylation 
Since its first reported use by Piccialli in 1998, osmium tetroxide 49 has become a 
widely used and effective method to access cis-vicinial diols directly from alkenes.139 
The ability to synthesise vicinial diols with high catalytic efficiency coupled with the 
mildness and generality makes it an attractive pathway despite the high toxicity, 
volatility and cost associated with osmium tetroxide.140 Though a stoichiometric amount 
of osmium tetroxide is required for a full conversion, the development of a catalytic 
process employing oxidants such as hydrogen peroxide, sodium hypochlorite, potassium 
ferricyanide and N-methylmorpholine-N-oxide (NMO) 54 (Upjohn Reaction) have 
become commonplace.  
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Scheme 10. Mechanism of the catalytic osmium tetroxide dihydroxylation (Upjohn)  
The mechanism of this catalytic dihydroxylation has been widely investigated.141-143 
Osmium tetroxide 49 initially adds across the alkene bond to generate an osmate ester 50 
which is then hydrolysed to produce the desired cis-vicinial diol 19.144  The catalyst is 
then regenerated by the use of a stoichiometric amount of a secondary oxidant (in this 
case NMO) as demonstrated by Scheme 10.145 
The exact mechanism of the osmium tetroxide addition across the double bond has been 
widely debated. Initially, it was proposed that a [3+2] cycloaddition occurred,146 
however, Sharpless challenged this hypothesis, believing a [2+2] cycloaddition followed 
by an expansion of the metallocycle was indeed responsible for this key step (Scheme 
11).147,148 Through recent computational studies and detailed experimental investigation 
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it was deduced that the [3+2] addition of the osmium tetroxide was energetically more 
favourable.149-152 
Scheme 11. [2+2] versus [3+2] addition of osmium tetroxide to alkene functionalities  
Standard Upjohn dihydroxylation conditions145 were used  in this study to produce exo-
vicinal diols 58-61, where the formation of the diol moiety in the exo-orientation 
provides the overall ‘kink’ in the amphiphile structure. It was found that the exo product 
was furnished exclusively in this reaction, with no trace of the endo product being 
observed by 1H NMR spectroscopy. This has been attributed to steric hindrance 
preventing the osmium tetroxide from approaching from underneath the fused ring 
system as represented in Scheme 12.    
 
Scheme 12. Exclusive exo-product formation from dihydroxylation 
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Imides 43-47 were treated with NMO (1.5 eq.) and a catalytic amount of osmium 
tetroxide (2.5 wt.% in tert-butanol) and stirred for 72 hours at room temperature in a 
acetone/water solution (4:1). Aqueous work-up followed by purification via column 
chromatography gave brown oils in moderate yields of 51% and 67% for compounds 58 
and 59, respectively. Analysis of these two separate products by 1H NMR spectroscopy 
identified the loss of the key resonances associated with the alkene moiety at ~ δ 6.0 
ppm, suggesting the successful installation of the diol moiety of compounds 58 and 59. 
This was accompanied by new resonances at ~ δ 3.43 ppm corresponding to the protons 
associated to the newly formed HC-OH bonds. 
 
Scheme 13. Dihydroxylation of compounds 43-46  
While compound 60 was shown by 1H NMR spectroscopic analysis to have reacted to 
completion, purification proved troublesome resulting in a substantial loss of product. 
Despite several attempts to overcome this issue with various modifications in the eluent, 
typical losses of 20-30% were observed and since compound 60 was obtained in a 
usable crude yield (63%), the mixture was used in subsequent steps and purified 
thereafter. 
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Table 4. Optimisation of the dihydroxylation of compound  46  
Entry Time (hours) OsO4 (μmol) Conversion (%) Yield (%) 
1 72 8 59 18 
2 72 16 65 46 
3 48b 125a >99 59 
4 22c 94a >99 52 
5 24d 188 a >99 71 
6e 16 94a >99 84 
a OsO4 changed to 4 wt. % in H2O 
b Product retreated with an additional 125 μmol OsO4, 1.5 eq. NMO for an additional 16 hrs 
c Staggered addition of OsO4, 47 μmol initially, then another 47 μmol after 6 hrs 
d Staggered addition of OsO4, 94 μmol initially, then another 94 μmol after 4 hrs 
e Reaction was heated to 50 °C 
 
Compound 61 failed to react to completion with only a 50% conversion by 1H NMR 
spectroscopic analysis using the initial conditions. Subsequent retreatment resulted in a 
slight improvement in conversion to 59% to give a crude yield of 18% (Table 4, entry 
1). 
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Modification of the reaction conditions with an increase in osmium tetroxide used 
resulted in a better conversion of 65%, however, the crude mass recovery remained poor 
at 46% (Table 4, entry 2). The previously utilised osmium tetroxide in tert-butanol (2.5 
wt.%) solution was then substituted for the more concentrated 4 wt.% in H2O, which 
after 48 hours had already almost exceeded the previous conversion with a conversion of 
63%.  After retreatment with an additional 125 μmol of osmium tetroxide and 1.5 eq. 
NMO for an another 16 hours, 1H NMR spectroscopic analysis showed no alkene 46 
present and a crude yield of 59% was obtained (Table 4, entry 3).  
 It was hypothesised that the osmium tetroxide was potentially degrading in situ, in this 
case, due to a slow reaction. As such, a protocol in which a staggered addition of 
osmium tetroxide after several hours was employed ensuring that fresh, and catalytically 
active osmium tetroxide, was present in solution. This method afforded a crude yield of 
52% with full conversion (Table 4, entry 4) with slightly less osmium tetroxide than 
what was previously used in entry 3, indicating that the osmium tetroxide might have 
been degrading before an adequate reaction could take place in the previous attempts. 
Building on this theory, 4 hours after the initial addition of 94 μmol of osmium tetroxide 
and 1.5 eq of NMO, an additional 94 μmol osmium tetroxide was added along with 
another 1.5 eq of NMO and stirred for 24 hours (Table 4, entry 5) resulted in a 
substantial increase in crude yield to 71%. Alongside these investigations, heating the 
solution in an effort to speed up the reaction was also examined. A substantial increase 
in crude yield was observed (84%), this time when the reaction was heated at 50 °C for 
24 hours (Table 4, entry 6). Given that this latter method consumed less osmium 
tetroxide and furnished a product of higher crude yield and purity, it was considered the 
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optimal procedure. This method negated the need for the staggered addition of the 
reagents over time and, as such, was the method used from here on. 
Similarly to 60, compound 61 also proved troublesome to purify via column 
chromatography. Several attempts were made to achieve adequate purification, however, 
all resulted in a substantial loss in product yield (typically 30-50%), and, as such, 
compound 61 was also used as a crude mixture in the subsequent steps and purified 
thereafter.  
Attempts at dihydroxylation of compound 47 gave only complex mixtures and as such 
this compound was removed from this investigation. The impact on the overall study 
that this elimination would have was considered to be minimal given the wide range of 
chain lengths still viable. 
2.4.2 Acetal Formation 
With diols 58-61 in hand, attention then turned towards the connection of the 
hydrophobic region of the amphiphiles through an aldehyde dehydration to form an 
acetal moiety. Acetals have been used traditionally in carbohydrate chemistry and are 
the main means of protecting 1, 2 and 1, 3-diols, however, their use in asymmetric 
synthesis has highlighted their value as reactive functional groups as demonstrated by 
the Kishi137 and Johnson138 groups.123   The formation of a 1, 3-dioxolane, as planned in 
this project, from the diol moiety allows facile modifications in the hydrocarbon length 
by simple utilisation of an aldehyde that possesses the desired chain length. 
Additionally, the substitution of an aldehyde for a ketone will yield a double 
hydrocarbon chain allowing for added versatility in the hydrophobic domain, potentially 
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changing key self-assembly properties such as the critical packing parameter (Section 
1.5.2). 
The first step in the mechanism of this cyclodehydration reaction is the protonation of 
the aldehyde 18 carbonyl to form an oxonium ion 62 (Scheme 14). This activated 
species is then attacked by a –OH moiety of the diol to form a hemi acetal 63. A proton 
shift then occurs, giving 64, followed by the elimination of H2O to form a second 
oxonium ion 65 which is then attacked by the other –OH of the diol moiety. Loss of the 
proton from this alcohol results in the desired acetal 17 and the regeneration of the acid 
catalyst. As this reaction is reversible, the removal of water from the reaction mixture is 
integral, promoting full conversion by shifting the equilibrium towards the acetal. As 
such, an inorganic drying agent, typically molecular sieves or magnesium sulphate, must 
be used.  
 
Scheme 14. Mechanism  of the cyclodehydration of an aldehyde and 1,  2-diol to form a   
1, 3-dioxolane  
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To obtain the desired acetals, solutions of diols 58-61 in dichloromethane were reacted 
with either dodecyl 66 (C12) or hexadecyl 67 (C16) aldehyde in the presence of a catalytic 
amount of trifluroacetic acid and anhydrous magnesium sulphate overnight. After 
filtration, aqueous work-up and subsequent purification via silica gel column 
chromatography, analysis by 1H NMR spectroscopy showed the presence of a triplet 
resonance at ~ δ 4.60 ppm that corresponded to the desired acetal moiety. This was 
reinforced by the characteristic resonances that indicated the appropriate aliphatic chain 
for each amphiphile. Yields were good to moderate in most cases (88% → 38%) as 
outlined in Table 5, however, significant challenges arose in the purification of these 
compounds as limited visualisation via thin layer chromatography (KMnO4 stain, UV 
light, Iodine stain) resulted in unforeseen co-elution of the desired product and potential 
degradation products of the aldehyde. These purification issues prevented the isolation 
of compounds 74 and 75 (Table 5, entries 13 and 15) and significantly hampered the 
yields obtained for compounds 70 and 72 (Table 5, entries 5 and 9). 
Due to these low yields, a different acid source was investigated to minimise potential 
aldehyde degradation. Since p-toluenesulfonic acid is commonly used for acetal 
formations and is a milder acid, the use of catalytic trifluroacetic acid was substituted for 
an excess of p-toluenesulfonic acid and the reaction mixtures were stirred at 35 °C 
overnight. Purification of these products proved easier with this method with no 
apparent aldehyde degradation, even though visualisation was still poor, resulting in 
higher yields of 77% and 64% for compounds 70 and 72, respectively (Table 5, entries 6 
and 10), and the previously unobtainable compounds 74 and 75 were successfully 
isolated in high yields of 76% and 88%, respectively (Table 5, entries 14 and 16). 
However, there were some significant losses in yield using this method for compounds 
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68 and 73 (Table 5, entries 2 and 12) and a slight decrease in yield for compound 71 
(Table 5, entry 8). Though due to the use of milder conditions coupled with the ease of 
purification the use of p-toluenesulfonic acid was deemed the most appropriate method 
to furnish amphiphiles 68-75. 
 
Table 5. Yields of acetal products comparing different acid sources used  
Entry Product n m Acid Source Yield (%) 
1 68 1 10 TFA 78 
2 68 1 10 TsOH 61 
3 69 1 14 TFA 70 
4 69 1 14 TsOH 78 
5 70 2 10 TFA 38 
6 70 2 10 TsOH 77 
7 71 2 14 TFA 81 
8 71 2 14 TsOH 75 
9 72 4 10 TFA 46 
10 72 4 10 TsOH 64 
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11 73 4 14 TFA 64 
12 73 4 14 TsOH 39 
13 74 5 10 TFA N/A* 
14 74 5 10 TsOH 76 
15 75 5 14 TFA N/A* 
16 75 5 14 TsOH 88 
* Product was unable to be isolated using silica gel chromatography 
2.4.3 Benzyl Carbamate Deprotection  
The final step of the synthesis was to liberate the amine head group by cleavage of the 
benzyloxy carbonyl protecting group. This deprotection can be facilitated by (i) 
dissolving metal reduction, (ii) acidolysis or (iii) catalytic hydrogenolysis. Catalytic 
hydrogenation with palladium on activated carbon (Pd/C) is a highly efficient method of 
cleaving the benzyloxy carbonyl group and is highly suitable in this case, as the acetal 
moiety is inert to the hydrogenation conditions and the head group is obtained as a 
neutral amine. 
The deprotection of the benzyl carbarmate proceeds through a two-step mechanism, the 
first of which is the catalytic hydrogenolysis of the benzyloxy group. While the exact 
mechanism of this step is not entirely known, it is understood that the benzyl carbamate 
76 co-ordinates to the palladium catalyst via the electron rich aromatic ring so that the 
ester moiety is in close proximity to the hydrogen atoms bound to the palladium and can 
then subsequently undergo homolytic cleavage (Scheme 15).125 An unstable carbamic 
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acid intermediate 78 is produced, which decomposes to form the deprotected amine 81 
and carbon dioxide 80. 
Scheme 15. The deprotection of benzyl carbamate via  palladium catalysed hydrogenation  
To facilitate the cleavage, Pd/C (10% w/w) was dispersed in methanol followed by the 
addition of the respective acetal and the reaction solution stirred under a hydrogen gas 
atmosphere overnight. The resulting mixture was vacuum filtered through a celite plug 
to remove the heterogeneous catalyst and the filtrate concentrated in vacuo to give the 
deprotected amphiphiles as oils in excellent yields (> 80%) for the majority of the 
compounds as outlined in Table 6 (entries 1-7). However, compound 89 was produced in 
a lower yield of 67% (Table 6, entry 8), which is consistent with the problems observed 
throughout the synthesis with compounds incorporating longer aliphatic chains. The 
yield obtained, while not as high as the rest of the amphiphile suite, was still 
synthetically viable. 1H NMR spectroscopic analysis of all neutral amines showed the 
loss of the key resonances associated with the benzyloxy carbonyl group at δ 7.2 ppm 
and δ 5.1 ppm. The triplet at ~ δ 4.60 ppm corresponding to the presence of the acetal 
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moiety was also seen indicating the successful deprotection of the benzyloxy carbonyl 
group without any degradation of the remaining compound. 
 
 
Table 6. Hydrogenolysis yields of amphiphiles 82-89  
Entry Product n m Yield (%) 
1 82 1 10 92 
2 83 1 14 83 
3 84 2 10 88 
4 85 2 14 89 
5 86 4 10 89 
6 87 4 14 84 
7 88 5 10 80 
8 89 5 14 67 
2.5 Conversion to Hydrochloride Salt 
With eight amphiphiles in hand, attention turned towards converting the amine head 
group to a positively charged ammonium chloride head group. Many pharmaceuticals 
are delivered in the hydrochloride salt form with the European pharmacopoeia citing 
over 200 hydrochlorides as the active ingredient in pharmaceuticals.153 Transforming 
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the head group into a hydrochloric salt is an efficient way of improving the overall 
aqueous solubility of amphiphiles, increasing the hydrophilicity of the head group 
moiety as well as improving the ease of handling of the amphiphiles. Often converting 
an amine to its corresponding hydrochloride salt can produce homogenous powders. 
Accessing a hydrochloride salt involves reacting the free amine with HCl, which would 
typically be a concern given the acetal moiety present, however, previous work with 
similar acetal groups has shown aliphatic acetals, such as the ones described here, to be 
stable for 18 hrs at pH 1 with no acetal degradation occurring.154 This is not unusual as 
acetals with substrates that contain a basic amino group have been found to be quite 
resistant to hydrolysis as protonation takes place at the amino group first resulting in a 
positive charge that then repels the protonation of the O-acetal and subsequently 
hampers hydrolysis.123  
Initially, the conversion of the amphiphiles to the corresponding hydrochloride salts was 
undertaken using commercially available ethereal hydrochloric acid. The amphiphilies 
were diluted with methanol and sonicated until dissolved before the addition of 
approximately 2 mL of HCl in ether (1M). The solution was then further sonicated to 
ensure complete dissolution before the removal of the solvent in vacuo to afford bright 
yellow/green pastes. This method was quick and easy, however, it introduced an array of 
unidentified impurities into the pure amphiphiles and, as such, an alternative method 
was investigated. 
Pure hydrochloride gas can also be used to convert the desired amphiphiles into 
hydrochloride salts and, in general, is a much cleaner method. The amphiphiles were 
suspended in Milli-Q water with the aid of sonication, then hydrochloride gas, produced 
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through commercial sodium chloride and concentrated sulphuric acid (Figure 16), was 
bubbled directly into the reaction vessel until the solution turned from opaque to clear, 
indicating that the head group was now charged, and therefore, more amenable to 
dissolution in water. The resulting solutions were frozen at -80 °C overnight then 
lyophilised to furnish homogenous powders. Although this method was more time 
consuming and had more safety risks associated with it, it furnished protonated 
amphiphiles of excellent purity.  
 
Figure 16. Setup of HCl gas generation 
2.6 Solubility of HCl Salt Amphiphiles 
Since the physicochemical evaluation of the self-assemblies was to be carried out in 
water, the aqueous solubilities of the positively charged amphiphiles were of utmost 
importance. Compounds 82-85 all demonstrated adequate aqueous solubility  in 
concentrations expected to be utilised in the examination of their self-assembly 
properties (> 1 mg/mL), however, it was discovered that compounds 86-89 (Figure 17) 
were very insoluble in water (< 1 mg/mL) and, consequently, could not be carried 
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through to the physicochemical evaluation investigation. It was postulated that the 
combined spacer and hydrophobic chain lengths of these amphiphiles have been 
extended to a point in which the hydrophobic properties of the amphiphile overcome the 
hydrophilicity of the head group and as such are insoluble in an aqueous environment. 
Given the aims of these first generation amphiphiles included the investigation of head 
group spacer length and self-assembly it was determined that the synthesis of an 
amphiphile that had an approximately equivalent distance between cationic head group 
and ‘kink’ but with increased solubility, would be advantageous to the overall study of 
the amphiphilic library. Modifying the head group spacer to include a diethylene glycol-
like moiety, such as 98 and 99 (Figure 17), was an ideal way of increasing the water 
solubility of the amphiphiles whilst allowing control of the spacer length. Ethylene 
glycol units assist in water solubility for organic compounds that are regularly used as 
part of the hydrophilic portion of amphiphiles and surfactants. 
 
Figure 17. Comparing the spacer chain lengths of the new dioxy amines 98  and 99  with 
that of the water insoluble 86  and 87  
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2.7 Synthesis of Dioxyethylene Amphiphiles  
Since poor solubility was an issue with the previous amphiphilic library, especially as 
the length of the head group spacer increased, a set of amphiphiles were designed with 
enhanced solubility in mind (Scheme 16). Ethylenedioxy bis-ethylamine was chosen as 
an ideal head group and spacer unit as it possesses a comparable chain length to that of 
the octyl amphiphiles with the added advantage of two oxygens situated along the 
carbon chain. This in itself is an example of how the synthetic procedure is amenable to 
many modifications. 
 
  Scheme 16. Proposed synthesis of the dioxyethylene spacer amphiphiles  based on 
previous synthesis  
As with the first library of amphiphiles, the ethylenedioxy bis-ethylamine 90 required 
mono-protection of the one of the free amines (Scheme 16). Carboxybenzyl protection is 
still a suitable protecting group for this new amine and, as such, 5 equivalents of 
ethylenedioxy bis ethylamine 90 were dissolved in dichloromethane and cooled to 0 °C 
before the slow dropwise addition of benzyl chloroformate 28. After stirring overnight at 
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room temperature and subsequent aqueous washes the product obtained showed 
resonances that indicated the formation of the desired benzyl carbamate 91 when 
analysed by 1H NMR spectroscopy. The crude material showed suitable purity and yield 
(73%) to be continued onto the next step without further purification. 
Imide synthesis was performed initially using the standard conditions required for 
compounds 34-38. Briefly, the mono-protected ethylenedioxy amine 91 was dissolved in 
toluene and norbornene anhydride 21 was added before the solution was subjected to 
microwave irradiation at 100 °C for 20 minutes. Aqueous work-up and subsequent 
purification by silica gel chromatography gave a clear oil that proved to be the desired 
imide 92, however, the compound was obtained in poor yield (21%). An extension of 
reaction time to 30 minutes improved the yield to 49%, however, increasing the 
temperature to 120 °C with the same reaction time of 30 minutes substantially improved 
the yield to 92% (Scheme 17). 
 
Scheme 17. Synthesis of head group moiety and diol ‘handle’ for the hydrophobic chain  
Standard Upjohn dihydroxylation conditions were again used for the synthesis of 
ethylenedioxy diol 93, with ethylenedioxy imide 92 being treated with NMO (1.5 eq.) 
and a catalytic amount of osmium tetroxide (2.5 wt.% in tert-butanol) and stirred for 72 
hours at room temperature in a 4:1 acetone/water solution. Aqueous work-up followed 
by purification via column chromatography gave a yellow oil in a moderate yield (63%) 
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and analysis of this product by 1H NMR spectroscopy identified the loss of the key 
resonances at ~ δ 6.0 ppm, associated with the alkene moiety, indicating the reaction had 
proceeded to completion and that the product was the desired ethylenedioxy diol 93. 
With the ethylenedioxy diol 93 in hand, attention turned towards the cyclodehydration of 
this diol and the relevant aldehydes to furnish the desired acetals bearing the same chain 
lengths (m = 10, 14) as the previous amphiphilic library for the direct comparison of 
spacer unit. With the previous collection of amphiphiles two different acid sources were 
examined, with no significant difference in yield, however, purification of the product 
was proven to be more troublesome when trifluoroacetic acid was employed. In the case 
of the ethylenedioxy acetals it was found that the use of trifluoroacetic acid gave 
significantly better isolated yields (79% and 60% for compounds 96 and 97, 
respectively) than that furnished by p-toluenesulfonic acid (42% and 35 %, respectively) 
at mild temperature (35 °C) (Scheme 18). While the potential degradation of the 
aldehyde may still be occurring as observed for the previous compounds 68-75, the 
increase in polarity of compounds 96 and 97 and subsequent change in Rf, prevented the 
co-elution of the desired products with the assumed aldehyde degradation products and, 
as such, purification was carried out successfully. 
The two ethylenedioxy acetals 96 and 97 were immediately deprotected using catalytic 
hydrogenation, using the same conditions as previously used for the initial amphiphilic 
library, to afford the desired ethylenedioxy amphiphiles 98 and 99 in good yields (80% 
and 75%, respectively). The isolated materials were then converted to the corresponding 
hydrochloride salt using hydrochloride gas (Section 2.5) and the aqueous solvent 
removed using lyophilisation to afford homogenous powders. 
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Scheme 18. Synthesis of compounds 98  and 99  from diol 93  
The solubility and handle-ability of these two amphiphiles far surpassed that of 
compounds 86 and 87 and, as such, were continued on to the physicochemical 
evaluation to aid the comparison of spacer length (and now composition) and self-
assembly properties. This chapter has presented the optimized synthesis of norbornane 
containing amphiphiles 82-87 and 98-99. The synthesis consists of six steps which 
furnish the desired ‘kinked’ amphiphiles in good overall yields. With all compounds 82-
85 and 98-99 in hand, the focus of this project turned towards the evaluation of the 
physicochemical properties of this amphiphilic library.  
These investigations have been presented in a recent publication, Squire, J. S.; Sutti, A.; 
Durand, G.; Conlan, X. A.; Henderson, L. C. Synthesis and preliminary investigations 
into norbornane-based amphiphiles and their self-assembly. New J Chem 2013, 37, 
1895. 
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Chapter 3  
In order to physically characterise the colloidal self-assemblies formed when compounds 
82-85 and 98-99 are subjected to water (hydrated), several physicochemical properties 
need to be investigated. Typically, the determination at which the concentration of an 
amphiphile promotes self-assembly (the critical aggregation concentration, CAC), size 
and shape of these resulting aggregates are necessary to determine the suitability of the 
assemblies to the desired application. Since these amphiphiles were designed with drug 
delivery in mind, the properties associated with the self-assemblies formed by 
amphiphiles 82-85 and 98-99 are of utmost importance. The investigations to follow 
form the second half of the previously mentioned publication, Squire, J. S.; Sutti, A.; 
Durand, G.; Conlan, X. A.; Henderson, L. C. Synthesis and preliminary investigations 
into norbornane-based amphiphiles and their self-assembly. New J Chem 2013, 37, 
1895. 
3.1 Investigating the Lipophilic Nature of the Norbornane Amphiphiles 
Given the unique structure of the amphiphiles in this study, investigations into the 
overall lipophilicity were required before embarking on further physicochemical 
evaluations. Of specific interest was the extent to which the norbornane core contributes 
to the overall molecular lipophilicity, whether it should be considered as part of the 
lipophilic region required elucidation, and would allow more informed conclusions to be 
drawn in relation to  molecular-to-aggregate structure. 
𝑙𝑜𝑔𝑃 = 𝑙𝑜𝑔 ൬
𝐶௢௖௧௔௡௢௟
𝐶௪௔௧௘௥
൰ 
Equation 2. Determination of the partition coefficient using n-octanol/water  
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Traditional means of determining the lipophilic character of a molecule uses the n-
octanol/water partition coefficient (logP) where the ratio of the molar concentration of 
an organic compound in n-octanol saturated with water to the molar concentration in 
water saturated with n-octanol as denoted by Equation 2. 
However, due to the importance of logP in small molecule drug design,155 various 
computational methods can be used to estimate logP values, providing a quick insight 
into the lipophilic nature of organic compounds.141 The most commonly used calculation 
protocols include (i) the Fragment method developed by Rekker,142 Hansch143 and 
refined by Klopman156 and (ii) the atom based system developed by Broto153 and 
Ghose.157-160 The prediction of logP values for compounds 82-89 and 98-99, in this 
study, were calculated using the atomic contribution approach where individual atoms in 
the molecule are assigned additive contributions to the molecular logP using the 
classification of atoms into chemically distinct types.161 This data is then fit to a range of  
experimentally determined logP values within the software’s database.161 While there 
are some limitations and concerns associated with using this approach over a fragment 
method,162 for the purposes of this investigation the use of an atom-based calculation 
was appropriate and the use of AlogPs software163,164 enabled the generation of 
predicated partition coefficients for compounds 82-89 and 98-99. The single norbornane 
unit and some common linear n-alkylammonium chlorides are also provided for 
comparison purposes (Table 7).  
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Table 7. Predicted and determined lipophilicity 
Entry Compound n m nCa logPb logkʹwc 
1 Norbornane - - - -1.65d - 
2 82 1 10 12 1.77 1.01 
3 83 1 14 16 3.28 1.13 
4 84 2 10 14 2.00 0.89 
5 85 2 14 18 3.44 1.18 
6 86 4 10 18 3.13 1.25 
7 87 4 14 22 4.22 1.30 
8 88 5 10 20 3.66 1.33 
9 89 5 14 24 4.65 1.33 
10 98 N/Ae 10 16f 1.91 1.119 
11 99 N/Ae 14 20f 3.29 1.1893 
12 C12H23NH3Cl - - 12 1.64 - 
13 C14H29NH3Cl - - 14 2.53 - 
14 C16H33NH3Cl - - 16 3.26 - 
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15 C18H39NH3Cl - - 18 3.95 - 
a Number of alkyl carbons within amphiphiles, for norbornane-based compounds nC = (2n + m), with the 
acetal carbon being omitted 
b Determined by AlogPs software 
c Determined by RP-HPLC 
d Data from reference 110 
e Spacer chain = ((CH2)2O)2CH2 
f For dioxy amine compounds, nC = (n + m) where n = number of carbons in spacer chain excluding the 
oxygen molecules 
 
First, the variations in the aliphatic tail (m) and the effect on logP was examined. From 
the predicted logP values it was observed that an extension of the alkyl chain for 
compounds 82 and 83 by four methylene units resulted in an increase in overall 
lipophilicity by approximately 1.9 times (Table 7, entry 2 vs. 3). A similar scenario was 
observed when comparing compound 84 vs. 85 (Table 7, entry 4 vs. 5), compound 86 
vs. 87 (Table 7, entry 6 vs. 7), and compound 88 vs. 89 (Table 7, entry 8 vs. 9), where 
the installation of four methylene units within the aliphatic chain in each comparison 
increased the lipophilicity approximately 1.7, 1.3 and 1.3 times, respectively. This 
demonstrates that the predicted effect of increasing the length of the alkyl chain (i.e. 
increasing m) has on the lipophilicity is more pronounced when the diamine spacer 
length is short. Interestingly, comparison of the dioxy amine containing amphiphiles 98 
and 99 resulted in an increase of lipophilicity by 1.7 times with the addition of four 
methylene units (Table 7, entry 10 vs. 11).  
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Figure 18. Comparison of amphiphiles 86 ,  87 ,  98  and 99  
Although the distance between the rigid scaffold and the cationic head group in 
compounds 98 and 99 is approximately equivalent to an octane unit possessed by 
compounds 86 and 87 (Figure 18), the incorporation of two oxygen molecules within the 
chain results in a predicted lipophilicity that is more in line with compounds possessing 
ethylene units, such as compounds 82 and 83. In fact, the lipophilicity of compound 98 
is only 1.7 times smaller than compound 99 that possess an m value with four more 
methylene units. This result is not surprising considering the polar oxygen atoms would 
be counter-balancing the hydrophobicity of the methylene units. This magnitude of 
variation mirrors that of compounds 84 and 85 where the increase in m of four 
methylene units in the latter, also increases the lipophilicity by 1.7 times (Figure 19). 
When comparison was made between the variations in n for compounds possessing the 
same length aliphatic chain (m), a much different trend was observed. Compounds 82 
and 84, possessing an m length of 10, showed only a slight increase in logP value at 
roughly 1.1 times for an increase of n by two methylene units. Comparison of 82 with 
86 and 88, led to more lipophilic compounds (1.8 and 2.1 times respectively) when 
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compared to compound 82. Interestingly, when comparing compound 98, which 
incorporates an ether linkage and the same alkyl chain length (m = 10), a similar trend 
was observed. The lipophilicity of compound 98 is similar to compounds 82 and 84 
despite the relative distance from the scaffold to head group being significantly smaller 
(n = 1 and 2, respectively) than compound 98 (n ~ 8) (Figure 19).  Comparison of the 
longer alkyl chain length (m = 14) containing compounds (83, 85, 87, 89 and 99) the 
same trends with variations in n were observed.  
 
Figure 19. Increase in lipophilici ty of dioxy compounds 98  and 99  is of the same 
magnitude as ethyl and butyl unit compounds  
These differences suggest that the choice of diamine for the spacer unit is of much less 
importance in determining the overall lipophilicity than originally expected, however, 
the incorporation of a dioxy amine chain can substantially decrease the overall 
77 
 
lipophilicity of the amphiphile. As such, the incorporation of the dioxy amine chain may 
induce interesting self-assembly characteristics. 
With these predicted logP values providing some insight into the lipophilic nature of the 
amphiphilic library, confirmation of these estimated values via experimental means was 
undertaken. Since the determination of the partition coefficient using the n-octanol/water 
method is laborious and time consuming, an alternative method commonly used for 
amphiphiles was employed. Determination of the capacity factor kw through Reverse-
Phase High Performance Liquid Chromatography (RP-HPLC) is a reliable, rapid means 
of comparing the lipophilicity of organic compounds and has been successfully utilised 
in the comparison of bile acids,165 hemi-fluorinated surfactants,166 biphenyl species167 
and penicillins.168 The calculation of logkʹw was achieved using a multi-step procedure 
where the capacity factor (k) was first determined using Equation 3 below. 
𝑘 =  
௧ೝି ௧బ
௧బ
 
Equation 3. Determination of capacity factor (k)  
 
The amphiphiles were sequentially injected onto a cyano-column with increasing 
amounts of organic modifier in the eluent at ratios of methanol/water 90:10, 70:30, 
50:50 and the respective retention times were recorded and plotted. Subsequent 
extrapolation of k vs. concentration of organic modifier back to pure water was used to 
determine the value of kw (simplified schematic in Graph 1). The log (base 10) of this 
value was then determined to give the logkʹw value. 
where;   tr = retention time of amphiphile in specified mix of methanol/water 
t0= elution time of methanol alone 
78 
 
 
Graph 1. Schematic of the extrapolation of k vs. concentration to determine value of kw 
The logkʹw obtained is a more direct, alternative measure of lipophilicity to that of logP, 
however, it should be noted that the logkʹw is not a replacement value for logP. 
Nevertheless, the trends observed with the variations in hydrophobic chain and spacer 
chain length for logP should mirror those shown by comparison of the logkʹw values.  
Indeed this was the case, as the logP trends were supported by the experimentally 
obtained logkʹw values, however the magnitude of lipophilic variation is much smaller 
when comparing the effect the structural variations had on logkʹw. Discrepancies in the 
classical octanol partition method and HPLC methods have been previously observed for 
short cationic peptides, most likely due to interactions with the stationary phase of the 
column.139 Given the nature of the cationic head group of these amphiphiles, similar 
interactions may be attributing to the variations observed between the predicted and 
experimental values. 
When comparing the norbornane based amiphiphiles to the linear n-alkylammonium 
chloride derivatives of similar chain length (Table 7, entries 12-15) it appears as though 
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the norbornane core contributes minimally to the overall lipophilicity of the 
amphiphiles. For example, n-dodecylammonium chloride exhibits a similar logP value 
to that of amphiphile 82 (1.64 and 1.77, respectively) with both compounds possessing 
12 methylene carbons. Additionally, n-octadecylammonium chloride has a higher 
predicted lipophilicity than compounds 85 and 86, with all three having 18 methylene 
carbons, indicating that the norbornane scaffold is not lipophilic in itself despite being 
mostly hydrocarbon based.  
This interesting finding could be due to the presence of polar oxygen atoms within the 
acetal and the imide at each end of the scaffold effectively negating the lipophilic 
hydrocarbon core of the bicycle (Figure 20).  
 
Figure 20. The presence of polar oxygens within the scaffold could negate the lipophilic 
effect of the hydrocarbon bicyclic core 
With a deeper understanding of the lipophilicity of these compounds attention turned 
towards the formulation of these amphiphiles into self-assemblies. 
3.2 Formulation of Amphiphiles into Assemblies 
Many physicochemical properties are influenced by the methods used to prepare, or 
‘formulate’, the self-assembly solution and, as such, careful consideration must be made 
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as to how the amphiphiles are formulated into their corresponding colloidal 
suspensions.27  
Fortunately, this dependence on preparation technique allows a tailorable means of 
potentially controlling the size, and morphology, of the resulting aggregates. There are 
three main types of vesicle/liposomal aggregates, small unilamellar vesicles (SUV), 
large unilamellar vesicles (LUV) or multilamellar vesicles (MLV), which can be formed 
during the process of self-assembly preparation (Figure 21). 
There are a variety of formulation methods available, however, to produce vesicles of 
any sort, the amphiphile must be introduced into an aqueous environment. Contrary to 
the term “spontaneous self-assembly” it is generally accepted that energy input into the 
system is required to obtain aggregates of liposomal form.169,170 The energy imparted 
into the system is most commonly some sort of mechanical agitation, however 
electrostatic means such as a change of counter ions, pH or ionic strength, can also be 
employed.171 
 
Figure 21. Schematic representation of the three main classes of vesicle agg regates 
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Injection formulation methods, where the amphiphile is dissolved in an organic solvent 
that is either miscible (e.g. ethanol) or immiscible (e.g. ether) with water is injected into 
the aqueous phase and stirred vigorously, are simple and negate the need for any 
physical treatment, such as sonication, thereafter. Major drawbacks for this technique 
are the additional step of removing the organic solvent and the low concentration of 
vesicles produced. Similarly, demulsification methods also introduce the amphiphile into 
the aqueous phase with an organic solvent, however, unlike the injection method, the 
organic phase is not immediately removed. The solution is instead left standing to 
emulsify, allowing the amphiphilic molecules to orientate themselves into a monolayer 
surrounding water droplets. With the evaporation of the organic solvent this amphiphile 
monolayer re-organises to form liposomes. 
While the previous two methods are widely used, the most common technique of 
formulating self-assemblies is the hydration method. The direct addition of water 
(hydration) to an amphiphilic solid or wax does not normally induce sufficient mixing to 
promote self-assembly, resulting in most of the amphiphilic compound remaining 
unhydrated. Therefore the amphiphilic compound needs to be prepared into a thin-lipid 
film or a porous cake of freeze dried powder. 
Typical formulations of this sort are of mixed lipid composition and must be first 
dissolved and mixed in an organic solvent (generally chloroform) to achieve a 
homogenous mix of lipid before the solvent is removed via a stream of dry nitrogen or 
argon resulting in a thin lipid film. Formulations consisting of just one type of 
amphiphile do not require this additional preparation and can be hydrated directly from 
the freeze-dried powder of the amphiphilic compound. The dry lipid film or cake is then 
hydrated by adding an aqueous medium and followed by agitation. 
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This method results in heterogeneous dispersions of multilamellar vesicles (MLV), with 
similar morphology to an onion, which can then be treated to form small unilamellar 
vesicles. Typically mechanical agitation is used by a variety of means including the use 
of a French press cell, microfluidiser, sonication or extrusion, however, electrostatic 
techniques can also be used such as a change of counter ion, pH or ionic strength.171  
The most common mechanical methods are extrusion and bath sonication. The extrusion 
method is a technique whereby the multilamellar vesicle dispersion is forced through a 
polycarbonate filter with a defined pore size, typically under high pressure, in order to 
yield vesicles with a diameter close to that of the pore size of the filter used.172 This 
simple protocol results in monodispersed, unilamellar vesicles with mean size diameters 
and distributions that can be easily reproduced from batch-to-batch, however, this 
method can be exceptionally time consuming, particularly on large scales. 
Disruption of the MLVs can also be achieved using acoustic energy either directly, from 
a probe tip, or indirectly, from a bath sonicator, with the latter being more advantageous 
as there is no direct contact between the sonicator and the vesicle suspension.171 This 
method has the highest energy input and is far less laborious and time consuming than 
the extrusion method. Given that exact sonication conditions are nearly impossible to 
reproduce, batch-to-batch variations in diameter size and distribution are often 
observed.173   
For this project, small unilamellar vesicles were required as to meet the size limitations 
associated with nanoparticle drug delivery (Section 1.5.2) and since the amphiphilic 
compounds could be readily obtained as porous powders after lyophilisation, it was 
determined that the direct hydration method followed by sonication would be the most 
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suitable technique for formulating amphiphilic compounds 82-85 and 98-99 into 
colloidal suspensions. 
Since these amphiphiles will be evaluated as single lipid solutions and not as mixed lipid 
compositions, the amphiphiles were hydrated with Milli-Q water directly from the 
lyophilised powders, negating the need for additional preparation. As mechanical 
agitation is the most common method of producing the small unilamellar vesicles 
desired, a sonication protocol was established where the aqueous suspensions were 
sonicated for 30 minutes at 30 °C in a bath sonicator, before being allowed to equilibrate 
at room temperature overnight. Sonication was chosen over the extrusion method as a 
less laborious protocol was ideal given the size of our amphiphilic library and the 
number of replicates required for each technique. 
Given the sensitivity of the techniques utilised for the physicochemical evaluation of 
colloids in this project and that filtration can influence vesicle size, the solutions were 
then passed through filters with a pore size of 0.45 μm to eliminate particulate 
contaminates before undertaking each evaluation technique to promote batch-to-batch 
consistency. 
With a firm formulation protocol established, the physicochemical evaluation of these 
suspensions could then be undertaken. 
3.3 Determination of the Critical Aggregation Concentration 
3.3.1 Critical Aggregation Concentration 
The critical aggregation concentration (CAC) is one of the most useful and simplest 
means of evaluating the self-assembly behavior of amphiphilic solutions and can provide 
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valuable insight into any biological or industrial value the colloidal system may 
possess.174 
The physicochemical properties of aqueous surfactant solutions show a strong 
dependence on concentration. This phenomenon occurs due to the hydrophobic moiety 
of the amphiphile disrupting the organisation of water when it is subjected to an aqueous 
environment and is known simply as “the hydrophobic effect”.175 This organisational 
distortion increases the free energy of the system requiring the amphiphile monomers to 
concentrate at the surface of the solution and orientate the hydrophobic region away 
from the aqueous solvent in order to minimise the free energy (Figure 22, A).176 Another 
alternative mechanism of lowering this free energy is the aggregation of the monomers 
into various self-assembly structures where the hydrophobic groups can be shielded 
from the water (Figure 22, B).177  
 
Figure 22. Schematic representation of concentration dependent aggregati on formation in 
aqueous solvent  
As such, it can be observed that at low concentrations aggregates are not detectable, 
however, over a specific concentration threshold (the CAC) aggregates become 
detectable and any additional surfactant added to the system will form into aggregates 
A B 
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(Figure 22).178,179 The concentration at which the monomer surfactants start to assemble 
into aggregates is referred to as the critical aggregation concentration (CAC).  
3.3.2 Experimental Methods of Determining the Critical Aggregation 
Concentration 
The CAC is experimentally determined by plotting a physical property as a function of 
surfactant concentration, with many properties exhibiting abrupt changes at the CAC, as 
demonstrated in Figure 23.  
 
Figure 23. Schematic representation of the concentration dependence of some p hysical 
properties for surfactant solutions  
There are many different methods, incorporating a variety of physical properties, used to 
determine the CAC of amphiphilic solutions, with such methods divided into two classes 
based on the type of change in property being examined. Direct methods are those in 
which the change in a property of the amphiphilic solution and encompasses methods 
such as surface tension, electrical conductivity,180 and NMR spectroscopy.128-132,181,182 
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Indirect methods include spectrometric and voltametric techniques and examine the 
change in a property of another substance within the amphiphilic solution with the 
increase in amphiphile concentration.174 The most common method of indirectly 
determining the CAC include the use of fluorescence probes, a method, along with the 
monitoring of the surface tension, that will be discussed in detail herein. For a more 
thorough discussion on all the techniques available the reader is referred to the excellent 
review by Mukerjee et al.174 
Monitoring of Surface Tension to Determine CAC 
The surface tension of a solution is very sensitive to the formation of aggregates and, 
therefore, can be a useful parameter for determining the CAC of amphiphilic 
suspensions.183 As the concentration of an amphiphilic solution increases the surface 
tension rapidly decreases, plateauing as it becomes nearly independent of the 
concentration.184 By plotting the surface tension (γ) against the logarithmic 
concentration of the amphiphile, the CAC can be determined from the concentration in 
which a sharp decrease in surface tension occurs. (Figure 24, solid line) 
Figure 24. Differences in surfaces tension with increase of amphiphile concentration with 
(i) a pure amphiphilic solution (solid line) and (ii) a amphiphilic solution  with an 
impurity (dotted line)  
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There are two common methods to determine the CAC via changes in surface tension. 
The first, the Du Noüy ring technique, measures the force required to detach a wire loop 
from the liquid surface,185 as this force is proportional to the surface tension. The most 
popular method measures the weight of the meniscus formed when a plate is pulled from 
the surface of the solution and is known as the Wilhelmy plate method.185 The weight 
obtained from a force balance is equivalent to the vertical component of surface tension. 
Although the surface tension method is the most widely used technique for determining 
CACs, it is very sensitive to impurities, with even a 0.01% impurity producing a 
pronounced minimum in the curve as demonstrated in Figure 24 (dotted line).186  For a 
more detailed discussion of the Wilhemy and Du Noüy techniques please refer to the 
literature.185, 186 
Fluorescence Probe Method 
There are many fluorescent probes that are sensitive to microenvironment changes and 
show unique characteristic changes in their emission bands.187 Such probes can be used 
to determine the CAC of an amphiphilic dispersion as variation in spectral distribution 
(such as maximum wavelength or intensity), quantum yield or fluorescence lifetime can 
be utilised to detect when aggregation occurs.188 Suitable probes are generally 
hydrophobic and display a different vibrational structure when in a polar environment to 
that of a non-polar environment. As such, the concentration at which the probe is 
incorporated from the aqueous environment into the hydrophobic region of an assembly 
can be measured by monitoring these differences in emission.189   
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Figure 25. Fluorescence spectrum of pyrene, demonstrating typical pyrene emission in 
water showing first and third vibronic peaks  
The use of the symmetrical, aromatic compound, pyrene as an extrinsic probe has 
become a popular method of determining CACs since the first reported use in 1976 by 
Kalyanasundaram and Thomas.133,190-192 Pyrene is an ideal candidate as it has low 
solubility in water, a long fluorescence lifetime and is very sensitive to the polarity of its 
surrounding environment. The intensity of its first and third vibronic peaks change with 
the polarity of the microenvironment (Figure 25).183 Monitoring the ratio of these two 
peaks can be used to determine the CAC as below this concentration the ratio will 
correspond to a polar environment (typically a I:III ratio of ~ 0.7). However, with the 
onset of self-assembly the pyrene will then be incorporated into the hydrophobic region 
of the aggregate and a sharp increase in the ratio of intensities will be observed (up to a 
I:III ratio of ~ 0.95).133 Like most other methods, the concentration at which this ratio 
increase is observed is deemed the CAC. Although widely used, this technique is subject 
to some criticism as the presence of a lipophilic probe can encourage aggregation, 
resulting in a slightly augmented CAC.193 
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 3.3.3 Determination of the CAC for the 1st Generation Amphiphilic Library 
With careful consideration of the techniques available, it was established that the CAC 
of amphiphiles 82-85 and 98-99 would be determined using the popular pyrene ratio 
method. To ensure complete confidence in this technique, given the associated concerns 
with probe induced aggregation, a second method, surface tension via a Wilhelmy plate, 
will also be used to measure the CACs of selected compounds, 82 and 84.  A 
comparison of the values obtained from the two different methods may alleviate any 
doubts in the use of a lipophilic probe. (Note: the required instrument was not present at 
Deakin University at the time and the determination of the CAC by surface tension was 
carried out by the author in the laboratory of a collaborator at the University of Avignon, 
France). 
Through a series of dilutions from a stock solution (1 mg/mL), vesicle suspensions of 
varying concentrations (0.0001 - 1 mg/mL) were prepared from compounds 82-85 and 
98-99. Excess crystalline pyrene was then added to each sample and the resulting 
dispersion was then sonicated for 30 minutes and left to equilibrate overnight as 
previously discussed in Section 3.2. The samples were then carefully passed through 
0.45 μm filters to ensure no free pyrene was present in the solution and each sample was 
prepared in triplicate at each dilution. With the solutions adequately prepared, the 
emission spectra were obtained for each triplicate concentration and the average ratio of 
the intensity of the first (II) and third (IIII) was plotted against the corresponding 
concentration. A graphical representation and a worked example of the CAC curve is 
shown in Graph 2 and Equation 4 which shows the CAC determination for 84. 
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Graph 2. Representative graphical interpretation of the change in I I:I I I I  with increasing 
concentration for compound 84 .  For graphs of compounds 82-85  and 98-99  please see the 
experimental section 
 
Compounds 82-85 and 98-99 all presented an abrupt change in the intensity ratio, 
indicating the successful formation of self-assemblies. The intersection of the two slopes 
corresponding to the data at high and low concentration denotes the CAC value, and as 
such, using the relative equations of each slope the CAC values for compounds 82-85 
and 98-99 were determined as demonstrated in Equation 4. 
 
Equations of each slope:                    y = 0.0564ln(x) + 0.9819 
            y = 0.0006ln(x) + 0.7936 
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Determination of intercept (x): 
∴ 0.0564 ln(𝑥) + 0.9819 = 0.0006 ln(𝑥) + 0.7936 
               0.1883 =  −0.0558 ln(𝑥) 
             ln(𝑥) =  
0.1883
−0.0558
 
       ln(𝑥) =  −3.37 
              𝑥 = 0.0344 𝑚𝑔/𝑚𝐿 
Equation 4. Representative calculation to determine the intersection o f the two slopes, 
i.e. the CAC of compound 84 . For the calculations of compounds 82-85  and 98-99   please 
see the experimental section  
For all compounds 82-85 and 98-99, the CAC values obtained are very low (Table 8) 
compared to values routinely reported in the literature. These low values indicate that a 
biological application, such as drug delivery, is quite feasible as dilution of the self-
assembly in the bloodstream can cause aggregation break down for compounds 
possessing a higher CAC. Additionally, the low CACs also suggest that the aggregates 
forming could be vesicular in nature as it is typically seen that assemblies consisting of 
bilayers have much lower CAC values than that of spherical micelles.27,194 
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Table 8. CAC values for compounds 82-85  and 98-99  from pyrene encapsulation method 
Entry Compound n m nCa 
CAC 
(mg/L) (μmol/L) 
1 82 1 10 13 30.8 ± 2.1 70 ± 5 
2 83 1 14 17 22.6 ± 3.1 50 ± 7 
3 84 2 10 15 34.4 ± 1.1 70 ± 2 
4 85 2 14 19 29.3 ± 3.7 60 ± 7 
5 98 N/Ab 10 17c 135.1 ± 29.1 254 ± 53 
6 99 N/Ab 14 21c 48.4 ± 1.5 82 ±  3 
a Number of alkyl carbons within amphiphiles, for norbornane-based compounds nC = (2n + m +1), with 
the acetal carbon being omitted 
b Spacer chain = ((CH2)2O)2CH2 
c For dioxy amine compounds, nC = (n + m + 1) where n = number of carbons in spacer chain excluding 
the oxygen molecules 
 
Interestingly, the CACs obtained for compound 82-85 were all similar (50-70 μmol/L) 
(Table 8, entries 1-4). Due to the hydrophobic effect, structural changes to the 
amphiphilic molecule should decrease or increase the CAC value accordingly, however, 
in this case it seems that amphiphiles 82-85 are fairly insensitive to variations in the 
molecular structure. For instance, when evaluating the effect of changes to the alkyl 
chain length (m), compounds 82 and 83 display only a slight decrease in the CAC 
(Table 8, entry 1 vs. 2) from 70 to 50 μmol/L even though there is an additional four 
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methylene units in m of the latter. It is typically observed for compounds with a 
common head group that the CAC usually decreases 5-15 times with the addition of two 
methylene units,106,107 and as such, the small decrease seen when comparing 82 and 83 
of only 1.4 times is highly unusual. Similarly, when comparing compounds 84 and 85 
where, again, the alkyl chain length is increased by four methylene units, the CAC is 
only 1.2 times lower (Table 8, entry 3 vs. 4). These findings, although unusual, have 
been observed previously by Kunitake and co-workers, who found single-chain 
amphiphiles containing a rigid segment in their structure (Section 1.5.2) were indifferent 
to structural modifications to the overall amphiphile composition.105 These amphiphiles 
containing rigid segments were also shown to form bilayered vesicles, further supporting 
the formation of vesicle aggregates for compounds 82-85. 
Conversely, compounds 98-99, incorporating the dioxy amine group showed CAC 
values that were more consistent with typical trends observed for single-chained 
amphiphiles. Amphiphile 99 had a CAC value 3 times lower than that of amphiphile 98 
(Table 8, entry 5 vs. 6), with the addition of four methylene units in the hydrophobic 
region and so, in this case, results in a decrease in CAC. Although this decrease is still 
not of the magnitude commonly reported for classic single chain surfactants, it suggests 
the rigid segment is still influencing the overall behavior of the self-assemblies but to a 
lesser extent than that of compounds 82-85.   
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Table 9. Comparison of CAC values with logP and logk ʹw 
Entry Compound n m nCa logPb logkʹwc CACd (μmol/L) 
1 82 1 10 13 1.77 1.01 70 ± 5 
2 83 1 14 17 3.28 1.13 50 ± 7 
3 84 2 10 15 2.00 0.89 70 ± 2 
4 85 2 14 19 3.44 1.18 60 ± 7 
5 98 N/Ae 10 17f 1.91 1.119 254 ± 53 
6 99 N/Ae 14 21f 3.29 1.1893 82 ±  3 
a Number of alkyl carbons within amphiphiles, for norbornane-based compounds nC = (2n + m +1), with 
the acetal carbon being omitted 
b Determined by AlogPs software 
c Determined by RP-HPLC 
d Determined by pyrene fluorescence method 
e Spacer chain = ((CH2)2O)2CH2 
f For dioxy amine compounds, nC = (n + m + 1) where n = number of carbons in spacer chain excluding 
the oxygen molecules 
 
This interesting observation whereby the length of  diamine spacer has had an influence 
on the alkyl chain length trends presented by the CAC is further compounded when 
comparing diamine spacer modifications (n). Similar CACs were observed for both the 
butyl (n = 2) and ethyl (n = 1) diamine groups with the same alkyl chain length (Table 9, 
entry 1 vs. 3 and 2 vs. 4, respectively) agreeing with the experimentally obtained 
partition co-efficients that showed an increase in diamine spacer length (n) did not 
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significantly affect the overall lipophilicity. This correlates well with the previous 
hypothesis that the length of the diamine spacer does not play a pivotal role in overall 
hydrophobicity. When comparing the dioxy amine containing compounds 98 and 99 to 
their corresponding alkyl chained butyl (n = 2) and ethyl (n = 1) diamine compounds 
(Table 9, entries 1, 3 and 5 and 2, 4 and 6, respectively) it can be seen that both 
compounds have a higher CAC than their shorter diamine counterparts. This is 
unexpected as the overall number of alkyl carbons for compounds 98 and 99 is indeed 
higher (nC = 17 and 21, respectively) than compounds 82 and 83, respectively, which 
suggests a lower CAC should be observed. While compound 99 has a CAC that is within 
the same range as its butyl (n = 2) 85 and ethyl (n = 1) 83 counterparts, compound 98 
shows a large increase in CAC in comparison to the butyl (n = 2) 82 and ethyl (n = 1) 84 
compounds of the same alkyl chain. This dioxy amine influence may be attributed to the 
additional solubility this moiety imparts on the amphiphile and such hypothesis can 
account for the large difference in CAC values obtained for both compounds. 
Amphiphile 98 has less hydrophobicity due to its shorter hydrophobic region, therefore 
would have an increased solubility than that of compound 99. 
Further investigation into these unusual findings showed that the CACs of compounds 
82-85 were, when compared to n-alkyl ammonium surfactants, in good agreement with 
such surfactants with a C16 alkyl chain. Indeed, n-decyl ammonium chloride has a 
reported CAC of ~ 0.05 M195 with that of its n-tetradecyl derivative is ~ 3 mM,174 while 
the hexadecyl ammonium bromide is reported to have a CAC of ~ 30 μM,196 a range 
coinciding with that of amphiphiles 82-85.  
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Given these unexpected results, the determination of the CAC for two selected 
compounds 82 and 84 via monitoring the surface tension using the Wilhelmy plate 
technique was undertaken to ensure confidence in the values obtained (Table 8).  
Concentrated stock solutions of amphiphiles 82 and 84 in Milli-Q water were prepared 
as previously discussed in Section 3.2 and the surface activity at the air/water interface 
was monitored as the solution was diluted using a Krüss tensiometer. The measurements 
were run in triplicate with fresh samples to ensure confidence of the values obtained. To 
obtain a sufficient plateau at the higher concentrations (i.e. after the CAC) solutions are 
required to be of a higher concentration than needed in the previous fluorescence 
technique. As the concentration of the solution decreased, an increase of surface tension 
was observed as expected for compounds 82 and 84, with the CAC determined as 
summarised in Table 10.  
 
 Table 10. CAC values for compounds 82  and 84  from surface tension method  
Entry Compound n m nCa 
CAC 
(mg/L) (μmol/L) 
1 82 1 10 13 45.4 ± 15.1 100 ± 30 
2 84 2 10 15 28.5 ± 14.6 60 ± 30 
a Number of alkyl carbons within amphiphiles, for norbornane-based compounds nC = (2n + m +1), with 
the acetal carbon being omitted 
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The CACs obtained by this secondary method were in good agreement with the 
previously established values for 82 and 84, considering the aforementioned probe 
induced aggregation, with CACs of 100 and 60 μmol/L, respectively. Since these two 
values obtained via surface tension were consistent with the corresponding values 
obtained by fluorescence, the determination of the CAC using the pyrene fluorescence 
technique was used exclusively with confidence. 
The unusual CAC results obtained that deviated from traditional amphiphilic compounds 
have been attributed to the unique architecture present in these amphiphiles. Due to the 
weakly non-polar nature of the norbornane core (Section 3.1), and the kink imparted on 
the overall molecular design, its insertion within the hydrophobic region of the 
amphiphile may alter aggregation behavior. As an example, Menger and co-workers 
found that the insertion of a non-carbon unit, a sulfide group, caused an increase in CAC 
by 2- to 3- fold (Figure 26).197,198  
Figure 26. Menger and co-workers observed a 2- to 3- fold increase in CAC with the 
insertion of a sulfide in the hydrophobic chain when compared to the equivalent 
hydrocarbon chained DTAB 198 
As such, it is possible that the norbornane core could decrease the entropic gain on 
aggregation by changing the water structure around the monomer into a less ordered 
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one. Alternatively, packing constraints could arise from the rigid and bulky norbornane 
moiety.  
While the CAC gives important insight into the concentration dependent self-assembly 
of these amphiphiles, further physicochemical investigations are required to fully 
understand these unique systems and, as such, attention turned towards determining 
aggregate size and morphology. 
3.4 Determination of Aggregate Size  
Aggregate size is of utmost importance for the successful delivery of chemotherapeutics 
to tumour tissue. There are many ways to determine the particle size of nanomaterials 
including dynamic light scattering and various advanced microscopy techniques. 
3.4.1 Dynamic Light Scattering 
While there are many techniques available for determining nanoparticle size, very few of 
these are able to do so in solution in the cost effective manner required for routine use.199 
Dynamic light scattering (DLS) is a well-established, non-invasive and non-destructive 
technique that can measure the size of nanoparticles accurately, reliably and repeatedly 
on a routine basis. Also referred to as Photon Correlation Spectroscopy (PCS) or 
Quasielastic Light Scattering (QELS), dynamic light scattering has become one of the 
most popular particle sizing techniques since its development with the appearance of 
suitable lasers in the 1960’s.  
The colloid solution is illuminated by a monochromatic laser and the time-dependent 
fluctuations in the intensity of scattered light, occurring due to random Brownian 
motion, are recorded with a photon detector at a specified scattering angle.  By 
observing the intensity fluctuations over time the decay of correlation can be 
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determined, with larger particles displaying a slower decay due to their slower diffusion. 
The comparison of intensity, time and correlation delay time is then used to determine a 
correlation function displayed as a correlogram. 
The correlogram of the correlation decay can provide a myriad of information about the 
composition of the sample. The mean size of the particles within the solution can be 
estimated from the time at which the correlation starts to substantially decay, with larger 
particles producing a correlation signal that takes a long period of time to decay while 
more rapid signal decays are observed for smaller particles (Figure 27). The rate of the 
decay can be indicative of the polydispersity of the sample with monodisperse samples 
showing a steep correlation decay curve.   
 
Figure 27. Representat ion of the correlation decay curve s for small and large particles  
From the correlation function, the rate of diffusion and subsequently the hydrodynamic 
diameter, which is the diameter of a rigid sphere with the same translational diffusion 
coefficient as the nanoparticle being measured, can be calculated. For a more in depth 
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discussion of dynamic light scattering theory please refer to Appendix A at the 
conclusion of this thesis. 
Interpretation of Dynamic Light Scattering Output 
Dynamic light scattering determines the hydrodynamic diameter as an estimated 
distribution of sizes within a sample and while it is common practice to quote the mean 
sample size as the hydrodynamic diameter, it is necessary to describe the extent of the 
variation in the sample to be entirely representative of the sample as a whole. 
Figure 28. Schematic demonstrating the size distributions in relation to PDI and HHW for 
a bimodal distribution  
The polydisperisty index (PDI) is a dimensionless scale in which the variation of particle 
size within the sample can be measured and compared.  For a highly monodispersed 
standard the PDI would be around 0.05 (Figure 28, left), however, this value is rarely 
seen in non-standard suspensions. As such, a PDI between 0.2-0.5 is deemed appropriate 
with a narrow to moderate distribution occurring (Figure 28, centre). A PDI value of 
over 0.7 indicates a very broad distribution and suggests that the sample may not be 
suitable for analyses by dynamic light scattering. The PDI is given for data that aligns 
well with the cumulant analysis method (detailed in Appendix A), and only be quoted 
for measurements with data that satisfy the requirements needed for such analysis. 
Distributions that are bimodal or fail to fit these requirements cannot be described using 
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the PDI and, as such, an alternative method of describing the variation in a sample must 
be used. The half-height width of the distribution peak is commonly employed in this 
case, where the size distribution is detailed by the width of the peak at half the maxima 
(Figure 28, right). 
The size distribution obtained from the DLS is a plot of the relative intensity of light 
scattered by particles of various sizes and is known as the intensity size distribution. 
This intensity distribution can, however, be slightly misleading due to Rayleigh 
scattering, where if the particles are smaller than the wavelength of the laser used, then 
the scattering from the illuminated particle will be fundamentally equal in all directions 
(i.e. Isotropic).200  
The Rayleigh approximations indicate that a 50 nm particle will scatter one million 
times as much as a 5 nm particle, as the intensity of scattering of a particle is 
proportional to its diameter to the power of six, with light from the larger particle 
potentially swamping the scattered light from the smaller particles (Figure 29). 
Additionally, in a mixture of large and small particles the contribution to the total light 
scattered by the smaller particles will be extremely small making measurements of this 
sample type difficult.  
Figure 29. Schematic of number, volume and intensity distributions of a bimodal mixture 
of 5 and 50 nm particles present in equal numbers  
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If the intensity distribution obtained is presented as a single, moderately smooth peak it 
can be assumed that the size distribution obtained is representative of the actual sample. 
However, if there are two peaks or significant tailing, conversion of the intensity 
distribution to a volume distribution may be necessary to gain a more realistic view of 
the importance of the second peak or tail. 
Volume distribution describes the relative proportion of multiple components in a 
sample based on their mass or volume rather than their ability to scatter light. To convert 
the intensity distribution to the volume distribution Mie theory is used as it is the only 
theory to adequately examine the whole range of sizes necessary.201  Essentially, Mie 
theory can be used to calculate the scattering intensities as a function of particle size. 
Such functions are too complex for discussion in this dissertation and therefore the 
reader is directed towards the excellent, in depth examination by Bohren and 
Huffman.202 
Since the intensity distribution presents the amount of scattering light and the Mie 
scattering formula gives the extent to which a particle of a particular diameter scatters, a 
number distribution can then be deduced from these results. However, the calculation of 
volume and number from the intensity distribution relies on the assumption that there is 
no error associated with the first order result. Due to the nature of the DLS technique, 
results obtained are subject to inherent peak broadening and as such, errors in the 
representation of the intensity distribution will be invariably present. Notably, small 
errors in the intensity distribution can cause large errors in the number distribution.  
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3.4.2 Determination of Hydrodynamic Diameter of 1st Generation Amphiphiles 
Before the hydrodynamic diameter could be determined, the establishment of protocols 
for the satisfactory preparation and measurement of samples for this particular technique 
were required. Instrumentation and data analysis considerations were needed to be 
addressed to minimise error in the results obtained. Briefly, the development of a 
standard operating procedure comprising of repeated measurements, monitoring the 
quality of the data obtained and an investigation of the batch-to-batch consistency. For 
more detail of these considerations please refer to Appendix A. 
The CAC of amphiphiles 82-85 and 98-99 indicates the concentration at which 
aggregation first starts to occur, however, an optimum concentration for the 
measurement of the particle size via dynamic light scattering was required. This ensures 
the measurements were undertaken on fully formed, stable self-assemblies. The ideal 
concentration must be above the CAC value previously determined, however, too high a 
concentration can result in multiple scattering where light scattered by one particle will 
be re-scattered by another and therefore creating error in the result obtained. To 
determine the optimum concentration at which the dynamic light scattering 
measurements should be performed, samples of amphiphiles 82-85 and 98-99 were 
prepared, as per Section 3.2, at concentrations coinciding to 2.5, 5, and 10 times the 
respective CAC for each amphiphile. The solutions were filtered through 0.45 μm 
syringe filters directly into the glass cuvette immediately before measurement to reduce 
potential dust particle contaminants.  
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Figure 30. Representative correlograms of concentration of colloids of 2.5 × CAC (left) 
and 10 × CAC(right) showing significant improvement in noise at the higher 
concentration 
The resulting correlograms, polydispersity indexes and hydrodynamic diameters were 
compared at each concentration to assess the quality and stability of the solutions. At the 
lowest concentrations examined (2.5 times CAC), the correlograms produced were 
noisy, indicating that at these low concentrations the assemblies are unstable (Figure 30, 
left). Additionally, the hydrodynamic diameters estimated were quite large (typically 
above 300 nm) and with large polydispersities, making these concentrations unsuitable 
for the adequate characterisation of the self-assemblies. At slightly higher concentrations 
(5 times CAC) the variation in the samples improved, with the correlation data 
presenting as a smooth curve, and a moderate reduction in the mean hydrodynamic 
diameters and PDI (Correlogram not shown). With a further increase of concentration to 
10 times the CAC, a substantial reduction in size is observed and the quality of the 
sample is improved significantly for all compounds 82-85 and 98-99 (Figure 30, right). 
From these comparisons it was determined that the ideal concentration of the 
amphiphilic suspensions for the measurement of the hydrodynamic diameter was at 10 
times the determined CAC.   
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With the optimal concentrations for amphiphiles 82-85 and 98-99 established, the 
hydrodynamic diameters were determined as outlined in Table 11. 
 
Table 11. Hydrodynamic diameters determined via  dynamic light scattering for 
amphiphiles 82-85  and 98-99  
Entry Compound DH (nm)a,b Polydispersity Index (PDI) 
1 82 59 (100%) 0.244 
2 83 79 (89%) 24 (10%) 55c 
3 84 142 (100%) 0.195 
4 85 91 (100%) 0.188 
5 98 220 (100%) 0.096 
6 99 7 (100%) 0.198 
a Hydrodynamic diameter determined at 10 × the CAC value at 25 °C with volume distribution 
b Values in parenthesis are the percent of the population observed 
c Given the bimodal distribution, cumulant analysis was not appropriate for this data and as such the HHW 
is quoted, in nm, to indicate the dispersity of the sample  
 
As can be seen, amphiphiles 82-85 self-assemble into aggregates of sizes (59-142 nm) 
within what is desired for potential drug delivery (30-200 nm). Most results gave good 
distributions with moderate polydispersity as indicated by the polydispersity indexes 
obtained, however, compound 83 repeatedly displayed a bimodal distribution indicating 
that this colloidal suspension contained assemblies of two distinct size ranges of 79 and 
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24 nm (Table 11, entry 2). While the smaller sized population accounted for 
approximately only 10% of the total sample it was concluded through repeated 
measurements that this population was indeed real and not an artifact of the DLS 
measurement.   
Interestingly, from small structural variations in the amphiphilic composition, a wide 
variety of particle sizes can be accessed despite displaying similar CAC values, in 
particular by extending the alkyl chain length of compound 84, by four methylene units 
85, a significant decrease in aggregate size is observed (Table 11, entry 3 vs. 4).  
Compound 98 was found to assemble into aggregates with much larger hydrodynamic 
diameters (220 nm), while, surprisingly, 99 (m = 14) displayed extremely small 
aggregates of just 7 nm. This small aggregate size suggests that micelles could be the 
preferred self-assembled morphology for this amphiphile. 
Colloidal suspensions containing nanoparticle self-assemblies tend to suffer from 
limitations arising from inadequate stability, typically hours to days. To address the 
stability of the suspensions prepared in this case, the assembly sizes of these 
amphiphiles were monitored over several weeks. The solutions were kept at room 
temperature and the hydrodynamic diameter was measured periodically with and 
without sonication 24 hours prior. 
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Graph 3. Representative stability over four weeks (compound 84) with sonication (in 
black) and without sonication (blue) 
 The hydrodynamic diameter of the suspensions without sonication were observed to 
increase steadily over a period of two weeks before stabilising at a reasonably large 
particle size (typically over 400 nm). However, those suspensions that were subjected to 
sonication before each periodic measurement displayed hydrodynamic diameters that 
remained similar to that observed for the freshly prepared sample, with only small 
variations in size being observed, for a period of four weeks (Graph 3).   From this 
investigation it is hypothesised that over time, the assemblies settle into large 
agglomerates that can be broken up into smaller aggregates with sonication, which re-
assemble into the original formation. 
3.5 Visualisation of the Morphology of the Self-assemblies 
Although dynamic light scattering is a useful tool in determining the hydrodynamic 
diameter of the self-assemblies, further investigation into the exact morphology of the 
aggregates is required as dynamic light scattering assumes that the particles are spherical 
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in shape. As previously discussed in Section 1.5.2, amphiphilic compounds can 
assemble into a wide variety of shapes, particularly those containing a rigid segment in 
their architecture. Thus without further investigation into the morphology of the 
assemblies, the hydrodynamic diameters obtained could be misleading.203   
Advanced microscopy techniques can be utilised to visualise the self-assemblies and 
confirm not only their shape but their size as well. There are many techniques available 
for this purpose with atomic force microscopy (AFM), confocal microscopy, scanning 
electron microscopy (SEM), and transmission electron microscopy (TEM) being among 
the most commonly employed methods. 
While effective in providing a three dimensional profile of the surface of a sample with 
ultra-high resolution, AFM commonly disrupts the liposome structure resulting in 
flattening and deformation. 204,205 Similarly the use of SEM is also rather limited for the 
visualisation of colloidal self-assemblies as samples need to be dried or gold coated 
before measurement under vacuum conditions.205 This preparation and even the electron 
measurement can damage the structure of delicate nanoparticle structures such as 
liposomes or micelles.204 Additionally this technique cannot resolve the internal 
structure of aggregates.206 Confocal microscopy is also limited as it cannot resolve 
structures that are less than 200 nm in size and is therefore unsuitable in this case as 
suggested by the dynamic light scattering data obtained. 205 
For colloidal nanoparticles in solution, TEM is generally the technique of choice for 
determining morphology and structure at the nanometer level. Conventional TEM 
requires solution samples to be dried from a suspension onto a substrate of 10-30 nm 
thick carbon or polymer film that is supported by a metal grid.207 Since organic materials 
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are generally translucent to the electron beam, the artificial enhancement of the contrast 
is typically needed for adequate visualisation. This is achieved by the negative staining 
of the sample with a salt solution of a strongly electron scattering heavy metal 
compound such as uranyl acetate or potassium phosphotungstate. Both the drying and 
the negative staining procedures can affect the assembly morphology and, as such, care 
in interpretation is necessary.208  There are several TEM techniques that avoid these 
downfalls associated with traditional TEM, the most common of which is cryogenic-
TEM (cryo-TEM) where 100 nm thick films of the aqueous sample are plunged into a 
coolant such as liquid ethane. The self-assemblies of interest are immediately embedded 
on the electron-transparent film of vitrified amorphous ice and can therefore be 
visualised in their near-native aqueous state without the possibility of dehydration and 
subsequent flattening.209 Since this technique does not disrupt the morphology of the 
self-assemblies whilst still provides high resolution images, it was determined the cryo-
TEM would be the technique of choice to visualise the self-assemblies. 
3.5.1 Visualisation of Self-assembly Morphology via TEM and Cryo-TEM 
Cryo-TEM visualisation of the self-assemblies formed by compounds 82-85 and 98-99 
was performed by Lynne Waddington of CSIRO under conditions described in Section 
7.2.6.  
Initially, the visualisation of compound 82 proved to be problematic as the suspension 
seemed to be too dilute for imaging using the cryo-TEM technique, however, good 
visualisation was achieved after negatively staining the sample with potassium 
phosphotungstate (KPT). From the negatively stained images it was seen that compound 
82 presented in the form of small vesicle aggregates of approximately 65 nm in size with 
several non-closed liposomes (Figure 31). Although there can be some morphological 
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changes induced by the negative stain, the size of the vesicles measured by TEM are in 
good agreement with that obtained by DLS (59 nm) indicating that in this particular case 
the negative staining has had little to no effect on the aggregates size. This confirms that 
compound 82 forms vesicles of ideal size for drug delivery and contains a bilayer that 
could encapsulate small hydrophobic molecules for this purpose. 
 
Figure 31. Self-assemblies of approximately 65 nm in size of compound 82  with negative 
staining 
The visualisation of compound 83 by cryo-TEM proved to be very interesting with the 
appearance of two different morphological forms. The dominant feature of this 
suspension was elongated forms of cigar-shaped vesicles, however, a number of striated 
tube-like structures were also present (Figure 32). These rod-like aggregates where not 
as common as the cigar-like vesicles but were abundant enough to be considered a real 
feature of the colloid. The presence of these two different assemblies could account for 
the bimodal distribution obtained from DLS especially given the ratio of small (rod-like 
B) to larger (cigar-shape A) aggregates observed via TEM were similar to that obtained 
for the two separate distributions presented from the DLS analysis. The approximate 
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sizes obtained from the Cryo-TEM images (cigar-shape A ~ 57 nm wide, 163 nm long 
and rod-like B ~ 20 nm wide, 245 nm long) are not in accordance to the hydrodynamic 
diameters obtained previously, however, the hydrodynamic diameters are obtained using 
data analysis that assumes particles are spherical in size. This assumption when applied 
to non-spherical particles can give misleading results and therefore can explain the 
discrepancies in the particle sizes obtained from each technique.  
 
Figure 32. Self-assemblies of compound 83  with two morphologies A. cigar shape 
vesicles (~57 nm wide, 165 nm long) and B. Rod-like vesicles (~20 nm wide, 245 nm 
long) via  Cryo-TEM 
The formation of tubular and rod-like assemblies from compound 83 may prove to be 
advantageous for a drug delivery system as previously discussed in Section 1.5.2, 
nanoparticles possessing a cylindrical morphology can show an increase in cellular 
nanoparticle uptake. Furthermore this morphological variance demonstrates the 
versatility in the amphiphilic architecture utilised in this library, as a small modification 
in chain length for compound 82 (m =10) to compound 83 (m = 14) has resulted in a 
completely different morphology. With this structural versatility a drug delivery system 
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can be potentially tailored to provide increased efficiency in drug delivery depending on 
the ideal morphological structure required for the specific task (i.e. spherical 
nanoparticle vs. rod-like nanoparticle delivery). 
The investigation of compound 84 under cryo-TEM showed large vesicles of classical 
liposomal structure (Figure 33, left). The observed morphology was very similar to that 
presented by Bordes et al., where the vesicle formation was attributed to the stacking of 
the norbonane bicyclic structure employed as a counter ion in their case.109,110 The 
assembly diameters where measured to be approximately 150-250 nm which is larger 
than that measured by DLS, however, assemblies visualised via Cryo-TEM can be at 
risk of ‘flattening’ during analysis due to the nature of the technique and, as such, are 
still comparable to the size obtained by DLS.209 
 
Figure 33. Self-assemblies of compound  84  presenting as vesicles ranging from 150 nm –  
250 nm (left) and 85  presenting as vesicles ranging from 70 nm –  90 nm (right)  
 
113 
 
Similarly, the self-assemblies of compound 85 also presented as classic spherical 
vesicles when visualised under Cryo-TEM. Although the aggregates seen were quite 
polydisperse, with sizes ranging from 30-500 nm, the majority of the assemblies 
observed displayed diameters between 70-90 nm (Figure 33, right) which corresponded 
well with the hydrodynamic diameter obtained via DLS of 91 nm. Most of the vesicles 
were smooth with no substructure although occasional smaller vesicles were observed 
with a slight “orange peel” texture.   
Again, with a small modification in the chain length of compounds 84 and 85, variations 
in the morphology of the assemblies, this time in regards to size, are observed. This 
further highlights the versatility of this amphiphilic library, with subtle modifications in 
the hydrophobic region and the spacer chain. This resulted in spherical self-assemblies 
spanning the entire ideal size range (30-200 nm) associated with successful passive drug 
delivery to tumour tissue. Since size influences cellular uptake and ultimate destination 
of nanoparticles within the body (See Section 1.5.2), easy access to amphiphiles that 
form assemblies close to the lower, medium and upper size limit for EPR delivery (i.e. 
assemblies from compound 82 at ~65 nm, compound 85 at ~70-90 nm and compound 84 
at ~150-250 nm, respectively) is indeed advantageous for the tailoring of these 
assemblies to specific drug delivery applications. Additionally, the formation of rod-like 
assemblies from the small change in the hydrophobic domain further widens the 
possibilities for this amphiphilic library as drug delivery systems.  
The wide variety of morphologies displayed by this amphiphilic library with only small 
changes in chemical structure is unusual and unexpected, however, these results could 
be attributed to the ability of the amphiphiles to stack together to create the lipid bilayer. 
As previously discussed in Section 1.5.2, the position of a rigid segment within an 
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amphiphile can have large ramifications on the overall morphology of the self-
assemblies.210 By varying the value of n and m the rigid ‘kinked’ portion of the 
amphiphiles has been effectively moved within the overall architecture, and therefore 
the ability to stack must be determined by a delicate balance of n and m, which in turn, 
determines the aggregate morphology and size.  
Interestingly, when visualised with negatively stained TEM, compounds 98 and 99 
showed assemblies pertaining to a micellar composition with no evidence of a lipid 
bilayer (Figure 34, left and right, respectively). Micelles of approximately 10 nm where 
the dominate feature in the suspensions of both compounds, however, compound 99 also 
possessed stacked disc structures in the 40-60 nm size range and larger spherical 
particles (~ 100 nm). 
 
Figure 34. Self-assemblies of compound 98  (left) showing micelles of approximately 10 
nm in size and compound 99  (right) showing micelles with mixed sizes from 10 nm to 100 
nm 
While the sizes obtained from TEM for compound 98 do not correspond to the 
hydrodynamic diameter previously obtained (220 nm), it was noted during the TEM 
visualisation that the micelles observed had clumped together to form larger 
agglomerates that could be responsible  for the larger hydrodynamic diameter measured 
200 nm 200 nm 
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by DLS. In the case of compound 99, the size of the individual micelles observed (~ 10 
nm) are in agreement with the hydrodynamic diameter obtained via DLS of 7 nm, 
however, the DLS did not suggest the presence of other larger aggregates. This oversight 
from the DLS measurement is not surprising given the polydispersity observed through 
TEM was quite high and may have been unsuitable for DLS measurement.   
Micelle forming surfactants generally exhibit higher CACs than amphiphiles that self-
assemble into liposomes. As such, the CAC values determined for compounds 98 and 
99, which were un-expectantly higher than compounds 82-85, were indicative of the 
formation of micelles and, thus, displayed different trends than that observed for the 
liposome forming compounds 82-85. It is hypothesised that the incorporation of a dioxy 
amine unit may disrupt the stacking ability exhibited by amphiphiles 82-85 and therefore 
prevent the formation of a lipid bilayer. Electron repulsion by the oxygen molecules 
located along the hydrocarbon chain connecting the head group with the norbornane 
core could have a significant role in the prevention of stacking. Alternatively the 
increased polar nature that this unit imparts could contribute to an overall larger head 
group which would influence the CPP and result in micelles.   
This chapter presents the physicochemical evaluation of amphiphiles 82-85 and 98-99. 
These assemblies were shown to have a diverse range of particle size and morphology 
and were characterised using CAC techniques, DLS and TEM. 
The data presented in this chapter has been published as part of two works, Squire, J. S.; 
Sutti, A.; Durand, G.; Conlan, X. A.; Henderson, L. C. Synthesis and preliminary 
investigations into norbornane-based amphiphiles and their self-assembly. New J Chem 
2013, 37, 1895 and Squire J.S.; Conlan X.A.; Henderson L.C. Synthesis and 
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comparative physical-chemical characterisation of neutral and cationic amphiphiles 
using RP-HPLC. Curr. Anal. Chem. 2013; 9: 653 - 658 
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Chapter 4  
With the first generation of self-assembling norbornane amphiphiles showing promise as 
potential drug delivery systems (Chapters 2 and 3), focus turned towards the synthesis of 
a second generation of amphiphiles. These would possess a recognition ligand moiety at 
the cationic head group, towards the development of an active targeting breast cancer 
drug delivery system. 
By attaching the estrogen receptor antagonist, Tamoxifen (Figure 35, in green), via a 
linker group, onto the hydrophilic region of the amphiphile, self-assemblies with 
peripheral targeting ligands could be produced (Figure 35).  
 
Figure 35. Amphiphilic design of Tamoxifen bearing compounds  potentially leading to 
targeted liposomes 
The Tamoxifen unit itself is hydrophobic, and its incorporation onto the hydrophilic 
domain of the amphiphile could disrupt the balance of the hydrophobic/hydrophilic 
forces and, in turn, prevent spontaneous self-assembly. In an effort to overcome this 
potential issue, an oxyethylene spacer chain was employed to increase the overall 
hydrophilicity of this region (Figure 35), alongside the cationic head group moiety, and 
to improve aqueous solubility. Additionally, Banerjee et al.54,78 have shown that the 
largely hydrophobic steroid estrogen can be incorporated onto the hydrophilic region of 
an amphiphile without consequence to the self-assembled nanoparticle. 
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4.1 Direct Conjugation to Afford Tamoxifen Functionalised Amphiphiles  
Expanding on the synthetic protocols developed previously within this thesis, a synthetic 
pathway to incorporate the Tamoxifen unit onto the hydrophilic portion of the 
amphiphile was devised (Scheme 19). Formation of imide 103 with ethoxyamino 
alcohol 104 allows for the formation of an oxygen-derived leaving group, such as a 
tosylate or mesylate (Ts or Ms) 103. Such a leaving group can undergo nucleophilic 
attack by desmethyl-Tamoxifen 102, to give compound 101. Subsequent 
dihydroxylation and acetal formation would result in the desired compounds, with the 
ability to vary the length of the hydrophobic chain (m) as previously established in 
Section 2.4. 
 
Scheme 19. Retrosynthetic design of 2 ndgeneration amphiphiles bearing tamoxifen moeity  
The first step in the synthetic pathway involved imide formation using the previously 
synthesised norbornane anhydride 21 and 2-(2-aminoethoxy)ethanol 104.  The choice of 
spacer unit between the norbornane core and the Tamoxifen unit enables the desired 
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incorporation of an oxyethylene chain in an effort to increase the polarity of the 
hydrophilic head group region increasing overall solubility. The incorporation of 
oxyethylene groups has previously been used to improve solubility with success as 
discussed in Section 2.7, and, as such, was considered the best option in this instance. 
Since the terminal amine of 2-(2-aminoethoxy)ethanol 104 is more nucleophilic than the 
hydroxyl terminal, protection of the OH group was not necessary. 
 
Scheme 20. Imide 105 formation  
Previous conditions established in Section 2.3.2 (Scheme 20) were employed, and after 
aqueous workup gave a yellow oil. Analysis by 1H NMR spectroscopy, showed one 
resonance for the double bond at δ 6.0 ppm in addition to the oxyethylene groups, 
confirming the formation of the desired imide 105 in an excellent yield of 88% and in 
greater than 95% purity. 
In order to facilitate the incorporation of the Tamoxifen unit, the hydroxyl terminal of 
105 required conversion to a suitable leaving group. The most common method of 
transforming a hydroxyl into an oxygen based leaving group is by the formation of a 
sulfonate ester, either p-toluenesulfonate (tosylate) or methanesulfonate (mesylate).125 
Tosylates are easily accessed from the treatment of the alcohol with p-toluenesulfonyl 
chloride in the presence of a base and proceed through a classic SN2 mechanism as 
detailed in Scheme 21.  
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Scheme 21. Mechanism of the conversion of an alcohol to a tosylate via  SN2 mechanism 
Treatment of imide 105 with a slight excess of p-toluenesulfonyl chloride 108 in the 
presence of triethylamine (NEt3) gave the desired tosylate 107 in an excellent yield of 
85% (Scheme 22). 1H NMR spectroscopic analysis of this compound showed the 
presence of a typical p-substituted phenyl ring at ~ δ 7.8 and 7.3 ppm corresponding to 
the aromatic region and a singlet resonance at δ 2.41 ppm for the methyl group of the 
tosyl moiety. 
 
Scheme 22. Tosylation of compound 105  to furnish tosylate 107  in excellent yield  
Before the conjugation with tosylate 107, Tamoxifen 1 required demethylation in order 
to convert the tertiary amine 1 into a secondary amine 102. One of the leading methods 
of demethylation of tertiary amines is by the use of α-chloroethyl chloroformate (AcE-
Cl), first reported by Olofson and co-workers in 1984.211  
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This two-step procedure begins with the nucleophilic substitution of the tertiary amine 
with the acid chloride functionality of α-chloroethyl chloroformate 109 resulting in salt 
110.212 A methyl group is then lost via nucleophilic attack by the chloride ion to produce 
intermediate 111 and methyl chloride.  At this stage all solvent is removed in vacuo and 
the remaining material dissolved in methanol. Nucleophilic attack by methanol on the 
alkyl chloride 111 gives the pseudo-acetal 112, and generates hydrochloric acid.213 
Subsequent decomposition of 112 to carbon dioxide and dimethylacetal gives secondary 
amine 113 which is then protonated to give the desired demethylated product 102 as the 
hydrochloride salt.  
Scheme 23. Accepted mechanism of the demethylation of a tertiary amine using α-
chloroethyl chloroformate  
 
A recent synthetic procedure reported by Dreaden et al.53 was adapted whereby 
Tamoxifen 1 and α-chloroethyl chloroformate 109 were heated to reflux for 24 hours in 
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dichloromethane followed by the removal of the solvent (Scheme 24). The resulting 
yellow oil was then dissolved in methanol and the solution heated to reflux for a further 
3 hours. The removal of the solvent produced a white solid in excellent yield (95%) 
which analysis by 1H NMR spectroscopy showed resonances consistent with the 
literature for desmethyl-Tamoxifen 102.53 
Scheme 24. Demethylation of Tamoxifen 1  
With tosylate 107 and desmethyl Tamoxifen 102 in hand, attention turned towards the 
conjugation of the Tamoxifen unit onto the norbornane scaffold (Scheme 25). A simple 
SN2 substitution of the tosylate group for the nitrogen unit of the Tamoxifen should 
provide a relatively easy method of tethering to the norbornane scaffold. 
Scheme 25. Conjugation of demethylated Tamoxifen 102  to norbornane scaffold  
 
An adapted procedure reported, again, from Dreaden et al.53 was utilised in which imide 
107 and desmethyl-Tamoxifen 102 were dissolved in THF before the addition of 
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potassium carbonate and the resulting solution was heated to reflux overnight. 1H NMR 
spectroscopic analysis of the crude material suggested the presence of the desired 
compound 101 amongst a complex mixture of products. Despite several attempts at 
purification via silica gel chromatography, using a variety of different eluent 
compositions, isolation of compound 101 was not achieved.  
In an attempt to improve this step, the substitution of the tosylate leaving group for the 
more reactive mesylate group was explored. Although the mechanism to which it 
proceeds is different to that of p-tosylchloride (Scheme 26),125 the mesylation of 
compound 105 was achieved using the same conditions for that of tosylate 107 in a 
respectable 77%.  
Scheme 26. Mechanism of the mesylation of imide 105  
 
While the formation of a tosylate proceeds through the SN2 mechanism, the presence of 
an acidic proton on the methyl portion of mesylchloride causes this reaction to progress 
through an E1cB elimination. After deprotonation of the acidic proton with a base, 
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sulfene 116 is formed with the loss of the chlorine atom. Nucleophilic attack of the 
alcohol moiety of compound 105 at the sulphur produces a carbon anion which, after a 
proton transfer, then gives the desired mesylate 118. 
Unfortunately, the use of mesylate 118 in the analogous reaction with desmethyl-
Tamoxifen 102 was unsuccessful and the purification of the resulting complex mixture 
failed to isolate the desired compound 101. As such, this pathway was deemed 
unsuitable for isolation of 100 and a different pathway was sought. 
4.2 Alternative Pathway for the Direct Conjugation of Tamoxifen 
Functionalised Amphiphiles 
Since the purification of compound 101 proved troublesome, an alternative pathway to 
synthesise compounds 119 and 120 was developed (Scheme 27).  
 
 
Scheme 27. Retrosynthet ic design of alternative pathway consisting of the conjugation 
step as the last transformation in the sequence  
 
It was hypothesised that rearrangement of the previous pathway to include the 
Tamoxifen conjugation step as the last synthetic step in the reaction sequence (Scheme 
126 
 
27) would be advantageous as this product may prove to be less challenging to purify. It 
was also hoped that the reactions preceding the conjugation would be high yielding to 
allow easy scale up of compounds 121 and 122.  
The dihydroxylation of previously synthesised imide 105 was the first step in this 
alternative pathway. The versatility and ease of adjoining the hydrophobic portion of the 
amphiphile via an acetal linkage from this diol moiety has been demonstrated previously 
in Section 2.4.1.  
 
Scheme 28. Attempted dihydroxylation of imide 105  
Previously optimised dihydroxylation conditions were employed to synthesise diol 123, 
however, the desired product could not be isolated after aqueous workup. Considering 
123 has a high number of hydrogen bond acceptors and donors the loss of this 
compound during work up was most likely due to diol 123 being water soluble and 
subsequently failing to be extracted into the organic layer. It was thought that the 
tosylation of the hydroxyl group of imide 105 before dihydroxylation should promote 
the solubility of this compound in organic solvent (Scheme 29).  
 
 
Scheme 29.The successful dihydroxylation of tosylate 107  
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The previously synthesised tosylated imide 107 was subjected to dihydroxylation 
conditions followed by an aqueous work-up resulted in a crude mixture indicating the 
presence of the desired diol 124.  Purification via silica gel column chromatography 
gave a light brown oil in an excellent yield of 83% and analysis of this product by 1H 
NMR spectroscopy identified the loss of the key resonances associated with the alkene 
at ~ δ 6.0 ppm, indicating the successful introduction of the diol moiety of compound 
124.  
 
Scheme 30. Synthesis of compounds 125  and 126  in good yields  
Diol 124 was then treated with either dodecyl 66 or hexadecyl 67 aldehyde to furnish 
acetals 125 and 126, respectively. Using the milder conditions of an excess of p-
toluenesulfonic acid and mild heating as previously established (Section 2.4.2), acetals 
125 and 126 were isolated in good yields (76% and 73%, respectively) as shown in 
Scheme 30.   
With access to tosylated acetals 125 and 126 on large scales (~ 4 g) and in good yields, 
the reaction with desmethyl-Tamoxifen could then be reattempted in order to access 
target compounds 119 and 120 and assess the benefits of fully synthesising the 
hydrophobic region before undertaking this step. Identical reaction conditions were 
utilised as previously discussed (THF, K2CO3, heated to reflux), with 1H NMR 
spectroscopic analysis revealing a complex mixture of products and starting materials. 
Purification of these two separate complex mixtures via silica gel column 
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chromatography resulted in the successful, although tedious, isolation of compounds 119 
and 120 in poor yields (21% and 16%, respectively, Scheme 31).  
Scheme 31. Synthesis of compounds 119  and 120  
Despite attempts at optimisation, such as varying the base, reaction time, solvent and 
temperature used and the purification eluents, no improvement to these yields were 
made. Although the amount of product isolated for compounds 119 and 120 was 
inadequate for ongoing physicochemical evaluation, a preliminary particle size 
measurement via DLS indicated the formation of nano-sized assemblies for both 
amphiphiles 119 and 120 of approximately 68 and 96 nm, respectively. While these 
measurements were not repeated in triplicate under the standard operating procedures 
established in Section 3.4.2 and, therefore, hydrodynamic diameters obtained cannot be 
reported with confidence, the presence of nano-sized aggregates was promising. This 
indication that the amphiphilic behaviour had not been disrupted by the addition of the 
hydrophobic Tamoxifen unit to the hydrophilic region prompted the investigation into a 
different linker moiety. A modification in the method of conjugating the Tamoxifen unit 
to the norbornane scaffold could lead to the synthesis of amphiphilic compounds bearing 
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the Tamoxifen unit in high enough yields to fully evaluate the physicochemical 
properties of assemblies derived from amphiphiles of this nature. 
4.3 Triazole Linker Tamoxifen Functionalised Amphiphiles 
The previous attempted synthesis of Tamoxifen functionalised amphiphiles highlighted 
the need for a conjugation method that yields the desired product in high yield with 
minimum side products. The use of “click chemistry” to reliably join the Tamoxifen unit 
to the norbornane scaffold would be highly advantageous due to the generality of 
reaction substrates and the formation of the intended products in high yields with little to 
no by-products.214  
During the 1960’s Husigen and co-workers215 reported a wide variety of 1,3-dipolar 
cycloadditions between azides and alkynes to give 1,2,3-triazoles.216 The vesicle 
formation of amphiphiles containing triazole units has been previously investigated by 
Bhattacharya and Biswas.217 As such, the inclusion of such a moiety as a linker group 
between the Tamoxifen unit and the norbornane scaffold of the desired amphiphile was 
deemed appropriate. 
With this alternative linker in mind, a new retrosynthetic pathway was designed 
incorporating a copper catalysed azide-alkyne cycloaddition (CuAAC) to afford triazole 
130 was devised. To access this triazole, azidation of the previously synthesised tosylate 
107 and the propagylation of desmethyl-Tamoxifen to give 131 would be undertaken to 
produce the required starting materials 132 and 131 for this featured synthetic step. 
Triazole-linked amphiphiles 127 and 128 would then be accessed from the now well 
established incorporation of the hydrophobic region via dihydroxylation and subsequent 
acetal formation.  
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Scheme 32. Retrosynthetic design of 2 nd generation amphiphiles bearing T amoxifen unit 
with triazole linker group 
Displacement of a tosylate by an azide ion can be utilised as an indirect method of 
converting an alcohol to an azide. Alkali metal azides, typically sodium azide, are 
commonly used as the azide source and give simple and high yielding access to alkyl 
azides (Scheme 33). 
 
Scheme 33. Azide displacement of tosylate moiety o n compound 107  to furnish azide 132  
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The reaction was initially performed with tosylate 107 dissolved in THF before the 
addition of sodium azide and the resulting solution and heated to reflux overnight. After 
aqueous workup, 1H NMR spectroscopic analysis indicated the presence of only starting 
materials, with the key resonances of the tosylate of multiplets at ~ δ 7.8 and 7.3 ppm 
and a singlet resonance at δ 2.41 ppm. The insolubility of sodium azide in organic 
solvents was attributed to this failure to react and as such the more polar solvent, DMF 
was used to replace THF as the reaction medium and heated to reflux.  
While analysis by 1H NMR spectroscopy of the crude material obtained showed the lack 
of  tosylate resonances, it also suggested the loss of the C=C bond due to the lack of the 
alkene resonance at ~ δ 6.00 ppm. Further examination of the literature revealed the 
susceptibility of azide addition via 1, 3- dipolar addition type reactions with strained 
alkene bonds present in bicyclic compounds as first reported by Alder and co-workers in 
the 1930’s.218,219 Scheiner and co-workers illustrated this occurrence with the example 
described in Scheme 34.220 
 
Scheme 34. Scheiner et al.220 demonstrated azide addition with norbornene 133  
Despite this, when the reaction was undertaken in a miscible organic/aqueous solvent 
system of acetonitrile and water (8:1) and at milder temperature, initial analysis by 1H 
NMR spectroscopy of the crude product obtained showed the desired product 132. 
Incorporation of the azide was confirmed by infrared spectroscopic analysis with the 
presence of the strong asymmetric stretch at ~ 2110 cm-1 indicative of an organic azide 
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moiety.221 Purification via silica gel column chromatography proved troublesome with 
several attempts resulting in the failed isolation of the desired product. As such, the 
crude product was immediately used in the subsequent steps without further purification.  
With the azide 132 now synthesised, attention turned towards the propargylation of 
desmethyl-Tamoxifen 102 to afford the alkyne 131 required for the successful “click” 
transformation. This alkyne could be easily accessed via treatment with propargyl 
bromide 136 as depicted in Scheme 35.  
 
Scheme 35. Propargylation of desmethyl  Tamoxifen 102  to afford alkyne 131  
Desmethyl Tamoxifen 102 was dissolved in toluene before the addition of propargyl 
bromide 136 and triethylamine. The resulting solution was stirred overnight at 80 °C and 
after aqueous workup and subsequent silica gel column chromatography, a white solid 
was obtained in a good yield of 76%. Analysis via 1H NMR spectroscopy revealed the 
triplet resonance associated with the alkyne moiety at ~ δ 2.20 ppm indicating the 
successful synthesis of alkyne 131.  
With azide 132 and alkyne 131 successfully furnished, the linking of the two molecules 
via a click transformation could then be investigated. 
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4.3.1 Copper Catalysed Azide-Alkyne Cycloadditon 
Nearly forty years after Huisgen and co-workers first published the 1, 3-dipolar 
cycloaddition to furnish triazoles,215 the discovery of a superior copper catalysed version 
was simultaneously reported by the independent groups of Sharpless and Meldal in 
2001.222,223 The use of a copper catalyst accelerated the reaction at room temperature by 
107 times and enabled it to proceed under aqueous conditions.224 Furthermore while the 
uncatalysed transformation yields a mixture of 1, 4- and 1, 5- regio-isomers, the copper 
mediated reaction exclusively furnishes only the 1, 4-triazole in excellent yields and 
purities that are independent of the steric or electronic natures of any substituents.216  
 
Scheme 36. Proposed mechanism of the CuAAC reaction  
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The proposed mechanism detailed in Scheme 36 has not yet been completely elucidated 
despite several investigations over the last decade, with the complexation of the Cu(I) 
species still under much debate.  
The first step in this mechanism is the co-ordination of alkyne 137 to copper, 
significantly acidifying the terminal hydrogen of the alkyne and thus, enabling it to be 
deprotonated in aqueous medium to form the Cu(I) acetylide intermediate 139. The 
azide is then co-ordinated to the Cu(I) acetylide species to form complex 141 which 
could be in the form of two intermediates, either A or B. Intermediate A is formed by the 
co-ordination of the acetylide and the azide to only one copper atom, while B denotes 
this co-ordination to different copper atoms which is also probable. While intermediate 
A is generally accepted to be the complex formed, this configuration does not account 
for several aspects of data obtained for this reaction. Intermediate B on the other hand 
could explain most of the observations obtained.225   
Transition states 142 C or D are then proposed after the key C-N bond forming event 
between the position 3 nitrogen and the acetylide moiety. The resulting Cu(I) triazole 
143 then rearranges to give the 1, 4-disubstuted 1,2,3-triazole 144.  
Scheme 37. CuAAC reaction with alkyne  131  and azide 132  to produce triazole 130  
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In order to join the previously synthesised halves, azide 132 and alkyne 131, the alkyne 
was dissolved in an aqueous solution of copper sulphate and saturated ascorbic acid 
before the addition of azide 132 and the reaction mixture was then heated via microwave 
irradiation for 30 minutes at 100 °C (Scheme 37). Microwave irradiation can 
significantly shorten reaction times of the copper catalysed azide-alkyne cycloaddition 
while maintaining excellent yields, purity and selectivity.216 After an aqueous workup, 
the crude material obtained was analysed via 1H NMR spectroscopy to reveal a mixture 
of unidentified products. In light of the previous problems with potential azide addition 
to the alkene moiety, it was determined that the formation of the hydrophobic region 
before the attempt of the click reaction would circumvent this issue (Scheme 38). With 
azides 145 and 146 easily accessed from tosylates 125 and 126, respectively, previously 
synthesised on large scales in Section 4.2. 
 
Scheme 38. Azidation of compound 125  and 126   
Using the conditions previously established as optimal (pg. 131), tosylates 125 and 126 
were treated with sodium azide and the resulting crude products were analysed by 1H 
NMR spectroscopy that confirmed no key resonances from the tosylate moiety were 
present. Again, infrared spectroscopic analysis confirmed the successful formation of the 
organic azides 145 and 146 with the presence of the strong asymmetric stretch at 2108 
and 2112 cm-1, respectively. While crude mass recovery was promising (89% and 91% 
respectively), purifications associated with the earlier synthesised azide 132 were also 
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problematic in these cases, with the isolation of compounds 145 and 146 proving 
impossible. Since their crude purities were > 85% by 1H NMR spectroscopy, these 
azides were used in the subsequent steps immediately and purified thereafter. 
With azides 145 and 146 in hand, attention turned towards the CuAAC reaction between 
these two components.  Initially this reaction was undertaken with azide 146 at room 
temperature overnight, using a copper sulphate/ascorbic acid system. After aqueous 
work-up, 1H NMR spectroscopic analysis showed resonances attributed to only the 
starting materials, indicating the reaction had not proceeded to any observable degree. 
Given literature success with the use of microwave irradiation,216 the reaction was 
repeated with the same conditions, however, this time the reaction was heated at 100 °C 
for 30 minutes using microwave irradiation. Upon inspection of the 1H NMR spectra, it 
was evident that the reaction had occurred due to the strong presence of the key 
resonance at ~ δ 7.6 ppm corresponding to the aromatic proton of the triazole moiety. 
The crude product was then purified using silica gel column chromatography to isolated 
triazole 128 in a moderate yield of 51%. It was envisioned that this moderate yield could 
be improved with modifications in the copper source, temperature and reaction time, and 
as such, a number of optimisation reactions were performed as outlined in Table 12.  
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Table 12. Optimisation of CuAAC reaction with azides 145  and 146  
Entry Product m Catalysta Solvent 
Temp 
(°C) 
Timeb 
(hrs) 
Yield 
(%) 
1 128 14 CuSO4c H2O rt 16 -d 
2 128 14 CuSO4c H2O 100 0.5 51 
3 128 14 CuSO4c H2O 100 1 40 
4 128 14 Cu2O CHCl3 70 0.5 - d 
5 128 14 CuCl CHCl3 rt 16 7 
6 128 14 CuCl CHCl3 70 0.5 61 
7 128 14 CuCl CHCl3 100 0.5 68 
8 127 10 CuCl CHCl3 100 0.5 50 
a Loading is 10 mol% 
b Heated using microwave irradiation unless at room temperature 
c Ascorbic acid added (20 mol%)  
d Starting materials were recovered 
 
Interestingly, an extension of reaction time to 1 hour (Table 12, entry 3) decreased the 
yield by 11%, while a change in copper source to copper (I) oxide in an organic solvent 
(Table 12, entry 4) resulted in only starting materials being recovered. Copper (I) 
chloride in chloroform was then used at room temperature resulting in a low yield of 7% 
(Table 12, entry 5) and increasing the temperature to 70 °C under microwave irradiation 
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for 30 minutes resulted in an increase in yield to 61% (Table 12, entry 6). A further 
increase in reaction temperature produced triazole 128 in a good yield of 68% (Table 12, 
entry 7). The application of these reaction conditions for azide 145 furnished triazole 
127 in a good yield of 50% (Table 12, entry 8). 
Both amphiphiles 127 and 128, bearing the Tamoxifen unit through a triazole linker, 
were able to be synthesised and purified in moderate yields resulting in a significantly 
improved overall yield for the entire synthetic pathway. The use of a triazole linker 
joined by the popular CuAAC click reaction furnished amphiphiles 127 and 128 in 
sufficient quantity (> 100 mg) to pursue the evaluation of the aqueous physicochemical 
properties of these amphiphiles. In light of these evaluations, amphiphiles 127 and 128 
were converted to their corresponding hydrochloride salts using gaseous HCl as 
described in Section 2.5 and lyophilised to obtain dry, homogenous powders.  
4.4 Physicochemical Evaluation 
With powders of 127 and 128 in hand, the focus of this study turned to the evaluation of 
the important physicochemical properties of these amphiphiles. As with the previous 
amphiphilic library, the determination of the CAC, DH and the visualisation of the 
morphology of the resulting self-assemblies were of importance in determining the 
potential of these systems to drug delivery applications.  
Compounds 127 and 128 were formulated into colloids, as per previously described in 
Section 3.2, and were found to display adequate solubility at the concentrations required 
for the determination of their physicochemical properties. This was fortunate as the 
incorporation of the hydrophobic Tamoxifen unit on the hydrophilic region of the 
amphiphile may have presented some significant challenges in regards to overall 
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aqueous solubility. Following the success of determining the CAC values of the previous 
set of amphiphiles using the pyrene encapsulation method (Section 3.3.3), this technique 
was used to evaluate the concentration at which self-assembly occurs for compounds 
127 and 128. An abrupt change in the curve obtained was observed for both compounds 
127 and 128 indicating aggregation (the plot for 127 is shown in Figure 36). Thus 
indicating that the addition of the hydrophobic Tamoxifen unit to the hydrophilic region 
of the amphiphile has not significantly disrupted the hydrophilic/hydrophobic balance 
that is necessary for self-assembly. 
 
Figure 36.Graphical representation of the change in I I:I I I I  with increasing concentration 
for compound 127  
The CAC values obtained are considered low enough to withstand dilution in the 
bloodstream and, as such, demonstrate potential for drug delivery purposes, however, 
significant differences in CAC between the two compounds can be observed (Table 13).  
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Table 13. Physicochemical evaluation of compounds 127  and 128  
Entry Compound m CAC (μmol/L) DH (nm)a PDI 
1 127 10 510 56 0.174 
2 128 14 19 106 0.226 
a Hydrodynamic diameter determined at 10 × the CAC value at 25 °C with volume distribution 
 
As can be seen, these amphiphiles behave much more like traditional surfactant systems 
with amphiphile 128 displaying a CAC that was 27 times lower than that of its less 
hydrophobic counterpart, 127. The two ethylene units distinguishing 127 from 128 
should typically result in a 16-25 fold decrease in CAC for the latter.177 The very low 
CAC value obtained for 128 was expected since the increase in hydrophobicity in the 
alkyl chain as well as the addition of the Tamoxifen unit should result in a decrease in 
CAC. However, 127 possessed a significantly higher CAC value than the previous 
library of amphiphiles (510 μmol/L versus 50-70 μmol/L). This is surprising as the 
Tamoxifen unit on the head group of the amphiphile should contribute to an increased 
overall hydrophobicity and, in turn, produce a CAC value much lower than the 
amphiphiles without this moiety. Given these results it is apparent that with an extension 
of the alkyl chain of two ethylene units the hydrophobic/hydrophilic balance is 
significantly changed with the shorter chain length 127. This is evident by 127  
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displaying a CAC value that is consistent with the Tamoxifen unit having no 
hydrophobic effect on the overall self-assembly ability. 
With these values in mind, the hydrodynamic diameter of the aggregates formed from 
compounds 127 and 128 were determined using dynamic light scattering at 10 times the 
CAC as previously described in Section 3.4.2. The self-assemblies of both compounds 
were found to be moderately polydispersed with an average hydrodynamic diameter of 
59 nm and 106 nm respectively, and low PDI’s as indicated by Table 13. The particle 
diameters obtained are within the suitable range for passive drug delivery to tumour 
tissue via the EPR effect and, like the first generation of amphiphiles, were found to 
keep a consistent size distribution over a period of three weeks providing the sample was 
sonicated briefly 12 hours prior to measurement. 
To evaluate the morphology of these aggregates, Cryo-TEM was again employed, and 
undertaken by Lynne Waddington of CSIRO under conditions described in Section 
7.3.3.  
Visualisation of compound 127 revealed polydispersed liposomal aggregates ranging 
from approximately 100-400 nm in size with bilayers of 4-5 nm (Figure 37, main). 
While these aggregates are larger than the hydrodynamic diameter observed, the high 
polydispersity observed through cryo-TEM can account for this variation in sizes 
measured by the two techniques. The DLS technique becomes problematic when a high 
variation in particle size is present within a sample, as further described in Appendix A. 
Some of the liposomal structures were fused to spherical self-assembled aggregates with 
no observable fine structures as shown in Figure 37 (insert). 
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Figure 37. Cryo-TEM visualisation of compound 127  showing liposomal assemblies 
ranging from 100 - 400 nm in size (main) and fused self-assemblies (insert)  
When compound 128 was visualised in the same manner, only diffuse spherical 
amorphous aggregates with no defined lamellar, micellar or liposomal structure were 
observed (Figure 38).  
Figure 38. Cryo-TEM of compound 128  showing spherical amorphous aggregates with no 
defined lamellar, micellar or liposomal structure  
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This lack of organised self-assembly for 128 is most likely caused by the incorporation 
of the hydrophobic Tamoxifen unit to the hydrophilic region of the amphiphile. While 
the balance of hydrophobic and hydrophilic forces remain agreeable for the formation of 
aggregates for compound 127, the addition of a more hydrophobic aliphatic chain may 
cause a large global increase in lipophilicity and, in turn, results in the compounds loss 
of defined amphiphilic nature. Being highly lipophilic at both ends of the molecule 
would inhibit an ordered self-assembly process, and thus, cause a disordered amorphous 
assembly similar to those observed though would still provide a CAC value. Future 
work to overcome this issue would be the investigation of oxyethylene spacer units of 
varying lengths as well as the modification of the cationic linker to include a more 
hydrophilic portion. 
While the properties evaluated show promise for the successful application of compound 
127 to chemotherapeutic delivery to tumour tissue via passive delivery, the 
characteristics investigated cannot measure the receptor-mediated targeting delivery 
ability that these compounds are hypothesised to possess. As such, this chapter has 
presented a proof of concept that an estrogen-receptor ligand can be incorporated onto 
the head group of the amphiphilic structure and still self-assemble into liposomes 
displaying properties desirable for drug delivery applications. However, careful 
consideration in the balance of hydrophobic and hydrophilic regions is required for the 
successful ordered self-assembly. Further investigation utilising specific receptor 
targeting techniques would be required to accurately determine the receptor targeting 
ability of these compounds. 
500 nm 
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The data presented in this chapter has been published within;  Squire, J. S.; Durand, G.; 
Waddington, L.; Sutti, A.; Henderson, L. C. Temperature responsive self-assemblies of 
“kinked” amphiphiles. Aust. J. Chem. 2013, 66, 899. 
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Chapter 5 
Investigations into stimuli controlled release 
properties of 1st and 2nd generation colloidal 
assemblies 
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Chapter 5  
With the physicochemical evaluation of compounds 82-85, 98-99 and 127 showing their 
self-assemblies to possess the physical characteristics of potential drug delivery systems, 
attention turned towards investigating other properties which could induce the release of 
any encapsulated pharmaceutical within the self-assemblies (Figure 39). 
Figure 39. Schematic representation of the controlled release of cargo using heat  
While the self-assemblies in this study show ideal size, morphology and CAC for the 
successful delivery of a pharmaceutical into tumour tissue via passive and, for 
compound 127, potentially active targeting, the challenge is then to selectively liberate 
encapsulated cargo (Figure 39). The goal of this approach is for the liposome to reach its 
biological target without any prior, unwanted cargo leakage into healthy tissue, leading 
to off-target side effects. A controlled cargo  release presents the main obstacle for many 
liposomal drug delivery systems, however, research in this area remains abundant, and 
various methods of controlling release have been investigated.226-229 
There are two main types of controlled release strategies employed, the first takes 
advantage of environmental stimuli that are unique to tumour tissue, for example, the 
slightly acidic pH or changes in redox environment due to glutathione concentrations, 
while the second utilises externally applied stimuli such as temperature, magnetic field 
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or ultrasound after accumulation of the liposomes within the tumour tissue via the EPR 
effect.230,231  
5.1 Temperature Stimulated Release 
The use of temperature stimuli as an external or “remote” trigger is fast becoming a 
popular approach to overcoming the significant challenges associated with the controlled 
release of liposomal encapsulated pharmaceuticals.232 The concept of temperature 
sensitive liposomes that will release their cargo at a targeted site, due to applied 
temperature, was first introduced by Yatvin and co-workers in 1978.233 They 
hypothesised that while the liposomes would be stable at normal physiological 
temperatures, at elevated temperatures the liposomal wall would be permeable to the 
encapsulated cargo.  
 
Figure 40. Schematic representation of drug release from temperature responsive 
liposomes 
 
Yatvin and co-workers theorised that upon heating, the amphiphile head groups become 
more mobile and as the temperature continues to increase the hydrophobic chains 
change their orientation from a gel-like crystalline state to a liquid-like disordered state 
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(Figure 40).227 This phase transition allows leaky interface regions to develop at the 
boundaries between the motionless solid domains and the melting liquid domains which 
then allow the release of the encapsulated materials (Figure 40). 
Additionally, the benefits of administering mild hyperthermia alongside radio- and 
chemotherapies has been established over the past twenty years with a synergistic effect 
between heat and chemotherapy showing improved patient outcomes when compared to 
chemotherapy alone.227 Heating the tumour tissue above normal body temperature 
(typically between 40-45 °C) promotes blood flow to the tumour tissue and increases 
vascular permeability compared to normal tissue.234  Additionally, the increased 
temperature disrupts various biological functions of the cancer cells without affecting 
normal cells. The required heat stimulus can be achieved by focussed ultrasound 
irradiation or a radiofrequency electrode implantation at the tumour site.229 
An excellent example of a temperature sensitive liposome exhibiting successful 
controlled release of a chemotherapeutic is the liposome formulation ThermoDox®. 
Introduced by Needham and co-workers in 1999,  currently in Phase III clinical trials for 
hepatocellular carcinoma and Phase II trials for breast cancer and colorectal liver 
metastases.229 This liposomal formulation comprises of the lipids 
dipalmitoylphosphatidylcholine (DPPC), monostearoylphosphatidylcholine (MSPC) and 
PEG 2000-DSPE in 90:10:4 molar ratio, a combination which exhibits a gel-to-liquid 
phase transition at approximately 41 °C making it ideal for hyperthermic treatment.235  
Of the many stimuli to investigate as potential methods for assembly changes, in this 
project, heat was chosen as it was easy to monitor aggregate behaviour at variable 
temperature while still being relevant to the cause at hand. It was determined that the 
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investigation into temperature dependent assembly behaviour would provide adequate 
insight into the potential for these drug delivery systems to release their contents in a 
controlled manner. The monitoring of the hydrodynamic diameter by DLS over a range 
of temperature changes provided a simple and efficient means of examining the effect 
that temperature imposes on these aggregates and while this technique does not 
investigate the release of encapsulated material with the increase in temperature, it is an 
ideal first step in determining the suitability of these compounds for this purpose. 
The self-assemblies from compounds 82-85 characterised in Chapter 3 were deemed 
appropriate for this study and, as such, were formulated in colloidal suspensions as 
described for the previous DLS experiments in Section 3.4.2. The hydrodynamic 
diameters of the assemblies were measured from 5-55 °C in increments of 10 °C, with a 
3 minute equilibration time at each temperature. The average hydrodynamic diameter 
from ten scans was taken at each temperature increment and the entire collective 
experiment was repeated in triplicate with fresh samples to ensure consistency in any 
changes observed.  
 
Figure 41. Four compounds selected for temperature stimuli investigation  
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As can be observed from Graph 4, the self-assemblies from compounds 82 and 84, 
bearing the identical shorter aliphatic chain (m = 10), demonstrated consistant 
hydrodynamic diameters (30-60 nm) over the temperature range of 5-45 °C. However, 
dramatic changes were observed in both cases when heated further to 55 °C, whereby 
the diameter size of the assemblies increased by a factor of approximately three (140-
160 nm). 
Graph 4. Observed changes in hydrodynamic diameter of amphiphiles 82  and 84  with 
increasing temperature  
Interestingly, compounds 83 and 85, bearing the longer aliphatic chain (m = 14), showed 
a reverse of this trend (Graph 5). A sharp decrease of hydrodynamic diameter, by a 
factor of two and six, respectively, was observed over the temperature ranges of 25-
35 °C and 45-55 °C, respectively. The approximate 10 °C difference in the onset of the 
thermal transition for 83 compared to 85 can only be attributed to the ethylene extension 
of the alkyl spacer (n) separating the head group with the norbornane core. 
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Graph 5. Observed changes in hydrodynamic diameter of amphiphiles 83  and 85  with 
increasing temperature  
 
Since the duration of these experiments can be up to 5 hours, confirmation that these 
transitions are indeed temperature induced and not the result of equilibration during the 
experiment was required. Therefore a time lapse experiment was undertaken on all 
compounds with a consistent temperature of 25 °C and the hydrodynamic diameters 
were monitored over the same time period as the previous variable temperature 
investigations. In these cases, no change in diameter was observed for all compounds 
82-85 indicating that the changes observed are indeed temperature dependent. 
Considering the hydrophobic region of these self-assemblies, we attributed the observed 
changes in hydrodynamic diameter, displayed by 82-85, to be the result of a gel-to-liquid 
transition in the lipid phase.  This phenomenon has been observed in other self-
assemblies and at similar temperatures as reported by Ta and Koning et al.236-238 
In addition to the time lapse study, the temperature experiments were also run in reverse, 
with the temperature decreasing from 55 °C to 5 °C. Surprisingly, the same size 
hydrodynamic diameters were observed at each temperature for the reverse temperature 
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range, further confirming the existence of changes in aggregate behavior with 
temperature differences. These forward and backward thermal studies were conducted 
on freshly prepared colloid suspensions and on samples that had previously been heated 
and cooled before measurement. In all cases a consistent behavior was observed 
indicating that the transitions produced are indeed reversible and reproducible.  
Similar investigations into the behavior of the assemblies of compounds 127 and 128 
(Figure 42) with variable temperature were also undertaken. Compound 127, bearing the 
shorter aliphatic chain (m = 10), demonstrated a similar temperature response to that of 
compounds 82 and 84 also bearing the shorter alkyl chain (Graph 6). 
 
Figure 42. Tamoxifen bearing amphiphiles 127  and 128 
In this case, the hydrodynamic diameter steadily increased with the increase in 
temperature before becoming more pronounced when heating the colloid from 35-55 °C, 
resulting in a rapid transition in size from 79 to 118 nm. This particular trend where 
hydrodynamic diameter increases with increasing temperature, is presumably 
determined by the hydrophobic region of the amphiphiles as m = 10 is the only common 
feature between compounds 82, 84 and 127. 
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 Graph 6. Observed changes in hydrodynamic diameter of tamoxifen bearing amphiphile 
127  with temperature  
No observable change in hydrodynamic diameter was measured at any temperature 
when compound 128 was investigated in the same manner. Given the non-liposomal 
morphology observed by cryo-TEM (Figure 38, Section 4.4) this was not surprising as a 
non-organised amorphous aggregate would not likely possess a corresponding sharp 
transition temperature indicating a gel-to-liquid phase transition. 
In an attempt to determine the nature of this thermal transition, a range of differential 
scanning calorimetry (DSC) studies were undertaken on these amphiphiles over a wider 
temperature range (5-100 °C) at scan rates of 5 and 10 °C/min.  DSC was conducted on 
both the aqueous colloid and the solid amphiphiles as powders, however, no thermal 
transitions were detected within this temperature range at either scan rate or sample. The 
lack of thermal transition was attributed to the bulk solid material not being 
representative of the self-assembly in an aqueous environment, while the aqueous 
colloid may not contain enough of the amphiphile to give a measureable thermal change 
by DSC.  The latter point is highly likely since the CAC values for compounds 82-85 are 
very low. 
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These size changes with temperature increase indicate that there is potential for a 
controlled release aspect of these colloidal drug delivery systems. Whilst further in vitro 
and in vivo studies are needed to confirm the suitability of these assemblies to deliver 
pharmaceuticals to tumour tissues, these initial physiochemical evaluation findings are 
promising with compounds 82, 84 and 127 displaying an increase in hydrodynamic 
diameter within the temperature range of 35-45 °C. Conversely to this trend observed, 
compounds 83 and 85 with the longer aliphatic chain (m = 14) demonstrated a decrease 
in hydrodynamic diameter over similar temperature ranges. The transitions observed all 
occur in a useable range of temperatures and the dependence on the hydrophobic portion 
of the amphiphiles observed for these transitions indicate a possible avenue for the 
tailoring of these compounds to possess finer tuned transition temperatures. 
These investigations have been presented in a recent publication, Squire, J. S.; Durand, G.; 
Waddington, L.; Sutti, A.; Henderson, L. C. Temperature responsive self-assemblies of 
“kinked” amphiphiles. Aust. J. Chem. 2013, 66, 899. 
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Concluding Comments 
A synthetic pathway was designed and established to afford amphiphiles possessing a 
rigid norbornane core linking the hydrophobic and hydrophilic regions. The synthetic 
pathway was designed to allow modifications of the hydrophilic and hydrophobic 
portions in an easy and versatile manner to permit systematic changes in the position of 
the “kink” imparted by the rigid norbornane scaffold as detailed by Scheme 39. 
 
Scheme 39. Synthetic pathway of 1st  generation of amphiphiles bearing norbornane 
scaffold 
Highlights of this synthesis include the easy modification of the ammonium head group 
to include a variety of different spacer lengths (n) via dehydration of norbornene 
anhydride with various diamines. The Upjohn dihydroxylation was used to afford an 
exo-vic-diol moiety that provides a synthetic ‘handle’ to connect the hydrophobic region 
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through a cyclodehydration to give 1, 3-dioxolanes (acetals). This hydrophobic region 
can be easily modified with aldehydes of varying (m) lengths to give one, or potentially 
replaced with a ketone, to provide two hydrophobic chains. 
 
Figure 43. Ten amphiphiles, 82-89  and 98-99  were synthesised with varying m and n 
regions 
From this synthesis, ten amphiphiles were furnished bearing systematic modifications in 
(n) and (m) values, as well as variations in the composition of the spacer chain between 
the head group and linker scaffold, as outlined in Figure 43.  
From this first amphiphilic library, six compounds were then selected to undergo 
physicochemical evaluation to access their suitability as a potential drug delivery system 
(Table 14). In order to physically characterise the colloidal self-assemblies formed when 
compounds 82-85 and 98-99 were formulated into water, several physicochemical 
properties needed to be investigated. These included determination of the overall 
lipophilicity of the compound using predicted logP values and experimentally obtained 
logkʹw, the critical aggregation concentration (CAC), hydrodynamic diameter (via 
dynamic light scattering) and self-assembly morphology using TEM and Cryo-TEM. 
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 Table 14. First generation of amphiphiles synthesised bearing a norbornane  
 scaffold linker group  
Entry Compound n m logPa logkʹwb 
CACc 
(μM) 
DHd 
(nm) 
1 82 1 10 1.77 1.01 70 ± 5 59 
2 83 1 14 3.28 1.13 50 ± 7 79, 24 
3 84 2 10 2.00 0.89 70 ± 2 142 
4 85 2 14 3.44 1.18 60 ± 7 91 
5 86 4 10 3.13 1.25 - - 
6 87 4 14 4.22 1.30 - - 
7 88 5 10 3.66 1.33 - - 
8 89 5 14 4.65 1.33 - - 
9 98 ((CH2)2O)2CH2 10 1.91 1.119 254 ± 53 220 
10 99 ((CH2)2O)2CH2 14 3.29 1.1893 82 ± 3 7 
a Determined by AlogPs software 
b Determined by RP-HPLC 
c Determined by pyrene fluorescence method 
d Hydrodynamic diameter determined at 10 × the CAC value at 25 °C with volume distribution 
 
 
These physicochemical investigations revealed several interesting properties of the 
colloidal self-assemblies of the compounds chosen, with amphiphiles 82-85 observed to 
have CACs that were fairly insensitive to variations made in the chemical structure in 
direct contrast to traditional surfactants. While compounds 98 and 99 exhibited CAC 
values that aligned more closely with traditional single tailed surfactants, the difference 
between the two CAC values were not of the magnitude commonly observed with other 
systems. Furthermore, through dynamic light scattering it was shown that the self-
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assemblies of these compounds formed aggregates that showed a large variation of sizes 
and morphologies with structural changes in (n) and (m). With various extensions of 
alkyl chain lengths of (n) and (m) for compounds 82-85 a range of self-assembly sizes 
(59 nm-142 nm) were accessed and by incorporating an dioxyethylene unit within (n) a 
large variation in aggregate size was observed when increasing the length of (m) 
(compound 98 vs. 99). Visualisation via TEM and Cryo-TEM confirmed these sizes and 
confirmed the formation of spherical vesicles for compounds 82, 84 and 85, however, 
rod-like vesicles were found to be the dominate feature for compound 83. The two 
compounds possessing the dioxyethylene unit (98 and 99) were shown to form micelles 
rather than vesicles.  
With the first generation of norbornane amphiphiles demonstrating a wide variety of 
tailor-able assemblies with small modifications to amphiphilic structure, focus turned 
towards developing a targeted drug delivery system for the treatment of breast cancer 
tumours.  By incorporating the estrogen receptor antagonist, Tamoxifen, via a linker 
group, onto the hydrophilic region of the amphiphile, self-assemblies with peripheral 
targeting ligands were synthesised with variations in the linker group (tertiary amine or 
triazole linker) and the length of the hydrophobic portion (m). Various synthetic routes 
were undertaken to access these Tamoxifen functionalised amphiphiles (Scheme 40). 
Attempts to access amine linked 119 and 120 through pathway A proved fruitless and so 
the alternative pathway B was explored. While this route was successful in synthesising 
compounds 119 and 120, they were isolated in poor yields and, as such, an alternative 
triazole linker was investigated. Access to triazoles 127 and 128 through pathway C was 
also problematic, however, these compounds  were successfully synthesised in good 
yields via pathway D. 
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Scheme 40. Synthesis of Tamoxifen functionalised amphiphiles 119-120  and 127-128  
showing divergence due to problems encountered  
Compounds 127 and 128 were then subjected to the same physicochemical 
investigations as the previous library. These compounds behaved much more like 
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traditional surfactants, with the CAC value for amphiphile 127 being approximately 27 
times higher than that of 128.  The DH of these compounds were also determined by 
DLS at room temperature and were found to be 56 nm and 106 nm for 127 and 128, 
respectively.  Cryo-TEM of 127 showed liposomal aggregates of sizes larger than that 
obtained via DLS while compound 128 showed only the presence of diffuse spherical 
amorphous aggregates with no defined lamellar, micellar or liposomal structure. This 
observation of no liposomal or lamellar structure to the aggregates of 128 is attributed to 
the modification of the polar head group, with the increase in hydrophobicity disrupting 
the ordered self-assembly process.  
In addition to the physicochemical evaluation of the synthesised amphiphiles, 
investigation into further properties that could indicate the successful controlled release 
of any encapsulated pharmaceutical within the aggregates was undertaken. 
Graph 7. Observed changes in hydrodynamic diameter of amphiph iles 82-85  with increase 
in temperature  
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Investigations into assembly behavior over a range of temperatures (5-55 °C) were 
undertaken using DLS to monitor any changes of the hydrodynamic diameter of 
assemblies from compounds 82-85 and compound 127. It was observed that for the 
amphiphiles bearing the C12 aliphatic chain (m) (82, 84 and 127) the hydrodynamic 
diameter dramatically increased over 45 °C to 55 °C by a factor of ~ 3. Conversely 
compounds 83 and 85 displayed a decrease in hydrodynamic diameter by a factor of 2 
and 6 over the ranges of 25-35 °C and 35-55 °C, respectively (Graph 7). 
While no actual release of encapsulated material was investigated, the size changes 
observed with temperature increase indicates that there is potential for a controlled 
release aspect of these colloidal drug delivery systems. Whilst further in vitro and in vivo 
studies are needed to confirm the suitability of these assemblies to deliver 
pharmaceuticals to tumour tissues, these initial physiochemical evaluation findings are 
promising.  
In conclusion, this project has established a versatile synthetic methodology for the 
production of amphiphiles bearing various structural modifications including the 
incorporation of a targeting ligand. These amphiphiles were evaluated for their 
suitability towards drug delivery and were found to not only possess adequate properties 
for the passive delivery of pharmaceuticals into tumour tissue, but also exhibit promising 
temperature dependent qualities that indicate the potential ability to control the release 
of these encapsulated pharmaceuticals.  
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Experimental 
7.1 Chapter 2  
7.1.1 General Experimental 
All 1H and 13C NMR spectra were recorded on a Jeol JNM-EX 270 MHz, or Eclipse 400 
MHz FT-NMR 400 MHz as indicated. Samples were dissolved in deuterated chloroform 
(CDCl3) with the residual solvent peak used as an internal reference (CDCl3 – δH 7.26 
ppm or DMSO – δH 2.5 ppm). Proton spectra are reported as follows: chemical shift δ 
(ppm), (integral, multiplicity (s = singlet, br s = broad singlet, d = doublet, dd = doublet 
of doublets, t = triplet, q = quartet, m = multiplet), coupling constant J (Hz), proton 
assignment). 
Thin Layer Chromatography (TLC) was performed using aluminium-backed Merck 
TLC Silica gel 60 F254 plates, and samples were visualised using 254 nm ultraviolet 
(UV) light, and potassium permanganate/potassium carbonate oxidising dip (1:1:100 
KMnO4:K2CO3:H2O w/w).  
Column chromatography was performed using silica gel 60 (70-230 mesh). All solvents 
used were AR grade. Specialist reagents were obtained from Sigma-Aldrich Chemical 
Company and used without further purification.  Petroleum spirits (pet. spirits) refers to 
the fraction boiling between 40-60 °C. 
High Resolution Mass Spectra (HRMS) were recorded on a 6210 MSD TOF mass 
spectrometer (Agilent Technologies, Australia) or LC Agilent 1200 MS 6520 QTOF 
with dual electrospray ionization source with the following conditions: drying gas 
nitrogen (7.0 L/min, 325 ºC); nebuliser gas nitrogen (15 psi); capillary voltage 3.0 kV; 
vaporiser temperature 29 ºC; and cone voltage 40 V.  Methanol was used as the mobile 
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phase.  Samples were dissolved in methanol, with less than 1 mg of sample per mL of 
solvent. 
Fourier transform infrared (FT-IR) spectra were recorded on a Bruker ALPHA Platinum 
ATR FT-IR Spectrometer. The following abbreviations apply to peak intensity: w = 
weak, m = medium, s = strong, br = broad. 
Microwave reactions were conducted using a CM Discover S-Class Explorer 48 
Microwave Reactor, operating on a frequency of 50/60 Hz and continuous irradiation 
power from 0 to 200 W. All reactions were performed in 10 mL or 35 mL septa vials 
with snap caps, with the following conditions: pressure (17 bar); power max (off); and 
stirring (high). 
7.1.2 Synthesis of 1st generation of amphiphiles 82-89 
Synthesis of norbornene anhydride 21 
Maleic anhydride 23 (3.88 g, 39.6 mmol) was dissolved in a solution of 1:1 
EtOAc/petroleum spirits (80 mL) before being cooled to 0 ºC. Cyclopentadiene 24 (2.6 
g, 39.6 mmol) was added drop-wise and the resulting solution stirred at 0 ºC until a 
precipitate was formed. The suspension was then heated to 80 ºC until this precipitate 
was re-dissolved and the solution left overnight to recrystallise. Subsequent filtering and 
washing with ice cold petroleum spirits resulted in white crystals that were shown by 1H 
NMR spectroscopy to be consistent with literature values239 for the desired norbornene 
anhydride 21 (5.67, 87%) in > 95% purity which was then used without further 
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purification. 1H NMR (270 MHz, CDCl3): δ 6.31 (2H, s, H8 H9), 3.56 (2H, m, H2 H6), 
3.50 (2H, m, H1 H7), 1.76 (1H, s, H10), 1.54 (1H, s, H10). 
Synthesis of N-(benzyloxy carbonyl)-1,4-butanediamine 35 
A solution of 1,4-diaminobutane 30 (5.72 mL, 56.7 mmol) in CH2Cl2 (100 mL) was 
cooled to 0 ºC and a  solution of benzylchloroformate 28 (1.62 mL, 11.3 mmol) and 
CH2Cl2 (150 mL) was added dropwise over 1 hr.  The reaction was then stirred at rt for 
24 hrs. The resulting mixture was transferred to a separating funnel where it was washed 
with saturated aqueous NaCl (3 × 30 mL).  The organic phase was dried (MgSO4), 
filtered and solvents removed in vacuo to afford a white powder.  1H NMR spectroscopy 
data was found to be consistent with literature values126 for the desired 
monobenzylcarbamate diamine 35 (2.07g, 82%) in > 95% purity which was then used 
without further purification. 1H NMR (270 MHz, CDCl3): δ 7.33-7.29 (5H, m, Ar-H), 
5.06 (2H, s, H8), 3.73 (2H, s, H5), 3.15 (2H, s, H3), 2.66-2.60 (2H, m, H4), 1.29 (2H, s, 
H1), NH not observed. 
Synthesis of N-(benzyloxy carbonyl)-1,2-diaminoethane 34 
Synthesis of N-(benzyloxy carbonyl)-1,2-diaminoethane 34 was carried out as per 
previously described for N-(benzyloxy carbonyl)-1,4-butanediamine 35, with 1,2-
diaminoethane  29 (6.67 mL, 0.10 mol) and benzylchloroformate 28 (2.85 mL, 0.02 mol)  
to afford a white paste. 1H NMR spectroscopic data was found to be consistent with 
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literature values126 for the desired monobenzylcarbamate diamine 34 (3.48g, 90%) in > 
95% purity which was then used without further purification. 1H NMR (270 MHz, 
CDCl3): δ 7.36-7.29 (5H, m, Ar-H), 5.10 (2H, s, H6), 3.20-3.22 (2H, m, H3), 2.83-2.75 
(2H, m, H2), 1.30 (2H, s, H1), NH not observed. 
Synthesis of N-(benzyloxy carbonyl)-1,8-octyldiamine 36 
Synthesis of N-(benzyloxy carbonyl)-1,8-octyldiamine 36 was carried out as per 
previously described N-(benzyloxy carbonyl)-1,4-butanediamine 35, with 1,8-
diaminooctane 31 (3.00 g, 0.021 mol) and benzylchloroformate 28 (0.6 mL, 4.2 mmol)  
to afford a white powder. 1H NMR spectroscopy data was found to be consistent with 
literature values126 for the desired monobenzylcarbamate diamine 36 (0.985 g, 84%) in > 
95% purity which was then used without further purification. 1H NMR (270 MHz, 
CDCl3): δ 7.16-7.11 (5H, m, Ar-H), 4.89 (2H, s, H12), 3.58 (2H, m, H9), 2.95-2.91 (2H, 
m, H2), 2.50-2.45 (2H, m, H3), 1.26-1.23 (2H, m, H1), 1.11 (10H, br s, H4-H8), NH not 
observed. 
Synthesis of N-(benzyloxy carbonyl)-1,10-decyldiamine 37 
Synthesis of N-(benzyloxy carbonyl)-1,10-decyldiamine 37 was carried out as per 
previously described for N-(benzyloxy carbonyl)-1,4-butanediamine 35, with 1,10-
diaminodecane 32 (1.00 g, 5.80 mmol) and benzylchloroformate 28 (0.17 mL, 1.20 
mmol)  to afford a white powder. 1H NMR spectroscopy data was found to be consistent 
with literature values126 for the desired monobenzylcarbamate diamine 37 (0.208 g, 
168 
 
57%) in > 95% purity which was then used without further purification. 1H NMR (270 
MHz, CDCl3): δ 7.34-7.30 (5H, m, Ar-H), 5.08 (2H, s, H14), 3.77 (2H, m, H11), 2.63-
2.60 (2H, m, H2), 1.46-1.40 (4H, m, H3 H4), 1.26 (14H, br s, H1 H5-H10), NH not 
observed. 
Synthesis of N-(benzyloxy carbonyl)-1,12-dodecyldiamine 38 
Synthesis of N-(benzyloxy carbonyl)-1,12-dodecyldiamine 38 was carried out as per 
previously described for N-(benzyloxy carbonyl)-1,4-butanediamine 35,  with 1,12-
diaminododecane 33 (2.00 g, 0.010 mol) and benzylchloroformate 28 (0.28 mL, 0.002 
mol)  to afford a white powder. 1H NMR spectroscopy data was found to be consistent 
with literature values126 for the desired monobenzylcarbamate diamine 38 (0.556 g, 
83%) in > 95% purity which was then used without further purification. 1H NMR (270 
MHz, CDCl3): δ 7.33-7.29 (5H, m, Ar-H), 5.08 (2H, s, H16), 3.77 (2H, m, H13), 3.15 
(2H, m, H2), 2.68-2.60 (2H, m, H3), 1.47-1.41 (4H, m, H4 H5), 1.25 (16H, br s, H1 H6-
H12), NH not observed. 
Synthesis of N-(benzyloxycarbonylaminobutyl)-4-aza-tricyclo[5.2.1.02,6]dodec-3,5-
one 44 
To a 35 mL microwave vial containing mono-protected diaminobutane 35 (873 mg, 3.90 
mmol), norbornene anhydride 21 (430 mg, 2.6 mmol) was dissolved in toluene (15 mL).  
The solution was then subjected to microwave irradiation at 100 ºC for 30 mins.  The 
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resulting solution was diluted with CH2Cl2 (30 mL) and was transferred to a separating 
funnel where it was washed with saturated aqueous NaCl (2 × 25 mL) followed by a 
wash with HCl (2M, 20 mL) and finally NaHCO3 (3 × 25 mL).   The combined organic 
phases were dried (MgSO4) and solvent removed in vacuo to give reddish brown viscous 
oil. 1H NMR spectroscopy analysis showed it to be the desired diaminobutane imide 44 
(1.29 g, 90%) in > 95% purity which was then used without further purification. 1H 
NMR (270 MHz, CDCl3): δ 7.34-7.19 (5H, s, Ar-H), 6.01 (2H, s, H9 H8), 5.01 (2H, s, 
H8'), 3.28-3.26 (4H, m, H1' H2'), 3.18-3.08 (4H, m, H5' H4'), 1.73-1.68 (1H, d, H10), 
1.52-1.42 (5H, m, H1 H7 H2 H6 H10), NH not observed; 13C NMR (100 MHz, CDCl3): 
δ 177.87, 156.59, 136.71, 134.51, 129.91-128.16 (5 × C), 66.82, 52.31, 45.79, 44.96, 
40.56, 37.91, 27.31, 25.16; HRMS (ESI m/z): Calcd. For [C21H24N2O4 H] + 369.18161, 
found 369.17592;  ν(max) cm -1: 3338 m, 2942 m, 2870 m, 1683 s, 1527 m, 1172 m.  
Synthesis of  N-(benzyloxycarbonylaminoethyl)-4-aza-tricyclo[5.2.1.02,6]dec-3,5-one 
43 
 Synthesis of imide 43 was carried out as previously described for compound 44 with 
mono-protected diaminoethane 34 (2 g, 10 mmol) and norbornene anhydride 21 (1.13 g, 
7.0 mmol) to produce a yellow oil. 1H NMR spectroscopy analysis showed it to be the 
desired diaminoethane imide 43 (2.2 g, 94%) in > 95% purity which was then used 
without  further purification. 1H NMR (270 MHz, CDCl3): δ 7.47-7.31 (5H, s, Ar-H), 
6.03 (2H, s, H8 H9), 5.04 (2H. s, H6'), 3.46-3.48 (2H, d, J = 5.4Hz, H1'), 3.27-3.32 (2H, 
m, H2'), 3.17 (2H, s, H2 H6), 1.67-1.69 (1H, d, J = 5.4Hz, H10), 1.46-1.49 (3H, d, J = 
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8.1Hz, H1 H7, H10), NH not observed; 13C NMR (100 MHz, CDCl3): δ 177.96, 156.35, 
136.63, 134.51, 128.57-128.17 (5 × C), 66.77, 52.31, 45.87, 44.94, 37.80; HRMS (ESI 
m/z): Calcd. For [C19H21N2O4]+ 341.1496, found 341.1478;  ν(max) cm -1: 3349 m, 2945 
m, 1691 s, 1525 m, 1188 m. 
Synthesis of N-(benzyloxycarbonylaminooctyl)-4-aza-tricyclo[5.2.1.02,6]hexadec-3,5-
one 45 
 Synthesis of imide 45 was carried out as previously described for compound 44 with 
mono-protected diaminooctane  36 (100 mg, 0.359 mmol) and norbornene anhydride 21 
(29.5 mg, 0.180 mmol) to produce a yellow oil. 1H NMR spectroscopy analysis showed 
it to be the desired diaminooctane imide 45 (48.8 mg, 64%) in > 95% purity which was 
then used without  further purification. 1H NMR (270 MHz, CDCl3): δ 7.33-7.35 (5H, s, 
Ar-H), 6.15 (2H, s, H8 H9), 5.1 (2H, s, H12'), 3.21-3.56 (6H, m, H1' H1 H7 H2 H6), 
1.69-1.72 (1H, d, J = 8.1 Hz, H10), 1.43-1.48 (5H, m, H10 H2' H3'), 1.22 (10H, m, H4' 
H5' H6' H7' H8'), NH not observed; 13C NMR (100 MHz, CDCl3): δ177.51, 156.20, 
136.49, 128.80, 128.37, 65.99, 52.30, 45.80, 44.98, 41.34, 38.34, 29.18, 26.85, 26.68 
HRMS (ESI m/z): Calcd. For [C25H33N2O4]+ 425.2435 found 425.2428;  ν(max) cm -1: 
3333 m, 2935 m, 2854 m, 1687 s, 1558 m, 1137, m. 
Synthesis of N-(benzyloxycarbonylaminodecyl)-4-aza-tricyclo[5.2.1.02,6]octadec-3,5-
one 46 
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Synthesis of imide 46 was carried out as previously describe for compound 44 with 
mono-protected diaminodecane 37 (1.05 g, 0.003 mol) and norbornene anhydride 21 
(563 mg, 0.002 mol) to produce a yellow oil. 1H NMR spectroscopy analysis showed it 
to be the desired diaminodecane imide 46 (1.22 g, 79%) in > 95% purity which was then 
used without  further purification. 1H NMR (270 MHz, CDCl3): δ7.32-7.30 (5H, s, Ar-
H), 6.11 (2H, s, H8 H9), 5.05 (2H, s, H14'), 3.34-3.18 (8H, m, H1' H2' H1 H7 H2 H6), 
1.68-1.71 (1H, d, J = 8.1 Hz, H10), 1.47-1.45 (5H, m, H10 H3' H4'), 1.23 (12H, m, H5' 
H6' H7' H8' H9' H10'), NH not observed; 13C NMR (100 MHz, CDCl3): δ 177.86, 
156.48, 137.01, 134.47, 128.57-128.12 (5 × C), 66.59, 52.27, 45.77, 44.96, 38.49, 29.42, 
29.36, 26.92 HRMS (ESI m/z): Calcd. For [C27H37N2O4]+ 453.2748, found 453.2763; 
ν(max) cm -1: 3348 m, 2926 m, 2854 m, 1692 s, 1531 m, 1129 m. 
Synthesis of N-(benzyloxycarbonylaminobutyl)-4-aza-tricyclo[5.2.1.02,6]dodec-3,5-
one-8, 9-diol 59 
Diaminobutane imide 44 (1.03 g, 2.70 mmol) was dissolved in a 4:1 solution of 
acetone/water (30 mL) and NMO (493 mg, 4.0 mmol) was added and stirred until 
dissolved. Osmium tetroxide (0.3 mL, 2.5% wt.% in t-BuOH) was added and the black 
solution stirred for 72 hrs at room temperature. The reaction was quenched with sodium 
metabisulfite (2 mL, 0.53 M) and the solution diluted with EtOAc (30 mL) before being 
transferred to a separating funnel where it was washed with saturated aqueous NaCl (3 × 
25 mL).  The organic phase was dried (MgSO4) and solvent was removed in vacuo to 
afford a dark brown oil. Purification by silica gel column chromatography was 
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performed with 80% EtOAc - 20% pet. spirit eluent and the resulting brown oil was 
shown by 1H NMR spectroscopy to be the desired diaminobutane diol 59 (733 mg, 
67%).  1H NMR (270 MHz, CDCl3): δ 7.30-7.27 (5H, s, Ar-H), 5.01 (2H, s, H8'), 3.98 
(1H, s, H5'), 3.64 (2H, s, 2 × OH), 3.44-3.39 (4H, t, J = 8.1 Hz, H8 H9 H1'), 3.11-3.09 
(2H, d, J = 5.4 Hz, H4'), 2.63 (2H, s, H2 H6), 2.39 (2H, br s, H1 H7), 2.08-2.04 (2H, d, J 
= 10.8, H2'), 1.48-1.40 (4H, m, H3' H10), NH not observed; 13C NMR (100 MHz, 
CDCl3): δ 177.30, 156.85, 136.40, 128.64-128.33 (5 × C), 70.19, 66.92, 45.82, 40.68, 
38.27, 36.00, 29.75, 27.55, 25.16; HRMS (ESI m/z): Calcd. For [C21H26N2O6Na] + 
425.16886, found 425.16858;  ν(max) cm -1: 3368 br, 2942 m, 1689 s, 1537 m, 1139 m. 
Synthesis of N-(benzyloxycarbonylaminoethyl)-4-aza-tricyclo[5.2.1.02,6]dec-3,5-one-
8, 9-diol 58 
Synthesis of diaminoethane diol 58 was carried out as previously described for 
compound 59 with diaminoethane imide 43 (1.04 g, 3.0 mmol), NMO (539 mg, 4.6 
mmol) and OsO4 (0.3 mL, 2.5% wt.% in t-BuOH) to produce a dark brown oil. 
Purification by silica gel column chromatography was performed with 90% EtOAc - 
10% Pet. spirit eluent and the resulting light brown oil was shown by 1H NMR 
spectroscopy to be the desired diaminoethane diol 58 (578 mg, 51%). 1H NMR (270 
MHz, CDCl3): δ  7.32 (5H, s, Ar-H), 5.09 (2H, s, H6'), 3.64 (2H, s, 2 × OH), 3.58-3.55 
(2H, m, H8 H9), 3.37-3.35 (2H, d, J = 5.4Hz, H1'), 2.9 (2H, s, H2'), 2.61 (2H, s, H2 H6), 
2.11-2.09 (1H, d, J = 5.4Hz, H10), 1.43-1.39 (3H, t, J = 5.4Hz, H10 H1 H7), NH not 
observed; 13C NMR (100 MHz, CDCl3): δ 177.54, 156.92, 136.39, 128.63-128.32 (5 × 
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C), 70.15, 67.12, 45.76, 39.22, 35.99; HRMS (ESI m/z): Calcd. For [C19H23N2O6]+ 
375.1551, found 375.1578; ν(max) cm -1: 3368 br, 2924 m, 2854 m, 1692 s, 1533 m, 1145 
m. 
Synthesis of N-(benzyloxycarbonylaminooctyl)-4-aza-tricyclo[5.2.1.02,6]hexadec-3,5-
one-8, 9-diol 60 
Synthesis of diaminooctane diol 60 was carried out as previously described for 
compound 59 with diaminooctane imide 45 (228 mg, 0.54 mmol), NMO (94.4 mg, 0.81 
mmol) and OsO4 (0.3 mL, 4 wt.% in H2O) to produce a dark brown oil which was then 
used without further purification. Purification by silica gel column chromatography was 
attempted for analysis purposes with 80% EtOAc - 20% Pet. spirit eluent and the 
resulting light brown oil was shown by 1H NMR spectroscopy to be the desired 
diaminooctane diol 60 (72 mg). 1H NMR (400 MHz, CDCl3): δ 7.34 (5H, s, Ar-H), 5.07 
(2H, s, H12'), 3.73 (2H, s, 2 × OH), 3.43 (2H, s, H8 H9), 3.17-3.15 (2H, d, J = 8.0 Hz, 
H8'), 3.04 (1H, s, H2), 2.67 (1H, s, H6), 2.14-2.11 (1H, d, J = 12.0 Hz, H10), 1.73 (1H, 
s, H10), 1.52-1.47 (4H, d, J = 20 Hz, H1 H7, H1'), 1.28 (4H, m, H2' H3'), 1.25 (8H, m, 
H4' H5' H6' H7'), NH not observed; 13C NMR (100 MHz, CDCl3): δ 177.04, 156.85, 
136.47, 128.63-128.23 (5 × C), 70.26, 66.93, 46.01, 45.76, 40.77, 36.02, 29.85, 28.60, 
27.80, 26.63, 26.01; HRMS (ESI m/z): Calcd. For [C25H35N2O6]+ 459.2490, found 
459.2475; ν(max) cm -1: 3347 br, 2929 m, 2856 m, 1692 s, 1534 m, 1139 m. 
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Synthesis of N-(benzyloxycarbonylaminodecyl)-4-aza-tricyclo[5.2.1.02,6]octadec-3,5-
one-8, 9-diol 61 
Synthesis of diaminodecane diol 61 was carried out as previously described for 
compound 59 with diaminodecane imide 46 (673 mg, 1.5 mmol), NMO (262.1 mg, 2.23 
mmol) and OsO4 (94 μ mol, 4 wt.% in H2O) at 50 °C for 24 hrs. The resulting black oil 
was shown by 1H NMR spectroscopy to be the desired diaminodecane diol 61 (334 mg, 
46%).  Numerous attempts at purification by silica gel column chromatography were 
unsuccessful and the crude product was used without further purification. Assignment of 
the crude material is as follows. 1H NMR (270 MHz, CDCl3): 1H NMR (270 MHz, 
CDCl3): δ 7.32-7.29 (5H, m, Ar-H), 5.08 (2H, s, H14'), 3.66 (2H, br s, 2 × OH), 3.40-
3.34 (2H, t, J = 8.1 Hz, H8 H9), 2.64-2.62 (4H, m, H1 H7 H10'), 2.01-1.97 (2H, br s, 
H10), 1.44-1.41 (8H, m, H1' H2' H3' H2 H6), 1.22-1.16 (12H, m, H4' H5' H6' H7' H8' 
H9'), NH not observed; 13C NMR (100 MHz, CDCl3): δ 177.13, 156.67, 136.64, 128.60-
128.19, 70.15, 66.74, 45.97, 38.76, 35.97, 29.93-29.07 (5 × C), 28.91, 26.86; HRMS 
(ESI m/z): Calcd. For [C27H38N2NaO6]+ 509.2622, found 509.2614; ν(max) cm -1: 3350 br, 
2926 m, 2854 m, 1685 s, 1533 m, 1151 m. 
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Synthesis of 4-undecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]-10-aza-dodec-9,11-one-N-
(benzyloxycarbonylaminobutyl) 70 
To a solution of dodecyl aldehyde 66 (0.08 mL, 0.38 mmol) in CH2Cl2 (30 mL), 
diaminobutane diol 59 (102 mg, 0.25 mmol) was added and stirred until dissolved. To 
this solution, MgSO4 was added, followed by the addition of p-toluenesulfonic acid  
(193 mg, 1.01 mmol). The resulting solution was warmed to 35 °C and stirred for 24 hrs 
before being filtered and the solvent was removed in vacuo to give a light brown oil. 
Purification by silica gel column chromatography was performed with a 70% Pet. spirit 
– 30% EtOAc eluent  and the resulting caramel oil was shown by 1H NMR spectroscopy 
analysis to be the desired diaminobutane dodecyl acetal 70 (111 mg, 77%). 1H NMR 
(270 MHz, CDCl3): δ 7.33 (5H, s, Ar-H), 5.07 (2H, s, H8'), 4.63-4.60 (1H, t, J = 2.7 Hz, 
H4), 3.84 (2H, s, H1 H7), 3.43 (2H, d, J = 5.4 Hz, H2 H6), 3.20-3.18 (2H, d, J = 5.4 Hz, 
H4’), 3.07 (2H, s, H8 H12), 2.83 (2H, s, H1'), 2.35-2.29 (1H, t, J = 12.15 Hz, H13), 
2.01-1.98 (1H, d, J = 12.15 Hz, H13), 1.61-1.51 (4H, m, H2' H3'), 1.24 (20H, br s, H14-
H23), 0.88-0.83 (3H, t, J = 13.5 Hz, H24), NH not observed;  13C NMR (100 MHz, 
CDCl3): δ 176.4, 156.5, 136.6, 128.6-128.20 (5 × C), 104.2, 77.5,  66.8, 44.5, 40.5, 38.2, 
37.4, 35.9, 32.7, 31.9, 29.8-29.2 (6 × C), 27.5, 25.1, 24.3, 22.8, 14.2; HRMS (ESI m/z): 
Calcd. For [C25H44N2O4]+ 435.3217, found 435.3233; ν(max) cm -1: 2923 s, 2853 s, 1698 s, 
1521  m, 1132 m. The purified dodecyl acetal 70 was dissolved in MeOH (50 mL) 
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followed by the addition of palladium on activated carbon  (31 mg, 10% w/w). The 
resulting suspension was stirred under H2(g) for 24 hrs before being vacuum filtrated 
through a celite plug and the filtrate removed in vacuo to give a white paste. Analysis by 
1H NMR spectroscopy showed significant aggregation though the lack of the singlet 
resonance at δ 5.07 ppm and aromatic multiplet at δ 7.33 ppm indicated the successful 
deprotection of the benzyl carbamate to afford compound 84 (211 mg, 88%). HRMS 
(ESI m/z): Calcd. For [C25H43N2O4] + 435.32246, found 435.32593; ν(max) cm -1: 2923 s, 
2853 s, 1697 s. 
Synthesis of 4-pentadecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]-10-aza-dodec-9,11-one-
N-(benzyloxycarbonylaminobutyl) 71 
Synthesis of diaminobutane hexdecyl acetal 71 was performed as per previously 
described for diaminobutane dodecyl acetal 70 with diaminobutane diol 59 (246 mg, 
0.613 mmol) and hexadecyl aldehyde 67 (221 mg, 0.919 mmol) to afford a light yellow 
oil. Purification by silica gel column chromatography was performed with a 70% Pet. 
spirit – 30% EtOAc eluent and the resulting caramel oil was shown by 1H NMR 
spectroscopy analysis to be the desired diaminobutane hexadecyl acetal 71 (286 mg, 
75%). 1H NMR (270 MHz, CDCl3): δ 7.38-7.28 (5H, m, Ar-H), 5.06 (2H, s, H8'), 4.62-
4.59 (1H, t, J = 5.4 Hz, H4), 3.84 (2H, s, H1 H7), 3.44-3.40 (2H, t, J = 5.4 Hz, H2 H6), 
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3.22-3.17 (2H, d, J = 13.5 Hz, H4'), 3.08-3.06 (2H, m, H8 H12), 2.83-2.81 (2H, m, H1'), 
2.02-1.97 (2H, d, J = 13.5 Hz H13), 1.62-1.32 (4H, m, H2' H3'), 1.22 (28H, br s, H14-
H27), 0.88-0.83 (3H, t, J = 5.4 Hz, H28), NH not observed;  13C NMR (100 MHz, 
CDCl3): δ 179.7, 156.5, 136.5, 128.6-128.2 (5 × C), 104.1, 77.6, 66.8, 44.5, 42.7, 40.5, 
38.2, 35.9, 34.2, 32.0, 29.8-29.03 (10 × C), 27.5, 25.1, 24.7, 22.8, 14.2; HRMS (ESI 
m/z): Calcd. For [C37H57N2O6] + 625.42184, found 625.42001; ν(max) cm -1: 3368 m, 2924 
s, 2853 s, 1697 s, 1532 m, 1137 m. Deprotection of diaminobutane hexadecyl acetal 71 
(377 mg, 0.60 mmol)  was then carried out as per previously described for 
diaminobutane dodecyl acetal 70 with palladium on activated carbon  (38 mg, 10% w/w) 
to afford a white paste. Analysis by 1H NMR spectroscopy showed significant 
aggregation though the lack of the singlet resonance at δ 5.06 ppm and aromatic 
multiplet at ~ δ 7.33 ppm indicated the successful deprotection of the benzyl carbamate 
to afford compound 85 (263 mg, 89%). HRMS (ESI m/z): Calcd. For [C29H51N2O4] + 
491.38506, found 491.38906; ν(max) cm -1: 2920 s, 2851 s, 1698 s. 
Synthesis of 4-undecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]-10-aza-dec-9,11-one-N-
(benzyloxycarbonylaminoethyl) 68 
 Synthesis of diaminoethane dodecyl acetal 68 was performed as per previously 
described for diaminobutane dodecyl acetal 70 with diaminoethane diol 58 (212 mg, 
0.566 mmol) and dodecyl aldehyde 66 (0.19 mL, 0.849 mmol) to afford a light yellow 
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oil. Purification by silica gel column chromatography was performed with a 60% Pet. 
spirit – 40% EtOAc eluent and the resulting caramel oil was shown by 1H NMR 
spectroscopy analysis to be the desired diaminoethane dodecyl acetal 68 (188 mg, 61%). 
1H NMR (270 MHz, CDCl3): δ 7.32 (5H, s, Ar-H), 5.02 (2H, s, H6'), 4.59-4.55 (1H, t, J 
= 10.8 Hz, H4), 3.83 (2H, s, H1 H7), 3.58-3.57 (2H, t, J = 4.0 Hz, H2 H6), 3.38-3.36 
(2H, d, J = 5.4 Hz, H2'), 2.96-2.95 (1H, d, J = 2.7 Hz, H8), 2.78 (1H, s, H12), 2.33-2.27 
(1H, t, J = 8.1 Hz, H13), 1.99-1.95 (1H, d, J = 10.8 Hz, H13), 1.58-1.57 (2H, m, H1'), 
1.31 (18H, bs, H14-H23), 0.88-0.84 (3H, t, J = 10.8 Hz, H24), NH not observed; 13C 
NMR (100 MHz, CDCl3): δ 176.8, 156.6, 136.5, 128.6-128.3 (5 × C), 104.3, 78.4, 66.9, 
44.6, 39.8, 38.3, 35.9, 34.0, 32.7, 31.10, 29.7-29.5 (6 × C), 24.33, 22.8, 14.3; HRMS 
(ESI m/z): Calcd. For [C31H45N2O6]+ 541.3272, found 541.3301; ν(max) cm -1: 3360 m, 
2924 s, 2854 s, 1699 s, 1522 m, 1142 m. Deprotection of the diaminoethane dodecyl 
acetal 68 (459 mg, 0.85 mmol)  was then carried out as per previously described for 
diaminobutane dodecyl acetal 70 with palladium on activated carbon (46 mg, 10% w/w) 
to afford a white paste. Analysis by 1H NMR spectroscopy showed significant 
aggregation though the lack of the singlet resonance at δ 5.02 ppm and aromatic 
multiplet at ~ δ 7.32 ppm indicated the successful deprotection of the benzyl carbamate 
to afford compound 82 (319 mg, 92%). HRMS (ESI m/z): Calcd. For [C23H39N2O4] + 
407.29116, found 407.29316; ν(max) cm -1: 2954 s, 2853 s, 1699 s. 
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Synthesis of 4-pentadecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]-10-aza-dec-9,11-one-N-
(benzyloxycarbonylaminoethyl) 69 
 Synthesis of diaminoethane hexadecyl acetal 69 was performed as per previously 
described for diaminobutane dodecyl acetal 70 with diaminoethane diol 58 (309 mg, 
0.83 mmol) and hexadecyl aldehyde 67 (298 mg, 1.24 mmol) to afford a light yellow oil. 
Purification by silica gel column chromatography was performed with a 70% Pet. spirit 
– 30% EtOAc eluent  and the resulting caramel oil was shown by 1H NMR spectroscopy 
analysis to be the desired diaminoethane hexadecyl acetal 69 (383 mg, 78%).  1H NMR 
(270 MHz, CDCl3): δ 7.32 (5H, s, Ar-H), 5.02 (2H, s, H6'), 4.58-4.55 (1H, t, J = 2.7 Hz, 
H4), 3.83 (2H, s, H1 H7), 3.60-3.56 (2H, t, J = 5.4 Hz, H2 H6), 3.40-3.34 (2H, d, J = 5.4 
Hz, H2'), 2.97-2.93 (1H, m, H8), 2.79-2.78 (1H, t, J = 2.7, H12), 2.34-2.28 (1H, t, J = 
9.45 Hz, H13), 1.99-1.95 (1H, d, J = 9.45 Hz, H13), 1.60-1.57 (2H, m, H1'), 1.34 (28H, 
br s, H14-H27), 0.88-0.83 (3H, t, J = 13.5 Hz, H28), NH not observed; 13C NMR (100 
MHz, CDCl3): δ 174.7, 156.6, 136.4, 128.6-128.4 (5 × C), 104.1, 77.6, 66.9, 44.5, 39.6, 
38.3, 37.2, 34.0, 32.7, 32.0, 29.8-29.2 (10 × C), 24.8, 22.7, 14.21; HRMS (ESI m/z): 
Calcd. For [C35H53N2O6]+ 597.3898, found 597.3912; ν(max) cm -1: 3354 m, 2922 s, 2853 
s, 1698 s, 1526 m, 1120 m. Deprotection of the diaminoethane hexadecyl acetal 69 (62 
mg, 0.10 mmol) was then carried out as per previously described for diaminobutane 
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dodecyl acetal 70 with palladium on activated carbon (6 mg, 10% w/w) to afford a white 
paste. Analysis by 1H NMR spectroscopy showed significant aggregation though the 
lack of the singlet resonance at δ 5.02 ppm and aromatic multiplet at ~ δ 7.34 ppm 
indicated the successful deprotection of the benzyl carbamate to afford compound 83 (40 
mg, 83%). HRMS (ESI m/z): Calcd. For [C27H47N2O4] + 463.35376, found 463.36276; 
ν(max) cm -1: 2916 s, 2849 s, 1698 s. 
Synthesis of 4-undecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]-10-aza-hexadec-9,11-one-
N-(benzyloxycarbonylaminooctyl) 72 
Synthesis of diaminooctane dodecyl acetal 72 was performed as per previously 
described for diaminobutane dodecyl acetal 70 with diaminooctane diol 60 (135 mg, 
0.294 mmol) and dodecyl aldehyde 66 (0.13 mL, 0.589 mmol) to afford a brown oil. 
Purification by silica gel column chromatography was performed with a 60% Pet. spirit 
– 40% EtOAc eluent  and the resulting caramel oil was shown by 1H NMR spectroscopy 
analysis to be the desired diaminooctane dodecyl acetal 72 (235 mg, 64%).  1H NMR 
(270 MHz, CDCl3): δ 7.34-7.33 (5H, m, Ar-H), 5.07 (2H, s, H12'), 4.60-4.58 (1H, t, J = 
2.7 Hz, H4), 3.85 (2H, s, H1 H7), 3.42-3.37 (2H, t, J = 8.1 Hz, H6 H12), 3.19-3.12 (2H, 
q, J = 5.4 Hz, H8'), 3.08-3.05 (1H, m, H8), 2.83 (1H, br s, H12), 2.34-2.26 (1H, m, H13), 
1.97 (1H, s, H13), 1.65-1.58 (2H, m, H1'), 1.48-1.46 (6H, m, H2' H3' H4'), 1.26- 1.24 
(26H, m, H14-H23 H5'-H7'), 0.87-0.83 (3H, t, J = 5.4 Hz, H24), NH not observed; 13C 
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NMR (100 MHz, CDCl3): δ 176.41, 156.48, 136.75, 128.60-128.14 (5 × C), 104.14, 
78.32, 66.63, 44.48, 41.12, 38.68, 35.87, 33.95, 32.69, 31.97, 29.69, 29.67-29.16 (6 × 
C), 27.76, 26.89, 24.87, 22.76, 22.76, 14.18; HRMS (ESI m/z): Calcd. For 
[C37H57N2O6]+ 625.4211, found 625.4224; ν(max) cm -1: 3365 m, 2965 m, 2850 m, 1694 s, 
1537 m, 1129 m. Deprotection of the diaminooctane dodecyl acetal 72 (235 mg, 0.375 
mmol) was then carried out as per previously described for diaminobutane dodecyl 
acetal 70 with palladium on activated carbon (24 mg, 10% w/w) to afford a cream paste. 
Analysis by 1H NMR spectroscopy showed significant aggregation though the lack of 
the singlet resonance at δ 5.03 ppm and aromatic multiplet at ~ δ 7.32 ppm indicated the 
successful deprotection of the benzyl carbamate to afford compound 86 (147 mg, 89%). 
HRMS (ESI m/z): Calcd. For [C29H51N2O4]+ 491.3843, found 491.3861; ν(max) cm -1: 
2927 s, 2850 s, 1699 s. 
Synthesis of 4-pentadecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]-10-aza-hexadec-9,11-
one-N-(benzyloxycarbonylaminooctyl) 73 
Synthesis of diaminooctane hexadecyl acetal 73 was performed as per previously 
described for diaminobutane dodecyl acetal 70 with diaminooctane diol 60 (164 mg, 
0.358 mmol) and hexadecyl aldehyde 67 (129 mg, 0.537 mmol) to afford a brown oil. 
Purification by silica gel column chromatography was performed with a 60% Pet. spirit 
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– 40% EtOAc eluent and the resulting caramel oil was shown by 1H NMR spectroscopy 
analysis to be the desired diaminooctane hexadecyl acetal 73 (95 mg, 39%) in > 95% 
purity which was then used immediately in the next deprotection step.  1H NMR (270 
MHz, CDCl3): δ 7.35-7.33 (5H, m, Ar-H), 5.12 (2H, s, H12'), 4.60-4.58 (1H, t, J = 2.7 
Hz, H4), 3.85 (2H, s, H1 H7), 3.40-3.37 (2H, t, J = 8.1 Hz, H2 H6), 3.20-3.12 (2H, q, J = 
5.4 Hz, H8'), 3.07-3.06 (1H, m, H8), 2.88-2.83 (1H, m, H12), 2.35-2.29 (1H, t, J = 9.45 
Hz, H13) 2.01-1.97 (1H, d, J = 9.45 Hz, H13), 1.48-1.46 (6H, m, H1' H2' H3'), 1.40-1.35 
(6H, m, H4' H5' H6'), 1.23-1.20 (30H, m, H14-H27 H7'), 0.88-0.86 (3H, t, J = 2.7 Hz, 
H28), NH not observed; 13C NMR (100 MHz, CDCl3): 176.37, 156.47, 136.74, 128.89-
128.20 (5 × C), 104.08, 78.33, 66.69, 44.58, 42.73, 41.14, 38.72, 32.69, 32.11, 29.78-
28.41 (10 × C), 27.80, 24.22, 22.80, 14.22; HRMS (ESI m/z): Calcd. For [C41H65N2O6]+ 
681.4837, found 681.4862; ν(max) cm -1: 3368 m, 2924 m, 2853 m, 1697 s, 1532 m, 1137 
m. Deprotection of the diaminooctane hexadecyl acetal 73 (95 mg, 0.140 mmol)  was 
then carried out as per previously described for diaminobutane dodecyl acetal 70 with 
palladium on activated carbon (20 mg, 10% w/w) to afford a cream paste. Analysis by 
1H NMR spectroscopy showed significant aggregation though the lack of the singlet 
resonance at δ 5.02 ppm and aromatic multiplet at ~ δ 7.36 ppm indicated the successful 
deprotection of the benzyl carbamate to afford compound 87 (80 mg, 84%). HRMS (ESI 
m/z): Calcd. For [C33H59N2O4]+ 547.4469, found 547.4476; ν(max) cm -1: 2920 s, 2851 s, 
1699 s. 
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Synthesis of 4-undecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]-10-aza-octadec-9,11-one-
N-(benzyloxycarbonylaminodecyl) 74 
Synthesis of diaminodecane dodecyl acetal 74 was performed as per previously 
described for diaminobutane dodecyl acetal 70 with diaminodecane diol 61 (361 mg, 
0.742 mmol) and dodecyl aldehyde 67 (0.25 mL, 1.11 mmol) to afford a brown oil. 
Purification by silica gel column chromatography was performed with a 60% Pet. spirit 
– 40% EtOAc eluent  and the resulting caramel oil was shown by 1H NMR spectroscopy 
analysis to be the desired diaminodecane dodecyl acetal 74 (368 mg, 76%). 1H NMR 
(270 MHz, CDCl3): δ 7.33 (5H, br s, Ar-H), 5.08 (2H, s, H14'), 4.61-4.57 (1H, t, J = 
5.4Hz, H4), 3.85 (2H, br s, H1 H7), 3.43-3.37 (2H, t, J = 8.1 Hz, H10’), 3.18-3.15 (1H, 
d, J = 8.1 Hz, H2), 3.09-3.06 (1H, q, J = 5.4 Hz H6), 2.83 (2H, br s, H8 H12), 2.36-2.20 
(1H, m, H13), 2.01-1.97 (1H, d, J = 10.8 Hz, H13), 1.64-1.59 (6H, m, H1' H2' H3'), 1.24 
(32H, m, H14-H23 H4'-H9'), 0.88-0.84 (3H, t, J = 5.4 Hz, H24), NH not observed; 13C 
NMR (100 MHz, CDCl3): 174.32, 156.50, 136.73, 128.59-128.22 (5 × C), 104.34, 
78.33, 66.67, 44.48, 42.71, 38.79, 35.89, 34.06, 32.69, 31.99, 30.00-29.09 (6 × C), 
27.02, 24.26, 22.77, 14.20; HRMS (ESI m/z): Calcd. For [C39H61N2O6]+ 653.4524, 
found 653.4543; ν(max) cm -1: 3349 m, 2922 m, 2870 m, 1695 s, 1538 m, 1142 m. 
Deprotection of the diaminodecane dodecyl acetal 74 (368 mg, 0.564 mmol) was then 
carried out as per previously described for diaminobutane dodecyl acetal 70 with 
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palladium on activated carbon (37 mg, 10% w/w) to afford a cream paste. Analysis by 
1H NMR spectroscopy showed significant aggregation though the lack of the singlet 
resonance at δ 5.03 ppm and aromatic multiplet at ~ δ 7.32 ppm indicated the successful 
deprotection of the benzyl carbamate to afford compound 88 (234 mg, 80. HRMS (ESI 
m/z): Calcd. For [C27H47N2O4] + 463.35376, found 463.36276; ν(max) cm -1: 2922 s, 2870 
s, 1699 s. 
Synthesis of 4-hexadecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]-10-aza-octadec-9,11-
one-N-(benzyloxycarbonylaminodecyl) 75 
Synthesis of diaminodecane hexadecyl acetal 75 was performed as per previously 
described for diaminobutane dodecyl acetal 70 with diaminodecane diol 61 (132 mg, 
0.271 mmol) and hexadecyl aldehyde 67 (98 mg, 0.406 mmol) to afford a brown oil. 
Purification by silica gel column chromatography was performed with a 70% Pet. spirit 
– 30% EtOAc eluent  and the resulting caramel oil was shown by 1H NMR spectroscopy 
analysis to be the desired diaminodecane hexadecyl acetal 75 (165 mg, 88%). 1H NMR 
(270 MHz, CDCl3): δ 7.34-7.33 (5H, m, Ar-H), 5.08 (2H, s, H14'), 4.59-4.57 (1H, t, J = 
2.7 Hz, H4), 3.85 (2H,br s, H1 H7), 3.43-3.37 (2H, t, J = 8.1 Hz, H10’), 3.20-3.13 (1H, 
q, J = 5.4 Hz, H2), 3.08-3.05 (1H, q, J = 2.7 Hz, H6), 2.83 (2H, br s, H8 H12), 2.34-2.29 
(1H, m, H13), 2.01-1.97 (1H, d, J = 10.8 Hz, H13), 1.60-1.36 (6H, m, H1' H2' H3'), 
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1.27-1.19 (40H, m, H14-H27 H4'-H9'), 0.88-0.83 (3H, t, J = 5.4 Hz, H28), NH not 
observed; 13C NMR (100 MHz, CDCl3): δ 176.42, 156.54, 136.76, 128.45-128.00 (5 × 
C), 104.03, 78.26, 66.50, 44.40, 42.64, 38.65, 35.76, 34.02, 32.63, 31.95, 27.74, 26.92-
26.69 (10 × C), 25.78, 24.77, 22.72, 14.14; HRMS (ESI m/z): Calcd. For 
[C43H68N2NaO6]+ 731.4969, found 731.4952; ν(max) cm -1: 3359 m, 2923 m, 2853 m, 
1699 s, 1558 m, 1144 m. Deprotection of the diaminodecane hexadecyl acetal 75 (46 
mg, 0.066 mmol) was then carried out as per previously described for diaminobutane 
dodecyl acetal 70 with palladium on activated carbon (4.6 mg, 10% w/w) to afford a 
cream paste. Analysis by 1H NMR spectroscopy showed significant aggregation though 
the lack of the singlet resonance at δ 5.02 ppm and aromatic multiplet at ~ δ 7.36 ppm 
indicated the successful deprotection of the benzyl carbamate to afford compound 89 (26 
mg, 67%). HRMS (ESI m/z): Calcd. For [C35H63N2O4] + 575.47896, found 575.48496; 
ν(max) cm -1: 2920 s, 2851 s, 1698 s. 
7.1.3 Synthesis of dioxy ethylene amphiphiles 98-99 
Synthesis of N-(benzyloxycarbonyl(2-(2-(2-aminoethoxy)ethoxy)ethyl) 91 
 A solution of ethylenedioxy bis ethylamine 90 (3.37 mL, 3.37 mmol) in CH2Cl2 (100 
mL) was cooled to 0 ºC and a solution of benzylchloroformate 28 (0.1 mL, 0.675 mmol) 
and CH2Cl2 (150 mL) was added drop-wise over 1 hr.  The reaction was then stirred at rt 
for 24 hrs. The resulting mixture was transferred to a separating funnel where it was 
washed with saturated aqueous NaCl (3 × 30 mL).  The organic phase was dried 
(MgSO4), filtered and solvent removed in vacuo to afford a white powder. 1H NMR 
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spectroscopy data was found to be consistent with literature values240 for the desired 
mono-protected ethylenedioxy amine 91 (660 mg, 73%) in > 95% purity which was then 
used without further purification. 1H NMR (270 MHz, CDCl3): δ 7.35-7.29 (5H, m. Ar-
H), 5.58 (1H, br s, H10), 5.08 (2H, s, H12), 3.60-3.47 (4H, m, H3 H5), 3.40-3.36 (4H, 
m, H6 H8), 2.85 (2H, m, H9), 2.42 (2H, s, H2), NH2 not observed. 
Synthesis of N-(benzyloxycarbonyl(2-(2-(2-aminoethoxy)ethoxy)ethyl)-4-aza-
tricyclo[5.2.1.02,6]hexadec-3,5-one 92  
To a 35 mL microwave vial containing mono-protected ethylenedioxy amine 91 (500 
mg, 1.87 mmol), norbornene anhydride 21 (205 mg, 1.25 mmol) was added and 
dissolved with PhMe (15 mL).  The solution was then subjected to microwave 
irradiation at 120 ºC for 30 mins.  The resulting solution was diluted with CH2Cl2 (30 
mL) and transferred to a separating funnel where it was washed with saturated aqueous 
NaCl (2 × 25 mL) followed by HCl (2M, 20 mL) and finally NaHCO3 (3 × 25 mL).   
The combined organic phases were dried (MgSO4) and solvent removed in vacuo to give 
a clear viscous oil. Purification via silica gel chromatography was peformed with 100% 
EtOAc eluent and the resulting clear oil was shown by 1H NMR spectroscopic analysis 
to be the desired ethylenedioxy imide 92 (739 mg, 92%). 1H NMR (270 MHz, CDCl3): δ 
7.35-7.30 (5H, s, Ar-H), 6.05 (2H, s, H8 H9), 5.09 (2H, s, H12'), 3.53 (2H, s, H1'), 3.52-
3.49 (2H, t, J = 5.4 Hz, H2'), 3.47 (2H, s, H4'), 3.38-3.36 (2H, d, J = 5.4 Hz, H7'), 3.32 
(2H, s, H8'), 2.82 (2H, s, H2 H6), 2.29 (2H, s, H1 H7), 1.68 (2H, s, H10), NH not 
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observed; 13C NMR (100 MHz, CDCl3): δ 177.79, 156.63, 136.75, 134.46, 128.57- 
128.13 (5 × C), 70.43, 70.16, 69.84, 66.70, 52.13, 45.84, 44.97, 41.03, 37.46; HRMS 
(ESI m/z): Calcd. For [C23H29N2O6] + 429.20201, found 429.20237; ν(max) cm -1: 3343 m, 
2942 m, 1690 s, 1524 m. 
Synthesis of N-(benzyloxycarbonyl(2-(2-(2-aminoethoxy)ethoxy)ethyl)-4-aza-
tricyclo[5.2.1.02,6]hexadec-3,5-one-8, 9-diol 93  
Ethylenedioxy imide 92 (608 mg, 1.42 mmol) was dissolved in a 4:1 solution of 
acetone/water (30 mL) and NMO (250 mg, 2.13 mmol) was added and stirred until 
dissolved. Osmium tetroxide (0.1 mL, 4 wt.% in H2O) was added and the black solution 
stirred for 72 hrs at room temperature. The reaction was quenched with sodium 
metabisulfite (2 mL, 0.53 M) and the solution diluted with EtOAc (30 mL) before being 
transferred to a separating funnel where it was washed with saturated aqueous NaCl (3 × 
25 mL).  The organic phase was dried (MgSO4) and solvent removed in vacuo to afford 
a dark brown oil. Purification by silica gel column chromatography was performed with 
90% EtOAc - 10% Pet. spirit eluent and the resulting yellow oil was shown by 1H NMR 
spectroscopy to be the desired ethylenedioxy diol 93 (417 mg, 63%).  1H NMR (270 
MHz, CDCl3): δ 7.35-7.30 (5H, s, Ar-H), 5.08 (2H, s, H12'), 3.83 (2H, s, H2'), 3.73- 
3.71 (2H, t, J = 2.7 Hz, H1'), 3.66-3.67 (2H, d, J = 2.7 Hz, H7'), 3.57 (2H, s, H4'), 3.54-
3.52 (2H, t, J = 5.4 Hz, H5'), 3.37-3.35 (2H, d, J = 5.4 Hz, H8 H9), 3.01 (2H, s, H8'), 
2.85 (2H, s, H2 H6), 1.71 (2H, s, H1 H7), 0.90-0.82 (2H, m, H10), NH not observed; 13C 
NMR (100 MHz, CDCl3): δ 177.34, 157.03, 136.79, 128.57-128.18 (5 × C), 77.51, 
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70.24, 70.09, 69.95, 67.15, 50.59, 46.26, 41.54, 40.79, 37.82; HRMS (ESI m/z): Calcd. 
For [C23H31N2O8]+ 463.20749, found 463.20731; ν(max) cm -1: 3351 br, 2874 m, 1690 s, 
1528 m. 
Synthesis of 4-undecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]-10-aza-hexadec-9,11-one-
N-(benzyloxycarbonyl(2-(2-(2-aminoethoxy)ethoxy)ethyl) 96  
 To a solution of dodecyl aldehyde 67 (0.1 mL, 0.450 mmol) in CH2Cl2 (30 mL), 
ethylenedioxy diol 93 (100 mg, 0.216 mmol) was added and stirred until dissolved. To 
this solution, MgSO4 was added, followed by the addition of trifluoroacetic acid (I mL). 
The resulting solution was stirred for 24 hrs at rt before being filtered and the solvent 
removed in vacuo to give a yellow oil. Purification by silica gel column chromatography 
was performed with a 50% Pet. spirit – 50% EtOAc eluent  and the resulting yellow oil 
was shown by 1H NMR spectroscopy analysis to be the desired ethylenedioxy dodecyl 
acetal 96 (107 mg, 79%). 1H NMR (270 MHz, CDCl3): δ 7.32-7.17 (5H, m, Ar-H), 5.02 
(2H, s, H12'), 4.55-4.51 (1H, t, J = 5.4 Hz, H4), 3.92 (2H, s, H2'), 3.59-3.55 (2H, q, J = 
5.4, 8.1 Hz, H1'), 3.52  (2H, s, H7'), 3.49 (2H, s, H4'), 3.45-3.43 (2H, d, J = 5.4 Hz, H2 
H6), 3.34-3.29 (2H, m, H8'), 2.98 (2H, s, H8 H12), 2.74 (2H, s, H1 H7), 1.57-1.52 (4H, 
m, H13 H14), 1.29-1.11 (18H, m, H15-H23), 0.86-0.79 (3H, m, H24), NH not observed; 
13C NMR (100 MHz, CDCl3): δ 178.48, 156.67, 136.84, 128.59-128.18 (5 × C), 104.00, 
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78.27, 70.38, 69.82, 67.11, 66.65, 44.47, 42.80, 41.05, 37.82, 35.87, 32.74, 31.99, 29.71-
29.41 (6 × C), 24.83, 22.76, 14.20; HRMS (ESI m/z): Calcd. For [C35H53N2O8] + 
629.37964, found 629.37942 ν(max) cm -1: 3354 m, 2924 s, 2855 s, 1701 s. The purified 
ethylenedioxy dodecyl acetal 96 (100 mg, 0.159 mmol) was dissolved in MeOH (50 mL) 
followed by the addition of palladium on activated carbon (10 mg, 10% w/w). The 
resulting suspension was stirred under H2 (g) for 24 hrs before being vacuum filtrated 
through a celite plug and the filtrate removed in vacuo to give a yellow oil. Analysis by 
1H NMR spectroscopy showed significant aggregation though the lack of the singlet 
resonance at δ 5.07 ppm and aromatic multiplet at ~ δ 7.32 ppm indicated the successful 
deprotection of the benzyl carbamate to afford compound 98 (63 mg, 80%). HRMS (ESI 
m/z): Calcd. For [C27H46N2O6]+ 495.34341, found 495.34309; ν(max) cm -1: 2934 s, 2865 
s, 1698 s. 
Synthesis of 4-hexadecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]-10-aza-hexadec-9,11-
one-N-(benzyloxycarbonyl(2-(2-(2-aminoethoxy)ethoxy)ethyl) 97  
To a solution of hexadecyl aldehyde 67 (78 mg, 0.324 mmol) in CH2Cl2 (30 mL), 
ethylenedioxy diol 93 (100 mg, 0.216 mmol) was added and stirred until dissolved. To 
this solution, MgSO4 was added, followed by the addition of trifluoroacetic acid (1 mL). 
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The resulting solution was stirred for 24 hrs at rt before being filtered and the solvent 
was removed in vacuo to give a yellow oil. Purification by silica gel column 
chromatography was performed with a 50% Pet. spirit – 50% EtOAc eluent  and the 
resulting yellow oil was shown by 1H NMR spectroscopy analysis to be the desired 
ethylenedioxy hexadecyl acetal 97 (90 mg, 60%). 1H NMR (270 MHz, CDCl3): δ 7.29-
7.23 (5H, m, Ar-H), 5.09 (2H, s, H12'), 4.58-4.56 (1H, t, J = 2.7 Hz, H4), 3.99 (2H, s, 
H2'), 3.63-3.59 (2H, t, J = 5.4 Hz, H1'), 3.56  (2H, s, H7'), 3.51-3.47 (2H, t, J = 5.4 Hz, 
H4'), 3.44-3.42 (2H, d, J = 5.4 Hz, H2 H6), 3.37-3.35 (2H, m, H8'), 3.02 (2H, s, H8 
H12), 2.78 (2H, s, H1 H7), 1.49-1.31 (4H, m, H13 H14), 1.30-1.19 (26H, m, H15-H27), 
1.14-1.06 (3H, m, H28), NH not observed; 13C NMR (100 MHz, CDCl3): δ 176.48, 
15.53, 136.84, 128.54-128.09 (5 × C), 104.00, 77.41, 70.38, 70.32, 69.81, 67.11, 44.48, 
42.80, 41.23, 37.82, 36.35, 32.75, 32.01, 29.77-29.44 (10 × C), 24.58,  22.78, 14.21; 
HRMS (ESI m/z): Calcd. For [C39H61N2O8] + 685.44224, found 685.44142; ν(max) cm -1: 
3359 m, 2923 s, 2853 s, 1699 s. The purified ethylenedioxy hexadecyl acetal 97 (90 mg, 
0.131 mmol) was dissolved in MeOH (50 mL) followed by the addition of palladium on 
activated carbon (9 mg, 10% w/w). The resulting suspension was stirred under H2 (g) for 
24 hrs before being vacuum filtrated through a celite plug and the filtrate removed in 
vacuo to give a yellow oil. Analysis by 1H NMR spectroscopy showed significant 
aggregation though the lack of the singlet resonance at δ 5.08 ppm and aromatic 
multiplet at ~ δ 7.33 ppm indicated the successful deprotection of the benzyl carbamate 
to afford compound 99 (54 mg, 75%). HRMS (ESI m/z): Calcd. For [C31H55N2O6] + 
551.40601, found 551.40692; ν(max) cm -1: 2918 s, 2845 s, 1697 s. 
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7.1.4 Conversion of amphiphiles 82-89 and 98-99 to hydrochloride salts 
Hydrochloride gas, produced through commercial sodium chloride and concentrated 
sulphuric acid was bubbled directly through aqueous (Milli-Q) solutions of amphiphiles 
82-89 and 98-99. The amphiphilic solution turned from opaque to clear as an indication 
that the head group was now charged and therefore more amenable to dissolution in 
water. The resulting solutions were frozen at -80 °C overnight then lyophilised to furnish 
homogenous powders. 
7.2 Chapter 3 
7.2.1 Formulation of self-assemblies 
Freshly lyophilised amphiphiles were hydrated using Milli-Q water (resistivity of 18.2 
MΩ.cm) to the desired concentration.  The colloids were sonicated at room temperature 
for 30 mins and left overnight at room temperature to stabilise.  The colloids were then 
extruded through a 0.45 μm syringe filter prior to analysis. 
7.2.2 Determination of Logkʹw 
The  analytes  were  sequentially  injected  onto  the  column  with increasing  amounts  
of  organic  modifier  in  the  eluent (H2O/MeOH). Runs were undertaken at ratios of 
90:10, 70:30 and 50:50 MeOH/H2O.  The value of kw was determined by extrapolation 
of the k vs. conc. of organic modifier back to pure water.  The log (base 10) of this value 
was then carried out to give the logkw value.  Dead time of the system was determined 
by injecting acetone through the system and monitoring its retention time. 
7.2.3 Determination of CAC using pyrene fluorescent probe method 
The fluorescence properties of pyrene were determined using a Varian Cary Eclipse 
fluorescence spectrophotometer.  The surfactant solutions were prepared 24 hrs prior to 
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the measurements using  Milli-Q  water  (resistivity  of  18.2  MΩ.cm)  at a  range  of  
concentrations  (1-0.0001  mg/mL).  Excess crystalline pyrene was then added to the 
surfactant aqueous solutions and heated at 30 °C for 30 mins in a sonic bath before 
allowing to equilibrate at rt for 23 hrs.  The  solutions  were  then  filtered through  a  
0.45  μm  filter  prior  to  measurement.  The emission spectra of pyrene were acquired 
by exciting samples at 335 nm (Ex slit width 5 nm, Em slit width 5 nm). The spectra 
were then used to determine the ratio of II/III as shown; 
Compound 82: 
 
Equations of each slope:                    y = 0.0287ln(x) + 0.8987 
            y = 0.0012ln(x) + 0.8029 
Determination of intercept (x): 
∴ 0.0287 ln(𝑥) + 0.8987 = 0.0012 ln(𝑥) + 0.8029 
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              0.0958 =  −0.0275 ln(𝑥) 
            ln(𝑥) =  
0.0958
−0.0275
 
      ln(𝑥) =  −3.48 
            𝑥 = 0.0308 𝑚𝑔/𝑚𝐿 
Compound 83: 
 
Equations of each slope:                    y = 0.0237ln(x) + 0.8805 
            y = -0.002ln(x) + 0.7831 
 
Determination of intercept (x): 
        ∴ 0.0237 ln(𝑥) + 0.8805 = −0.002 ln(𝑥) + 0.7831 
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                  0.0974 =  −0.0257 ln(𝑥) 
                    ln(𝑥) =  
0.0974
−0.0257
 
           ln(𝑥) =  −3.79 
                 𝑥 = 0.0226 𝑚𝑔/𝑚𝐿 
Compound 85: 
 
Equations of each slope:                    y = -0.003ln(x) + 0.7804 
            y = 0.0222ln(x) + 0.8693 
 
Determination of intercept (x): 
         ∴ 0.033 ln(𝑥) + 0.7804 = 0.0222 ln(𝑥) + 0.8693 
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                 0.0889 =  −0.0252 ln(𝑥) 
                  ln(𝑥) =  
0.0889
−0.0252
 
        ln(𝑥) =  −3.53 
              𝑥 = 0.0293 𝑚𝑔/𝑚𝐿 
Compound 98: 
 
Equations of each slope:                    y = 0.0026ln(x) + 0.8443 
            y = 0.5768ln(x) + 1.9936 
 
Determination of intercept (x): 
              ∴ 0.0026 ln(𝑥) + 0.8443 = 0.5768 ln(𝑥) + 1.9936 
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                  −1.1493 =  0.5742 ln(𝑥) 
                         ln(𝑥) =  
−1.1493
0.5742
 
            ln(𝑥) =  −2.002 
                   𝑥 = 0.1351 𝑚𝑔/𝑚𝐿 
Compound 99: 
 
Equations of each slope:                    y = 0.1117ln(x) + 1.1782 
            y = 0.5768ln(x) + 1.9936 
 
Determination of intercept (x): 
                      ∴ 0.1117 ln(𝑥) + 1.1782 = −8 × 10ିସ ln(𝑥) + 0.8375 
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                  −0.3407 =  0.1125 ln(𝑥) 
                         ln(𝑥) =  
−0.3407
0.1125
 
            ln(𝑥) =  −3.0284 
                  𝑥 = 0.0484 𝑚𝑔/𝑚𝐿 
7.2.4 Determination of CAC using surface tension method 
The surface tension properties of amphiphiles in solution at the air/water interface was 
determined by the Wilhelmy plate technique. The surfactant solution was prepared 24 
hrs prior to the measurements using Milli-Q water (resistivity of 18.2 MΩ.cm, surface 
tension of 72.0 mN/m at 20 oC). The solution was heated at 60 °C for 1 hr in a sonic bath 
so as to solubilise the compound before being left to equilibrate at rt for 23 hrs. 
Immediately prior to the measurement the solution was filtered through a 0.45 μm filter 
and 20 mL of the filtered surfactant solution was transferred in a glass trough. Surface 
tensions were determined by dilution technique. In a typical experiment, ~ 50 to 70 
concentration steps were used with ~ 20 mins between each concentration step. The 
platinum plate was cleaned by flaming before experiments. The glassware was cleaned 
with sulfochromic solution then rinsed with Milli-Q water. All measurements were made 
at 20 ± 0.5 °C. 
7.2.5 Determination of particle size using dynamic light scattering 
The dynamic light scattering measurements were performed with a Zetasizer Nano ZS 
(Malvern Instruments) at a scattering angle of 173°. The concentrations of the 
surfactants were sufficiently low enough (0.46 mM-0.72 mM) to avoid multiple 
scattering from the aggregates.  Solutions were prepared at 10 × CAC from a stock 
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solution of 1 mg/mL in Milli-Q water and sonicated for 30 mins to ensure adequate 
dissolving before being left to equilibrate overnight. All solutions were filtered with 0.45 
μm filter directly into the cuvette immediately before measurement to avoid interference 
from dust particles. Measurements were taken at 25 ºC unless otherwise stated.  
Representative DLS output demonstrating the particle size distribution of 
compound 85; 
 
7.2.6 TEM and Cryo-TEM 
All TEM and Cryo-TEM experiments were carried out by Lynne Waddington at CSIRO. 
A laboratory-built humidity-controlled vitrification system was used to prepare the 
samples for Cryo-TEM. Humidity was kept close to 80% for all experiments, and 
ambient temperature was 22 °C.   200-Mesh copper grids coated with perforated carbon 
film (Lacey carbon film: ProSciTech, Qld, Australia) were glow discharged in nitrogen 
to render them hydrophilic.  Aliquots (4μL) of the sample were pipetted onto each grid 
prior to plunging.  After 30 secs adsorption time the grid was blotted manually using 
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Whatman 541 filter paper, for ~ 2 secs. Blotting time was optimised for each sample. 
The grid was then plunged into liquid ethane cooled by liquid nitrogen. Frozen grids 
were stored in liquid nitrogen until required.   The samples were examined using a Gatan 
626 cryoholder (Gatan, Pleasanton, CA, USA) and Tecnai 12 Transmission Electron 
Microscope (FEI, Eindhoven, The Netherlands) at an operating voltage of 120 KV. At 
all times low dose procedures were followed, using an electron dose of 8-10 
electrons/Å2 for all imaging. Images were recorded using an Eagle 4kx4k CCD camera 
(FEI, Eindhoven, The Netherlands) using magnifications in the range 15 000 – 60 000x 
7.3 Chapter 4 
7.3.1 Synthesis of conjugated Tamoxifen amphiphiles 119 and 120 
Synthesis of 2-[2-(2-hydroxyethoxy)ethyl]-4-aza-tricyclo[5.2.1.02,6]hex-3,5-one 105 
To a 35 mL microwave vial containing 2-(2-aminoethoxy)ethanol 104 (2.28 mL, 23 
mmol), norbornene anhydride 21 (2 g, 12.2 mmol) was added and dissolved with PhMe 
(15 mL).  The solution was then subjected to microwave irradiation at 100 ºC for 20 
mins.  The resulting solution was diluted with CH2Cl2 (30 mL) and was transferred to a 
separating funnel where it was washed with saturated aqueous NaCl (2 × 25 mL) 
followed by HCl (2M, 20 mL) and finally NaHCO3 (3 × 25 mL).   The combined 
organic phases were dried (MgSO4) and solvent removed in vacuo to give a yellow 
viscous oil. 1H NMR spectroscopy analysis showed it to be the desired ethoxy imide 105 
(2.63 g, 88%) in > 95% purity which was then used without further purification. 1H 
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NMR (270 MHz, CDCl3): δ 6.09 (2H, t, J = 2.7 Hz, H8 H9), 3.65-3.63 (2H, d, J = 5.4 
Hz, H1'), 3.59-3.47 (2H, m, H2'), 3.39-3.35 (2H, m, H5'), 3.29-3.22 (2H, m, H4'), 2.59 
(2H, br s, H2 H6), 1.83 (2H, br s, H1 H7), 1.74-1.69 (1H, dt, J = 10.8, 16.2 Hz, H10), 
1.55-1.49 (1H , dt, J = 8.1, 13,5 Hz, H10), OH not observed;  13C NMR (100 MHz, 
CDCl3): δ 178.10, 134.41, 72.22, 67.70, 61.58, 52.16, 45.81, 44.94, 37.86; HRMS (ESI 
m/z): Calcd. For [C13H18NO4] + 252.12303, found 252.12400; ν(max) cm -1: 3452 br, 2944 
m, 2871 m, 1684 s. 
Synthesis of 2-(2-ethoxy)ethyl-methylbenzenesulfonate-4-aza-
tricyclo[5.2.1.02,6]dodec-3,5-one 107 
To a solution of ethoxy imide 105 (2.74 g, 10.8 mmol) in CH2Cl2 (30 mL), p-
toluenesulfonyl chloride 108 (3.09 g, 16.2 mmol) was added and stirred until dissolved. 
NEt3 was added (1.5 mL, 10.8 mmol) and the resulting solution was stirred for under 
nitrogen for 24 hrs before being diluted with CH2Cl2 (30 mL) and was transferred to a 
separating funnel where it was washed with saturated aqueous NaCl (3 × 25 mL) and the 
combined organic phases dried (MgSO4) and solvent removed in vacuo to give a beige 
viscous oil. Purification by silica gel column chromatography was performed with a 
50% Pet. spirit – 50% EtOAc eluent and the resulting oil was shown by 1H NMR 
spectroscopy analysis to be the desired tosyl imide 107 (3.70 g, 85%). 1H NMR (270 
MHz, CDCl3): δ  7.76 -7.73 (2H, d, J = 8.1 Hz, Ar-H), 7.33-7.30 (2H, d, J = 8.1 Hz, Ar-
H), 6.01-6.59 (2H, t, J = 8.1 Hz, H8 H9), 4.06-4.04 (2H, t, J = 2.7 Hz, H5'), 3.57-3.53 
(2H, m, H1'), 3.46-3.39 (2H, m, H4'), 3.32-3.31 (2H, m, H2'), 3.23-3.22 (4H, m, H2 H6 
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H1 H7), 2.41 (3H, s, H12'), 1.70-1.65 (1H, d, J = 12.15 Hz, H10), 1.51-1.47 (1H, d, J = 
12.15 Hz, H10); 13C NMR (100 MHz, CDCl3): δ 177.71, 144.93, 134.48-134.36, 132.93, 
130.06, 129.86, 69.22, 67.99-67.31, 52.19, 45.85, 44.87, 37.30, 21.80; HRMS (ESI m/z): 
Calcd. For [C20H24NO6S]+ 406.13188, found 406.13400; ν(max) cm -1: 2946 m, 2873 m, 
1697 s. 
Synthesis of Desmethyl Tamoxifen 102 
The synthetic procedure was adapted from Dreaden et al.53 Briefly, a solution of 
Tamoxifen 1 (500 mg, 1.35 mmol) and CH2Cl2 was cooled to 0 °C before the addition of 
α-chloroethyl chloroformate 109 (0.23 mL, 2.0 mmol). The resulting solution was stirred 
for the 15 mins at 0 °C before being heated to reflux for 24 hrs. The solvent was then 
removed in vacuo, and the resulting clear oil redissolved in MeOH before being heated 
to refluxed for a further 3 hrs. The solvent was removed in vacuo to give a yellow solid. 
Purification by silica gel column chromatography was performed with a 10% MeOH in 
CHCl3 eluent and the resulting white solid was shown by 1H NMR spectroscopy analysis 
to be consistent with literature values53 for the desired demethylated Tamoxifen 102 
(506 mg, 95%). 1H NMR (270 MHz, DMSO-d6): δ  8.98 (1H, br s, H26), 7.41-7.11 
(10H, m, Ar-H), 6.79-6.76 (2H, d, J = 8.1 Hz, H17 H18), 6.68-6.64 (2H, d, J = 10.8 Hz, 
H5 H6), 4.12-4.08 (2H, t, J = 5.4 Hz, H2), 3.14-3.10 (2H, t, J = 5.4 Hz, H1), 2.48 (3H, s, 
H27), 2.39-2.36 (2H, d, J = 5.4 Hz, H12), 0.87-0.83 (3H, t, J = 5.4 Hz, H13). 
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Synthesis of 2-(2-ethoxy)ethyl-methylbenzenesulfonate-4-aza-
tricyclo[5.2.1.02,6]dodec-3,5-one-8, 9-diol 124 
Tosyl Imide 107 (1.44 g, 3.0 mmol) was dissolved in a 4:1 solution of acetone/water (30 
mL) and NMO (628 mg, 5.0 mmol) was added and stirred until dissolved. Osmium 
tetroxide (0.2 mL, 4 wt.% in H2O) was added and the black solution stirred for 16 hrs at 
rt. The reaction was quenched with sodium metabisulfite (2 mL, 0.53 M) and the 
solution diluted with EtOAc (30 mL) before being transferred to a separating funnel 
where it was washed with saturated aqueous NaCl (3 × 25 mL).  The organic phase was 
dried (MgSO4) and solvent was removed in vacuo to afford a yellow oil. Purification by 
silica gel column chromatography was performed with 100% EtOAc eluent and the 
resulting pale yellow oil was shown by 1H NMR spectroscopy to be the desired tosyl 
diol 124 (1.09 g, 83%).  1H NMR (400 MHz, CDCl3): δ 7.79-7.77 (2H, d, J = 8.0 Hz, 
Ar-H), 7.38-7.36 (2H, d, J = 8.0 Hz, Ar-H), 4.12-4.07 (2H, m, H5'), 3.86 (2H, s, H1'), 
3.67-3.58 (4H, m, H4' H8 H9), 3.29 (2H, br s, H2'), 3.08-3.06 (2H, m, H2 H6), 2.70 (2H, 
br s, H1 H7), 2.45 (3H, s, H12'), 2.16-2.13 (1H, d, J = 12.0 Hz, H10), 1.49-1.46 (1H, d, J 
= 12.0 Hz, H10), 2 × OH not observed; 13C NMR (100 MHz, CDCl3): δ 177.06, 145.53, 
130.20, 129.11, 128.30, 128.17, 128.15, 70.03, 69.92, 68.10, 67.29, 46.06, 45.81, 37.92, 
36.18; HRMS (ESI m/z): Calcd. For [C20H26NO8S]+ 440.13736, found 440.13965; 
ν(max) cm -1: 3454 br, 2952 m, 1697 s. 
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Synthesis of 4-undecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]dodec-3,5-one-2-(2-
ethoxy)ethyl-methylbenzenesulfonate 125 
To a solution of dodecyl aldehyde 66 (0.34 mL, 1.52 mmol) in CH2Cl2 (30 mL), tosyl 
diol 124 (333 mg, 0.760 mmol) was added and stirred until dissolved. To this solution, 
MgSO4 was added, followed by the addition of p-toluenesulfonic acid (577 mg, 3.03 
mmol). The resulting solution was warmed to 35 °C and stirred for 24 hrs before being 
filtered and the solvent was removed in vacuo to give a light brown oil. Purification by 
silica gel column chromatography was performed with a 60% Pet. spirit – 40% EtOAc 
eluent  and the resulting caramel oil was shown by 1H NMR spectroscopy analysis to be 
the desired dodecyl acetal 125 (348 mg, 76%). 1H NMR (270 MHz, CDCl3): δ 7.77-7.74 
(2H, d, J = 8.1 Hz, Ar-H), 7.35-7.32 (2H, d, J = 8.1 Hz, Ar-H), 4.58-4.54 (1H, t, J = 5.4 
Hz, H4), 4.08-4.05  (2H, m, H5'), 3.84 (2H, br s, H2'), 3.63-3.54 (2H, m, H1'), 3.10-3.08 
(2H, m, H4'), 2.81-2.79 (2H, m, H2 H6), 2.43 (3H, s, H12'), 2.02-1.96 (4H, m, H1 H7 
H8 H12), 1.69-1.57 (4H, m, H14, H13), 1.39-1.22 (18H, m, H15-H23), 0.87-0.83 (3H, t, 
J = 5.4 Hz, H24); 13C NMR (100 MHz, CDCl3): δ 174.41, 144.98, 132.98, 130.15, 
129.82, 127.95, 104.27, 77.45, 69.12, 68.14, 67.17, 44.51, 42.90, 42.57, 37.68, 35.92, 
32.76, 31.99, 29.64 - 29.41 (6 × C), 24.23, 22.76, 14.28 HRMS (ESI m/z) : Calcd. For 
[C32H48NO8S]+ 606.30951, found 606.31166; ν(max) cm -1: 2942 m, 2854 m, 1700 s. 
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Synthesis of 4-pentadecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6] dodec-3,5-one--2-(2-
ethoxy)ethyl-methylbenzenesulfonate 126 
To a solution of hexadecyl aldehyde 67 (295 mg, 1.22 mmol) in CH2Cl2 (30 mL), tosyl 
diol 124 (360 mg, 0.819 mmol) was added and stirred until dissolved. To this solution, 
MgSO4 was added, followed by the addition of p-toluenesulfonic acid (623 mg, 3.28 
mmol). The resulting solution was warmed to 35 °C and stirred for 24 hrs before being 
filtered and the solvent was removed in vacuo to give a light brown oil. Purification by 
silica gel column chromatography was performed with a 60% Pet. spirit – 40% EtOAc 
eluent  and the resulting caramel oil was shown by 1H NMR spectroscopy analysis to be 
the desired tosyl hexadecyl acetal 126 (398 mg, 73%). 1H NMR (400 MHz, CDCl3): δ 
7.79-7.76 (2H, d, J = 12.0 Hz, Ar-H), 7.36-7.34 (2H, d, J = 8.0 Hz, Ar-H), 4.59-4.56 
(1H, t, J = 8.0 Hz, H4), 4.10-4.07  (2H, m, H5'), 3.86 (2H, br s, H2'), 3.64-3.56 (2H, m, 
H1'), 3.11-3.10 (2H, m, H4'), 2.83-2.81 (2H, m, H2 H6), 2.45 (3H, s, H12'), 2.02-1.99 
(4H, d, J = 12.0 Hz, H1 H7 H8 H12), 1.64-1.56 (4H, m, H14, H13), 1.40-1.24 (26H, m, 
H15-H27), 0.89-0.85 (3H, t, J = 8.0 Hz, H28);  13C NMR (100 MHz, CDCl3): δ 176.41, 
144.98, 132.90, 130.07-129.90 (5 × C), 128.10, 127.94, 104.50, 77.42, 69.11, 68.15, 
67.18, 44.50, 42.66, 37.69, 32.00, 29.74-29.44 (10 × C), 24.24, 22.78, 14.21 HRMS 
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(ESI m/z): Calcd. For [C36H56NO8S]+ 662.37211, found 662.37125; ν(max) cm -1: 2923 m, 
2853 m, 1702 s. 
Synthesis of 4-undecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6] dodec-3,5-one-6-(2-(2-((2-
(4-((Z)-1,2-diphenylbut-1-en-1-yl)phenoxy)ethyl)(methyl)amino)ethoxy) ethyl) 119 
The synthetic procedure was adapted from Dreaden et al,53 whereby dodecyl acetal 125 
(350  mg, 0.58  mmol) was added to a solution of desmethylated Tamoxifen 102 (152 
mg, 0.39 mmol) in THF. Potassium carbonate was added (532 mg, 3.85 mmol) and the 
resulting solution was heated to reflux for 16 hrs. The solution was then diluted with 
CH2Cl2 and filtered before being transferred to a separation funnel where it was washed 
with saturated aqueous NaHCO3 (3 × 25 mL). The combined organic phases were then 
dried (MgSO4) and solvent removed in vacuo to give a pale yellow oil.  Purification by 
silica gel column chromatography was performed with a 5% MeOH in CH2Cl2 eluent 
and the resulting yellow oil was shown by 1H NMR spectroscopic analysis to be the 
desired amphiphile 119 (69 mg, 21%). 1H NMR (400 MHz, CDCl3): δ 7.36-7.08 (10H, 
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m, Ar-H), 6.76-6.73 (2H, d, J = 12.0 Hz, Ar-H), 6.54-6.50 (2H, d, J = 16.0 Hz, Ar-H), 
4.59-4.56 (1H, t, J = 4.0 Hz, H4), 3.93-3.87 (2H, m, H9'), 3.63-3.49 (4H, m, H1' H2'), 
3.07-3.04 (2H, m, H4'), 2.82-2.80 (2H, m, H2 H6), 2.75-2.71 (2H, t, J = 8.0 Hz, H8'), 
2.63-2.56 (2H, m, H8 H12), 2.48-2.40 (4H, q, J = 12.0, 24.0 Hz, H12' H5'), 2.30 (3H, s, 
H7'), 2.00-1.96 (2H, d, J = 16.0 Hz, H1 H7), 1.69-1.56 (4H, m, H13, H14), 1.32-1.23 
(18H, m, H15-H23), 0.93-0.83 (6H, m, H23 H13'); 13C NMR (100 MHz, CDCl3): δ 
176.46, 143.79, 142.41, 138.33, 132.04, 130.87, 130.76, 129.77, 129.53, 128.20, 127.98, 
127.85, 127.38, 126.64, 126.16, 125.76, 114.20,  104.17, 78.85, 67.44, 56.94, 56.34, 
44.56, 43.12, 42.75, 35.85, 35.03, 32.75, 31.99, 29.69, 29.10, 24.25, 22.77, 14.20, 13.67 
HRMS (ESI m/z): Calcd. For [C50H67N2O6]+ 791.49936, found 791.49871; ν(max) cm -1: 
2924 m, 2854 m ,1702 s. 
Synthesis of 4-pentadecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6] dodec-3,5-one-6-(2-(2-
((2-(4-((Z)-1,2-diphenylbut-1-en-1-yl)phenoxy)ethyl)(methyl)amino)ethoxy) ethyl) 
120 
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The synthetic procedure was adapted from Dreaden et al,53 whereby hexadecyl acetal 
126 (300 mg, 0.453 mmol) was added to a solution of desmethylated Tamoxifen 102 
(119 mg, 0.302 mmol) in THF. Potassium carbonate was added (417 mg, 3.02 mmol) 
and the resulting solution was heated to reflux for 16 hrs. The solution was then diluted 
with CH2Cl2 and filtered before being transferred to a separation funnel where it was 
washed with saturated aqueous NaHCO3 (3 × 25 mL). The combined organic phases 
were then dried (MgSO4) and solvent removed in vacuo to give a pale yellow oil.  
Purification by silica gel column chromatography was performed with a 5% MeOH in 
CH2Cl2 eluent and the resulting yellow oil was shown by 1H NMR spectroscopy analysis 
to be the desired amphiphile 120 (41 mg, 16%). 1H NMR (400 MHz, CDCl3): δ 7.35-
7.07 (10H, m, Ar-H), 6.76-6.74 (2H, d, J = 8.0 Hz, Ar-H), 6.54-6.52 (2H, d, J = 8.0 Hz, 
Ar-H), 4.59-4.57 (1H, t, J = 4.0 Hz, H4), 3.92 (2H, br s, H9'), 3.65-3.56 (4H, m, H1' 
H2'), 3.08-3.06 (2H, m, H4'), 2.82-2.81 (4H, br s, H2 H6 H8'), 2.64 (2H, br s, H8 H12), 
2.47-2.42 (4H, q, J = 8.0, 16.0 Hz, H12 H5'), 2.35 (3H, br s, H7'), 2.00-1.98 (2H, d, J = 
8.0 Hz, H1 H7), 1.63-1.58 (4H, m, H13 H14), 1.37-1.23 (26H, m, H15-H27), 0.93-0.85 
(6H, m, H28 H13'); 13C NMR (100 MHz, CDCl3): δ 176.40, 143.89, 142.48, 141.43, 
138.29, 131.95, 129.78, 129.54, 128.17, 127.95, 126.59, 126.10, 113.44, 104.09, 78.32, 
67.02, 57.23, 56.64, 44.50, 43.43, 42.77, 37.82, 35.87, 35.01, 32.78, 32.01, 29.78-29.58 
(10 × C), 24.27, 22.78, 14.21, 13.67; HRMS (ESI m/z): Calcd. For [C54H75N2O6]+ 
847.56196, found 847.56356; ν(max) cm -1: 2924 m, 2853 m, 1703 s. 
7.3.2 Synthesis of triazole amphiphiles 127 and 128 
Synthesis of 2-(2-azidoethoxy)ethyl-4-aza-tricyclo[5.2.1.02,6]dodec-3,5-one 132 
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Tosyl imide 107 (728 mg, 1.80 mmol) was dissolved in a solution of 8:1 MeCN/H2O 
before the addition of sodium azide (817 mg, 12.56 mmol). The resulting solution was 
then heated to reflux for 24 hrs before being diluted with CH2Cl2 (30 mL) and 
transferred to a separating funnel where it was washed with saturated aqueous NaCl (3 × 
25 mL) and the combined organic phases dried (MgSO4) and solvent removed in vacuo 
to give a beige viscous oil. Attempts at purification by silica gel column chromatography 
were unsuccessful and, as such, the crude oil that was shown by 1H NMR spectroscopy 
analysis to be the desired azide imide 132 (362 mg, 73%) was used in further steps. The 
assignment of the crude product is as follows. 1H NMR (270 MHz, CDCl3): δ 6.04-6.05 
(2H, m, H8 H9), 3.67-3.64 (2H, t, J = 5.4 Hz, H1'), 3.58-3.54 (2H, m, H2'), 3.51 (2H, br 
s, H4'), 3.34-3.33 (2H, m, H5'), 3.30-3.27 (2H, t, J = 5.4 Hz, H2 H6), 3.25-3.22 (2H, q, J 
= 2.7, 5.4 Hz, H1 H7), 1.70-1.67 (1H, d, J = 8.1 Hz, H10), 1.51-1.48 (1H, d, J = 8.1 Hz, 
H10); HRMS (ESI m/z): Calcd. For [C13H17N4O3]+ 277.1280, found 277.12764; 
ν(max) cm -1: 2945 m, 2106 s (azide), 1689 s. 
Synthesis of Ethanamine,2-[4-[(1E)-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-
methyl-propargyl 131 
 Propargyl bromide 136 (0.175 mL, 2.03 mmol) was added to a solution of 
desmethylated Tamoxifen 102 (400 mg, 1.01 mmol) in PhMe and stirred. NEt3 was 
added and the solution heated to reflux for 16 hrs before being diluted with CH2Cl2 (30 
mL). The solution was then transferred to a separating funnel where it was washed with 
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saturated aqueous NaCl (3 × 25 mL), the combined organic phases dried (MgSO4) and 
solvent removed in vacuo to give a pale yellow solid. Purification by silica gel column 
chromatography was performed with a 80% Pet. spirit –20% EtOAc eluent  and the 
resulting white solid was shown by 1H NMR spectroscopic analysis to be the desired 
propargylated Tamoxifen 131 (304 mg, 76%). 1H NMR (400 MHz, CDCl3): δ 7.37-7.09 
(10H, m, Ar-H), 6.77-6.74 (2H, d, J = 12.0 Hz, H17 H18), 6.57-6.53 (2H, d, J = 16.0 Hz, 
H5 H6), 3.94-3.90 (2H, t, J = 8.0 Hz, H2), 3.41-3.40 (2H, d, J = 4.0 Hz, H28), 2.81-2.77 
(2H, t, J = 8.0 Hz, H1), 2.49-2.40 (2H, q, J = 12.0, 24.0 Hz, H12), 2.36 (3H, s, H27), 
2.21-2.19 (1H, t, J = 4.0 Hz, H30), 0.94-0.88 (3H, t, J = 12.0 Hz, H13); 13C NMR (100 
MHz, CDCl3): δ 156.81, 143.91, 142.52, 141.44, 138.35, 135.72, 131.95, 129.81- 127.97 
(5 × C), 113.51, 78.56, 73.45, 65.80, 54.45, 46.06, 42.30, 29.81, 29.11, 13.71; HRMS 
(ESI m/z): Calcd. For [C28H30NO]+ 396.23219, found 396.23240; ν(max) cm -1: 3291 m, 
1704 m, 1572 s, 1173 s, 703 s. 
Attempted synthesis of 6-(2-(2-(4-(((2-(4-((Z)-1,2-diphenylbut-1-en-1-
yl)phenoxy)ethyl)(methyl)amino)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethyl)-4-aza-
tricyclo[5.2.1.02,6]dodec-3,5-one 130 
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To a 35 mL microwave vial containing organic azide 132 (100 mg, 0.362 mmol) was 
dissolved in CuSO4 solution (1 mL, 25 mg/mL in H2O) and ascorbic acid solution (2 
mL, 20 mg/mL in H2O). Propargylated Tamoxifen 131 (143 mg, 0.362 mmol) was 
added and the solution was then subjected to microwave irradiation at 100 ºC for 30 
mins before being diluted with CH2Cl2 (30 mL). The solution was then transferred to a 
separating funnel where it was washed with 4M HCl (3 × 25 mL) followed by H2O (20 
ml). The combined organic phases were dried (MgSO4) and solvent removed in vacuo to 
give a green oil. 1H NMR spectroscopic analysis showed that the desired triazole 130 
was not obtained possibly due to the reactivity of the azide with the alkene moiety. 
Synthesis of 4-undecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]dodec-3,5-one-2-(2-
azidoethoxy) ethyl 145 
Dodecyl acetal 125 (348 mg, 0.575 mmol) was dissolved in a solution of 8:1 
MeCN/H2O before the addition of sodium azide (262 mg, 4.03 mmol). The resulting 
solution was then heated to reflux for 24 hrs before being diluted with CH2Cl2 (30 mL) 
and transferred to a separating funnel where it was washed with saturated aqueous NaCl 
(3 × 25 mL). The combined organic phases dried (MgSO4) and solvent removed in 
vacuo to give a white solid. Attempts at purification by silica gel column 
chromatography were unsuccessful and, as such, the crude product that was shown by 
1H NMR and Mass spectroscopic analysis to contain the desired dodecyl azide 145 (243 
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mg, 89%, crude) which was then purified in the subsequent steps. Characterisation of the 
crude material is as follows. 1H NMR (400 MHz, CDCl3): 4.61-4.59 (1H, t, J = 4.0 Hz, 
H4), 3.93 (4H, s, H1' H2'), 3.68-3.65 (2H, t, J = 12.0 Hz, H4'), 3.62-3.59 (2H, t, J = 4.0 
Hz, H2 H6), 3.34-3.32 (2H, t, J = 4.0 Hz, H5'), 3.12-3.08 (2H, m, H8 H12), 2.84-2.83 
(2H, m, H1 H7), 2.02-1.99 (2H, d,  J = 12.0 Hz, H14), 1.64-1.59 (2H, m, H13), 1.40- 
1.23 (18H, m, H15-H23), 0.87-0.85 (3H, t, J = 4.0 Hz, H24); δ 13C NMR (100 MHz, 
CDCl3): δ  176.48, 104.14, 78.34, 69.45, 67.29, 50.82, 44.53, 42.77, 37.72, 35.88, 34.58, 
32.75, 31.98, 29.70-29.35 (6 × C), 24.26, 22.75, 14.19; HRMS (ESI m/z): Calcd. For 
[C25H41N4O5]+ 477.30715, found 477.30950; ν(max) cm -1: 2992 m, 2854 m, 2108 s 
(azide), 1700 s. 
Synthesis of 4-pentadecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]dodec-3,5-one-2-(2-
azidoethoxy) ethyl 146 
Hexadecyl acetal 126 (2.0 g, 3.0 mmol) was dissolved in a solution of 8:1 MeCN/H2O 
before the addition of sodium azide (1.37 g, 21.10 mmol). The resulting solution was 
then heated to reflux for 24 hrs before being diluted with CH2Cl2 (30 mL) and 
transferred to a separating funnel where it was washed with saturated aqueous NaCl (3 × 
25 mL). The combined organic phases were then dried (MgSO4) and solvent removed in 
vacuo to give a white solid. Attempts at purification by silica gel column 
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chromatography were unsuccessful and, as such, the crude product that was shown by 
1H NMR and  Mass spectroscopic analysis to contain the desired hexadecyl azide 146 
(1.45 g, 91%, crude) was then purified in the subsequent steps. 1H NMR (400 MHz, 
CDCl3): δ 4.61-4.58 (1H, t, J = 4.0 Hz, H4), 3.93 (4H, s, H1' H2'), 3.66-3.64 (2H, t, J = 
4.0 Hz, H4'), 3.62-3.58 (2H, t, J = 8.0 Hz, H2 H6), 3.34-3.30 (2H, t, J = 8.0 Hz, H5'), 
3.10-3.08 (2H, m, H8 H12), 2.84-2.82 (2H, m, H1 H7), 1.99 (2H, s, H14), 1.63-1.57 
(2H, m, H13), 1.40-1.19 (26H, m, H15-H27), 0.87-0.83 (3H, t, J = 8.0 Hz, H28); 13C 
NMR (100 MHz, CDCl3): δ 176.45, 104.26, 78.35, 69.46, 67.22, 50.83, 44.53, 42.86, 
37.72, 32.76, 32.00, 29.74-29.44 (10 × C), 24.28, 22.78, 14.20; HRMS (ESI m/z): Calcd. 
For [C29H49N4O5]+ 533.36975, found 533.37242; ν(max) cm -1: 2917 m, 2850 m, 2112 s 
(azide), 1698 s. 
Synthesis of 4-pentadecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]dodec-3,5-one-6-(2-(2-
(4-(((2-(4-((Z)-1,2-diphenylbut-1-en-1-yl)phenoxy)ethyl)(methyl)amino) methyl)-
1H-1,2,3-triazol-1-yl)ethoxy)ethyl 128 
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To a 35 mL microwave vial containing hexadecyl azide 146 (100 mg, 0.189 mmol) 
CuCl (1.87 mg, 0.0189 mmol) was added and dissolved with CHCl3 (15 mL). 
Propargylated Tamoxifen 131 (75 mg, 0.189 mmol) was added and the solution was then 
subjected to microwave irradiation at 100 ºC for 30 mins before being diluted with 
CHCl3 (30 mL). The biphasic mixture was then transferred to a separating funnel where 
it was washed with 4M HCl (3 × 25 mL) followed by H2O (20 ml). The combined 
organic phases were dried (MgSO4) and solvent removed in vacuo to give a green oil. 
Purification by silica gel column chromatography was performed with a 100% EtOAc 
eluent followed by a 100% EtOH eluent and the resulting yellow oil was shown by 1H 
NMR spectroscopic analysis to be the desired triazole amphiphile 128 (119 mg, 68%). 
1H NMR (400 MHz, CDCl3): δ 7.62 (1H, br s, H10'), 7.35-7.31 (4H, m, Ar-H), 7.27- 
7.21 (2H, m, Ar-H), 7.18-7.07 (4H, m, Ar-H), 6.76-6.74 (2H, d, J = 8.0 Hz, Ar-H), 6.54-
6.52 (2H, d, J = 8.0 Hz, Ar-H), 4.55-4.53 (1H, t, J = 4.0 Hz, H4), 4.43-4.41 (2H, t, J = 
4.0 Hz, H5'), 3.99 (2H, br s, H15'), 3.85 (1H, s, H11'), 3.82-3.76 (4H, m, H1' H2'), 3.62-
3.69 (3H, t, J = 4.0 Hz, H2 H6 H11'), 3.53-3.51 (2H, t, J = 4.0 Hz, H4'), 3.09-3.08 (4H, 
m, H14' H 18'), 2.82 (2H, br s, H8 H12), 2.46-2.37 (3H, m, H13'), 2.00-1.97 (2H, d, J = 
12.0 Hz, H1 H7), 1.63-1.59 (2H, m, H14), 1.38-1.24 (28H, m, H15-H27 H13), 0.92-0.85 
(6H, m, H19' H28); 13C NMR (100 MHz, CDCl3): δ 176.38, 156.68, 143.90, 138.27, 
135.70, 131.93, 129.77, 129.53, 128.18, 127.96, 126.59, 126.11, 124.22, 113.43, 104.21, 
78.31, 68.89, 67.52, 65.69, 55.33, 52.56, 50.18, 44.48, 42.73, 37.69, 35.83, 32.77, 32.00, 
29.78-29.44 (10 × C), 29.09, 24.23, 22.77, 14.21, 13.67; HRMS (ESI m/z): Calcd. For 
[C57H78N5O6]+ 928.59466, found 928.59438; ν(max) cm -1: 2923 m, 2853 m, 1701 s. 
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Synthesis of 4-undecyl-3,5-dioxatetracyclo[5.2.1.08,12.32,6]dodec-3,5-one-6-(2-(2-(4-
(((2-(4-((Z)-1,2-diphenylbut-1-en-1-yl)phenoxy)ethyl)(methyl)amino) methyl)-1H-
1,2,3-triazol-1-yl)ethoxy)ethyl 127 
To a 35 mL microwave vial containing dodecyl azide 145 (258 mg, 0.542 mmol) CuCl 
(5.37 mg, 0.0542 mmol) was added and dissolved with CHCl3 (15 mL). Propargylated 
Tamoxifen 131 (214 mg, 0.542 mmol) was added and the solution was then subjected to 
microwave irradiation at 100 ºC for 30 mins before being diluted with CHCl3 (30 mL). 
The biphasic mixture was then transferred to a separating funnel where it was washed 
with 4M HCl (3 × 25 mL) followed by H2O (20 mL). The combined organic phases 
were dried (MgSO4) and solvent removed in vacuo to give a green oil. Purification by 
silica gel column chromatography was performed with a 100% EtOAc eluent followed 
by a 100% EtOH eluent and the resulting yellow oil was shown by 1H NMR 
spectroscopy analysis to be the desired triazole amphiphile 127 (238 mg, 50%). 1H NMR 
(400 MHz, CDCl3): δ 7.63 (1H, br s, H10’), 7.33-7.31 (4H, m, Ar-H), 7.27-7.21 (2H, m, 
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Ar-H), 7.18-7.08 (4H, m, Ar-H), 6.76-6.74 (2H, d, J = 8.0 Hz, Ar-H), 6.54-6.52 (2H, d, J 
= 8.0 Hz, Ar-H), 4.55-4.53 (1H, t, J = 4.0 Hz, H4), 4.44-4.42 (2H, t, J = 8.0 Hz, H5'), 
4.00 (2H, br s, H15'), 3.86 (1H, s, H11'), 3.70-3.82 (4H, m, H1' H2'), 3.62-3.60 (3H, t, J 
= 4.0 Hz, H2 H6 H11'), 3.54-3.50 (2H, t, J = 8.0 Hz, H4'), 3.09-3.08 (4H, m, H14' H10'), 
2.82 (2H, br s, H8 H12), 2.47-2.38 (3H, m, H13'), 2.00-1.97 (2H, d, J = 12.0 Hz, H1 
H7), 1.64-1.59 (2H, m, H14), 1.38-1.24 (18H, m, H15-H23 H13), 0.93-0.85 (6H, m, 
H24 H19'); 13C NMR (100 MHz, CDCl3): δ 176.41, 156.67, 143.89, 142.47, 141.47, 
138.27, 135.72, 131.93, 129.77, 129.53, 128.18, 127.95, 126.59, 126.11, 113.44, 104.22, 
78.31, 68.90, 67.52, 65.66, 55.31, 52.55, 50.18, 44.49, 43.35, 42.74, 37.69, 35.83, 32.76, 
31.99, 29.71-29.41 (6 × C), 24.41, 24.23, 22.76, 14.20, 13.66; HRMS (ESI m/z): Calcd. 
For [C53H70N5O6]+ 872.53206, found 872.53396; ν(max) cm -1: 2924 m, 2854 m, 1700 s. 
7.3.3 Cryo-TEM 
All Cryo-TEM experiments were carried out by Lynne Waddington at CSIRO. A 
laboratory-built humidity-controlled vitrification system was used to prepare the samples 
for Cryo-TEM. Humidity was kept close to 80% for all experiments, and ambient 
temperature was 22 °C.   200-Mesh copper grids coated with perforated carbon film 
(Lacey carbon film: ProSciTech, Qld, Australia) and overlaid with very thin continuous 
carbon film were glow discharged in nitrogen to render them hydrophilic.  The thin 
carbon overlay was found to be necessary as the cationic particles were consistently 
attracted to the lacey film rather than being suspended in the holes.  Aliquots (4μL) of 
the sample were pipetted onto each grid prior to plunging.  After 30 secs adsorption time 
the grid was blotted manually using Whatman 541 filter paper, for approximately 2 secs. 
Blotting time was optimised for each sample. The grid was then plunged into liquid 
ethane cooled by liquid nitrogen. Frozen grids were stored in liquid nitrogen until 
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required.   The samples were examined using a Gatan 626 cryoholder (Gatan, 
Pleasanton, CA, USA) and Tecnai 12 Transmission Electron Microscope (FEI, 
Eindhoven, The Netherlands) at an operating voltage of 120 KV. At all times low dose 
procedures were followed, using an electron dose of 8-10 electrons/Å2 for all imaging. 
Images were recorded using an Eagle 4kx4k CCD camera (FEI, Eindhoven, The 
Netherlands) using magnifications in the range 15 000 – 60 000x 
7.4 Chapter 5 
Colloidal samples were prepared as described in Section 7.2.5 in triplicate and filtered 
directly into the cuvette before measurement. Samples were equilibrated at each 
temperature (5-55 ºC at 10 ºC intervals) for 3 mins prior to measurement. An average of 
10 measurements per temperature derived from between 15- 25 scans (determined by 
instrument) was taken to be the DH for each temperature. The equilibrium time was 
deemed appropriate as no significant variation in size was observed across the 10 
measurements for each sample. The DH was then plotted against temperature to display 
the trends observed. 
Time lapse experiments were conducted in the same manner, however, the temperature 
was kept consistently at 25 ºC.  
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Appendix A – Dynamic Light Scattering Further Reading 
A monochromatic laser (1) illuminates the colloid solution and the intensity of scattered 
light is measured with a photon detector. An attenuator (2) is used to reduce the intensity 
of this scattering to avoid detector overload. The detector can theoretically be placed at 
any position since the particles can scatter light in all directions (3), however the most 
commonly used angles are 90° and 173°.  
 
Figure 44. Schematic representation of dynamic light scattering setup  
 
Historically, the detector has been placed at the fixed angle of 90° (B), however this 
limits the detectable size range and samples have to be very dilute as to avoid multiple 
scattering. The use of detection at the 173° position (A), also known as backscatter 
detection, reduces multiple scattering as the incident beam does not have to travel 
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through the entire sample. Higher concentrations of sample can also be used as the light 
is passed through a shorter path length of the sample; additionally the effect of multiple 
scattering is at its minimum at 180°, further aiding concentrated samples.  
The digital signal processor then compares the intensity fluctuations at different time 
intervals (4). The intensity fluctuations observed over increasing time periods are 
different than those observed initially with later intensities having no correlation with 
the initial values, however, at shorter time intervals the particle positions are similar and 
are therefore correlated. This decay of correlation is dependent on particle size with 
larger particles displaying a slower decay due to their slower diffusion. Therefore by 
comparing the intensity at time t to itself at time t + τ where τ is the correlation delay 
time and repeating this process at successive, usually logarithmic, delay times a 
correlation function displayed as a correlogram can be obtained.  
This correlator information is then passed onto a computer where specialized software 
analyzes the data to determine particle size (5). Various algorithms are used to fit the 
measured correlation with two main approaches. The first is to fit a single exponential to 
the correlation function to obtain a mean size (quoted as the z-average diameter) 
together with an estimation of the width of distribution, denoted as the polydispersity 
index (PDI). This approach is termed the cumulants analysis. The second approach is to 
fit multiple exponential to obtain the distribution of particle sizes using non-negative 
least squares or CONTIN analysis. The composition and quality of the sample dictates 
which method is best used to display and interpret the data obtained. Regardless of the 
model to which the correlation data fitted by, the Stokes-Einstein equation will be 
employed to calculate the DH. 
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Equations 5. The rate of diffusion (D) can be calculated from correlation decay function 
(left) which then can be used to determine the D H using the Stokes-Einstein equation 
(right)  
The rate of diffusion (D) is then calculated from the correlation decay function using the 
equation below, and the Stokes-Einstein equation (Equation 5) can then be used to 
deduce the DH which is the diameter of a rigid sphere with the same translational 
diffusion coefficient as the nanoparticle being measured.  
The reproducibility of particle sizes obtained using dynamic light scattering can be 
somewhat troublesome. As the very nature of the technique is to examine colloidal 
particles in their native dynamic state it is common to observe slight variations in the 
measurements obtained, however, steps can be undertaken to minimize this effect. As a 
standard operating procedure, ten measurements each, comprising of between 12-20 
scans per sample, were undertaken with the average of these ten measurements being the 
reported hydrodynamic diameter. Careful monitoring of the correlation data and count 
rate ensured no aggregation or sedimentation of the suspension was occurring and that 
the data meet the quality required for the appropriate algorithms for each individual 
measurement. The measurements were then repeated with fresh amphiphilic solutions to 
determine batch to batch reproducibility. While some variation did occur between these 
where;   Γ = Exponential decay 
q = Modulus of scattering vector 
D = Translational diffusion coefficient 
 
where;   D = Translational diffusion coefficient 
k = Boltzmann constant 
T = Absolute temperature 
η =Viscosity of solution 
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batches, as expected with the use of sonication in the preparation of the solutions 
(Section 3.2), the differences were not substantial. 
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Synthesis and preliminary investigations into
norbornane-based amphiphiles and their
self-assembly†
Jennifer S. Squire,a Alessandra Sutti,b Gre´gory Durand,*cd Xavier A. Conlana and
Luke C. Henderson*ab
A range of norbornane based amphiphiles, which possess a rigid ‘kink’ in the centre of amphiphiles,
were accessed via a concise four step synthesis. The self-assembly properties of these novel compounds
were then investigated and the critical aggregation concentration (CAC), hydrodynamic diameter (DH)
by dynamic light scattering (DLS) and their morphology by cryogenic transmission electron microscopy
(cryoTEM) and negatively stained transmission electron microscopy (TEM) were determined. These
compounds while possessing similar CAC values (50–70 mM) exhibited a wide variety of particle size
(60–140 nm) and morphologies, including vesicles, cigar-shaped aggregates and rod-like micelles.
Considering the similarities in molecular structure we have proposed that the unique nature of the
molecular ‘kink’ is aﬀecting molecular assembly in which subtle changes in molecular structure have
large ramifications on aggregate size and morphology.
Introduction
Self-assembly of amphiphilic compounds has been of incred-
ible interest to the scientific community and is at the core of
many cutting-edge technologies in areas of medicine, nutra-
ceuticals, gene-delivery and in the various aspects of materials
science.1–4 It has been noted that even small changes in
molecular structure of the individual amphiphile can have
major ramifications on the morphology of the self-assembled
nanostructures that they produce. Therefore, in the continual
search for more advanced and ‘tailorable’ nanostructures, the
correlation between the molecular structure of amphiphiles
and the characteristics of the aggregates they form is of utmost
importance as this provides insights into molecular features
which contribute to potentially desirable properties for a given
system.
Recently, Matisons and co-workers5 stated that the inclusion
of a rigid portion in the centre of an amphiphile could lead to
the formation of lipid bi-layers and, depending on angular
displacement between hydrophobic tails caused by this rigidity,
may lead to the formation of ribbons or tube-like structures.
The rigid groups referred to by Matisons were typically a
conjugated series of unsaturated carbon–carbon bonds placed
between the polar head group and an unconstrained hydro-
phobic tail.
In this work we have installed a norbornane unit within the
core of a range of amphiphiles as this scaﬀold provides rigidity,
angular displacement while being entirely based on a saturated
hydrocarbon scaﬀold. We hypothesised that the inclusion of a
norbornane unit at the core of the amphiphile structure should
promote the formation of vesicles due to the aforementioned
eﬀects. The norbornane scaﬀold, bearing a primary amine, has
been employed as a counter-ion in a study by Bordes at al.6,7 In
this instance the amino portion of the norbornane was a
60/40 mixture of endo–exo and this system demonstrated large
variations in assembly size with minor changes in molecular
feature. This was largely attributed to the unique bicyclic
structure of the norbornane scaﬀold and its eﬀect on ion
pairing and assembly. The inclusion of the norbornane within
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the amphiphiles has provided the architecture with what we have
termed a molecular ‘kink’ and will be another area of novelty
explored in this work. Additionally, the synthetic methodology
employed within our group using the norbornane scaﬀold is
well established.8
In this manuscript we present a highly versatile synthesis for
accessing norbornane based amphiphilic compounds using
reagents which are ubiquitous within organic chemistry
laboratories worldwide. Additionally, we present preliminary
findings on the physicochemical properties of several amphi-
philes which include critical aggregation concentration (CAC),
hydrodynamic diameter (DH) and morphology using dynamic
light scattering (DLS) and cryogenic transmission electronic
microscopy (cryoTEM) and TEM.
Results and discussion
When considering the synthetic pathway to give amphiphiles of
general structure shown in Scheme 1, we were conscious of
developing a route that could be easily modified to facilitate
analogue synthesis. We began by using mono-protected alkyl-
diamines,8,9 with which we have had previous experience, of
various lengths to access imides 2–5 using microwave irradia-
tion and a slight excess (1.5 equivalents) of the mono-protected
amine.
This protocol worked well for most mono-protected amines
giving high to excellent yields of the corresponding imides (2, 3
and 5) however, compounds 4 and 6 were initially isolated in
very poor yields (typically o20%). Given these low yields brief
microwave optimisations were investigated for these two
amines, slightly increasing the reaction time, temperature
and equivalents of amine (55 min, 120 1C, 2 eq. of amine,
highlighted in Scheme 1 with asterisk) these compounds could
be isolated in synthetically useful yields shown in Scheme 1
(for optimisation table refer to ESI†).
With imides 2–5 in hand, our attention turned to installing
the hydrophobic portion of the amphiphiles. Imides 2–5 were
dihydroxylated using a typical osmium tetroxide–N-methyl-
morpholine-N-oxide (OsO4–NMO) in acetone system to exclu-
sively give the exo-vicinal diols 7–10 (Scheme 2),8 the selective
formation of the diol moiety in this orientation is imperative to
the overarching ‘kink’ in the amphiphile. Note that treatment
of 6 under these dihydroxylation conditions gave very low yields
(typically 10–20%). Despite attempts at optimisation of this
step synthetically viable yields remained elusive; as such this
imide was no longer pursued for further study.
Again, reasonable yields were realised with most compounds,
though it should be noted that the purification of these compounds
proved troublesome.
Installation of the hydrophobic portion of the amphiphiles
was carried out using a cyclodehydration protocol to give a
1,3-dioxolane (acetal) moiety under mildly acidic conditions.10
These acetals were purified and immediately deprotected by
catalytic hydrogenolysis to give the neutral amphiphiles which
were obtained in good yields over two steps (Scheme 3). The
overall yield for the synthesis of these novel norbornane-based
amphiphiles ranged from 42% to 12% in four steps.
As we were interested in the properties of the amphiphiles
in the cationic state, each of the amphiphiles 11–18 were
converted to their corresponding hydrochloride salt using
gaseous HCl.11 It is worth noting that the described synthetic
route can easily incorporate any amine or aldehyde combi-
nation, whether they are commercially available or tailored for
a specific means. For example, the nitrogen unit used for imide
formation could form part of small peptides, proteins or
aptamers for targeted therapeutic purposes.
Given the unusual structural nature of the amphiphiles
synthesised in this study we were curious about the lipophilic
nature of these compounds. Specifically, we were interested
whether the norbornane core is considered part of the lipo-
philic region and how much the cationic spacer unit versus the
alkyl chain (i.e. n versus m, Fig. 1) contributes to the overall
lipophilicity of these compounds.
Scheme 1 Synthesis of imides 2–6.
Scheme 2 OsO4–NMO mediated dihydroxylation of imides 7–10.
Scheme 3 Installation of linear hydrophobic chain via an acetal moiety and
removal of the Cbz protecting group.
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Therefore, the partition coeﬃcients of 11–18 were predicted
using the software ALOGPS12,13 and the values are given in
Table 1. The norbornane (Table 1, entry 1) is reported here as
an indication of what the core unit lipophilic properties are and
thus how the inclusion of separation between the unitsm and n
have on this overall characteristic. In addition to the calculated
values we experimentally determined the log kw0, a parameter
closely associated with log P which is commonly used for small
molecules and amphiphiles.14 For the sake of comparison, with
respect to log P linear n-alkylammonium chloride compounds
were added as well (Table 1, entries 10–13).
In comparing the partition coeﬃcient for compounds 11
and 12, it can be seen that extension of the alkyl chain installed
via the acetal moiety (m) by four methylene units results in a
significant increase of the overall lipophilicity by B1.9 times.
A similar scenario is observed when comparing compounds 13
and 14, compounds 15 and 16 and compounds 17 and 18,
where installation of four carbons on the aliphatic chain has
corresponded to an increase of the lipophilicity by B1.7, 1.3
and 1.3 times, respectively. This clearly shows that the pre-
dicted eﬀect of extending the alkyl chain on the lipophilicity is
more pronounced when the diamino spacer is short (Fig. 2).
Comparison of these same compounds (11 and 12, 13 and
14, 15 and 16, 17 and 18) with respect to the determined log kw0
values shows the same trend though the variation in lipo-
philicity is much smaller.
Continuing with this theme, analysis of compounds, 11 and
13, increasing n by two carbons shows only a mild increase in
log P value (B1.1 times) whereas, as expected, six (15) or eight
(17) carbons of the spacer length led to much more lipophilic
compounds, respectively, 1.8 and 2.1 times when compared to
compound 11 (Fig. 2). A similar scenario was observed when
comparing the n value in compounds 12, 14, 16 and 18 (Fig. 2).
Note that a correlation of both the log P and log kw0 with the
number of methylene units present in these compounds has
been undertaken and is presented in the ESI.†
These diﬀerences suggest that the choice of diamine which
is used for the synthesis has a much less pivotal role in
determining overall lipophilicy of the target compound. The
general trends observed by comparison of log P are supported
by log kw0 though, again, the magnitude of variation is much
smaller in the latter. Disparate results between the classical
octanol partitioning method and the HPLC methods have been
observed for short cationic peptides, most likely because of
interactions with the stationary phase of the column. Due to the
cationic nature of the polar heads, similar interactions may
explain the variation between the predicted and the experi-
mental values.15
Comparing the lipophilicity of the norbornane-based amphi-
philes to that of their linear n-alkyl ammonium chloride deriva-
tives of similar chain length, it appears that the norbornane
scaﬀold does not contribute much to the overall lipophilicity
despite being mostly hydrocarbon based (Table 1). A reason for
the lack of lipophilicity demonstrated by the norbornane core
may be due to the presence of the polar oxygens within the acetal
and carbonyls at each end of the scaﬀold; this in eﬀect may
negate the lipophilic hydrocarbon core of the bicycle.
Indeed n-dodecylammonium chloride exhibits a log P value
(1.64) very close to that of compound 11 (1.77) having 13 alkyl
carbons. With longer alkyl chains, more pronounced diﬀer-
ences are observed as the n-octadecylammonium chloride
exhibits a higher lipophilicity than compounds 14 and 15
although both have an overall number of alkyl carbons of 19
suggesting that the norbornane scaﬀold is not lipophilic by
itself. With this data in hand our attention turned to an
investigation of aggregation properties focusing on compounds
11–14. The selection of these four compounds provides a
comparison of alkyl chain length and amine spacer unit when
incorporated into this novel scaﬀold, additionally compounds
15–18 proved very insoluble in aqueous solution.
Fig. 1 Core scaﬀold for evaluation highlighting m and n spacer units.
Table 1 Predicted and determined lipophilicity values
Entry Compound n m nCa log P log kw0
b
1 Norbornane — — — 1.65c —
2 11 1 10 13 1.77 1.01
3 12 1 14 17 3.28 1.13
4 13 2 10 15 2.00 0.89
5 14 2 14 19 3.44 1.18
6 15 4 10 19 3.13 1.25
7 16 4 14 23 4.22 1.30
8 17 5 10 21 3.66 1.33
9 18 5 14 25 4.65 1.33
10 C12H23NH3Cl — — 12 1.64 —
11 C14H29NH3Cl — — 14 2.53 —
12 C16H33NH3Cl — — 16 3.26 —
13 C18H37NH3Cl — — 18 3.95 —
a Number of alkyl carbons within amphiphiles, for norbornane-based
compounds nC = (2n + m + 1), the acetal carbon being omitted.
b Determined by RP-HPLC. c Data from ref. 7.
Fig. 2 Graphical representation of A log P values versus number of methylene
units.
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Determination of critical aggregation concentration (CAC) by
encapsulation of pyrene
The critical aggregation concentration (CAC) of amphiphilic
species is of paramount importance when considering
their application to biological systems. In our hands, these
compounds proved troublesome to dissolve in water but
adequate solubilisation was achieved by heating at 60 1C under
ultrasonic agitation for an hour (see experimental section for
details). Once dissolved in water the CAC was determined by
monitoring the ratio of fluorescence emitted by the encapsula-
tion of pyrene.16,17
The ratio of pyrene emission peaks at 386 nm and 393 nm
(I386/393) was monitored over a series of concentrations ranging
from 1–0.0001 mg mL1, as per literature procedures.16,18 An
example of the CAC determination of compound 11 is shown in
the ESI† (Page S18), where a sharp increase in the I386/393 value
can be seen at 30.8 mg L1 (70 mM) suggesting that this is the
concentration at which aggregation has occurred, allowing the
encapsulation of pyrene in the aggregate core. The CAC data for
all compounds are summarised in Table 2.
As shown in Table 2, determination of CAC demonstrated
behaviour consistent with log kw0 data as the CAC values
exhibited by compounds 11–14 were fairly insensitive to
changes made to amphiphile structure. This observation corre-
lates well with those reported by Kunitake et al.19 who also used
a rigid scaﬀold in simple ammonium-based single chain
amphiphiles.16 When comparing 11 and 12, only a slight
decrease of the CAC, 22.6 mg L1 (50 mM), was observed for
the latter although it is has an additional four methylene longer
alkyl chain.
As frequently reported for a given polar head group, the
addition of two methylene units to the hydrocarbon chain of a
surfactant decreases 5–15 times the critical aggregation concen-
tration.20,21 A similar observation was made with compounds
13 and 14, the more hydrophobic derivative exhibited a CAC
value only 1.2 times lower than that of 13 (70 mM vs. 60 mM,
respectively) which possesses four fewer carbons. When com-
paring the CAC of compounds 11–14 to that of linear n-alkyl
ammonium compounds, we found out that they were somehow
in relative good agreement with a C16 surfactant. Indeed, the
CAC of n-decyl ammonium chloride was reported to be B0.05
M22 while that of its n-tetradecyl derivative is B3 mM23 and
that of the hexadecyl ammonium bromideB30 mM.24 Similarly,
n-hexadecyl-D-maltosylamine and n-hexadecyl-D-lactosylamine
were found to form aggregates at a threshold concentration
of B12 mM using fluorescence technique.25 Therefore, this
suggests that compounds 11–14 having CAC values ranging from
50 to 70 mM behave more or less like a C16 surfactant with no
significant eﬀect of n and m on the aggregation concentration.
When considering the eﬀect of the length of the diamino
spacer, n, a singular behaviour was also observed as for a given
alkyl chain, similar CAC values were observed for the butyl
diamino derivatives (13 and 14) when compared to the ethyl
diamino ones (11 and 12). This is, however, in agreement with
the partition coeﬃcients as we showed that increasing the
length of the spacer unit from 2C to 4C did not significantly
aﬀect the overall lipophilicity (Table 1). This, again, correlates
well to our previous hypothesis that the length of the diamino
spacer incorporated into this scaﬀold does not play a pivotal
role in overall compound hydrophobicity.
This further confirms the peculiar behaviour of these com-
pounds as they exhibit similar critical aggregation concentra-
tions to that of C16 surfactants.
24,25 Moreover, such a magnitude
of concentration is consistent with other single-chain surfactants
forming bilayer aggregates.19,25
We have attributed these unusual results, which contradict
commonly observed trends, to the unique architecture which is
present in these amphiphiles. Indeed, due to the weakly non-
polar nature of the norbornane core as discussed previously
(see partition coeﬃcient section), as well as its rigid structure
and the kink it provides to the overall molecular architecture,
its insertion within the hydrophobic part of the amphiphile
may alter aggregation and therefore could explain unexpected
behaviour. For instance, although the sulfur atom is usually
considered as a hydrophobic unit when inserted within the
hydrophobic chain of a surfactant, Menger and co-workers
found out that the insertion of a sulfide group causes an
increase in the CAC by 2- to 3-fold, the deeper the insertion,
the higher the increase.26,27
Taking this into account, on one hand, an increased CAC
may be explained by attractive interactions between the
norbornane core and water such as hydrogen bonding leading
to increased solubility. The norbornane group could also
decrease the entropic gain on micellisation by changing the
water structure around the monomer into a less ordered one.
On the other hand, packing constraints could arise from the
rigid and bulky norbornane inserted group. These eﬀects will
be further studied in future work.
Determination of hydrodynamic diameter (DH) by DLS
The hydrodynamic diameter of each amphiphile solution was
determined by Dynamic Light Scattering (DLS) at 25 1C. Hydro-
dynamic diameter for 11 showed a DH of 59 nm. Examination of
12 in an aqueous system showed a bimodal distribution
(Table 3, entry 2) of 79 and 24 nm, these data suggest that
the aggregates formed by 12 are in two distinct populations.
DLS analysis of 13 and 14, gave polydisperse aggregates of 142
and 91 nm, respectively.
Aggregates of B60–160 nm diameter is consistent with
the formation of vesicles as it has been observed with other
Table 2 CAC data for 11–14 via pyrene encapsulation
Entry Cpds n m nC
CACa
(mg L1) (mmol L1)
1 11 1 10 13 30.8 2.1 70 5
2 12 1 14 17 22.6 3.1 50 7
3 13 2 10 15 34.4 1.1 70 2
4 14 2 14 19 29.3 3.7 60 7
a Results are the average of triplicate experiments carried out at 18 1C in
MilliQ water.
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single-chain surfactants.19,25,28 For instance, a recently
designed triazole-based single-chain surfactant was found to
form vesicles whose size varies from 80–100 nm by TEM to
B170 nm by DLS.29 Moreover, Bhattacharya and Acharya
reported that freshly prepared solution of the single chain
n-hexadecyl-D-maltosylamine and n-hexadecyl-D-lactosylamine
compounds form vesicles of 50 to 80 nm diameter. Upon
aging, these vesicles transformed into tubular and lamellar
microstructures.25
Considering the data obtained by DLS, our attention turned
to obtaining morphological information of these aggregates
under cryoTEM conditions.
TEM and CryoTEM imaging
Compound 11 presented in the form of small vesicle aggregates
(Fig. 3) which were visualised by negative stain. Despite
potential morphological changes that can occur by negative
staining, there was excellent agreement between the DH obtained
via DLS and the observed vesicles, cf. 59 nm vs. 65 nm,
respectively.
Analysis of 12 (Fig. 4) gave a bimodal distribution in DLS
and proved very interesting when visualized by cryoTEM
showing two morphological forms, both of which were cylind-
rical. Examination in low contrast revealed elongated forms of
cigar-shaped vesicles as seen in Fig. 4 (labelled A). These
elongated vesicles were the dominant feature of the colloid,
though a number of striated tube-like structures were also seen,
although these were not as common as the cigar like vesicles
but are still considered to be a real feature of the sample (Fig. 4,
labelled B).
Interestingly, 13 has formed large vesicles of classical lipo-
somal structure (Fig. 5), a morphology very similar to that
observed by Bordes et al.7 which was attributed to the stacking
of their norbornane bicyclic structure. Compound 14 also
showed classic spherical vesicles (Fig. 6) which are quite poly-
disperse in size, with a range of 30–500 nm, however the
majority are observed to be between 70–90 nm, corresponding
well to the values obtained from DLS (cf. 91 nm). Most of the
vesicles are smooth with no substructure although occasional
smaller vesicles observed with a slight ‘‘orange peel’’ texture.
We have attributed these diﬀerences in morphology to the
ability of the amphiphiles to stack together, thus creating the
lipid bilayer. It has been shown that the position of the ‘‘rigid
portion’’ of amphiphiles can have ramifications on the overall
morphology of the self assemblies.30 In this study by varying
the value of n and m we have eﬀectively moved the rigid ‘kink’
within the overall architecture of the amphiphiles. As such their
ability to stack must be determined by a delicate balance of n
and m which, in turn, dictates the aggregate morphology, CAC
and size. It was noted that during the course of the CAC studies
Table 3 DH of aggregates
Entry Compound DH
a (nm)
1 11 59 (100%)
2 12 79 (89%)
24 (10%)
3 13 142 (100%)
4 14 91 (100%)
a Hydrodynamic diameter, determined at 10 the CAC value at 25 1C
with volume distribution.
Fig. 3 Compound 11 negatively stained showing vesicles approximately 65 nm
in diameter.
Fig. 4 Compound 12 showing two morphologies, A, cigar shaped vesicle
(57 nm wide, 163 nm long); B, rod-like micelle (20 nm wide, 245 nm long).
Fig. 5 CryoTEM images of 13 showing the formation of vesicles ranging from
150–250 nm.
Fig. 6 Compound 14 showing vesicle formation ranging from 70–90 nm.
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via surface tension measurements that the calculated head
group area at the interface is larger than typically seen in these
systems (data not shown). This may indicate unusual inter-
actions at the surface, possibly arising due to stacking phenom-
ena arising from the kink present in the amphiphile. The
assembly of these compounds may occur in a complementary
fashion, with all the kinks facing in the same direction or,
conversely, in an opposing orientation. Each of these assem-
bling motifs will result in vastly diﬀerent eﬀective critical
packing parameter (CPP)31 thus shedding light on the unusual
behaviour of these compounds. The molecular interactions of
these compounds and their potential assembly modes are
currently under investigation using computational methods
and will be reported in due course.
Conclusions
In conclusion, this manuscript has presented the synthesis and
preliminary investigations into the self-assembly characteris-
tics of several amphiphiles based on a norbornane scaﬀold.
This scaﬀold, while rigid in structure, provides a central ‘kink’
to the amphiphile which has a major eﬀect on how they
assemble in aqueous media. Prediction of partition coeﬃcient
values in silico suggested that the rigid norbornane core has
little-to-no eﬀect on overall compound hydrophobicity. This
was reinforced by the determination of log kw0 which showed
very small variation in lipophlicity among compounds investi-
gated. Additionally the length of the linking group between the
norbornane core and hydrophilic head group has minimal
eﬀect on CAC value and aggregate morphology as is consistent
with log kw0 values. Despite compounds 11–14 possessing
similar CAC values they demonstrated large variations in
aggregate size and morphology. Subtle changes in the distribu-
tion of methylene groups throughout the compounds influenced
the aggregate size (approximately 60–140 nm) and their morpho-
logy in aqueous solution.
Experimental
Dynamic light scattering
The light scattering measurements were performed with a
Zetasizer Nano ZS (Malvern Instruments) at a scattering angle
of 1731. The concentrations of the surfactants were suﬃciently
low enough (0.46–0.72 mM) to avoid multiple scattering from
the aggregates. Solutions were prepared at 10  CAC from a
stock solution of 1 mg mL1 in Milli-Q water and sonicated for
30 min to ensure adequate dissolving before being left to
equilibrate overnight. All solutions were filtered with 0.45 mm
filter directly into the cuvette immediately before measurement
to avoid interference from dust particles. Measurements were
taken at 25 1C unless otherwise stated.
Pyrene encapsulation measurements
The fluorescence properties of pyrene were determined using a
Varian Cary Eclipse fluorescence spectrophotometer. The sur-
factant solutions were prepared 24 h prior to the measurements
using Milli-Q water (resistivity of 18.2 MO cm) at a range of
concentrations (1–0.0001 mg mL1). Excess crystalline pyrene
was then added to the surfactant aqueous solutions and heated
at 30 1C for 30 min in a sonic bath before allowing to
equilibrate at room temperature 23 hours. The solutions were
then filtered through a 0.45 mM filter prior to measurement.
The emission spectra of pyrene were acquired by exciting
samples at 335 nm (Ex slit width 5 nm, Em slit width 5 nm).
The spectra were then used to determine the ratio of I386/393.
Determination of log kw0
The analytes were sequentially injected onto the column
with increasing amounts of organic modifier in the eluent
(water–methanol). Runs were undertaken at ratios of 90 : 10,
70 : 30 and 50 : 50 methanol–water. The value of kw was deter-
mined by extrapolation of the k vs. conc. of organic modifier
back to pure water. The log (base 10) of this value was then
carried out to give the log kw value. Dead time of the system was
determined by injecting acetone through the system and mon-
itoring its retention time.
CryoTEM and TEM
A laboratory-built humidity-controlled vitrification system was
used to prepare the samples for Cryo-TEM. Humidity was kept
close to 80% for all experiments, and ambient temperature was
22 1C. 200-Mesh copper grids coated with perforated carbon
film (Lacey carbon film: ProSciTech, Qld, Australia) were glow
discharged in nitrogen to render them hydrophilic. 4 mL
Aliquots of the sample were pipetted onto each grid prior to
plunging. After 30 seconds adsorption time the grid was blotted
manually using Whatman 541 filter paper, for approximately
2 seconds. Blotting time was optimised for each sample. The
grid was then plunged into liquid ethane cooled by liquid nitrogen.
Frozen grids were stored in liquid nitrogen until required. The
samples were examined using a Gatan 626 cryoholder (Gatan,
Pleasanton, CA, USA) and Tecnai 12 Transmission Electron
Microscope (FEI, Eindhoven, The Netherlands) at an operating
voltage of 120 KV. At all times low dose procedures were
followed, using an electron dose of 8–10 electrons per Å2 for
all imaging. Images were recorded using an Eagle 4k  4k CCD
camera (FEI, Eindhoven, The Netherlands) using magnifica-
tions in the range 15 000–60 000
Synthesis of N-(benzyloxy carbonyl)-1,4-butanediamine
A solution of 1,4-diaminobutane (5.72 mL, 5.67 mmol) in
CH2Cl2 (100 mL) was cooled to 0 1C and a solution of benzyl-
chloroformate (1.62 mL, 11.3 mmol) and CH2Cl2 (150 mL) was
added dropwise over 1 h. The reaction was then stirred at rt for
24 h. The resulting mixture was transferred to a separating
funnel where it was washed with saturated aqueous NaCl
(3  30 mL). The organic phase was dried (MgSO4), filtered
and solvents removed in vacuo to aﬀord a white powder.
1H NMR spectroscopy data was found to be consistent
with literature values8 for the desired monobenzylcarbamate
diamine (2.07 g, 82%) in >95% purity which was then used
without further purification.
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Synthesis of N-(benzyloxy carbonyl)-1,2-diaminoethane
Synthesis of N-(benzyloxy carbonyl)-1,2-diaminoethane was
carried out as per previously described for N-(benzyloxy carbonyl)-
1,4-butanediamine, with 1,2-diaminoethane (6.67mL, 10mmol)
and benzylchloroformate (2.85 mL, 20 mmol mol) to aﬀord a
white paste. 1H NMR spectroscopy data was found to be
consistent with literature values8 for the desired monobenzyl-
carbamate diamine (3.48 g, 90%) in >95% purity which was
then used without further purification.
Synthesis of N-(benzyloxy carbonyl)-1,8-octyldiamine
Synthesis of N-(benzyloxy carbonyl)-1,8-octyldiamine was carried
out as per previously described N-(benzyloxy carbonyl)-1,4-
butanediamine, with 1,8-diaminooctane (3.00 g, 0.021 mol)
and benzylchloroformate (0.6 mL, 0.0042 mol) to aﬀord a white
powder. 1H NMR spectroscopy data was found to be consistent
with literature values8 for the desired monobenzylcarbamate
diamine (0.985 g, 84%) in >95% purity which was then used
without further purification.
Synthesis of N-(benzyloxy carbonyl)-1,10-decyldiamine
Synthesis of N-(benzyloxy carbonyl)-1,10-decyldiamine was carried
out as per previously described for N-(benzyloxy carbonyl)-1,4-
butanediamine, with 1,10-diaminodecane (1.00 g, 0.0058 mol)
and benzylchloroformate (0.17 mL, 0.0012 mol) to aﬀord a
white powder. 1H NMR spectroscopy data was found to be
consistent with literature values8 for the desired monobenzyl-
carbamate diamine (0.208 g, 57%) in >95% purity which was
then used without further purification.
Synthesis of N-(benzyloxy carbonyl)-1,12-dodecyldiamine
Synthesis of N-(benzyloxy carbonyl)-1,12-dodecyldiamine was
carried out as per previously described for N-(benzyloxy carbonyl)-
1,4-butanediamine, with 1,10-diaminodecane (2.00 g, 0.010 mol)
and benzylchloroformate (0.28 mL, 0.002 mol) to aﬀord a white
powder. 1H NMR spectroscopy data was found to be consistent
with literature values8 for the desired monobenzylcarbamate
diamine (0.556 g, 83%) in >95% purity which was then used
without further purification.
Synthesis of benzyl [2-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-
4,7-methanoisoindol-2-yl)butyl]carbamate 3
To a 35 mL microwave vial containing mono-protected diamino-
butane (873 mg, 3.90 mmol), norbornene anhydride (430 mg,
2.6 mmol) was added and dissolved with toluene (15 mL). The
solution was then subjected to microwave irradiation at 100 1C
for 30 min. The resulting solution was diluted with CH2Cl2
(30 mL) and was transferred to a separating funnel where it was
washed with saturated aqueous NaCl (2  25 mL) followed by a
wash with HCl (2 M, 20 mL) and finally NaHCO3 (3  25 mL).
The combined organic phases were dried (MgSO4) and solvent
removed in vacuo to give reddish brown viscous oil. 1H NMR
spectroscopy analysis showed it to be the desired diamino-
butane imide 3 (1.29 g, 90%) in >95% purity which was then
used without further purification. 1H NMR (270 MHz, CDCl3):
d 7.34–7.19 (5H, s), 6.01 (2H, s), 5.01 (2H, s,), 3.28–3.26 (4H, m),
3.18–3.08 (4H, m), 1.73–1.68 (1H, d, J = 13.5 Hz), 1.52–1.42 (5H, m,
2  CH2); 13C NMR (67.5 MHz, CDCl3): d 177.87, 156.59–156.49,
136.71, 134.51, 129.91–128.16, 66.82–66.64, 52.31, 45.79, 44.96,
40.56, 37.91, 27.31, 25.16; HRMS (ESI m/z): calcd for
[C21H25N2O4]
+ 369.1809, found 369.1837; n(max) cm1: 3338 m,
2942 m, 2870 m, 1683 s, 1527 m, 1172 m.
Synthesis of benzyl [2-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-
4,7-methanoisoindol-2-yl)ethyl]carbamate 2
Synthesis of imide 2 was carried out as previously describe for
compound 3 with mono-protected diaminoethane (2 g, 0.01 mol)
and norbornene anhydride (1.13 g, 7.0 mmol) to produce a
yellow oil. 1H NMR spectroscopy analysis showed it to be the
desired diaminoethane imide 2 (2.2 g, 94%) in >95% purity
which was then used without further purification. 1H NMR
(270 MHz, CDCl3): d 7.47–7.31 (5H, s) 6.03 (2H, s) 5.04 (2H, s)
3.46–3.48 (2H, d, J = 5.4 Hz) 3.27–3.32 (2H, m) 3.17 (2H, s)
1.67–1.69 (1H, d, J = 5.4 Hz) 1.46–1.49 (1H, d, J = 8.1 Hz);
13C NMR (67.5 MHz, CDCl3): d 177.96, 156.35, 136.63, 134.51,
128.57–128.17, 66.77, 52.31, 45.87, 44.94, 37.80; HRMS (ESI m/z):
calcd for [C19H21N2O4]
+ 341.1496, found 341.1478; n(max) cm
1:
3349 m, 2945 m, 1691 s, 1525 m, 1188 m.
Synthesis of benzyl [2-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-
4,7-methanoisoindol-2-yl)octyl]carbamate 4
Synthesis of imide 4 was carried out as previously describe for
compound 3 with mono-protected diaminooctane (100 mg,
0.359 mmol) and norbornene anhydride (29.5 mg, 0.180 mmol)
to produce a yellow oil. 1H NMR spectroscopy analysis showed
it to be the desired diaminooctane imide 4 (49 mg, 64%) in
>95% purity which was then used without further purification.
1H NMR (270 MHz, CDCl3): d 7.33–7.35 (5H, s), 6.15 (2H, s), 5.10
(2H, s), 3.21–3.56 (6H, m), 1.69–1.72 (1H, d, J = 8.1 Hz), 1.43–
1.48 (5H, m), 1.22 (8H, s); 13C NMR (67.5 MHz, CDCl3): d 177.51,
156.20, 136.49, 128.80, 128.37, 65.99, 52.30, 45.80, 44.98, 41.34,
38.34, 29.18, 26.85, 26.68; HRMS (ESI m/z): calcd for
[C25H33N2O4]
+ 425.2435 found 425.2428; n(max) cm
1: 3333 m,
2935 m, 2854 m, 1687 s, 1558 m, 1137 m.
Synthesis of benzyl [2-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-
4,7-methanoisoindol-2-yl)dodecanyl]carbamate 5
Synthesis of imide 5 was carried out as previously describe for
compound 3 with mono-protected diaminodecane (1.05 g,
0.003 mol) and norbornene anhydride (563 mg, 0.002 mol) to
produce a yellow oil. 1H NMR spectroscopy analysis showed it
to be the desired diaminodecane imide 5 (1.22 g, 79%) in >95%
purity which was then used without further purification.
1H NMR (270 MHz, CDCl3): d 7.32–7.30 (5H, s), 6.11 (2H, s),
5.05 (2H, s), 3.34–3.18 (8H, m), 1.68–1.71 (1H, d, J = 8.1 Hz),
1.47–1.45 (5H, m), 1.23 (10H, s); 13C NMR (67.5 MHz, CDCl3):
d 177.86, 156.48, 137.01, 134.47, 128.57–128.12, 66.59, 52.27,
45.77, 44.96, 38.49, 29.42, 29.36, 26.92; HRMS (ESI m/z): calcd
for [C27H37N2O4]
+ 453.2748, found 453.2763; n(max) cm1:
3348 m, 2926 m, 2854 m, 1692 s, 1531 m, 1129 m.
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Synthesis of benzyl [2-(5,6-dihydroxy-1,3-dioxooctahydro-2H-
4,7-methanoisoindol-2-yl)butyl]carbamate 8
Diaminobutane imide 3 (1.03 g, 2.70 mmol) was dissolved in a
4 : 1 solution of acetone–water (30 mL) and NMO (493 mg,
4.0 mmol) was added and stirred until dissolved. Osmium
tetroxide (0.3 mL, 4% in H2O) was added and the black solution
stirred for 72 h at room temperature. The reaction was
quenched with sodium metabisulfite (2 mL, 0.53 M) and the
solution diluted with EtOAc (30 mL) before being transferred to
a separating funnel where it was washed with saturated aqueous
NaCl (3  25 mL). The organic phase was dried (MgSO4) and
solvent was removed in vacuo to aﬀord a dark brown oil.
Purification by silica gel column chromatography was per-
formed with 80% EtOAc–20% petroleum spirit solution and
the resulting brown oil was shown by 1H NMR spectroscopy to
be the desired diaminobutane diol 8 (733 mg, 67%). 1H NMR
(270 MHz, CDCl3): d 7.30–7.27 (5H, s), 5.01 (2H, s), 3.98 (2H, s),
3.64 (2H, s), 3.44–3.39 (2H, t, J = 8.1 Hz), 3.11–3.09 (2H, d, J = 5.4 Hz),
2.63 (2H, s), 2.39 (2H, br s), 2.08–2.04 (2H, d, J = 10.8 Hz),
1.48–1.40 (4H, m); 13C NMR (67.5 MHz, CDCl3): d 177.30,
156.85, 136.40, 128.64, 70.19, 66.92, 45.82, 45.75, 40.68, 38.27,
36.00, 29.75, 27.55, 25.16 HRMS (ESI m/z): calcd for
[C21H26N2NaO6]
+ 425.1683, found 425.1657; n(max) cm
1: 3368 br,
2942 m, 1689 s, 1537 m, 1139 m.
Synthesis of benzyl [2-(5,6-dihydroxy-1,3-dioxooctahydro-2H-
4,7-methanoisoindol-2-yl)ethyl]carbamate 7
Synthesis of diaminoethane diol 7 was carried out as previously
describe for compound 8 with diaminoethane imide 2 (1.04 g,
3.0 mmol) and NMO (539 mg, 4.6 mmol) to produce a dark
brown oil. Purification by silica gel column chromatography
was performed with 90% EtOAc–10% petroleum spirit solution
and the resulting light brown oil was shown by 1H NMR
spectroscopy to be the desired diaminoethane diol 7 (578 mg,
51%). 1H NMR (270 MHz, CDCl3): d 7.32 (5H, s), 5.09 (2H, s),
3.64 (2H, s), 3.58–3.55 (4H, m), 3.37–3.35 (2H, d, J = 5.4 Hz), 2.90
(2H, s), 2.61 (2H, s), 2.11–2.09 (1H, d, J = 5.4 Hz), 1.43–1.39 (1H,
t, J = 5.4 Hz); 13C NMR (67.5 MHz, CDCl3): d 177.54, 156.92,
136.39, 128.63–128.32, 70.15, 67.12, 45.76, 39.22, 35.99 HRMS
(ESI m/z): calcd for [C19H23N2O6]
+ 375.1551, found 375.1578;
n(max) cm
1: 3368 br, 2924 m, 2854 m, 1692 s, 1533 m, 1145 m.
Synthesis of benzyl [2-(5,6-dihydroxy-1,3-dioxooctahydro-2H-
4,7-methanoisoindol-2-yl)octyl]carbamate 9
Synthesis of diaminooctane diol 9 was carried out as previously
describe for compound 8 with diaminooctane imide 4 (228 mg,
0.54 mmol) and NMO (94.4 mg, 0.81 mmol) to produce a dark
brown oil which was then used without further purification.
Purification by silica gel column chromatography was attempted
for analysis purposes with 80% EtOAc–20% petroleum spirit
solution and the resulting light brown oil was shown by
1H NMR spectroscopy to be the desired diaminooctane diol 9.
1H NMR (270 MHz, CDCl3): d 7.34 (5H, s), 5.07 (2H, s), 3.73
(2H, s), 3.43 (2H, s,), 3.17–3.15 (2H, d, J = 8.1 Hz), 3.04 (1H, s),
2.67 (1H, s), 2.14–2.11 (1H, d, J = 12.0 Hz), 1.73 (1H, s),
1.52–1.47 (4H, d, J = 20 Hz), 1.28 (2H, s), 1.25 (8H, s);
13C NMR (67.5 MHz, CDCl3): d 177.04, 156.85, 136.47,
128.63–128.23, 70.26, 66.93, 46.01, 45.76, 40.77, 36.02, 29.85,
28.60, 27.80, 26.63, 26.01 HRMS (ESI m/z): calcd for
[C25H35N2O6]
+ 459.2490, found 459.2475; n(max) cm
1: 3347 br,
2929 m, 2856 m, 1692 s, 1534 m, 1139 m.
Synthesis of benzyl [2-(5,6-dihydroxy-1,3-dioxooctahydro-2H-
4,7-methanoisoindol-2-yl)dodecanyl]carbamate 10
Synthesis of diaminodecane diol 10 was carried out as pre-
viously describe for compound 8 with diaminodecane imide 5
(673 mg, 1.5 mmol) and NMO (262 mg, 2.23 mmol) to produce a
black oil which was shown by 1H NMR spectroscopy to be the
desired diaminodecane diol 10 (334 mg, 46%). Numerous
attempts at purification by silica gel column chromatography
were unsuccessful so the crude product was used without
further purification. 1H NMR (270 MHz, CDCl3):
1H NMR
(270 MHz, CDCl3): d 7.32–7.29 (5H, m), 5.08 (2H, s), 3.66 (3H,
br s), 3.40–3.34 (2H, t, J = 8.1 Hz), 2.64–2.62 (2H, m), 2.01–1.97
(2H, br s), 1.44–1.41 (7H, m), 1.22–1.16 (13H, m); 13C NMR
(67.5 MHz, CDCl3): d 177.13, 156.67, 136.64, 128.60–128.19,
70.15, 66.74, 45.97, 38.76, 35.97, 29.93–29.07, 28.91, 26.86
HRMS (ESI m/z): calcd for [C27H38N2NaO6]
+ 509.2622, found
509.2614; n(max) cm1: 3350 br, 2926 m, 2854 m, 1685 s, 1533 m,
1151 m.
Synthesis of benzyl [2-(2-dodecyl-5,7-dioxooctahydro-6H-4,8-
methano[1,3]dioxolo[4,5-f]isoindol-6-yl)butyl]carbamate and
the corresponding deprotected amphiphile 13
To a solution of dodecyl aldehyde (0.3 mL, 1.36 mmol) in
CH2Cl2 (30 mL), diaminobutane diol 8 (366 mg, 0.909 mmol)
was added and stirred until dissolved. MgSO4 was added,
followed by the addition of p-toluenesulfonic acid (692 mg,
3.64 mmol). The resulting solution was warmed to 35 1C and
stirred for 24 h before being filtered and the solvent was
removed in vacuo to give a light brown oil. Purification by silica
gel column chromatography was performed with a 70% petro-
leum spirit–30% EtOAc solution and the resulting caramel oil
was shown by 1H NMR spectroscopy analysis showed it to be
the desired diaminobutane dodecyl acetal (314 mg, 61%) in
>95% purity which was then used immediately in the next
deprotection step. 1H NMR (270 MHz, CDCl3): d 7.33 (5H, s),
5.07 (2H, s), 4.63–4.60 (1H, t, J = 2.7 Hz), 3.84 (2H, s), 3.43 (2H,
d, J = 5.4 Hz, 2  CH), 3.20–3.18 (2H, d, J = 5.4 Hz), 3.07 (2H, s,
2  CH), 2.83 (2H, s), 2.35–2.29 (1H, t, J = 16.2 Hz), 2.01–1.98
(1H, d, J = 8.1 Hz), 1.61–1.51 (6H, m, 3  CH2), 1.24 (18H, bs),
0.88 (3H, t, J = 13.5 Hz, CH3);
13C NMR (67.5 MHz, CDCl3):
d 176.4, 156.5, 136.6, 128.6–128.20, 104.2, 101.8, 77.5–76.64,
66.8, 44.5, 42.7, 40.5, 38.2, 37.4, 35.9, 32.7, 31.9, 29.8–29.2, 27.5,
25.1, 24.3, 22.8, 14.2; HRMS (ESI m/z): calcd for [C33H49N2O6]
+
569.3585, found 569.3592; n(max) cm
1: 2923 s, 2853 s, 1698 s,
1521 m, 1132 m. Palladium on activated carbon (31 mg, 10% w/w)
was then suspended in methanol (50 mL) and left to stir before
the addition of the diaminobutane dodecyl acetal (314 mg,
0.55 mmol) in methanol (50 mL). The reaction mixture was
stirred under H2(g) for 24 h before being vacuum filtrated
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through a celite plug and the filtrate removed in vacuo to give a
white paste. Analysis by 1H NMR spectroscopy determined the
loss of the singlet resonance at d 5.07 ppm indicating the
successful deprotection of the benzyl carbamate to aﬀord
compound 13 (211 mg, 88%) in >95% purity which was then
used without further purification. HRMS (ESI m/z): calcd for
[C25H43N2O4 H
+] 435.3217, found 435.3233; n(max) cm1: 2923 s,
2853 s, 1697 s.
Synthesis of benzyl [2-(2hexaodecyl-5,7-dioxooctahydro-6H-4,8-
methano[1,3]dioxolo[4,5-f]isoindol-6-yl)butyl]carbamate and
the corresponding deprotected amphiphiles 14
Synthesis of diaminobutane hexadecyl acetal was performed as
per previously described for diaminobutane dodecyl acetal with
diaminobutane diol 8 (246 mg, 0.613 mmol) and hexadecyl
aldehyde (221 mg, 0.919 mmol) to aﬀord a light yellow oil.
Purification by silica gel column chromatography was per-
formed with a 70% petroleum spirit–30% EtOAc solution and
the resulting caramel oil was shown by 1H NMR spectroscopy
analysis showed it to be the desired diaminobutane hexadecyl
acetal (286 mg, 75%) in >95% purity which was then used
immediately in the next deprotection step. 1H NMR (270 MHz,
CDCl3): d 7.38–7.28 (5H, m), 5.06 (2H, s), 4.62–4.59 (1H, t, J =
5.4 Hz), 3.84 (2H, s), 3.44–3.40 (2H, t, J = 5.4 Hz, 2  CH),
3.22–3.17 (2H, d, J = 13.5 Hz), 3.08–3.06 (2H, m, 2  CH), 2.83–
2.81 (2H, m, 2  CH), 2.02–1.97 (2H, d, J = 13.5 Hz), 1.62–1.32
(6H, m, 3  CH2), 1.22 (26H, bs), 0.88–0.83 (3H, t, J = 5.4 Hz)
13C NMR (67.5 MHz, CDCl3): d 179.7, 176.4, 156.5, 139.4, 136.5,
128.6–128.2, 114.4, 104.1, 77.6–76.6, 66.8, 44.5, 42.7, 40.5,
38.2, 35.9, 34.2, 32.7, 32.0, 29.8–29.03, 27.5, 25.1, 24.7, 24.3,
22.8, 14.2; HRMS (ESI m/z): calcd for [C37H57N2O6]
+ 625.4211,
found 625.4200; n(max) cm1: 3368 m, 2924 s, 2853 s, 1697 s,
1532 m, 1137 m. Deprotection of diaminobutane hexadecyl
acetal (377 mg, 0.60 mmol) was then carried out as per
previously described for diaminobutane dodecyl acetal with
palladium on activated carbon (38 mg, 10% w/w) to aﬀord a
white paste. Analysis by 1H NMR spectroscopy determined the
loss of the singlet resonance at d 5.06 ppm indicating the
successful deprotection of the benzyl carbamate to aﬀord
compound 14 (263 mg, 89%) in >95% purity which was then
used without further purification. HRMS (ESI m/z): calcd for
[C29H51N2O4]
+ 491.3843, found 491.3824; n(max) cm
1: 2920 s,
2851 s, 1698 s.
Synthesis of benzyl [2-(2-dodecyl-5,7-dioxooctahydro-6H-4,8-
methano[1,3]dioxolo[4,5-f]isoindol-6-yl)ethyl]carbamate and
the corresponding deprotected amphiphile 11
Synthesis of diaminoethane dodecyl acetal 11 was performed as
per previously described for diaminobutane dodecyl acetal with
diaminoethane diol 7 (212 mg, 0.566 mmol) and dodecyl
aldehyde (0.19 mL, 0.849 mmol) to aﬀord a light yellow oil.
Purification by silica gel column chromatography was performed
with a 60% petroleum spirit–40% EtOAc solution and the
resulting caramel oil was shown by 1H NMR spectroscopy analysis
showed it to be the desired diaminoethane dodecyl acetal
(188 mg, 61%) in >95% purity which was then used immediately
in the next deprotection step. 1H NMR (270 MHz, CDCl3):
d 7.32 (5H, s), 5.02 (2H, s), 4.59–4.55 (1H, t, J = 10.8 Hz), 3.83
(2H, s), 3.58–3.57 (2H, t, J = 4.0 Hz, 2 CH), 3.38–3.36 (2H, d, J =
5.4 Hz), 2.96–2.95 (1H, d, J = 2.7 Hz, 1  CH), 2.78 (1H, s, 1 
CH), 2.33–2.27 (1H, t, J = 8.1 Hz), 1.99–1.95 (1H, d, J = 10.8 Hz),
1.58–1.57 (2H, m, CH2), 1.31 (18H, bs), 0.88–0.84 (3H, t, J =
10.8 Hz); 13C NMR (67.5 MHz, CDCl3): d 176.8, 156.6, 136.5,
128.6–128.3, 104.3, 78.4–76.7, 66.9, 44.6, 42.6, 39.8, 38.3, 35.9,
34.0, 32.7, 32.0, 31.10, 29.7–29.5, 24.33, 22.8, 14.3; calcd for
[C31H45N2O6]
+ 541.3272, found 541.3301; n(max) cm
1: 3360 m,
2924 s, 2854 s, 1699 s, 1522 m, 1142 m. Deprotection of the
diaminoethane dodecyl acetal (459 mg, 0.85 mmol) was then
carried out as per previously described for diaminobutane
dodecyl acetal with palladium on activated carbon (46 mg,
10% w/w) to aﬀord a white paste. Analysis by 1H NMR spectro-
scopy determined the loss of the singlet resonance at d 5.02 ppm
indicating the successful deprotection of the benzyl carbamate
to aﬀord compound 11 (319 mg, 92%) in >95% purity which
was then used without further purification. HRMS (ESI m/z):
calcd for [C23H39N2O4]
+ 407.2911, found 407.2931; n(max) cm
1:
2954 s, 2853 s, 1699 s.
Synthesis of benzyl [2-(2-hexadecyl-5,7-dioxooctahydro-6H-4,8-
methano[1,3]dioxolo[4,5-f]isoindol-6-yl)butyl]carbamate and
the corresponding deprotected amphiphile 12
Synthesis of diaminoethane hexadecyl acetal 12 was performed
as per previously described for diaminobutane dodecyl acetal
with diaminoethane diol 7 (250 mg, 0.668 mmol) and hexadecyl
aldehyde (240 mg, 1.00 mmol) to aﬀord a light yellow oil.
Purification by silica gel column chromatography was per-
formed with a 70% petroleum spirit–30% EtOAc solution and
the resulting caramel oil was shown by 1H NMR spectroscopy
analysis showed it to be the desired diaminoethane hexadecyl
acetal (276 mg, 70%) in >95% purity which was then used
immediately in the next deprotection step. 1H NMR (270 MHz,
CDCl3): d 7.32 (5H, s), 5.02 (2H, s), 4.58–4.55 (1H, t, J = 2.7 Hz),
3.83 (2H, s), 3.60–3.56 (2H, t, J = 5.4 Hz, 2  CH), 3.40–3.34 (2H,
d, J = 5.4 Hz), 2.97–2.93 (2H, m, 2  CH), 2.79–2.78 (2H, t, J =
2.7, 2  CH), 2.34–2.28 (1H, t, J = 8.1 Hz), 1.99–1.95 (1H, d,
J = 10.8 Hz), 1.60–1.57 (2H, m, CH2), 1.34 (26H, bs), 0.88 (3H, t,
J = 13.5 Hz); 13C NMR (67.5 MHz, CDCl3): d 174.7, 156.6, 136.4,
128.6–128.4, 104.1, 77.7–76.6, 66.9, 44.5, 42.6, 39.6, 38.3, 37.2,
34.0, 32.7, 32.0, 29.8–29.2, 24.8, 24.3, 22.7, 14.21; HRMS (ESI m/z):
calcd for [C35H53N2O6]
+ 597.3898, found 597.3912; n(max) cm
1:
3354 m, 2922 s, 2853 s, 1698 s, 1526 m, 1120 m. Deprotection of
the diaminoethane hexadecyl acetal (62 mg, 0.10 mmol) was
then carried out as per previously described for diaminobutane
dodecyl acetal with palladium on activated carbon (6 mg, 10%
w/w) to aﬀord a white paste. Analysis by 1H NMR spectroscopy
determined the loss of the singlet resonance at d 5.02 ppm
indicating the successful deprotection of the benzyl carbamate
to aﬀord compound 12 (40 mg, 83%) in >95% purity which was
then used without further purification. HRMS (ESI m/z): calcd
for [C27H47N2O4]
+ 463.3530, found 463.3527; n(max) cm
1: 2916 s,
2849 s, 1698 s.
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Synthesis of benzyl [2-(2-dodecyl-5,7-dioxooctahydro-6H-4,8-
methano[1,3]dioxolo[4,5-f]isoindol-6-yl)octyl]carbamate and
the corresponding deprotected amphiphiles 15
Synthesis of acetal 15 was performed as per previously described
for diaminobutane dodecyl acetal with diaminooctane diol
9 (135 mg, 0.294 mmol) and dodecyl aldehyde (0.13 mL,
0.589 mmol) to aﬀord a brown oil. Purification by silica gel
column chromatography was performed with a 60% petroleum
spirit–40% EtOAc solution and the resulting caramel oil was
shown by 1H NMR spectroscopy analysis showed it to be the
desired diaminooctane dodecyl acetal (235 mg, 64%) in >95%
purity which was then used immediately in the next deprotection
step. 1H NMR (270 MHz, CDCl3): d 7.34–7.33 (5H, m), 5.07
(2H, s), 4.60–4.58 (1H, t, J = 2.7 Hz), 3.85 (1H, s), 3.42–3.37
(2H, t, J = 8.1 Hz, 2  CH), 3.19–3.12 (2H, q, J = 5.4 Hz),
3.08–3.05 (2H, m, 2  CH), 2.83 (2H, br s, 2  CH), 2.34–2.26
(1H, m, bridge-H) 1.97 (1H, s, bridge-H), 1.65–1.58 (5H, m, 2 
CH2) 1.48–1.46 (2H, m, 1  CH2), 1.26–1.24 (27H, m), 0.85 (3H, t,
J = 5.4 Hz); 13C NMR (67.5 MHz, CDCl3): d 176.41–176.36, 156.48,
136.75, 128.60–128.54, 128.18, 128.14, 104.14, 78.32, 66.63, 44.48,
42.70, 41.12, 38.68, 35.87, 33.95, 32.69, 31.97, 29.69, 29.67–29.16,
27.76, 26.89, 26.66, 24.87, 24.24, 22.76, 22.75, 22.74, 21.10, 14.18;
HRMS (ESI m/z): calcd for [C37H57N2O6]
+ 625.4211, found
625.4224; n(max) cm
1: 3365 m, 2965 m, 2850 m, 1694 s, 1537 m,
1129 m. Deprotection of the diaminooctane dodecyl acetal
(235 mg, 0.375 mmol) was then carried out as per previously
described for diaminobutane dodecyl acetal with palladium on
activated carbon (24 mg, 10% w/w) to aﬀord a cream paste.
Analysis by 1H NMR spectroscopy determined the loss of the
singlet resonance at d 5.02 ppm indicating the successful depro-
tection of the benzyl carbamate to aﬀord compound 15 (147 mg,
89%) in >95% purity which was then used without further
purification. HRMS (ESI m/z): calcd for [C29H51N2O4]
+ 491.3843,
found 491.3861; n(max) cm1: 2927 s, 2850 s, 1699 s.
Synthesis of benzyl [2-(2hexadecyl-5,7-dioxooctahydro-6H-4,8-
methano[1,3]dioxolo[4,5-f]isoindol-6-yl)octyl]carbamate and
the corresponding deprotected amphiphiles 16
Synthesis of diaminooctane hexadecyl acetal 16 was performed
as per previously described for diaminobutane dodecyl acetal
with diaminooctane diol 9 (164 mg, 0.358 mmol) and hexadecyl
aldehyde (129 mg, 0.537 mmol) to aﬀord a brown oil. Purifica-
tion by silica gel column chromatography was performed with a
60% petroleum spirit–40% EtOAc solution and the resulting
caramel oil was shown by 1H NMR spectroscopy analysis
showed it to be the desired diaminooctane hexadecyl acetal
(95 mg, 39%) in >95% purity which was then used immediately
in the next deprotection step. 1H NMR (270 MHz, CDCl3):
d 7.35–7.33 (5H, m), 5.12 (2H, s), 4.60–4.58 (1H, t, J = 2.7 Hz),
3.85 (1H, s), 3.40–3.37 (2H, t, J = 8.1 Hz, 2  CH), 3.20–3.12
(2H, q, J = 5.4 Hz), 3.07–3.06 (2H, m, 2  CH), 2.88–2.83 (4H, m,
2 CH), 2.35–2.29 (1H, t, J = 8.1 Hz) 2.01–1.97 (1H, d, J = 10.8 Hz),
1.48–1.46 (6H, m, 3  CH2), 1.40–1.35 (6H, m, 3  CH2)
1.23–1.20 (30H, m), 0.87 (3H, t, J = 2.7 Hz, CH3);
13C NMR
(67.5 MHz, CDCl3): 176.37, 156.47, 136.74, 128.89–128.20, 104.08,
78.33, 66.69, 44.58, 42.73, 41.14, 38.72, 32.69, 32.11, 29.78, 27.80,
26.67, 24.22, 22.80, 14.22; HRMS (ESIm/z): calcd for [C41H65N2O6]
+
681.4837, found 681.4862; n(max) cm
1: 3368 m, 2924 m, 2853 m,
1697 s, 1532 m, 1137 m. Deprotection of the diaminooctane
hexadecyl acetal (95 mg, 0.140 mmol) was then carried out as
per previously described for diaminobutane dodecyl acetal with
palladium on activated carbon (20mg, 10%w/w) to aﬀord a cream
paste. Analysis by 1H NMR spectroscopy determined the loss of
the singlet resonance at d 5.02 ppm indicating the successful
deprotection of the benzyl carbamate to aﬀord compound 16
(80 mg, 84%) in >95% purity which was then used without further
purification. HRMS (ESI m/z): calcd for [C33H59N2O4]
+ 547.4469,
found 547.4476; n(max) cm
1: 2920 s, 2851 s, 1699 s.
Synthesis of benzyl [2-(2-dodecyl-5,7-dioxooctahydro-6H-4,8-
methano[1,3]dioxolo[4,5-f]isoindol-6-yl)decyl]carbamate and
the corresponding deprotected amphiphile 17
Synthesis of diaminodecane dodecyl acetal 17 was performed as
per previously described for diaminobutane dodecyl acetal with
diaminodecane diol 10 (361 mg, 0.742 mmol) and dodecyl
aldehyde (0.25 mL, 1.11 mmol) to aﬀord a brown oil. Purifica-
tion by silica gel column chromatography was performed with a
60% petroleum spirit–40% EtOAc solution and the resulting
caramel oil was shown by 1H NMR spectroscopy analysis
showed it to be the desired diaminodecane dodecyl acetal
(368 mg, 76%) in >95% purity which was then used immedi-
ately in the next deprotection step. 1H NMR (270 MHz, CDCl3):
d 7.33 (5H, br s), 5.08 (2H, s), 4.61–4.57 (1H, t, J = 5.4 Hz), 3.85
(3H, br s), 3.43–3.37 (1H, t, J = 8.1 Hz), 3.18–3.15 (1H, d, J =
8.1 Hz), 3.09–3.06 (2H, q, J = 5.4 Hz) 2.83 (2H, br s), 2.36–2.20
(1H, m) 2.01–1.97 (1H, d, J = 10.8 Hz), 1.64–1.59 (7H, m), 1.24
(35H, m), 0.88–0.84 (3H, t, J = 5.4 Hz); d 13C NMR (67.5 MHz,
CDCl3): 174.32, 156.50, 136.73, 128.59–128.22, 104.34, 78.33,
66.67, 44.48, 42.71, 38.79, 35.89, 34.06, 32.69, 31.99, 30.00–
29.09, 27.02, 24.78, 24.26, 22.77, 14.20; HRMS (ESI m/z): calcd
for [C39H61N2O6]
+ 653.4524, found 653.4543; n(max) cm
1: 3349 m,
2922 m, 2870 m, 1695 s, 1538 m, 1142 m. Deprotection of the
diaminodecane dodecyl acetal (368 mg, 0.564 mmol) was then
carried out as per previously described for diaminobutane dodecyl
acetal with palladium on activated carbon (37 mg, 10% w/w) to
aﬀord a cream paste. Analysis by 1H NMR spectroscopy deter-
mined the loss of the singlet resonance at d 5.02 ppm indicating
the successful deprotection of the benzyl carbamate to aﬀord
compound 17 (234 mg, 80%) in >95% purity which was then
used without further purification. HRMS (ESI m/z): calcd for
[C31H56N2O4]
+ 463.3537, found 463.3627; n(max) cm1: 2922 s,
2870 s, 1699 s.
Synthesis of benzyl [2-(2-hexaecyl-5,7-dioxooctahydro-6H-4,8-
methano[1,3]dioxolo[4,5-f]isoindol-6-yl)decyl]carbamate and
the corresponding deprotected amphiphiles 18
Synthesis of diaminodecane hexadecyl acetal 18 was performed
as per previously described for diaminobutane dodecyl acetal
with diaminodecane diol 10 (132 mg, 0.271 mmol) and hexa-
decyl aldehyde (98 mg, 0.406 mmol) to aﬀord a brown oil.
Purification by silica gel column chromatography was performed
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with a 70% petroleum spirit–30% EtOAc solution and the
resulting caramel oil was shown by 1H NMR spectroscopy
analysis showed it to be the desired diaminodecane hexadecyl
acetal (165 mg, 88%) in >95% purity which was then used
immediately in the next deprotection step. 1H NMR (270 MHz,
CDCl3): d 7.34–7.33 (5H, m), 5.08 (2H, s), 4.59–4.57 (1H, t, J =
2.7 Hz), 3.85 (3H, br s), 3.43–3.37 (1H, t, J = 8.1 Hz, 1  CH),
3.20–3.13 (1H, q, J = 5.4 Hz, CH), 3.08–3.05 (2H, q, J = 2.7 Hz, 2 
CH), 2.83 (2H, br s, 2  CH), 2.34–2.29 (1H, m) 2.01–1.97 (1H, d,
J = 10.8 Hz), 1.60–1.36 (7H, m, 3 CH2), 1.27–1.19 (39H, m), 0.85
(3H, t, J = 5.4 Hz) d 13C NMR (67.5 MHz, CDCl3): d 176.42, 156.54,
136.76, 128.45–128.00, 104.03, 78.26, 66.50, 44.40, 42.64,
38.65–38.59, 35.76, 34.02, 32.63, 31.95- 31.93, 27.74–27.70,
26.92–26.69, 25.78, 25.34, 24.77–24.17, 22.72–22.33, 20.93,
14.14; HRMS (ESI m/z): calcd for [C43H68N2NaO6]
+ 731.4969,
731.4952; found n(max) cm1: 3359 m, 2923 m, 2853 m, 1699 s,
1558 m, 1144 m. Deprotection of the diaminodecane hexadecyl
acetal (46 mg, 0.066 mmol) was then carried out as per pre-
viously described for diaminobutane dodecyl acetal with palla-
dium on activated carbon (4.6 mg, 10% w/w) to aﬀord a cream
paste. Analysis by 1H NMR spectroscopy determined the loss of
the singlet resonance at d 5.02 ppm indicating the successful
deprotection of the benzyl carbamate to aﬀord compound 18
(26 mg, 67%) in >95% purity which was then used without
further purification. HRMS (ESI m/z): calcd for [C35H62N2O4H]
+
575.4789, found 575.4863; n(max) cm
1: 2920 s, 2851 s, 1698 s.
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Synthesis and Comparative Physical-chemical Characterisation of Neutral 
and Cationic Amphiphiles Using RP-HPLC 
Jennifer S. Squirea, Luke C. Hendersona,b** and Xavier A. Conlana* 
a
Strategic Research Centre for Chemistry and Biotechnology, Deakin University, Pigdons Road, Waurn Ponds, Victoria, 
Australia, 3217; 
b
Institute for Frontier Materials, University, Pigdons Road, Waurn Ponds, Victoria, Australia, 3217 
Abstract: A series of norbornane containing amphiphiles was synthesized, their lipophilicity corresponding to neutral and 
cationic forms was then investigated using reverse phase HPLC (High Performance Liquid Chromatography). This series 
of amphiphiles incorporated varied lipophilic chain length and also varied distances between the polar/cationic head group 
from the norbornane scaffold. Our investigation included studying the impact of the stationary phase as a replication of a 
membrane for both cationic and neutral amphiphiles. The choice of stationary phase was shown to be a very important 
consideration for this type of measurement. In this connection, C18, Cyano and Polar columns were all investigated, the 
cyano column was observed to be the optimal stationary phase for the comparison of both charged and neutral am-
phiphiles. 
Keywords: Amphiphiles, cationic lipid, capacity factor, lipophilicity, high performance liquid chromatography. 
INTRODUCTION 
The interest in the lipophilicity of synthetic and naturally 
occurring compounds has increased dramatically over the 
past several decades. This interest stems from a broad range 
of fields such as; self-assembly, materials chemistry, drug 
delivery, gene therapy and of course the pharmaceutical sec-
tor, as the lipophilicity of a small molecules is one parameter 
of interest in Lipinski’s ‘Rule of 5’[1-5]. Traditional means 
of determining the lipophilic character of a molecule use the 
n-octanol/water partition coefficient, termed Log P. The 
lipophilicity can have major implications in the ability of a 
compound to permeate the cellular wall, cross the blood-
brain barrier or in vivo bio distribution, i.e. lipophilic com-
pounds will accumulate in stores of body fat. The broad ap-
plication of surfactants and amphiphiles in agriculture, bio-
sensors and drug delivery, among others, shows the impor-
tance of determining the lipophilicity as it can provide in-
formation on accumulation of lipid nanoparticles in envi-
ronmental systems and suitability of detecting certain ana-
lytes. Recent advances in self-assembly technologies have 
led to micelles, and liposomes, being used as nano-reactors 
for organic synthesis and as a means to selectively target and 
deliver small molecular therapeutics and genetic material, 
forming a major component of nano-medicine [6-7]. 
The determination of lipophilicity via the n-octanol/water 
partition method is laborious and time consuming with addi-
tional concerns raised about the suitability of n-octanol as a,  
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bulk solvent as a representation of the cellular wall. Such 
as alternative means to rapidly and reliably determine the 
lipophilicity of a compound have been developed; most 
importantly the determination of capacity factor (Kw) via 
reverse phase HPLC technology [8-9]. Due to the rapid 
generation of data and the ubiquitous presence of HPLC 
instruments within most organic and analytical chemistry 
laboratories, this protocol aligns itself particularly well to 
large libraries of compounds, and thus a large amount of 
data can be generated in a time and cost efficient manner 
using existing infrastructure. The use of Kw as a means to 
compare the lipophilicty of organic compounds has been 
used as a great effect in the comparison of bile acids [10], 
hemi-fluorinated surfactants [11], biphenyl species [12] and 
penicillins [13]. 
The stationary phase has the greatest influence on the 
separation of a molecule in HPLC. [14] This is of particular 
importance while using the stationary phase as a model 
system to garner analyte specific information about mem-
brane interaction. It is important to note that the HPLC 
conditions (high pressure, variable methanol content) and 
the nature of the stationary phase are very different from 
what can be found during the interaction process with a cell 
membrane. Although, this is a limitation of this methodol-
ogy that the data obtained are nevertheless important for a 
given series of compounds. The significance of the system 
under study is the comparison of the effect the charged 
state of the amphiphile will have on the interaction with the 
membrane model. A C18 column, which is commonly used 
for this type of study, is not suitable when dealing with an 
ionic species as the analyte will pass through the column 
with the void volume. A study utilizing a range of modern 
chromatographic stationary phases which offer various po-
larities (such as cyano and polar phases) has not been per-
formed for cationic and neutral amphiphiles. Several stud-
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ies have been performed using a range of media including 
normal paraffin hydrocarbons, immobilized octanol and 
biomimetic phases, such as immobilized artificial mem-
brane (IAM), human serum albumin (HAS) and -acid gly-
coprotein (AGP) [15].  
Of concerns raised with respect to using a C18 stationary 
phase as a cell wall mimic the most prominent is that this 
phase does not possess any polar area or hydrogen bonding 
capabilities at the very end of the carbon tail. Considering 
the layers of a cellular wall, there is, at the most exterior, a 
polar hydrophilic phosphate layer which provides stability to 
the extracellular aqueous environment. This polar region is 
then connected to a non-polar region of both saturated and 
unsaturated hydrocarbon chains in addition to the presence 
of cholesterol to provide rigidity.  
An excellent description of the complexity of using 
HPLC for the determination lipophilicity as a model for bio-
logical distribution is presented by Valko [15], where in gen-
eral the gradient retention times of a calibration set of com-
pounds give a straight line. By determining the slope and the 
intercept of the calibration curve, the chromatographic hy-
drophobicity index (CHI) can be determined. 
Valko notes that there are significant differences between 
CHI logD values and the octanol–water logD values. For 
neutral molecules, H-bond donor compounds generally show 
a lower CHI logD than the corresponding octanol–water 
logD. Charged molecules, however, tend to give higher CHI 
logD values than the octanol–water logD values. 
The presence of charge in a large lipophilic molecule 
makes it amphiphilic which directly affects the surface activ-
ity. This can cause significant discrepancies between bulk 
solvent partition and the chromatographic partition, where a 
large interface is involved. The pH dependence of gradient 
retention times is very important and it is to be considered 
when developing a model system [18]. The major differences 
are generated due to the structural differences between the 
lipophilicity of the ionized and unionized molecule and the 
commonly associated differences associated with the genera-
tion of logD–pH curves for weak acids and bases [19]. 
Generally the focus of much research and development in 
this area has been on the mobile phase; however, ideally this 
should not be performed until the optimum stationary phase 
has been selected. A linear gradient is commonly used to 
overcome the difficulties associated with isocratic elution, 
such as band broadening of late eluting components [15]. 
Gradient retention has been a successful method to estimate 
the 0 values. Typically, inter-laboratory studies are difficult 
due to a lack of standard practice among researchers and a 
body of data needs to be gathered on a range of stationary 
phases using a finite set of standards. This study goes some 
way in establishing this data for both neutral and cationic 
amphiphiles as a range of amphiphiles has been synthesised 
and their cationic versus neutral lipophilicity has been com-
pared using gradient mobile phase methodology with reverse 
phase chromatography columns. 
MATERIALS AND METHODS 
For detailed experimental details and compound charac-
terization, please refer to the electronic supplementary in-
formation. All materials were obtained from Sigma-Aldrich 
and were used as received.  
All 1H and 13C NMR spectra were recorded on a Jeol 
JNM-EX 270 MHz or Eclipse 400 MHz FT-NMR as indi-
cated. Samples were dissolved in deuterated chloroform 
(CDCl3) with the residual solvent peak used as an internal 
reference (CDCl3 – H 7.26 ppm). Proton spectra are re-
ported as follows: chemical shift  (ppm), (integral, multi-
plicity (s = singlet, br s = broad singlet, d = doublet, dd = 
doublet of doublets, t = triplet, q = quartet, m = multiplet), 
coupling constant J (Hz), assignment). 
Thin Layer Chromatography (TLC) was performed using 
aluminium-backed Merck TLC Silica gel 60 F254 plates, and 
samples were visualised using 254 nm ultraviolet (UV) light, 
and potassium permanganate/potassium carbonate oxidising 
dip (1:1:100 KMnO4:K2CO3:H2O w/w).  
Column Chromatography was performed using silica 
gel 60 (70-230 mesh). All solvents used were AR grade. 
Specialist reagents were obtained from Sigma-Aldrich 
Chemical Company and used without further purification. 
Petroleum spirits refer to the fraction boiling between  
40-60 °C. 
Microwave reactions were conducted using a CM Dis-
cover S-Class Explorer 48 Microwave Reactor, operating on 
a frequency of 50/60 Hz and continuous irradiation power 
200 W. All reactions were performed in 10 mL septa vials 
with snap caps, with the following conditions: pressure (17 
bar); power max (off); and stirring (high). 
SYNTHESIS OF AMPHIPHILES 
The following is a representative synthesis which can be 
modified to synthesize the entire range of amphiphiles exam-
ined in this study by choosing the appropriate diamine and 
aldehyde. 
GENERAL PROCEDURE FOR CATIONIC LIPIDS 
General Procedure for the Monobenzylcarbamate Pro-
tected Diamines 
H2N
N
H
O
O
 
A solution of 1,4-diaminobutane (5.72 mL, 0.0567 mol) 
in CH2Cl2 (100 mL) was cooled to 0 ºC and a solution of 
benzylchloroformate (1.62 mL, 0.0113 mol) and CH2Cl2 
(150 mL) was added drop wise over 1 hr. The reaction was 
then stirred at rt for 24hrs. The resulting mixture was trans-
ferred to a separating funnel where it was washed with satu-
rated aqueous NaCl (3  30 mL). The organic phase was 
dried (MgSO4), filtered and solvents removed in vacuo to 
afford a white powder. 1H NMR spectroscopy analysis 
showed it to be the desired diamine1 ( 2.0681g, 82%) in > 
95% purity which was then used without further purification. 
1H NMR (270 MHz, CDCl3):  7.32-7.26 (5H, m, Ar-H), 
5.22 (2H, s, NH2) 5.06 (2H,s, H5 ) 3.17-3.14 (2H, d, J = 8.1 
Hz, H4) 2.69 (2H, m, H1 ) 1.49-1.45 (4H, dd, J = 5.4, 13.5 
Hz, H2 H3). 
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Imide Formation 
N
O
O
NH
O
O
 
To a 35 mL microwave vial containing mono-protected 
diaminobutane (873 mg 3.90 mmol), norbonene anhydride 
(430 mg, 2.6 mmol) was added and dissolved with Toluene 
(15 mL). The solution was then subjected to microwave irra-
diation at 100 ºC for 30 mins. The resulting solution was 
diluted with CH2Cl2 (30 mL) and was transferred to a sepa-
rating funnel where it was washed with saturated aqueous 
NaCl (2  25 mL) followed by a wash with HCl (2M, 20 ml) 
and finally NaHCO3 (3  25 mL). The combined organic 
phases were dried (MgSO4) and solvent removed in vacuo to 
give a reddish brown viscous oil. 1H NMR spectroscopy 
analysis showed it to be the desired diaminobutane imide 
2(1.29 g 90%) in > 95% purity which was then used without 
further purification. 1H NMR (270 MHz, CDCl3):  7.34-
7.19 (5H, s, Ar-H), 6.01 (2H, s, H4), 5.01 (2H, s, H5’), 3.28-
3.26 (4H, m, H1 H1’) 3.18, 3.08 (4H, m, H2 H4’), 1.73-1.68 
(1H, d, bridge), 1.52-1.42 (7H, m, H2’ H3’ H3); HRMS (ESI 
m/z) : Calcd. For [C21H24N2O4 H]
+ 369.18161, found 
369.17592. 
Dihydroxylation of IMIDES 
N
O
O
NH
O
O
HO
HO
 
Diaminobutane imide (1.29 g, 3.49 mmol) was dis-
solved in a 4:1 solution of acetone/water (30 mL) and 
NMO (615 mg, 5.2 mmol) was added and stirred until 
dissolved. Osmium tetroxide (0.3 mL) was added and the 
black solution stirred for 72 hrs at room temperature. The 
reaction was quenched with sodium metabisulfite (2 mL, 
0.53 M) and the solution diluted with EtOAc (30 mL) be-
fore being transferred to a separating funnel where it was 
washed with saturated aqueous NaCl (3  25 mL). The 
organic phase was dried (MgSO4) and solvent was re-
moved in vacuo to obtain black oil. Purification by silica 
gel column chromatography was performed with 80% 
EtOAc - 20% Petroleum Spirit solution and the resulting 
brown oil was shown by 1H NMR spectroscopy to be the 
desired Diaminobutane Diol3(712 mg, 51%). 1H NMR 
(270 MHz, CDCl3):  7.30-7.27 (5H, s, Ar-H), 5.01 (2H, 
s, H5’), 3.98 (2H, s, H1’), 3.64 (2H, s, OH), 3.44-3.39 
(2H, t, J=8.1 Hz, H1), 3.11-3.09 (2H, d, J = 5.4 Hz, H4), 
2.63 (2H, s, H4’), 2.39 (2H, br s, H2), 2.08-2.04 ( 2H, d, J 
= 10.8, H3), 1.48-1.40 (4H, m, H2’ H3’); 13C NMR 
(67.5MHz, CDCl3):  177.30, 156.85, 136.40, 128.64, 
70.19, 66.92, 45.82, 45.75, 40.68, 38.27, 36.00, 29.75, 
27.55, 25.16 HRMS (ESI m/z) : Calcd. For [C21H26N2O6 
Na]+ 425.16886, found 425.16858. 
Acetal Formation 
N
O
O
NH
O
O
O
O
n
 
To a solution of hexadecyl aldehyde (221 mg, 0.919 
mmol) in CH2Cl2 (30 mL), diaminobutane diol (246 mg, 
0.613 mmol) was added and stirred until dissolved. MgSO4 
was added followed by the addition of p-toluenesulfonic 
acid(466 mg, 2.45 mmol). The resulting solution was 
warmed to 35°C and stirred for 24 hrs before being filtered 
and the solvent was removed in vacuo to give a or-
ange/brown oil. Purification by silica gel column chromatog-
raphy was performed with a 70% Petroleum Spirit – 30% 
EtOAc solution and the resulting caramel oil was shown by 
1H NMR spectroscopy to be the desired 4C amine spacer, 
16C tail acetal 4(286 mg, 75%).1H NMR (270 MHz, CDCl3): 
 7.38-7.28 (5H, m, Ar-H), 5.06 (2H, s, H5’), 4.62-4.59 (1H, 
t, J = 5.4 Hzm acetal H), 3.84 (2H, s, H1’), 3.44-3.40 (2H, t, 
J=5.4 Hz, H1), 3.22-3.17 (2H, d, J=13.5 Hz, H4’), 3.08-3.06 
(2H, m, H4), 2.83-2.81 (2H, m, H2), 2.02-1.97 (2H, d, J= 
13.5 Hz, H3), 1.62-1.32 ( 6H, m, H2’ H3’ CH2), 1.22 (26H, 
bs, aliphatic), 0.88-0.83 (3H, t, J= 5.4 Hz, CH3)
13C NMR 
(67.5MHz, CDCl3):  179.7, 176.4, 156.5, 139.4, 136.5, 
128.6-128.2, 114.4, 104.1, 77.6-76.6, 66.8, 44.5, 42.7, 40.5, 
38.2, 35.9, 34.2, 32.7, 32.0, 29.8-29.03, 27.5, 25.1, 24.7, 
24.3, 22.8, 14.2; HRMS (ESI m/z) : Calcd. For [ C37H56N2O6 
H]+ 625.42184, found 625.42001. 
Hydrogenation 
Palladium on activated carbon (29 mg, 10% w/w) was 
dissolved in methanol (50 mL) and left to stir before the ad-
dition of 4C amine spacer, 16C tail acetal 4(286 mg, 0.46 
mmol) in methanol (50 mL). The reaction mixture was 
stirred under H2 (g) for 24 hrs before being vacuum filtrated 
through a celite plug and the solvent removed in vacuo to 
give a white powder (0.160 g, 71%). HRMS (ESI m/z): 
Calcd. For [C29H51N2O4]
 + 491.38506, found 491.38906. 
Note that, due to the amphiphilic nature of these compounds, 
clean 1H and 13C NMR spectra are unable to be obtained due 
to aggregation in solution. 
HPLC CONDITIONS 
The samples were dissolved in HPLC grade methanol at 
a concentration of 1 mg/mL, with 20 μL injection volume, in 
the case of cationic samples 50 μL of 4 M hydrochloric acid 
was added to the vial to ensure complete protonation of the 
amino group. These samples were tested on a range of col-
umns C18 (Eclipse™ XBD – C18 4.6  150 mm 5m Agilent 
technologies) Polar (Synergi™ Polar-RP 80 Å LC Column 
150  4.6 mm 4 m Phenomenex) Cyano (Luna™5u CN 
100A 4.6  150 mm 5m Phenomenex). The amphiphiles 
were monitored at a wavelength of 220 nm using a UV-visible 
variable wave detector. All samples were analysed isocrati-
cally at methanol/water ratios of 50:50, 70:30, and 90:10. 
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Calculation of logKw 
The calculation of log Kw was achieved via a multi-step 
procedure. Firstly, the capacity factor (k) was determined 
using the equation: 
tr - to
to
k =
 
Where tr is the retention time of the analyte in a specified 
mix of methanol/water and to is the elution time of methanol 
alone.  
The analytes were sequentially injected onto the column 
with increasing amounts of organic modifier in the eluent 
(water/methanol). Runs were undertaken at ratios of 90:10, 
70:30 and 50:50methanol/water. The value of Kw was deter-
mined by extrapolation of the k vs. conc. of organic modifier 
back to pure water. The log (base 10) of this value was then 
carried out to give the log Kw value. 
Dead time of the system was determined by injecting 
acetone through the system and monitoring its retention time. 
RESULTS AND DISCUSSION 
The vast majority of surfactants and amphiphiles is linear 
in molecular structure, which imparts a large degree of free-
dom to the amphiphiles that may assist in the self assembly 
of the compounds into soft nanostructures, such as micelles 
and liposomes. In this study, we wished to introduce a rigid 
scaffold into the centre of the molecule, thus having a two-
fold effect: (i) this will impede the innate molecular freedom 
to a small extent and may impart novel behavior into the self 
assembled nanostructures, and (ii) the chosen rigid scaffold, 
norbornane, will impart a bend or ‘kink’ into the overall mo-
lecular architecture, again potentially effecting the ability of 
the compounds propensity to self assemble and thus shed-
ding light onto this largely unknown phenomenon.  
The synthesis we have devised is amenable to simple de-
rivatisation to give a diverse range of organic amphiphiles. 
The synthesis of 2 was achieved via a cyclodiamide forma-
tion giving unsaturated norbornene 2, using microwave irra-
diation and a monobenzylcarbamate protected diamine in 
toluene. This approach provided flexibility in the synthetic 
pathway as the carbon chain separating the diamines serves 
as a simple means of derivatisation while incorporation of 
microwave irradiation has shown to enhance the rate and 
crude purity of reaction products [16-17]. Once completed 
the alkene was smoothly converted to the corresponding vic-
diol using osmium tetroxide in a catalytic amount with N-
methyl morpholine-N-oxide as a co-oxidant. This gives ex-
clusively the exo- product arising from steric hinderance 
imparted by the imide moiety. Treatment of diol 3 with 
hexadecanal and a catalytic amount of p-toluene sulfonic 
acid (p-TSA) provides the acetal linking group while simul-
taneously furnishing the hydrophobic tail. This approach also 
lends itself to derivitisation as any number of aldehydes can 
be incorporated into this scaffold. Once the lipophilic region 
was installed the benzyl carbamate group was removed by 
hydrogenolysis to give the free amine, constituting the neu-
tral compounds which were evaluated in this study. Access 
to the cationic compounds was provided by simply treating 
the neutral compound with ethereal hydrochloric acid (1M) 
thus giving the corresponding hydrochloride salt. 
Due to the complexity of measuring the lipophilicity val-
ues of neutral and charged species, a study into the use of a 
broader range of stationary phase was undertaken in order to 
determine the conditions which are appropriate for both neu-
tral and cationic lipids. As the key influence is the polarity of 
the molecules of interest, three stationary phases were cho-
sen, including a non-polar C18, a moderately polar cyano and 
a polar reverse phase column. 
Upon initial investigation the cationic compounds were 
all observed to elute, at or very close to, the void volume 
when processed through the C18 column, though this result 
was expected we carried it out due to this being the most 
common methodology in the literature. Due to the lack of 
any significant retention assessment of the molecular interac-
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Scheme 1. Synthesis of amphiphiles for lipophilicity determination. 
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tion cannot be accurately expressed so the C18 was consid-
ered inappropriate for this type of measurement. With regard 
to the polar column, some retention was observed for the 
neutral species; however capacity factors were again consid-
ered too low for further consideration. The cyano column 
allowed retention of both the neutral and cationic species 
which enabled a data set to be generated that will give a real 
indication of a membrane interaction. Based on these results, 
the cyano column was used to determine the Log Kw of each 
of the molecules of interest. 
Not surprisingly, the neutral amphiphiles tend to have a 
greater log Kw than their cationic counterparts; this is pre-
sumably due to the large increase in polarity that coincides 
with the installation of a positive charge. Interestingly the 
difference in lipophillic character between cationic and neu-
tral amphiphiles varied greatly on a case to case basis.  
The comparison of neutral and cationic amphiphiles has 
revealed interesting trends regarding the impact a formal 
positive charge has on the overall lipophilicity of an am-
phiphilic compound. Examination of the log Kw figures of 
Table 1 shows that, for example, the capacity factor of both 
the neutral and cationic forms of 5/5a (entries 1 and 2 re-
spectively, Table 1) differ only slightly (log Kw 0.1673) 
and as such the change from neutral amine group to cationic 
ammonium hydrochloride has minimal impact on the overall 
lipophilicity of this compound. An even smaller cationic 
effect on lipophilicity was observed when comparing 6/6a 
(log Kw 0.1020). When comparing the molecular structure 
of compounds 5/5a and 6/6a, although there is a dramatic 
difference in the distance the amino group is from the nor-
bornane scaffold, there are a similar number of methylene 
groups present in each compound (16 CH2 for 5/5a and 20 
CH2 for 6/6a). Conversely, examination of entries 5 and 6, in 
this case compounds 7/7a has an overall shorter lipophilic 
tail and have a lower number of methylene groups present in 
the alkyl chains (14 CH2)and the comparison of log Kw 
demonstrates a much more pronounced difference in capac-
ity factor ( log Kw 0.8805) between neutral and cationic 
species. This indicates that the effect of the cationic charge 
has a larger impact on lipophilicity than in the previous ex-
ample, additionally the non-linear nature of the log Kw val-
ues suggests that there is a critical point at which the overall 
lipophilicity of the cationic species, presumably a balance 
between the charge/lipophilic effects, is solely determined 
by alkyl chain length. Similarly, entries 7 and 8, com-
pounds 8/8a, bearing 12 methylene units displayed a simi-
larly large discrepancy between the overall lipophilicity of 
neutral and cationic species (log Kw 0.8575). The final 
comparison was carried out between compounds 9/9a, by 
far possessing the largest number of methylene groups at 
24. In this final example, overall there is very minute dif-
ference in log Kw (0.0255) for the cationic and neutral 
forms of this compound, indicating that the ammonium 
functionality is severely overcompensated for by the large 
degree of lipophilicity present in this compound. This is 
interesting as it parallels a common chromatography phe-
nomenon known as ‘methylene selectivity’ which is inher-
ently linked to the hydrophobic interactions present during 
chromatographic separations. 
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5 n = 14 m = 2; 6 n = m = 10; 7 n = 10, m = 4
8 n = 10, m = 2; 9 n = 14, m = 10
5a n = 14 m = 2; 6a n = m = 10; 7a n = 10, m = 4
8a n = 10, m = 2; 9a n = 14, m = 10  
Table 1. Comparison of Capacity Constants for Cationic and Neutral Amphiphiles 
Entry Compound Number Tail Length (n) Amine Spacer (m) LogP/LogD
a,b 
Log Kw   Log Kw 
1 5 14 2 4.56 1.3109 
2 5a 14 2 4.94 1.1345 
0.1673 
3 6 10 10 7.36 1.4357 
4 6a 10 10 5.28 1.3335 
0.1020 
5 7 10 4 4.56 1.7746 
6 7a 10 4 2.37 0.8941 
0.8805 
7 8 10 2 4.05 1.8722 
8 8a 10 2 3.53 1.0147 
0.8575 
9 9 14 10 5.28 1.3608 
10 9a 14 10 7.36 1.3353 
0.0255 
aLogP or LogD depending of the amphiphile is neutral or cationic, respectively. Calculated using ACD Labs open access property calculator 
bLogD reported is for the compound at pH 7.4 (physiological pH) 
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The overall effect of a cationic charge on the capacity 
factor of a given compound is most likely a balancing act 
between the purely hydrophobic character of the molecule 
and the ammonium group. This is certainly reflected in 
the data provided in Table 1 whereby the log Kw for 
smaller, less hydrophobic compounds, was much higher 
than for compounds incorporating long alkyl tails and 
large methylene spacing groups between the norbornane 
and the amine/ammonium group. Considering each lipo-
philic portion (chains of length n and m) the data suggests 
that the hydrophobic tail tethered to the amphiphile via 
the acetal linkage has a more dominant effect of lipophil-
icity than the amine-norbornane spacer group. 
When designing amphiphiles, either neutral or ionic, their 
propensity to self assemble into desired morphologies (e.g. 
liposomes, micelles and lamellar structures) is very hard to 
predict. There is no formula available to ensure the correct 
distribution of both polar/cationic charges to lipophilicity is 
achieved in the final compound. Due to the difficulties asso-
ciated with quantifying the “lipid to charge ratio” for a given 
amphiphile, optimal amphiphilic structures are usually de-
termined experimentally. This requires the evaluation of 
transfection ability and cellular toxicity across easily trans-
fect-able cell lines, such as HEK and CHO, for small librar-
ies of systematically varied amphiphiles. The main difficulty 
in quantifying the “lipid to charge” ratio lies in the inability 
to equate ionic charge to lipophilic character in a given com-
pound. 
By comparing the ionic and neutral amphiphiles, we 
have demonstrated the ability to elucidate the impact of a 
cationic charge has on overall lipophilicity of a given am-
phiphile. Thus providing a means to indirectly measure 
the “lipid to charge” ratio in a high throughput and timely 
protocol.  
CONCLUSION 
In conclusion, we have presented the first comparison, 
using capacity factor, of cationic versus neutral amphiphilic 
species with respect to lipophilic character. This technique 
has provided insights into optimizing and rapidly determin-
ing a lipid-to-charge ratio for a given compound and the data 
presented indicates that a strong connection is present be-
tween methylene number and effect of cationic charge.  
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The synthesis of novel norbornane-based amphiphiles and the thermal response of their corresponding colloids is
presented. It was found that the hydrodynamic diameter (DH) expansion or contraction of 1–4 in response to increasing
temperature was governed by the length of the hydrophobic region possessed by the amphiphile (a 12 or 16 carbon chain).
These data were used as a starting point to extend into an active tumour targeting system whereby two amphiphiles were
modified to incorporate the oestrogen receptor antagonist Tamoxifen at the polar head group. This was achieved by a
triazole moiety while both the C12 (18) or C16 (19) hydrophobic chains were incorporated as the hydrophobic region in an
attempt to retain the response to thermal stimuli observed in our preliminary findings. These functionalised novel
amphiphiles possessed critical aggregation concentration values of 510 and 19 mM, while aqueous self-assemblies of 56
and 106 nm for 18 and 19 were observed. Imaging by cryogenic transmission electron microscopy showed 18 to possess
liposomalmorphology, while 19, bearing a C16 hydrophobic portion, formed non-defined amorphous aggregates. Finally,
the response to temperature of these assemblies was investigated with only the C12 variant 18 displaying a temperature
response in the 5–558C thermal window investigated.
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Introduction
The self-assembly of amphiphilic compounds has been of great
interest to the scientific community and is at the core of many
cutting-edge technologies in areas of medicine, nutraceuticals,
gene-delivery, and in various aspects of materials science.[1–10]
Complementing this field is the development of stimuli-
responsive self-assemblies that are able to release encapsulated
cargo under specific conditions. Common stimuli that are used
to initiate cargo release include temperature, pH, ultrasound,
light, and redox-based systems.[11–15a] The release of encapsu-
lated cargo may be facilitated by either (i) the disassociation
between the amphiphiles within the self-assembly or (ii) the
breakdown of the individual amphiphiles of which the nanos-
tructure is composed. These stimuli are designed to take
advantage of potential changes that occur when the ‘loaded’
nanostructure passes from the extracellular to intracellular
environment, for example, the change in extracellular to intra-
cellular pH, or the increase in glutathione which cleaves
disulfide bonds present in the amphiphile architecture. Alter-
natively, the method of release can be due to the destabilisation
of the lipid bilayer allowing for drug efflux, as proposed by
Torchilin[15b] or due to the formation of fine ‘grain boundaries’
which occur in the bilayer allowing for encapsulation release.[16]
The focus of this manuscript is thermally responsive self-
assemblies, a subject that has recently been reviewed by several
authors.[16–19] Self-assemblies that respond to temperatures just
above normal homeostatic biological temperature are of partic-
ular importance in cancer therapy as they represent a means to
selectively release therapeutic cargo specifically at the tumour
site, subsequently minimising toxicity to non-cancerous tissue.
In additional, localised mild hyperthermia has been found to
have synergistic effects when coupled with common chemo-
therapeutic agents such as Cisplatin and Doxorubicin.[20] The
synergistic effects arise due to the hyperthermic treatment
increasing blood flow to the tumour and increasing vascular
permeability, allowing deeper penetration into the tumour mass,
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and consequently increasing the chemotherapeutic effect. Simi-
larly, the increase in tumour permeability allows for the
increased accumulation of nanoparticles (such as liposomes)
within parts of the tumour not usually accessible due to a lack of
perfused vasculature. Therefore, temperature sensitive self-
assemblies have dual functionality as an adjuvant therapy with
hyperthermic treatment as they are exposed to more of the
tumour mass and can then be stimulated to release their
chemotherapeutic cargo.
Self-assemblies can be delivered to desired cells or cellular
mass (such as a tumour) by either passive or active targeting.
Passive targeting occurs predominantly through the enhanced
permeation and retention effect (EPR effect)[21–24] where
nanosized particles (typically, 400 nm) accumulate within a
tumour mass due to poorly constructed cellular vasculature
(Fig. 1), compounded by the poor lymphatic drainage typically
observed in tumours. Once the tumour is enrichedwith ‘loaded’
self-assemblies, the release of therapeutic cargo can be initiat-
ed by application of stimuli (e.g. heat) external to the body. The
use of passive targeting has had a great deal of success in
the treatment of tumours using a vast array of nanostructures
including micelles, liposomes, and nanoparticles of various
compositions.[21–24]
Active targeting is facilitated by the incorporation of ligands,
which possess a very high affinity for overexpressed cellular
receptors, onto the nanostructure surface. An excellent example
was demonstrated by Reddy and Banjeree[25] who used 17b-
oestradiol as a peripheral functionalisation on stealth liposomes
which target the GPR30 receptor on oestrogen dependent breast
cancer cells. In this scenario, the overexpressed receptors on the
cellular surface promoted uptake of the functionalised nanos-
tructures by receptor-mediated endocytosis and therefore pro-
vided a more focussed or ‘actively’ targeted therapy.
We recently reported preliminary investigations into a range
of amphiphiles that possessed a rigid norbornane structure
within the core of themolecule.[26] These amphiphiles displayed
a range of aggregate sizes and morphologies while their critical
aggregation concentration (CAC) values were relatively insen-
sitive to changes in the molecular structure. The unusual
behaviour of these amphiphiles was attributed to stacking
phenomena caused by the rigid core, similar to those proposed
by Matisons et al.[27] This manuscript presents the synthesis of
novel amphiphiles based on the norbornane scaffold which bear
Tamoxifen at the polar head group. These amphiphiles have
been physicochemically characterised, determining the CAC,
hydrodynamic diameter (DH), morphology (cryogenic transmis-
sion electron microscopy, cryo-TEM), and changes in DH in
response to increasing temperature.
Results and Discussion
Preliminary Temperature Response Investigation
Due to our experience with norbornane-derived amphiphiles
bearing an ammonium head group we began our investigation
by examining the changes inDH of amphiphiles 1]4 formulated
into self-assemblies at a range of increasing temperatures
(Fig. 2). We chose to investigate the assembly behaviour from 5
to 558C as, from a therapeutic standpoint, temperatures above or
below these values are not practical.[16]
For this investigation, the amphiphiles were categorised
based on the value of m, which constitutes the hydrophobic
region of the amphiphiles. As can be seen in Fig. 3, amphiphiles
1 and 2 possessing an m value of 10 demonstrated a consistent
DH (30–60 nm) from 5 to 458C.
When heating from 45 to 558C a dramatic change in DH was
observed whereby each aggregate increased by a factor of ,3
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Fig. 1. Combined active and passive targeting for cancer therapy (EPR effect: enhanced permeation and retention effect).
900 J. S. Squire et al.
(140–160 nm). To ensure this observation was not due to
temperature-induced accelerated equilibration of the aggre-
gates, we repeated this experiment employing the reverse
temperature gradient (cooling from 55 to 58C) in the same
108C increments.
Interestingly, the exact same behaviour was observed for
both the forward and backward temperature directions indicat-
ing a very dynamic system with a reversible temperature
response. Repeating these experiments with amphiphiles 3 and
4 (possessing an m value of 14) the reverse trend was observed.
A sharp decrease in DH, by a factor of 2 and 6, occurred at
25–358C and 35–558C, respectively (Fig. 3).
The approximate 108C difference in the initiation of the
thermal transition demonstrated by these compounds can only
be attributed to the ethylene extension of the alkyl chain spacing
the ammonium head group from the norbornane core present in
4 relative to 3.
Considering the hydrophobic region of these self-assemblies,
we attributed the observed changes in DH, displayed by 1]4, to
be the result of a gel-to-liquid transition in the lipid phase. This
phenomenon has been observed in other self-assemblies and at
similar temperatures as reported by several groups.[28]
In an attempt to determine the nature of this thermal transi-
tion, a range of differential scanning calorimetry (DSC) studies
was undertaken on these amphiphiles over a wider temperature
range (5–1008C) at scan rates of 5 and 10 8Cmin1. DSC was
conducted on both the colloid and the solid amphiphiles as
powders, however, no thermal transitions were detected within
this temperature range at either scan rate. We attributed this to
the bulk solid material not being representative of the self-
assembly in an aqueous environment, while the aqueous colloid
may not contain enough of the amphiphile to give ameasureable
thermal change by DSC. This latter point is highly likely since
the CAC values for compounds 1]4 are very low
(typically# 30 mM).[26]
Synthesis of Tamoxifen-Functionalised Amphiphiles
With these results in hand, it was considered that the temperature
response demonstrated by these amphiphiles would constitute a
suitable means to release encapsulated cargo. Our desire was to
transfer the thermal response observed in compounds 1–4 to an
active targeting colloid system based on the same scaffold. This
could be realised by grafting a small molecule that interacts with
overexpressed extracellular receptors onto the polar head group
on this class of amphiphile. A similar strategy has been suc-
cessfully used by incorporating Haloperidol or folic acid onto
the polar head group of liposomes. These ligands interact with
overexpressed sigma or oestrogen receptors, respectively, and
have demonstrated enhanced cellular uptake.[29,30]
As 70% of breast cancer cells overexpress oestrogen recep-
tors compared with healthy breast tissue, a focus on breast
cancer therapy was deemed advantageous.[25] The well estab-
lished oestrogen receptor antagonist, Tamoxifen, was chosen as
our targeting ligand to graft onto the polar head group of our
amphiphiles. Our choice of Tamoxifen was based on its rela-
tively simple chemical structure and when incorporated onto the
surface of a self-assembly it may possess a dual functionality (i)
as an active targeting moiety and (ii) simultaneously initiating a
chemotherapeutic response. We envisaged a series of com-
pounds conforming to the general structure presented in
Fig. 4. The effect on the CAC, DH, morphology, and thermal
response that the presence of Tamoxifen at the polar head group
induces on the colloid is of great interest given its lipophilic
nature.
Two variations of ‘linker’ (Fig. 4) to incorporate the Tamox-
ifen unit to the amphiphile structure were considered, the first
being directly by the methyl nitrogen unit on desmethyl-
Tamoxifen 16 (for preparation of 16, see below) and the second
by a copper azide–alkyne cycloaddition (CuAAC)-mediated
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Fig. 2. Norbornane amphiphiles 1–4 used in preliminary temperature
studies.
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triazole.[31,32] Our synthesis began with the formation of nor-
bornane imide 6 with aminoethoxyethanol from anhydride 5
which, under microwave irradiation, gave 6 in very high yield
(88%) and in. 95% crude purity. Subsequent treatmentwith p-
toluenesulfonylchloride gave 7 in excellent (85%) isolated
yield, followed by a dihydroxylation with OsO4/ N-methylmor-
pholine-N-oxide (NMO) in aqueous acetone (H2O/CH3COCH3,
1 : 4) to give the desired vic-diol 8 in an excellent (83%) yield
(Scheme 1).
Treatment with para-toluenesulfonic acid (pTSA) and dode-
canal provided 9 in a 76% yield and similarly, under the same
acidic conditions, the use of hexadecanal gave 10 in a similar
yield (73%) (Scheme 1). The use of an acetal group as means of
installing the hydrophobic region is uncommon and has been
reported in an evaluated amphiphile system one other time to the
best of our knowledge.[33] Compounds 9 and 10 are extremely
versatile intermediates and with these in hand attention turned
towards the linking of Tamoxifen to this scaffold by a simple
amine group (Scheme 2). Treatment of 9 and 10with desmethyl-
Tamoxifen 16 gave a complex mixture of products. Unfortu-
nately, isolation of 11 or 12 proved troublesome and only small
amounts of each could be recovered post chromatography. This
prevented further physicochemical evaluation due to the inade-
quate amount of material available, nevertheless, analytically
pure samples were obtained and fully characterised.
In light of these difficulties our attention turned to attachment
of the Tamoxifen unit by reliable CuAAC protocols. Substitu-
tion of the tosylate group for an azide moiety proceeded
smoothly for both 13 and 14 using a miscible organic/aqueous
system and sodium azide. These compounds were synthesised
on reasonable scales (1–2 g) with crude purities in excess of
85% (by 1H NMR spectroscopy) and were used immediately
without further purification.
Using azides 13 and 14 in a CuAAC attachment strategy
required the propargylation of desmethyl-Tamoxifen 16 which
was accessed in excellent yield (95%) using a demethylation
procedure described byDreaden et al.[34] (Scheme 3). Treatment
of 16 with propargyl bromide in the presence of triethylamine
gave the desired alkyne 17 in a good isolated yield (73%)
(Scheme 3).
Our initial attempts to tether the Tamoxifen group to our
amphiphiles focussed on using azide 14 (Scheme 4). A typical
reagent combination of CuSO4/sodium ascorbate in water
(Table 1, Entry 1) returned only unreacted starting material.
However, heating this reaction utilising microwave irradiation,
for 30min and 1 h, showed an immediate improvement (Table 1,
Entries 2 and 3, 51% and 40%, respectively) with the shorter
reaction time being optimal. Changing the reaction solvent to
accommodate reactant solubility and examination of alternate
sources of copper (Table 1, Entries 4 and 5) demonstrated that
5
(a) Ethoxyethyleneamine, 20 min, MW, PhMe, 100C, 88 %; (b) TsCl, Et3N, CH2Cl2, 16 h, 85 %;
(c) OsO4, NMO, acetone/water 4 : 1, rt, 16 h, 83 %; (d) Dodecanal or hexadecanal, pTSA, MgSO4, CH2Cl2, 16 h, 76 %, 73 %, respectively
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Scheme 1. Synthesis of norbornene–tosylates 9 and 10.
(a) Desmethyl tamoxifen 16, K2CO3, THF, reflux, 16 h; n  10, 21 %, n  14, 16 %)
(b) NaN3, MeCN/H2O, 50C,16 h (85 %, both cases)
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Scheme 2. Synthesis of Tamoxifen conjugates 11 and 12 and norbornyl–azides 13 and 14.
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Cu2O returned unreacted starting material while CuCl resulted
in a small amount of conversion (7%) at room temperature
in the absence of heat.
Therefore, heating by microwave irradiation in combination
with CuCl in chloroform for 30min at 708C and 1008C (Table 1,
Entries 6 and 7) gave the desired compound 19 in good yields of
61% and 68%, respectively. Repeating the latter reaction
conditions using azide 13 gave the desired compound 18 in
moderate yield (50%) (Table 1, Entry 8). The two desired
Tamoxifen conjugated amphiphiles 18 and 19 were then con-
verted into their cationic form using gaseous HCl and formulat-
ed into aqueous colloids.[35]
Determination of CAC, DH, Thermal Response,
and Morphology for 18 and 19
Several means have been used to determine the CAC in aqueous
systems, such as surface tension, conductivity, NMR spectros-
copy, and fluorescence spectroscopy by encapsulation of lipo-
philic probes including pyrene.[36–38] We have found that the
fluorescence of encapsulated pyrene has been the most reliable
and reproducible methodology for this class of amphiphile.
The encapsulation of pyrene was carried out according to
literature procedures,[39] and the ratio of emission peaks at 386
and 393 nm (I386/I393) was monitored over a series of concen-
trations ranging from 1 to 0.0001mgmL1. The CAC data for
all compounds by pyrene encapsulation are summarised in
17
(b)
(a) α-Chloroethyl chloroformate, reflux, PhMe, 16 h, then MeOH reflux, 3 h, 95 %
(b) Propargyl bromide, NEt3, reflux, CHCl3,16 h, 73 %.
O
N
R
15 R  Me
16 R  H.HCl
(a)
O
N
Scheme 3. Demethylation and propargylation of Tamoxifen.
Table 1. Optimisation of Cu azide]alkyne coupling to furnish 18 and 19
Entry Compound CatalystA AdditiveA Solvent Time [h] Temp.B [8C] Yield [%]
1 14 CuSO4 Ascorbate Water 16 25 —
C
2 14 CuSO4 Ascorbate Water 0.5 100 51
3 14 CuSO4 Ascorbate Water 1 100 40
4 14 Cu2O — CHCl3 0.5 70 —
C
5 14 CuCl — CHCl3 16 25 7
6 14 CuCl — CHCl3 0.5 70 61
7 14 CuCl — CHCl3 0.5 100 68
8 13 CuCl — CHCl3 0.5 100 50
ALoading is 10mol-%.
BHeated using microwave irradiation unless at room temperature.
CStarting materials were recovered.
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Scheme 4. Synthesis of Tamoxifen-conjugated amphiphiles 18 and 19.
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Table 2. In contrast to our previous work on norbornane-derived
scaffolds these compounds behave much more like traditional
surfactants, with the CAC value for amphiphile 18 being ,27
times higher than that of 19.
It has been noted in the literature that for eachmethylene unit
installed into the hydrophobic portion of an amphiphile a
corresponding ,5 fold decrease in CAC value is observed.[40]
Therefore, the two ethylene units distinguishing 18 from 19,
should result in an,20 fold decrease in CAC for the latter which
is confirmed here with a critical micelle concentration (CMC)
value of the latter compound 27 times lower than that of the
former one.
The DHs of these compounds were determined by dynamic
light scattering (DLS) at room temperature and were found to be
56 and 106 nm for 18 and 19, respectively. Both compounds
showed a moderate size distribution (DLS output shown in
Supplementary Material).[35]
Attention then turned to evaluating any temperature response
these aggregates may possess. Conducting variable temperature
DLS showed that 18 possessed a similar temperature response to
1 and 2. In this case, 18 showed a steady increase in DH with
increasing temperature which became more pronounced when
heating the colloid from 35 to 558C, resulting in a rapid
transition from 79 to 118 nm (Fig. 5). This aggregate size
transition is presumably determined by the hydrophobic region
of the molecules as m¼ 10 is the only common feature between
compounds 1, 2, and 18. Subjecting 19 to the same variable
temperature DLS showed no size transitions at all from 5 to
558C, even with the repetition of the experiment with an
increased temperature endpoint of 658C.
Visualisation of the aggregates was then undertaken to
determine the effect Tamoxifen at the cationic head groupwould
have on morphology. Cryo-TEM of 18 showed liposomal
aggregates (Fig. 6), some of which were fused to a spherical
self-assembly aggregate with no observable fine structure (see
Supplementary Material),[35] a feature consistent with those
observed by van Esch et al.[41] The lipid bilayers are ,4–5 nm
in accordance with our previous observations and thosemade by
Bordes et al. who incorporated a norbornane counterion into
various self-assemblies.[26,42,43]
Cryo-TEM images of 19 showed only the presence of diffuse
spherical amorphous aggregates with no defined lamellar,
micellar, or liposomal structure (images presented in the Sup-
plementary Material).[35] In all previous cases where a norbor-
nane motif has been incorporated into the amphiphile scaffold,
vesicles have been the preferred morphology.[26] We have
attributed the deviation from this trend demonstrated by 19 to
the modification of the polar head group. The hydrophobic
Tamoxifen group in concert with the hexadecyl aliphatic chain
may cause a large global increase in lipophilicity, thus causing
the compound to lose its amphiphilic nature. Being lipophilic at
both ends of the molecule would inhibit an ordered self-assem-
bly process causing a disordered amorphous assembly, similar
to those observed.
This latter result accounts for the lack of temperature
response displayed by 19whenmonitored by DLS. If no defined
aggregate phase is formed then it would be expected that no
corresponding sharp transition temperature indicating a gel-to-
liquid phase shift would be observed.
Conclusions
We have demonstrated the thermal response properties of sev-
eral norbornane-based amphiphiles. A trend was observed when
the formulations of 1–4 were heated from 5 to 558C in 108C
increments. Compounds bearing a longer (14 methylene unit)
chain shrunk at 25 and 358C while compounds bearing a shorter
(10 methylene unit) tail expanded at temperature transitions
from 45 to 558C, both changes being attributed to gel-to-liquid
transitions in the lipophilic bilayer.
This was used as the basis for the development of an active
targeting therapy colloid, whereby the oestrogen receptor antag-
onist Tamoxifen was grafted onto the polar head group of two
amphiphiles using a CuAAC approach. Functionalised amphi-
philes 18 and 19 were obtained in an efficient and high yielding
synthetic procedure. Physicochemical characterisation of these
amphiphiles showed a classical CAC relationship between
hydrocarbon length and changes in aggregation concentration
Table 2. Critical aggregate concentration (CAC) and hydrodynamin
diameter (DH) data for compounds 18 and 19 by pyrene encapsulation
and dynaminc light scattering, respectively
Entry Compound CACA DH
B [nm]
[mgL1] [mmol L1]
1 18 432 510 56
2 19 18 19 106
AResults are the average of triplicate experiments carried out at 188C in
Milli-Q water.
BDetermined at 10 times the CAC value at 258C with volume distribution.
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Fig. 5. Changes in hydrodynamic diameter with respect to temperature for
aggregates of 18.
Fig. 6. Cryogenic transmission electronmicroscopy images of 18 showing
liposomal structures.
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whereby the more hydrophobic 19 possessed a CAC value,25
times lower than 18 (19 v. 510mM). DLS showed the formation
of aggregates with a DH of 56 and 105 nm for 18 and 19.
Analysis of these aggregates by DLS with increasing tempera-
ture revealed an aggregate expansion from 79–118 nm correlat-
ing to an increase in temperature for 18, however, no response to
thermal stimulus for the more hydrophobic 19 was observed.
Finally, imaging by cryo-TEM suggested the formation of
liposomes for 18, while 19 showed only the formation of non-
defined amorphous assemblies. This was attributed to the
increase in overall lipophilicity of 19 once the Tamoxifen group
was grafted onto the polar head group. The formation of these
non-defined aggregates accounts for the lack of thermal
response observed for 19 at increasing temperature using
DLS. Current studies on the ability of 18 to interact with
oestrogen receptors, by surface plasmon resonance, and their
potential as transfection agents are currently being investigated
and will be disclosed in due course.
Experimental
General
All 1H and 13C NMR spectra were recorded on a Jeol JNM-EX
270MHz spectrometer as indicated. Samples were dissolved in
CDCl3 with the residual solvent peak used as an internal refer-
ence (CHCl3: dH 7.26 ppm). Proton spectra are reported as fol-
lows: chemical shift d (ppm), (integral, multiplicity (s¼ singlet,
br s¼ broad singlet, d¼ doublet, dd¼ doublet of doublets, t
¼ triplet, q¼ quartet, m¼multiplet), coupling constant J (Hz),
assignment).
Thin-layer chromatography (TLC) was performed using
aluminium-backed Merck TLC Silica gel 60 F254 plates, and
samples were visualised using 254 nm ultraviolet (UV) light,
and potassium permanganate/potassium carbonate oxidising dip
(1 : 1 : 100 KMnO4/K2CO3/H2O, w/w/w).
Column chromatography was performed using silica gel 60
(70–230 mesh). All solvents used were of AR grade. Specialist
reagents were obtained from Sigma–Aldrich Chemical Co. and
used without further purification. Petroleum spirits (Pet) refers
to the fraction boiling between 40 and 608C.
Microwave reactions were conducted using a CM Discover
S-Class Explorer 48 Microwave Reactor, operating on a fre-
quency of 50/60Hz and continuous irradiation power from 0 to
200Wor 20Wwhere specified. All reactions were performed in
10mL septa vials with snap caps, with the following conditions:
pressure:17 bar, power max: off, and stirring: high.
Formulation of Self-Assemblies
Freshly lyophilized amphiphiles were hydrated using MilliQ
water (resistivity of 18.2 MO cm) to the desired concentration.
The colloids were sonicated at room temperature for 30min and
left overnight at room temperature to stabilise. The colloids were
then extruded through a 0.45mm syringe filter before analysis.
Dynamic Light Scattering
The light scattering measurements were performed with a
Zetasizer Nano ZS (Malvern Instruments) at a scattering angle
of 1738. The concentrations of the surfactants were sufficiently
low enough (0.46–0.72mM) to avoid multiple scattering from
the aggregates. Solutions were prepared at 10CMC from a
stock solution of 1mgmL1 in Milli-Q water and sonicated for
30min to ensure adequate dissolving before being left to
equilibrate overnight. All solutions were filtered with a 0.45 mm
filter directly into the cuvette immediately before measurement
to avoid interference from dust particles. Measurements were
taken at 258C unless otherwise stated and repeated in triplicate.
Pyrene Encapsulation Measurements
The fluorescence properties of pyrene were determined using a
Varian Cary Eclipse fluorescence spectrophotometer. The sur-
factant solutions were prepared 24 h before the measurements
using milli-Q water (resistivity of 18.2MO cm) at a range of
concentrations (1 to 0.0001mgmL1). Excess crystalline pyr-
ene was then added to the surfactant aqueous solutions and
heated at 308C for 30min in a sonic bath before allowing
equilibration at room temperature for 23 h. The solutions were
then filtered through a 0.45mm filter before measurement. The
emission spectra of pyrene were acquired by exciting samples at
335 nm (Ex slit width 5 nm, Em slit width 5 nm). The spectra
were then used to determine the ratio of I386/I393.
Cryo-TEM
A laboratory-built humidity-controlled vitrification system was
used to prepare the samples for Cryo-TEM. Humidity was kept
close to 80% for all experiments, and ambient temperature was
228C. A 200 mesh copper grid coated with perforated carbon
film (Lacey carbon film: ProSciTech, Qld, Australia) and
overlaid with a very thin continuous carbon film was glow
discharged in nitrogen to render it hydrophilic. The thin carbon
overlay was found to be necessary as the cationic particles were
consistently attracted to the perforacted film rather than being
suspended in the holes. Aliquots of 4mL of the sample were
pipetted onto each grid before plunging. After 30 s adsorption
time the grid was blotted manually using Whatman 541 filter
paper for ,2 s. Blotting time was optimised for each sample.
The grid was then plunged into liquid ethane cooled by liquid
nitrogen. Frozen grids were stored in liquid nitrogen until
required. The samples were examined using a Gatan 626 cryo-
holder (Gatan, Pleasanton, CA, USA) and Tecnai 12 Trans-
mission Electron Microscope (FEI, Eindhoven, The
Netherlands) at an operating voltage of 120 kV. At all times low
dose procedures were followed, using an electron dose of 8–10
electrons A˚2 for all imaging. Images were recorded using an
Eagle 4k 4k CCD camera (FEI, Eindhoven, The Netherlands)
using magnifications in the range 15 000–60 000
Synthesis of Amphiphiles
For the synthesis of amphiphiles 1–4 and their corresponding
spectra please refer to previous publications from our group.[26]
Synthesis of 4,7-Methano-1H-isoindole-1,3(2H)-dione-
3a,4,7,7a-tetrahydro-2-[2-(2-hydroxy ethoxy)ethyl] 6
To a 35mL microwave vial containing 2-(2-aminoethoxy)eth-
anol (2.28mL, 23.0mmol), norbornene anhydride (2 g,
12.2mmol) was added and dissolved with toluene (15mL). The
solution was then subjected to microwave irradiation at 1008C
for 20min. The resulting solution was diluted with CH2Cl2
(30mL) and was transferred to a separating funnel where it was
washed with saturated aqueous NaCl (2 25mL) followed by a
wash with HCl (2M, 20mL), and finally NaHCO3 (3 25mL).
The combined organic phases were dried (MgSO4) and solvent
removed under vacuum to give a yellow viscous oil. 1H NMR
spectroscopy analysis showed it to be the desired ethoxy imide 6
(2.63 g, 88%) in. 95% purity which was then used without
further purification. dH (270MHz, CDCl3) 6.09 (2H, t, J 2.7),
3.65–3.63 (2H, d, J 5.4), 3.59–3.47 (2H, m), 3.39–3.35 (2H, m),
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3.29–3.22 (2H, m), 2.59 (2H, br s), 1.83 (2H, br s), 1.74–1.69
(1H, dt, J 10.8, 16.2), 1.55–1.49 (1H, dt, J 8.1, 13.5);
dC (200MHz, CDCl3) 178.10, 134.41, 72.22, 67.70, 61.58,
52.16, 45.81, 44.94, 37.86; m/z (HRMS ESI) Calc. for
[C13H18NO4]
þ 252.12303, found 252.12400; nmax /cm
1 3452
br, 2944m, 2871m, 1684 s.
Synthesis of 2-(2-(1,3-Dioxo-1,3,3a,4,7,7a-hexahydro-
2H-4,7-methanoisoindol-2-yl)ethoxy)ethyl
4-Methylbenzenesulfonate 7
To a solution of ethoxy imide 6 (2.74 g, 10.8mmol) in CH2Cl2
(30mL), p-toluenesulfonyl chloride (3.09 g, 16.2mmol) was
added and stirred until dissolved. Triethyl amine (TEA) was
added (1.5mL, 10.8mmol) and the resulting solution was stirred
under nitrogen for 16 h before being dilutedwithCH2Cl2 (30mL)
and transferred to a separating funnel where it was washed with
saturated aqueous NaCl (3 25mL). The combined organic
phases were dried (MgSO4) and solvent removed under vacuum
to give a beige viscous oil. Purification by silica gel column
chromatography was performed with a 50% petroleum spirit/
50%EtOAc solution and the resulting oil was shown by 1HNMR
spectroscopy analysis to be the desired tosylate 7 (3.70 g, 85%)
in. 95% purity. dH (270MHz, CDCl3) 7.76–7.73 (2H, d, J 8.1),
7.33–7.30 (2H, d, J 8.1), 6.01–6.59 (2H, t, J 8.1), 4.06–4.04
(2H, t, J 2.7), 3.57–3.53 (2H, m), 3.46–3.39 (2H, m), 3.32–3.31
(2H,m), 3.23–3.22 (4H,m), 2.41 (3H, s), 1.70–1.65 (1H, dt, J 8.1,
13.5), 1.51–1.47 (1H, d, J 10.8); dC (67.5MHz, CDCl3) 177.71,
144.93, 134.48–134.36, 132.93, 130.06, 129.86, 69.22, 67.99–
67.31, 52.19, 45.85–45.01, 44.87, 37.30, 21.80;m/z (HRMSESI)
Calc. for [C20H24NO6S]
þ 406.13188, found 406.13400; nmax
/cm1 2946m, 2873m, 1697 s.
Synthesis of 2-(2-(-5,6-Dihydroxy-1,3-dioxooctahydro-1H-
4,7-methanoisoindol-2-yl)ethoxy) Ethyl-4-
methylbenzenesulfonate 8
Tosylate 7 (1.44 g, 3.0mmol) was dissolved in a 4 : 1 solution of
acetone/water (30mL) and NMO (628mg, 5.0mmol) was
added and stirred until dissolved. Osmium tetroxide (0.2mL)
was added and the black solution stirred for 16 h at room tem-
perature. The reaction was quenched with sodium metabisulfite
(2mL, 0.53M) and the solution diluted with EtOAc (30mL)
before being transferred to a separating funnel where it was
washed with saturated aqueous NaCl (3 25mL). The organic
phase was dried (MgSO4) and solvent was removed under
vacuum to afford a yellow oil. Purification by silica gel column
chromatography was performed with 100% EtOAc and the
resulting pale yellow oil was shown by 1HNMR spectroscopy to
be the desired diol 8 (1.09 g, 83%). dH (400MHz, CDCl3) 7.79–
7.77 (2H, d, J 8.0), 7.38–7.36 (2H, d, J 8.0), 4.12–4.07 (2H, m),
3.86 (2H, s), 3.67–3.58 (2H, m), 3.29 (2H, br s), 3.08–3.06 (3H,
m), 2.70 (3H, br s), 2.45 (3H, s), 2.16–2.13 (1H, d, J 12.0), 1.49–
1.46 (1H, d, J 12.0); dC (200MHz, CDCl3) 177.06, 145.53,
130.20, 129.11, 128.30, 128.17, 128.15, 70.03, 69.92, 68.10,
67.29, 46.06, 45.81, 37.92, 36.18, 21.77;m/z (HRMS ESI) Calc.
for [C20H26NO8S]
þ 440.13736, found 440.13965; nmax /cm
1
3454 br, 2952m, 1697 s.
Synthesis of 2-(2-(-5,7-Dioxo-2-undecyloctahydro-6H-4,8-
methano[1,3]dioxolo[4,5-f]isoindol-6-yl)ethoxy)ethyl 4-
Methylbenzenesulfonate 9
To a solution of dodecyl aldehyde (0.34mL, 1.5mmol) in
CH2Cl2 (30mL), diol 8 (333mg, 0.76mmol) was added and
stirred until dissolved. MgSO4 was then added, followed by the
addition of p-toluenesulfonic acid (577mg, 3.0mmol). The
resulting solution was warmed to 358C and stirred for 16 h
before being filtered and the solvent removed under vacuum to
give a light brown oil. Purification by silica gel column chro-
matography was performed with a 60% petroleum spirit/40%
EtOAc solution and the resulting caramel oil was shown by 1H
NMR spectroscopy analysis to be the desired dodecyl acetal 9
(348mg, 76%) in. 95% purity. dH (270MHz, CDCl3) 7.77–
7.74 (2H, d, J 8.1), 7.35–7.32 (2H, d, J 8.1), 4.58–4.54 (1H, t,
J 5.4), 4.08–4.05 (2H, m), 3.84 (2H, br s), 3.63–3.54 (2H, m),
3.10–3.08 (2H, m), 2.81–2.79 (2H, m), 2.43 (3H, s), 2.02–1.96
(4H, m), 1.69–1.57 (4H, m), 1.39–1.22 (18H, m), 0.87–0.83
(3H, t, J 5.4); dC (200MHz, CDCl3) 174.41, 144.98, 132.98,
130.15, 129.82, 127.95, 104.27, 77.45, 69.12, 68.14, 67.17,
44.51, 42.90, 42.57, 37.68, 35.92, 32.76, 31.99, 29.64–29.41,
24.23, 22.76, 14.28;m/z (HRMS ESI) Calc. for [C32H48NO8S]
þ
606.30951, found 606.31166; nmax /cm
1 2942m, 2854m,
1700 s.
Synthesis of 2-(2-(-5,7-Dioxo-2-pentadecyloctahydro-6H-
4,8-methano[1,3]dioxolo[4,5-f]isoindol-6-yl)ethoxy)ethyl
4-Methylbenzenesulfonate 10
To a solution of hexadecyl aldehyde (295mg, 1.2mmol) in
CH2Cl2 (30mL), diol 8 (360mg, 0.82mmol) was added and
stirred until dissolved. MgSO4 was then added, followed by the
addition of p-toluenesulfonic acid (623mg, 3.3mmol). The
resulting solution was warmed to 358C and stirred for 16 h before
being filtered and the solvent removed under vacuum to give a
light brown oil. Purification by silica gel column chromatography
was performedwith a 60%petroleum spirit/40%EtOAc solution
and the resulting caramel oil was shown by 1H NMR spectros-
copy analysis to be the desired hexadecyl acetal 10 (398mg,
73%) in. 95% purity. dH (400MHz, CDCl3) 7.79–7.76 (2H, d,
J 12.0), 7.36–7.34 (2H, d, J 8.0), 4.59–4.56 (1H, t, J 8.0),
4.10–4.07 (2H, m), 3.86 (2H, br s), 3.64–3.56 (2H, m), 3.11–3.10
(2H, m), 2.83–2.81 (2H, m), 2.45 (3H, s), 2.02–1.99 (4H, d,
J 12.0), 1.64–1.56 (4H,m), 1.40–1.24 (26H,m), 0.89–0.85 (3H, t,
8.0); dC (200MHz, CDCl3) 176.41, 144.98, 132.90,
130.07–129.90, 128.10, 127.94, 104.50, 77.42, 69.11, 68.15,
67.18, 44.50, 42.66, 37.69, 32.00, 29.74–29.44, 24.24, 22.78,
14.21; m/z (HRMS ESI) Calc. for [C36H56NO8S]
þ 662.37211,
found 662.37125; nmax /cm
1 2923m, 2853m, 1702 s.
Synthesis of 6-(2-(2-((2-(4-((Z)-1,2-diphenylbut-1-en-1-yl)
phenoxy)ethyl)(methyl)amino)ethoxy) Ethyl)-2-
undecylhexahydro-5H-4,8-methano[1,3]dioxolo[4,5-f]
isoindole-5,7(6H)-dione 11
The synthetic procedure was adapted from Dreaden et al.[1]
Briefly, Tosyl dodecyl acetal 9 (350mg, 0.58mmol) was added
to a solution of demethylated Tamoxifen 16 (152mg,
0.39mmol) in THF. Potassium carbonate was added (532mg,
3.9mmol) and the resulting solution was refluxed at 708C for
16 h. The solution was then diluted with CH2Cl2 and filtered
before being transferred to a separation funnel where it was
washed with saturated aqueous NaHCO3 (3 25mL) and the
combined organic phases dried (MgSO4) and the solvent
removed under vacuum to give a pale yellow oil. Purification by
silica gel column chromatography was performed with a 5%
MeOH in CH2Cl2 solution and the resulting yellow oil was
shown by 1H NMR spectroscopy analysis to be the desired
hexadecyl Tamoxifen amphiphile 13 (69mg, 21%) in. 95%
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purity. dH (400MHz, CDCl3) 7.36–7.08 (10H, m), 6.76–6.73
(2H, d, J 12.0), 6.54 -6.50 (2H, d, J 16.0), 4.59–4.56 (1H, t, J
4.0), 3.93–3.87 (2H, m), 3.63–3.49 (4H, m), 3.07–3.04 (2H, m),
2.82–2.80 (2H, m), 2.75–2.71 (2H, t, J 8.0), 2.63–2.56 (2H, m),
2.48–2.40 (4H, q, J 12.0), 2.30 (3H, s), 2.00–1.96 (2H, d, J 16.0),
1.69–1.56 (2H, m), 1.32–1.23 (18H, m), 0.93–0.83 (6H, m); dC
(200MHz, CDCl3) 176.46, 143.79, 142.41, 138.33, 132.04,
130.87, 130.76, 129.77, 129.53, 128.20, 127.98, 127.85, 127.38,
126.64, 126.16, 125.76, 114.20, 104.17, 78.85, 67.44, 56.94,
56.34, 44.56, 43.12, 42.75, 35.85, 35.03, 32.75, 31.99, 29.69–
29.10, 24.25, 22.77, 14.20, 13.67; m/z (HRMS, ESI) Calc. for
[C50H67N2O6]
þ 791.49936, found 791.49871; nmax /cm
1
2924m, 2854m, 1702 s.
Synthesis of 6-(2-(2-((2-(4-((Z)-1,2-diphenylbut-1-en-1-yl)
phenoxy)ethyl)(methyl)amino)ethoxy) Ethyl)-2-
pentadecylhexahydro-5H-4,8-methano[1,3]dioxolo[4,5-f]
isoindole-5,7(6H)-dione 12
The synthetic procedure was adapted from Dreaden et al.[1]
Briefly, hexadecyl acetal 10 (300mg, 0.45mmol)was added to a
solution of demethylated Tamoxifen 16 (119mg, 0.30mmol) in
THF. Potassium carbonate was added (417mg, 3.02mmol) and
the resulting solution was refluxed at 708C for 16 h. The solution
was then diluted with CH2Cl2 and filtered before being trans-
ferred to a separation funnel where it was washed with saturated
aqueousNaHCO3 (3 25mL) and the combined organic phases
dried (MgSO4) and the solvent removed under vacuum to give a
pale yellow oil. Purification by silica gel column chromatog-
raphy was performed with a 5%MeOH in CH2Cl2 solution and
the resulting yellow oil was shown by 1H NMR spectroscopy
analysis to be the desired hexadecyl Tamoxifen amphiphile 12
(41mg, 16%) in. 95% purity. dH (400MHz, CDCl3)
7.35–7.07 (10H, m), 6.76–6.74 (2H, d, J 8.0), 6.54–6.52 (2H, d,
J 8.0), 4.59–4.57 (1H, t, J 4.0), 3.92 (2H, br s), 3.65–3.56 (4H,
m), 3.08–3.06 (2H, m), 2.82–2.81 (4H, br s), 2.64 (2H, br s),
2.47–2.42 (4H, q, J 8.0, 16.0), 2.35 (3H, br s), 2.00–1.98 (2H, d,
J 8.0), 1.63–1.58 (2H, m), 1.37–1.23 (26H, m), 0.93–0.85
(6H, m); dC (200MHz, CDCl3) 176.40, 143.89, 142.48, 141.43,
138.29, 131.95, 129.78, 129.54, 128.17, 127.95, 126.59, 126.10,
113.44, 104.09, 78.32, 67.02, 57.23, 56.64, 44.50, 43.43, 42.77,
37.82, 35.87, 35.01, 32.78, 32.01, 29.78–29.58, 24.27, 22.78,
14.21, 13.67; m/z (HRMS ESI) Calc. for [C54H75N2O6]
þ
847.56196, found 847.56356; nmax /cm
1 2924m,
2853m, 1703 s.
Synthesis of 2-Undecylhexahydro-5H-6-(2-(2-azidoethoxy)
ethyl)-4,8-methano[1,3]dioxolo[4,5-f]
isoindole-5,7(6H)-dione 13
Dodecyl acetal 9 (348mg, 0.58mmol) was dissolved in a
solution of 8 : 1MeCN/H2O before the addition of sodium azide
(262mg, 4.03mmol). The resulting solution was then refluxed
for 16 h before being diluted with CH2Cl2 (30mL) and trans-
ferred to a separating funnel where it was washed with saturated
aqueous NaCl (3 25mL) and the combined organic phases
dried (MgSO4) and solvent removed under vacuum to give a
white solid. Several attempts at purification by silica gel column
chromatography were performed unsuccessfully and, as such,
the crude product that was shown by 1H NMR and mass spec-
troscopic analysis to contain the desired dodecyl azide 13
(243mg, 89%) was used in subsequent steps. dH (400MHz,
CDCl3) 4.61–4.59 (1H, t, J 4.0), 3.93 (4H, s), 3.68–3.65 (2H, t,
J 12.0), 3.62–3.59 (2H, t, J 4.0), 3.34–3.32 (2H, t, J 4.0),
3.12–3.08 (2H,m), 2.84–2.83 (2H,m), 2.02–1.99 (2H, d, J 12.0),
1.64–1.59 (2H, m), 1.40–1.23 (18H,m), 0.87–0.85 (3H, t, J 4.0);
dC (200MHz, CDCl3) 176.48, 104.14, 78.34, 69.45, 67.29,
50.82, 44.53, 42.77, 37.72, 35.88, 34.58, 32.75, 31.98, 29.70–
29.35, 24.26, 22.75, 14.19; m/z (HRMS, ESI) Calc. for
[C25H41N4O5]
þ 477.30715, found 477.30950; nmax /cm
1
2992m, 2854m, 2108 s, 1700 s.
Synthesis of 2-Pentadecylhexahydro-5H-6-(2-(2-
azidoethoxy)ethyl)-4,8-methano[1,3]dioxolo [4,5-f]
isoindole-5,7(6H)-dione 14
Hexadecyl acetal 10 (2.0 g, 3.0mmol) was dissolved in a solu-
tion of 8 : 1 MeCN/H2O before the addition of sodium azide
(1.37 g, 21.1mmol). The resulting solutionwas then refluxed for
16 h before being diluted with CH2Cl2 (30mL) and transferred
to a separating funnel where it was washed with saturated
aqueous NaCl (3 25mL) and the combined organic phases
dried (MgSO4) and the solvent removed under vacuum to give a
white solid. Several attempts at purification by silica gel column
chromatography were performed unsuccessfully and, as such,
the crude product that was shown by 1H NMR spectroscopy
analysis to be the desired hexadecyl azide 12 (1.45 g, 91%) was
used in further steps. dH (400MHz, CDCl3) 4.61–4.58 (1H, t,
J 4.0), 3.93 (4H, s), 3.66–3.64 (2H, t, J 4.0), 3.62–3.58 (2H, t,
J 8.0), 3.34–3.30 (2H, t, J 8.0), 3.10–3.08 (2H, m), 2.84–2.82
(2H, m), 1.99 (2H, s), 1.63–1.57 (2H, m), 1.40–1.19 (26H, m),
0.87–0.83 (3H, t, J 8.0); dC (200MHz, CDCl3) 176.45, 104.26,
78.35, 69.46, 67.22, 50.83, 44.53, 42.86, 37.72, 32.76, 32.00,
29.74–29.44, 24.28, 22.78, 14.20; m/z (HRMS ESI) Calc. for
[C29H49N4O5]
þ 533.36975, found 533.37242; nmax /cm
1
2917m, 2850m, 2112 s, 1698 s.
Synthesis of N-Desmethyl Tamoxifen 16
Using a method described by Dreaden et al.[1] a solution of
Tamoxifen 15 (500mg, 1.4mmol) and CH2Cl2 was cooled to
08C before the addition of chloroethyl chloroformate (0.23mL,
2.0mmol). The resulting solution was stirred for 15min at 08C
before refluxing at 508C for 24 h. The solvent was then removed
under vacuum, and the resulting clear oil redissolved in MeOH
before being refluxed at 708C for a further 3 h. The solvent was
removed under vacuum to give a cream solid. Purification by
silica gel column chromatography was performed with a 10%
MeOH in CHCl3 solution and the resulting white solid was
shown by 1H NMR spectroscopy analysis to be consistent with
literature values[24] for the desired demethylated Tamoxifen 16
(506mg, 95%).
Synthesis of Ethanamine, 2-[4-[(1E)-1,2-Diphenyl-1-buten-
1-yl]phenoxy]-N,N-methyl-propargyl 17
Propargyl bromide (0.18mL, 2.03mmol) was added to a solu-
tion of demethylated Tamoxifen 16 (400mg, 1.01mmol) in
PhMe and stirred. TEA was added before the solution was
stirred at 808C for 16 h before being diluted with CH2Cl2
(30mL) and transferred to a separating funnel where it was
washed with saturated aqueous NaCl (3 25mL) and the
combined organic phases dried (MgSO4) and the solvent
removed under vacuum to give a pale yellow solid. Purification
by silica gel column chromatography was performed with a
80% petroleum spirit/20% EtOAc solution and the resulting
white solid was shown by 1H NMR spectroscopy analysis to be
the desired propargylated Tamoxifen 17 (304mg, 76%) in
. 95% purity. dH (400MHz, CDCl3) 7.37–7.09 (10H, m),
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6.77–6.74 (2H, d, J 12.0), 6.57–6.53 (2H, d, J 16.0), 3.94–3.90
(2H, t, J 8.0), 3.41–3.40 (2H, d, J 4.0), 2.81–2.77 (2H, t, J 8.0),
2.49–2.40 (2H, q, J 12.0), 2.36 (3H, s), 2.21–2.19 (1H, t, J 4.0),
0.94–0.88 (3H, t, J 12.0); dC (200MHz, CDCl3) 156.81, 143.91,
142.52, 141.44, 138.35, 135.72, 131.95, 129.81–127.97, 113.51,
78.56, 73.45, 65.80, 54.45, 46.06, 42.30, 29.81, 29.11, 13.71;
m/z (HRMS ESI) Calc. for [C28H30NO]
þ 396.23219, found
396.23240; nmax /cm
1 3291m, 1704m, 1572 s, 1173 s, 703 s.
Synthesis of 6-(2-(2-(4-(((2-(4-((Z)-1,2-Diphenylbut-1-en-1-
yl)phenoxy)ethyl)(methyl)amino)methyl)-1H-1,2,3-triazol-
1-yl)ethoxy)ethyl)-2-undecylhexahydro-5H-4,8-methano
[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-dione 18
To a 35mL microwave vial containing dodecyl azide 11
(258mg, 0.54mmol), CuCl (5.37mg, 0.054mmol) was added
and dissolved with CHCl3 (15mL). Propargylated tamoxifen 17
(214mg, 0.54mmol) was added and the solution was then
subjected to microwave irradiation at 1008C for 30min before
being diluted with CHCl3 (30mL). The solution was then
transferred to a separating funnel where it was washed with 4M
HCl (3 25mL) followed by a wash with H2O (20ml). The
combined organic phases were dried (MgSO4) and the solvent
removed under vacuum to give a green oil. Purification by silica
gel column chromatography was performed with 100% EtOAc
followed by 100%EtOH and the resulting yellow oil was shown
by 1H NMR spectroscopy analysis to be the desired triazole
amphiphile 18 (238mg, 50%) in. 95% purity. dH (400MHz,
CDCl3) 7.63 (1H, br s), 7.33–7.31 (4H, m), 7.27–7.21 (2H, m),
7.18–7.08 (4H, m), 6.76–6.74 (2H, d, 8.0), 6.54–6.52 (2H, d,
J 8.0), 4.55–4.53 (1H, t, J 4.0), 4.44–4.42 (2H, t, J 8.0), 4.00
(2H, br s), 3.86 (1H, s), 3.70–3.82 (4H, m), 3.62–3.60 (3H, t,
J 4.0), 3.54–3.50 (3H, t, J 8.0), 3.09–3.08 (6H, m), 2.82 (2H, br
s), 2.47–2.38 (2H, m), 2.00–1.97 (2H, d, J 12.0), 1.64–1.59 (3H,
m), 1.38–1.24 (18H, m), 0.93–0.85 (6H, m); dC (200MHz,
CDCl3) 176.41, 156.67, 143.89, 142.47, 141.47, 138.27, 135.72,
131.93, 129.77, 129.53, 128.18, 127.95, 126.59, 126.11, 113.44,
104.22, 78.31, 68.90, 67.52, 65.66, 55.31, 52.55, 50.18, 44.49,
43.35, 42.74, 37.69, 35.83, 32.76, 31.99, 29.71–29.41, 24.41,
24.23, 22.76, 14.20, 13.66; m/z (HRMS ESI) Calc. for
[C53H70N5O6]
þ 872.53206, found 872.53396; nmax /cm
1
2924m, 2854m, 1700 s.
Synthesis of 6-(2-(2-(4-(((2-(4-((Z)-1,2-Diphenylbut-1-en-1-
yl)phenoxy)ethyl)(methyl)amino)methyl)-1H-1,2,3-triazol-
1-yl)ethoxy)ethyl)-2-pentadecylhexahydro-5H-4,8-
methano[1,3]dioxolo[4,5-f]isoindole-5,7(6H)-dione 19
To a 35mL microwave vial containing hexadecyl azide 12
(100mg, 0.19mmol), CuCl (1.87mg, 0.019mmol) was added
and dissolved with CHCl3 (15mL). Propargylated Tamoxifen
17 (75mg, 0.19mmol) was added and the solution was then
subjected to microwave irradiation at 1008C for 30min before
being diluted with CHCl3 (30mL). The solution was then
transferred to a separating funnel where it was washed with 4M
HCl (3 25mL) followed by a wash with H2O (20mL). The
combined organic phases were dried (MgSO4) and the solvent
removed under vacuum to give a green oil. Purification by silica
gel column chromatography was performed with 100% EtOAc
followed by 100%EtOH and the resulting yellow oil was shown
by 1H NMR spectroscopy analysis to be the desired triazole
amphiphile 19 (119mg, 68%) in. 95% purity. dH (400MHz,
CDCl3) 7.62 (1H, br s), 7.35–7.31 (4H, m), 7.27–7.21 (2H, m),
7.18–7.07 (4H, m), 6.76–6.74 (2H, d, 8.0), 6.54–6.52 (2H, d,
J 8.0), 4.55–4.53 (1H, t, J 4.0), 4.43–4.41 (2H, t, J 4.0), 3.99 (2H,
br s), 3.85 (1H, s), 3.82–3.76 (4H, m), 3.62–3.69 (3H, t, J 4.0),
3.53–3.51 (3H, t, J 4.0), 3.09–3.08 (6H, m), 2.82 (2H, br s),
2.46–2.37 (2H,m), 2.00–1.97 (2H, d, J 12.0), 1.63–1.59 (3H,m),
1.38–1.24 (28H, m), 0.92–0.85 (6H, m); dC (200MHz, CDCl3)
176.38, 156.68, 143.90, 138.27, 135.70, 131.93, 129.77, 129.53,
128.18, 127.96, 126.59, 126.11, 124.22, 113.43, 104.21, 78.31,
68.89, 67.52, 65.69, 55.33, 52.56, 50.18, 44.48, 42.73, 37.69,
35.83, 32.77, 32.00, 29.78–29.44, 29.09, 24.23, 22.77, 14.21,
13.67; m/z (HRMS ESI) Calc. for [C57H78N5O6]
þ 928.59466,
found 928.59438; nmax /cm
1 2923m, 2853m, 1701 s.
Supplementary Material
All 1H and 13C NMR spectra for novel compounds, represen-
tative CMC determination, TEM images referred to in the text
and correlograms from DLS measurements during variable
temperature studies are available on the Journal’s website.
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